Military Allergy Program

0001 26th Annual Harold S. Nelson Allergy/Immunology Symposium
7:20 am to 5:00 pm
Programmed by the Military Allergy/Immunology Assembly of the AAAAI. Funded through an education grant from Teva Respiratory.
Convention Center, S230AB, Level II
Pre-registration and ticket required. No fee. Continental breakfast and box lunch included.
Credit: 8.00 CME / 9.60 CE
Moderator: Mark H. Tucker, MD
8:00 Morning Address: AERD and Aspirin Desensitization
Andrew A. White, MD FAAAAI
9:00 Break
9:15 Fellow Research and Clinical Case Presentations
11:30 Lunch and Bruton Lecture: Application of Flow Cytometry in Diagnosing and Understanding Primary Immune Deficiencies
Thomas A. Fleisher, MD FAAAAI
1:15 Research and Clinical Case Presentations
2:15 Break
2:30 Vaccine Healthcare Center Update
Renata J.M. Engler, MD FAAAAI
3:00 Military Aeroallergen Extract Laboratory Updates
Susan E. Kosisky, MA
Consultants to the Surgeons General Updates
3:30 Air Force
Stephen E. Scranton, MD
3:45 Army
Michael R. Nelson, MD PhD FAAAAI
4:00 Navy
Mark H. Tucker, MD
4:15 Business Meeting and Award Presentations

Upon completion of this session, participants should be able to: Describe the purpose of aspirin desensitization in AERD; Identify the different types of hypersensitivity; Discuss the role for challenge/desensitization in all types of aspirin reactions; Explain to a colleague the mechanics of how desensitization can safely be performed; Identify the appropriate flow cytometry tests that clarify specific PIDD diagnoses; Define the principles of intracellular flow cytometry in screening for specific PIDD; Outline the approach to evaluate immunologic functions using flow cytometry methods.
FRIDAY • MARCH 2, 2012

Fellows-in-Training Program

1011 FIT Symposium
7:00 am to 2:00 pm
Peabody, Windermere Ballroom W, Convention Level
Pre-registration and ticket required. No fee. Continental breakfast and box lunch included.
Credit: No CME / No CE

7:00 From FITs to Faculty: Meet Your Future Faculty: Networking with Prominent A/I Professors and Researchers
Moderator: Lawrence B. Schwartz, MD PhD FAAAAI

7:30 Introduction to the Program Directors Assembly
Lawrence B. Schwartz, MD PhD FAAAAI

7:40 Tales from Academia
Hugh A. Sampson, MD FAAAAI
Andrew Saxon, MD FAAAAI
Moderator: Martha K. Elias, MD

8:30 Welcome and Opening Remarks
Martha K. Elias, MD

9:05 Climate Change and its Effect on Aerobiology
Richard W. Weber, MD FAAAAI

9:35 Welcome from the President
Dennis K. Ledford, MD FAAAAI

9:45 Difficult Clinical Cases in Allergy: A Master Clinician’s Perspective
Dennis K. Ledford, MD FAAAAI

10:15 Break

10:30 Immunomodulation with Immunotherapy
Harold S. Nelson, MD FAAAAI

11:00 Accelerated Immunotherapy Approaches for Aeroallergens
David A. Khan, MD FAAAAI

11:30 Lunch Break

12:00 Hereditary Angioedema (HAE)
Gabriel Ortiz, MPAS PA-C DFAAPA

12:45 IVIG: Difficult Cases and Clinical Pearls
Debra A. Sedlak, MSN CPNP

1:30 The Allergic Gut
Sally A. Noone, RN MSN CCRC

2:15 Break

2:30 Workshops (Attendees will choose one of the following sessions.)
Pre-registration and ticket required. Fee: $20.
Credit: 1.50 CME / 1.80 CE

1101A: Punch Biopsy
Peabody, Bayhill 19, Lobby Level
Jeanette L. Arnold, RN MS CPNP

1101B: eNO
Peabody, Bayhill 20, Lobby Level
Edward O. Corazalla, MS RPFT

1101C: Atopic Dermatitis Patch Testing
Peabody, Bayhill 21, Lobby Level
Karol G. Timmons, RN MS CPNP

1101D: Food Allergy Lab
Peabody, Bayhill 23 & 24, Lobby Level
Sally A. Noone, RN MSN CCRC

Upon completion of this session, participants should be able to: Review the underlying mechanisms driving allergic and non-allergic upper airway disease processes; Recognize the clinical indications and administration techniques for immunotherapy; Explore novel approaches to immunotherapy.

Allied Health Course

1101 Advanced Practice Course
8:00 am to 4:00 pm
Peabody, Windermere Ballroom X, Convention Level
Pre-registration and ticket required. No fee. Lunch included.
Programmed by the AAAAI. Supported by an in-kind contribution from Aerocrine.
Credit: 5.50 CME / 6.60 CE
Morning Moderator: Gabriel Ortiz, MPAS PA-C DFAAPA
Afternoon Moderator: Nina A. Zimmermann, MSN RN ANP-BC AE-C

8:15 Masqueraders of Asthma: Chronic Cough in Adults
Nina A. Zimmermann, MSN RN ANP-BC AE-C

9:00 Masqueraders of Asthma: Pediatric Case Studies with PFT Examples
Edward O. Corazalla, MS RPFT

10:00 Management Issues in the Obese Asthmatic
Christine W. Wagner, CPNP CFNP AE-C

10:45 Alpha-1 Antitrypsin Deficiency
Jeanette L. Arnold, MSN RN C-FNP

12:00 Hereditary Angioedema (HAE)
Gabriel Ortiz, MPAS PA-C DFAAPA

12:45 IVIG: Difficult Cases and Clinical Pearls
Debra A. Sedlak, MSN CPNP

1:30 The Allergic Gut
Sally A. Noone, RN MSN CCRC

2:15 Break

2:30 Workshops (Attendees will choose one of the following sessions.)
Pre-registration and ticket required. Fee: $20.
Credit: 1.50 CME / 1.80 CE

1101A: Punch Biopsy
Peabody, Bayhill 19, Lobby Level
Jeanette L. Arnold, RN MS CPNP

1101B: eNO
Peabody, Bayhill 20, Lobby Level
Edward O. Corazalla, MS RPFT

1101C: Atopic Dermatitis Patch Testing
Peabody, Bayhill 21, Lobby Level
Karol G. Timmons, RN MS CPNP

1101D: Food Allergy Lab
Peabody, Bayhill 23 & 24, Lobby Level
Sally A. Noone, RN MSN CCRC

Upon completion of this session, participants should be able to: Differentiate between the patient assessment and differential diagnosis of chronic cough of the pediatric vs. adult patient populations; Identify various treatments of the diagnosis of chronic cough in pediatric and adult populations; Define obesity in adults and children and identify education strategies to assist patients in understanding the relationship between obesity and asthma; Recognize characteristics of pulmonary manifestations of Alpha-1 antitrypsin deficiency and recall the most common extrapulmonary manifestations of AAT deficiency; Recognize the signs and symptoms of HAE; Describe current practice in the diagnosis and treatment of EoE.
Clinical Research Workshop

1102 Health Literacy: What It Is and How You Measure It
8:00 to 9:15 am
Peabody, Bayhill 21, Lobby Level
Credit: 1.25 CME / 1.50 CE
Carol A. Jones, RN AE-C
Christine W. Wagner, CPNP CFNP AE-C
Upon completion of this session, participants should be able to: Define health literacy and its importance in a research setting; Describe ways to easily assess health literacy in a research setting; Identify techniques to provide patient education by incorporating health literacy techniques.

Chrysalis Program

1111 2012 Chrysalis Program
8:00 am to 12:00 pm
Peabody, Bayhill 17 & 18, Lobby Level
Pre-registration and ticket required. No fee.
Credit: No CME / No CE
8:00 Welcome and Introduction to A/I Training
Kimberly A. Risma, MD PhD FAAAAI
8:15 Food Allergy
A. Wesley Burks, MD FAAAAI
8:45 Immunodeficiency
Thomas A. Fleisher, MD FAAAAI
9:15 Eosinophilic Disorders
Amy D. Kilon, MD
9:45 Asthma
Gurjit K. Khurana Hershey, MD PhD FAAAAI
10:15 Break
10:30 Welcome from AAAAAI President
Dennis K. Ledford, MD FAAAAI
10:45 Atopic Dermatitis
Donald Y.K. Leung, MD PhD FAAAAI
11:15 Academic Career Paths
Kimberly A. Risma, MD PhD FAAAAI
11:30 Industry Career Paths
Thao T. Doan, MD
11:45 Private Practice Career Paths
Adina Kay Knight, MD

Course

1201 Basic Aeroallergen Course
9:00 am to 5:00 pm
Convention Center, S330GH, Level III
Pre-registration and ticket required. Fee: $250. Box lunch included.
Credit: 7.00 CME / 8.40 CE
Moderator: Estelle Levetin, PhD FAAAAI
9:10 Introduction to Fungal Aerobiology
W. Elliott Horner, PhD LEED AP FAAAAI
9:50 Fungal Spore Morphology
Estelle Levetin, PhD FAAAAI
10:40 Hands-On Instruction; Question & Answer
12:00 Lunch Break
1:00 Setting Up a Sampling Station
Estelle Levetin, PhD FAAAAI
1:30 Introduction to Pollen Aerobiology
Peter Van de Water, PhD
2:10 Pollen Morphology
Richard W. Weber, MD FAAAAI
3:00 Hands-On Instruction; Question & Answer
Upon completion of this session, participants should be able to: Discuss the fundamentals of fungal and plant reproductive biology, aerobiology and air sampling; Describe the basic features of spore and pollen morphology; Identify the major airborne pollen types and fungal spores.

1202 Difficult Cases (Part 1)
9:00 am to 12:00 pm
Convention Center, S310ABFE, Level III
Credit: 2.75 CME / 3.20 CE
Moderators: Dorothy S. Cheung, MD FAAAAI
Pramod S. Kelkar, MD FAAAAI
9:00 Eosinophilic Esophagitis / EGID
Seema Sharma Aceves, MD PhD FAAAAI
Princess U. Ogbogu, MD
10:10 Break
10:30 PFT Interpretation
Joseph D. Spahn, MD
Todd L. Hostetler, MD
11:05 Atopy in Older Adults
Paula J. Busse, MD FAAAAI
Vinay Mehta, MD
11:40 Question & Answer
Upon completion of this session, participants should be able to: Identify difficulties in the clinical management of eosinophilic gastrointestinal disease; Describe difficulties in the clinical management of innate immune defects; Explain difficulties in the interpretation of pulmonary function studies; Discuss difficulties in the clinical management of atopy in older adults.
Course 1203  Deeper Insights into the Mechanisms of Asthma and Allergic Inflammation
9:00 am to 12:00 pm
Convention Center, S330AB, Level III
Credit: 2.75 CME / 3.20 CE
Moderators: Svetlana P. Chapoval, MD PhD
Achsah Keegan, PhD
9:00 STAT6 Regulation of Th2/T reg Balance
Achsah Keegan, PhD
9:20 Lung DC Subsets and Differential Role in T Helper vs. T reg Responses
Anuradha Ray, PhD
9:40 Novel Endogenous Regulator of Th2 Inflammation: Epithelial Reticulon Nogo-B
Paulette Wright Andreotta, PhD
10:00 Novel Endogenous Regulators of Th2 Inflammation: Semaphorins
Hitoshi Kikutani, PhD
10:20 Break
10:40 Chitinase-Like Proteins in the Regulation of Th2 Inflammation
Jack A. Elias, MD
11:00 Regulation of Allergic Airway Disease by IFN- Gamma
Lauren Cohn, MD
11:20 Novel Therapy for Asthma
Stephen B. Liggett, MD
11:40 Question & Answer
Upon completion of this session, participants should be able to: Discuss recent developments regarding cell subpopulations and immune factors in allergic asthma complexity; Identify novel endogenous regulators of Th2 inflammation and their potential as novel therapeutic agents; Identify how increased knowledge of novel cellular and molecular regulators of allergic disease enables new therapeutic applications; Define novel mechanistic concepts in specific function of dendritic cells and regulatory T Cells in allergic disease.

Course 1204  NIAID Morning Course: Allergen Immunotherapy: Innovative Approaches
9:00 am to 12:00 pm
Convention Center, S310CDGH, Level III
Credit: 2.75 CME / 3.30 CE
Moderator: Marshall Plaut, MD FAAAAI
9:00 Subcutaneous vs. Sublingual Immunotherapy for Aeroallergens
Stephen R. Durham, MA MD
9:25 Oral Immunotherapy for Food Allergens
A. Wesley Burks, MD FAAAAI
9:50 Intralymphatic and Epicutaneous Immunotherapy
Thomas M. Kuendig, MD
10:15 Break
10:30 Peptide Immunotherapy
Mark Larche, PhD
10:55 New Insights into the Mechanisms of Immunotherapy
Kari C. Nadeau, MD PhD FAAAAI
11:20 Effects of Immunotherapy on Antigen-Specific T Cells
William W. Kwok, PhD
11:45 Question & Answer
Upon completion of this session, participants should be able to: Discuss current knowledge on the comparative efficacy of SCIT vs. SLIT and ongoing head-to-head comparison trials; Discuss recent data on food allergy immunotherapy comparing sublingual and oral approaches; Identify new forms of immunotherapy under development and discuss their potential usefulness and limitations; Discuss new insights in the mechanisms of immunotherapy.

Course 1205  Allergy Diagnostics and Immunotherapy: The Nuts, the Bolts, the Science and the Art (Part 1)
9:00 am to 12:00 pm
Convention Center, S320AB, Level III
Credit: 1.00 CME / 1.20 CE
Moderators: Desirée E.S. Larenas Linnemann, MD FAAAAI
Michael S. Tankersley, MD FAAAAI
9:00 All You Need to Know About Rush and Cluster Schedules
Thomas Chacko, MD
9:30 Special Situations that Need Dose-Adjustment During AIT
Christopher W. Calabria, MD
10:00 Hands-on Workshops (Attendees will rotate between two workshops.)
Pre-registration and ticket required to attend the hands-on workshops. Fee: $25.
Credit: 2.00 CME / 2.40 CE
1205A: Allergen Extract Preparation and Take the Media Fill Test
Convention Center, S320EF, Level III
Michael S. Blaiss, MD FAAAAI
Susan E. Kosisky, MA
Bryan L. Martin, DO FAAAAI
Cecilia Mikita, MD MPH FAAAAI
Michael R. Nelson, MD PhD FAAAAI
1205B: Preparing Your Office for Anaphylaxis and Other Emergencies
Convention Center, S320GH, Level III
Preparing Office Equipment and Staff
Dana V. Wallace, MD FAAAAI
Going Through a Code
Nabil El Sanad, MD
Upon completion of this session, participants should be able to: Discuss rush and cluster immunotherapy schedules, premedication and patient selection; Propose immunotherapy schedule adjustments after a gap in administration, adverse reactions and switching from one manufacturer to another; Discuss what equipment is needed in the office for treatment of an anaphylactic reaction; Demonstrate the ability to make a sterile immunotherapy vial.
Upon completion of this session, participants should be able to: Explain impulse oscillometry technique for pulmonary function testing in young children; Describe techniques for optimizing spirometry in preschool-aged children; Identify valid criteria for successful spirometry in preschool aged children.

Medical Administrator Workshop

1211 Patient Safety: Adverse Events as Guides to Care
9:00 to 10:15 am
Peabody, Bayhill 25 & 26, Lobby Level
Credit: 1.25 CME / 1.50 CE
Moderator: Jeanette Booker
Donald W. Aaronson, MD FAAAAI

Upon completion of this session, participants should be able to: Identify the basic tenets and common causes of medical errors in the allergist’s office; Anticipate and prevent medical errors before reaching the patient; Disclose errors when they do occur.

Clinical Research Workshop

1212 The Anatomy of the Clinical Trial Agreement (Contract) and Successful Budget Negotiation
9:30 to 10:45 am
Peabody, Bayhill 22, Lobby Level
Credit: 1.25 CME / 1.50 CE
Moderator: Cheryl Koif Bernstein, RN BSN CCRC
Kay Weiler, BSN JD MA

Upon completion of this session, participants should be able to: Identify the components of the Clinical Trial Agreement; Describe the importance of identifying the indemnification language in the Clinical Trial Agreement; Discuss principles of budget preparation and negotiation.

Medical Administrator Workshop

1301 CPT Coding for the Allergist in 2012
10:30 to 11:45 am
Peabody, Bayhill 20, Lobby Level
Credit: 1.25 CME / 1.50 CE
Teresa Thompson, CPC CMSCS CCC

Upon completion of this session, participants should be able to: Use the current guidelines for CPT and diagnosis coding; Comply with Medicare guidelines.

Clinical Research Workshop

1302 Data Management: Your Research Data from Collection to Paper
11:00 am to 12:15 pm
Peabody, Bayhill 23 & 24, Lobby Level
Credit: 1.25 CME / 1.50 CE
Jean Curtin-Brosnan, MA
Patrick J. Lenehan
Carrie L. Vibbert, RN BSN

Upon completion of this session, participants should be able to: Setup, maintain and modify case report forms to collect study data to be integrated into a data set; Design a basic database to include various types of research data including case reports and lab results; Interpret basic biostatistical results used in presenting research data.

Clinical Research Workshop

1303 The IRB and Research Ethics
11:00 am to 12:15 pm
Peabody, Bayhill 31, Lobby Level
Credit: 1.25 CME / 1.50 CE
David Belde, PhD
Tracy S. Estes, PhD RN FNP

Upon completion of this session, participants should be able to: Describe the historical development of, and need for, formal human subject protections; Identify common ethical issues associated with human subject research; Describe the role and function of the Institutional Review Board.
Medical Administrator Workshop

1501 Roundtable Luncheon: Nuts and Bolts of Practice Management
12:00 to 1:15 pm
Peabody, Bayhill 32, Lobby Level
Pre-registration and ticket required. Fee: $40. Box lunch included.
Credit: 1.25 CME / 1.50 CE
Dennis W. Boo, CPA
Jeanette Booker
Lena G. Combs, CPA
Thomas V. Durkee, CPA
Teresa Thompson, CPC CMSCS CCC
Upon completion of this session, participants should be able to: Recognize and discuss the operational challenges that exist within a clinic arena; Demonstrate enhanced knowledge in operations through peer to peer interaction with experts in marketing, human resources, social media, EHR and legal matters; Recognize operational best practices that are demonstrated in other clinics.

ARTrust™ Financial Planning

1551 Simple Wealth Planning: You Work Hard for Your Money, Does Your Money Work Hard for You?
12:30 to 2:00 pm
Convention Center, S322, Level III
Pre-registration and ticket required. Fee: $30. Box lunch included.
Credit: No CME / No CE
Peter M. Wilmot, CFP
MetLife

Program Directors’ Business Meeting

2:00 to 4:00pm
All Program Directors and Co-Directors are invited to attend this business meeting.

Course

1601 Technology in the Clinical Practice Made Ridiculously Simple
2:00 to 5:00 pm
Convention Center, S230EF, Level II
Credit: 3.00 CME / 3.60 CE
Moderators: Dan Dalan, MD FAAAAI
Tao Le, MD MHS FAAAAI
2:00 What Can Technology Do for Your Practice?
Tao Le, MD MHS FAAAAI
2:20 EHRs and the Meaningful Use of Life
Russell B. Leftwich, MD FAAAAI
3:00 Practice Management Systems and Other Office Automation Tools
Linda D. Green, MD FAAAAI
3:30 Mobile Devices: iPhones, iPads and Androids, Oh My!
Melinda M. Rathkopf, MD FAAAAI
4:10 Tools for Marketing and Communications
Vesselin Dimov, MD
4:40 Making the Technology Work and Pay Off
David J. Shulan, MD FAAAAI
Upon completion of this session, participants should be able to: Identify the implications of EHR meaningful use for the clinical practice; Describe practice management systems and office automation technologies appropriate for the clinical practice; Explain the role of mobile technologies in the practice; List web and social media tools for practice marketing and communications; Discuss strategies for successful technology implementation.

Course

1602 Difficult Cases (Part 2)
2:00 to 5:00 pm
Convention Center, S310ABFE, Level III
Credit: 2.75 CME / 3.20 CE
Moderators: David W. Hauswirth, MD FAAAAI
Pramod S. Kelkar, MD FAAAAI
2:00 Atopy in Pregnancy
Michael Schatz, MD MS FAAAAI
Eugene M. Choo, MD
2:35 Sleep Disorders
Eli O. Meltzer, MD FAAAAI
Christina E. Ciaccio, MD
3:10 Break
3:30 Mystery Difficult Cases
Phillip L. Lieberman, MD FAAAAI
Michael H. Land, MD
4:05 Reactions to Aspirin and NSAIDS
Donald D. Stevenson, MD FAAAAI
Tolly Epstein, MD
4:40 Question & Answer
Upon completion of this session, participants should be able to: Identify and address difficulties in the clinical management of atopy during pregnancy; Identify and address difficulties in the clinical management of sleep disorders; Identify and address difficulties in the clinical management of reactions to NSAIDs; Identify and address diagnostic difficulties unique to difficult mystery cases.

Course

1603 Endoscopic Evaluation and Management of Chronic Rhinosinusitis (Pre and Post-Surgery) Including Cultures
2:00 to 5:00 pm
Convention Center, S230CD, Level II
Pre-registration and ticket required. Fee: $25.
Credit: 3.00 CME / 3.60 CE
Moderator: Wellington S. Tichenor, MD FAAAAI
2:00 Anatomy, Endoscopic Videos and Case Management
Wellington S. Tichenor, MD FAAAAI
3:00 Radiology
S. James Zinreich, MD
4:00 Anatomy and Surgery
Robert C. Kern, MD
Upon completion of this session, participants should be able to: Describe the anatomy of the sinuses and related structures; Identify pathology on CT scan; Recall indications for surgery and complications of surgery; Perform endoscopy in pre- and post-surgical patients; Perform cultures of middle meatus and/or sinuses.
FRIDAY • MARCH 2, 2012

Course

1604  NIAID Afternoon Course: Links Between Innate and Adaptive Immunity
2:00 to 5:00 pm
Convention Center, S320CD, Level III
Credit: 2.75 CME / 3.30 CE
Moderator: Gang Dong, MD PhD

2:00  The Role of Microbial Flora in Immune Responses
Ronald Collman, MD

2:25  TSLP and Regulation of Allergic Inflammation
Steve Ziegler, PhD

2:50  Linking Innate and Adaptive Responses to Vaccines
Bali Pulendran, PhD

3:15  Break

3:30  Innate and Adaptive Immune Responses in Chronic Upper Airway Inflammation
Robert P. Schleimer, PhD FAAAAI

3:55  Innate and Adaptive Immunity in Allergic Respiratory Inflammation
Bart N. Lambrecht, MD PhD

4:20  Innate and Adaptive Immunity in the Gastrointestinal Tract
Gary B. Huffnagle, PhD

4:45  Question & Answer

Upon completion of this session, participants should be able to: Discuss current knowledge of the innate and adaptive immune responses; Describe the role of the microbiome on the innate and adaptive immune responses; Discuss new insights for the role of the innate immune response on the development of allergic disorders.

Course

1605  Allergy Diagnostics and Immunotherapy: The Nuts, the Bolts, the Science and the Art (Part 2)
2:00 to 5:00 pm
Convention Center, S320AB, Level III
Credit: 1.00 CME / 1.20 CE
Moderators: Linda Cox, MD FAAAAI
Ira Finegold, MD FAAAAI

2:00  Future of Inhalant Allergen Immunotherapy
Thomas B. Casale, MD FAAAAI

2:30  Use of Immunotherapy in the Treatment of Food Allergy
Hugh A. Sampson, MD FAAAAI

3:00  Hands-On Workshops (Attendees will rotate between two workshops.)
Pre-registration and ticket required. Fee: $25.
Credit: 2.00 CME/ 2.40 CE

1605A: Coding, Documentation and ABCs of Regulatory Guidelines
Convention Center, S320EF, Level III
Donald W. Aaronson, MD FAAAAI
David A. Brown, MD
Gary N. Gross, MD FAAAAI

1605B: Allergy Skin Testing: Basics and Beyond
Convention Center, S320GH, Level III
Skin Testing in Clinical Practice
John Oppenheimer, MD FAAAAI
Skin Testing for Clinical Trials
Peter S. Creticos, MD FAAAAI
Art and Science of Percutaneous Skin Testing
Sten K.G. Dreborg, MD PhD FAAAAI

Upon completion of this session, participants should be able to: Discuss novel variants of immunotherapy, some of them already on the market and others still under investigation; Discuss the usefulness of immunotherapy in food allergy and the current status of these investigations; Apply adequately the coding, documentation and regulatory guidelines for immunotherapy.

Course

1606  Allergens and “Dirt”: Molecular Pathways and Consequences for the Allergic Epidemic (Part 2)
2:00 to 5:00 pm
Convention Center, S320GH, Level II
Credit: 2.75 CME / 3.30 CE
Moderator: Matthew S. Perzanowski, PhD

2:00  Studying the Epidemiology of Asthma: Multiple Factors and Confounders
Gurjit K. Khurana Hershey, MD PhD FAAAAI

2:25  Geographic Determinants of the Asthma Epidemic
Thomas A.E. Platts-Mills, MD PhD FAAAAI

2:50  Gene-Environment Interactions and Asthma: Update
Fernando D. Martinez, MD

3:15  Break

3:30  The Risk of Atopy and Microbial Exposure: Where Do We Stand?
Erika Von Mutius, MD MSc

3:55  Asthma and the Urban Environment: Lessons from the Inner City Asthma Consortium
Rebecca S. Gruchalla, MD PhD FAAAAI

4:20  Lessons from the URECA Birth Cohort Study: Allergens, Microbes and More
James E. Gern, MD FAAAAI

4:45  Question & Answer

Upon completion of this session, participants should be able to: Explain how to perform well designed studies on the epidemiology of asthma; Describe current knowledge of gene-environment interactions that contribute to asthma; Apply current knowledge of microbial exposure as a determinant of atopy; Discuss how the urban environment impacts asthma; Explain how a birth cohort study aims to examine the multi-factorial origins of asthma; Identify the geographic determinants of asthma.
Course 1607  NIEHS Course: Epidemiologic Methods in Asthma and Allergy Research
2:00 to 5:00 pm
Convention Center, S331AB, Level III
Credit: 2.75 CME / 3.30 CE
Moderator: Darryl C. Zeldin, MD

2:00  Overview of Epidemiological Methods in Asthma and Allergy Research
Christine Cole Johnson, PhD MPH FAAAAI

2:20  Introduction to Genetic Epidemiology
Kathleen C. Barnes, PhD FAAAAI

2:40  Respiratory Disease Questionnaires
George T. O’Connor, MD

3:00  Outdoor Exposure Assessment
Jaime Hart, ScD

3:20  Break

3:35  Indoor Exposure Assessment
Darryl C. Zeldin, MD

3:55  Defining Allergy and Asthma Outcomes in Epidemiologic Studies
Dennis R. Ownby, MD FAAAAI

4:15  Publicly Available Databases of Asthma and Allergy Research
David M. Mannino, MD

4:35  Panel Discussion
Upon completion of this session, participants should be able to: Apply epidemiologic methods to asthma and allergy research; Identify exposure and outcome measures.

Course 1608  Interpretation of Pulmonary Function Tests
2:00 to 5:00 pm
Convention Center, S331CD, Level III
Pre-registration and ticket required. Fee: $25.
Credit: 3.00 CME / 3.60 CE
Moderator: Mark F. Sands, MD FAAAAI

2:00  Lung Pathophysiology and the PFT
Mark F. Sands, MD FAAAAI

2:30  Putting it All Together: From Physiology to Interpretation
Donald P. Tashkin, MD

3:05  Question & Answer

3:15  Hands-On Session
Donald W. Cockcroft, MD FAAAAI
Meredith C. McCormack, MD
Riccardo Polosa, MD PhD FAAAAI
Mark F. Sands, MD FAAAAI
Donald P. Tashkin, MD
John M. Weiler, MD FAAAAI

Upon completion of this session, participants should be able to: Discuss basic lung physiology and pathophysiology and mechanics relating to restrictive and obstructive disease; Discuss ATS/ERS criteria for diagnosis of simple and complex restrictive and obstructive defects; Discuss criteria for technically acceptable PFTs and corrective measures for technical problems; Define lung volumes, capacities and the effect of restrictive and obstructive diseases thereupon; Identify flow volume loop patterns in restrictive/obstructive/mixed and variable obstructive conditions; Independently interpret spirometry and complete PFTs, demonstrating skill in flow-volume loop pattern recognition.

Course 1609  Finding a Job and Getting Started in Practice
2:00 to 5:00 pm
Convention Center, S230AB, Level II
Credit: 3.00 CME / 3.60 CE
Moderator: Brian A. Smart, MD FAAAAI

2:00  Overview & Introductions

2:10  Finding a Job and Negotiating the Agreement
Weily Soong, MD

2:45  Getting Licensed and Transitioning into Practice
Brian A. Smart, MD FAAAAI

3:00  Basic Operations of a Practice
David L. Patterson, MD FAAAAI

3:45  Practice Finances 101
Marshall P. Grodofsky, MD FAAAAI

4:20  Marketing Your Practice
Stanley M. Fineman, MD MBA FAAAAI

Upon completion of this session, participants should be able to: Explain how to identify and join the right practice opportunity; Discuss the fundamentals of office management; Identify strategies for marketing a practice and building a patient base.

Course 1610  Upper Airway Disease and Comorbidities
2:00 to 5:00 pm
Convention Center, S330CD, Level III
Credit: 2.75 CME / 3.30 CE
Moderators: Motohiro Ebisawa, MD PhD FAAAAI
Anne-Marie A. Irani, MD FAAAAI
Ruby U. Pawankar, MD PhD FAAAAI
Allan S. Puterman, MD FAAAAI

2:00  Comorbidities of Allergic Rhinitis: Asthma, Rhinosinusitis and Otitis
Ruby U. Pawankar, MD PhD FAAAAI

2:25  Chronic Cough in Upper Airway Disease
Nelson A. Rosario, MD PhD FAAAAI

2:50  Viral Infections in Pediatric Upper Airway Disease
Omer Kalayci, MD

3:15  Break

3:30  Upper Airway Disease and Sleep Disorders
Richard J. Schwab, MD

3:55  Eosinophilic Esophagitis and Pollinosis
Carla Irani, MD FAAAAI

4:20  Upper Airway Disease and Oral Allergy Syndrome
Montserrat Fernández-Rivas, MD PhD

4:45  Question & Answer

Upon completion of this session, participants should be able to: Discuss the latest evidence on co-morbidities of allergic rhinitis, impact on quality of life and work productivity; Identify the cough symptomatology, mechanisms and impact of chronic cough in upper airway disease; Describe the role of viral infections in exacerbation of upper airway disease as they pertain to both the pathogenesis and treatment; Explain the comorbidity of sleep disorders with upper airway disease incidence, consequences and morbidity; Describe the inter-relation between pollinosis and eosinophilic esophagitis and underlying mechanisms; Discuss the symptom profile, mechanisms and specifics of treatment of oral allergy syndrome.
Course

1611 Refresher in Basic Immunology to Support a Cutting-Edge Allergy/Immunology Practice
2:00 to 5:00 pm
Convention Center, S310CDGH, Level III
2:00 Mechanisms of Adaptive Immunity
E. Richard Stiehm, MD FAAAAI
2:50 Subsets, Subsets, Subsets: Important Immune Cell Populations in the News and Our Literature
Kathleen E. Sullivan, MD PhD FAAAAI
3:30 When Immunity Becomes Confused: Immunological Understanding from Autoimmunity and Inflammatory Disease
John S. Sundy, MD PhD FAAAAI
3:55 When Immunity Breaks: Immunological Understanding from Primary Immunodeficiency
Francisco A. Bonilla, MD PhD FAAAAI
4:20 Recent Basic Immunological Discoveries that are Likely to Impact the Practice of Allergy and Immunology
Troy R. Torgerson, MD PhD
4:45 Question & Answer
Upon completion of this session, participants should be able to: Explain how the different components of the immune system are coordinated within the body to generate an immune response; Discuss recent developments regarding cell subpopulations and immune factors required for physiologic and aberrant (allergic or anti-self) immune responses; Identify how increased knowledge of signaling pathways enables new therapeutic applications in allergy/immunology.

Course

1612 Clinical Management of Allergic Skin Diseases
2:00 to 5:00 pm
Convention Center, S330AB, Level III
2:00 Diagnostic Testing in Atopic Dermatitis
Andreas Wollenberg, MD FAAAAI
2:30 Therapy of Atopic Dermatitis
Lynda C. Schneider, MD FAAAAI
3:00 Break
3:15 Management of Urticaria/Angioedema
Jonathan A. Bernstein, MD FAAAAI
3:45 Diagnostic Testing in Cutaneous Drug Reactions
David A. Khan, MD FAAAAI
4:15 Management of Cutaneous Drug Reactions
Neil Shear, MD
4:45 Question & Answer
Upon completion of this session, participants should be able to: Select appropriate diagnostic procedures in atopic dermatitis patients and develop a management strategy; Perform state-of-the-art diagnostics and treatment of urticaria and angioedema according to the new practice parameters; Select appropriate diagnostic procedures in diagnosis and management of drug allergies.

Course

1613 Biomarkers in Airway Diseases
2:00 to 5:00 pm
Convention Center, S330EF, Level III
2:00 The “Dream” Biomarker
Andrew H. Liu, MD FAAAAI
2:20 Sputum Cell Counts in Clinical Practice
Parameswaran K. Nair, MD
2:40 Exhaled NO: Easy, but How Useful?
Stanley J. Szefler, MD FAAAAI
3:00 Break
3:20 Measurements in Exhaled Breath Condensate
John Hunt, MD FAAAAI
3:40 Proteomics in Sputum
Ratko Djukanovic, MD
4:00 Urine Metabolomics
Darryl J. Adamko, MD
4:20 Gene Expression Profiling
Prescott Woodruff, MD MPH
4:40 Question & Answer
Upon completion of this session, participants should be able to: Explain what biomarkers can be measured in sputum, blood, and exhaled breath; Describe what is required for the reliable measurement of these biomarkers; Discuss the practicality of these measurement tools; Identify when measurements are required and how are they interpreted; Discuss current research related to biomarkers.

Medical Administrator Symposium

1614 Financial 102 for Medical Office Administrators
1:30 to 2:45 pm
Peabody, Bayhill 17 & 18, Lobby Level
1:30 Diagnosing Financial Problems
Brian W. Smith, Med. Admin.
1:55 Identification of Invoicing Issues
Sara L. Bora, CPA
2:20 Tax Relationships
2:40 The New Medical Billing Law
Lena G. Combs, CPA
3:05 Question & Answer
Upon completion of this session, participants should be able to: Identify the financial issues facing physician groups; Improve presentation of financial information to physician groups; Discuss financial reporting issues and basic recent tax changes.

Clinical Research Symposium

1615 An FDA Audit: Real Life Experiences
2:00 to 3:15 pm
Peabody, Bayhill 25 & 26, Lobby Level
2:00 An FDA Audit: Real Life Experiences
Karen L. Pinzone, RN AE-C CCRC
2:25 A Perspective from the FDA
Speaker to be announced.
2:50 Perspectives of a PI
Corinne Keet, MD
Upon completion of this session, participants should be able to: Describe what is involved in the preparation and completion of an FDA audit of a research study.
Medical Administrator Workshop  

1711 Meaningful Use of EHR and Capturing Stimulus Dollars
3:00 to 4:15 pm
Peabody, Bayhill 31, Lobby Level
Credit: 1.25 CME / 1.50 CE
Moderator: Jeannette Booker
Russell B. Leftwich, MD FAAAAI

Upon completion of this session, participants should be able to: Recognize the benefits of an EHR, including those gained through the American Recovery and Reinvestment Act of 2009 (HITECH Act); identify the meaningful use criteria and those software vendors that are currently certified to capture and report against those criteria; utilize proven methods to overcome resistance to change, remembering that “change is hard.”

Clinical Research Workshop  

1712 Ethics and Research
3:30 to 4:45 pm
Peabody, Bayhill 32, Lobby Level
Credit: 1.25 CME / 1.50 CE
Kim E. Mudd, RN MSN CCRP
Elizabeth D. Strong, RN CRC

Upon completion of this session, participants should be able to: Discuss the regulations that impact recruitment and remuneration; discuss the process of developing a plan that addresses minority and/or vulnerable populations; discuss the ethics of research in vulnerable and/or minority populations.

AAAAl Federation of RSLAAIS Assembly Forum

5:00 to 6:30 pm
Credit: No CME / No CE

5:00 Wine and Cheese Reception
5:10 Business Meeting
5:20 Promoting the Value of our Specialty
Sharon B. Markovics, MD FAAAAI
5:30 Does Allergen-Specific Immunotherapy Provide Cost/Benefits for Children with Allergic Rhinitis?
Cheryl S. Hankin, PhD

5:50 Advocating for our Specialty: How Outcomes can Impact Your Practice
Linda Cox, MD FAAAAI

6:10 Question & Answer; Panel Discussion
6:20 Current Directions of the RSLAAIS

Seminars

5:15 to 6:15 pm
Pre-registration and ticket required. Fee: $40. Refreshments included.
Sessions and refreshments limited to 30 people.
Credit: 1.00 CME / 1.20 CE

1811 Immunodeficiencies Discovered in the Last Five Years
Thomas A. Fleisher, MD FAAAAI
Gulbu Uzel, MD
Peabody, Celebration 1, Convention Level

Upon completion of this session, participants should be able to: Discuss the new Primary Immunodeficiency Diseases, with a focus on those described during the past five years; identify the newer technologies used for discovery of these and future disorders; explain the expanding overlap between immunodeficiency and inflammatory disorders.

1812 Challenges of Managing Multiple Food Allergies
Julie Wang, MD FAAAAI
Michael C. Young, MD FAAAAI
Peabody, Celebration 2, Convention Level

Upon completion of this session, participants should be able to: Identify the diagnostic and management challenges of multiple food allergies; recognize the nutritional, feeding and social risk factors; develop and implement a feeding plan for adequate nutrition, feeding skill and social development of children with multiple food allergies.

1813 Approach to Patients Presenting with Reactions to NSAIDs
Ronald A. Simon, MD FAAAAI
Katharine M. Woesnner, MD FAAAAI
Peabody, Celebration 3, Convention Level

Upon completion of this session, participants should be able to: Describe the different types of pseudoallergic and allergic reactions to ASA/NSAIDs and underlying diseases; discuss the approach to the evaluation of patients who give a history of reactions to ASA and other NSAIDs; discuss the approach to identifying and describing skin lesions.

1814 SLIT vs. SCIT in Children
Giovanni Passalacqua, MD
David P. Skoner, MD
Peabody, Celebration 4, Convention Level

Upon completion of this session, participants should be able to: Summarize experience with SLIT and compare and contrast its safety/efficacy vs. SCIT; appreciate recent data describing SLIT; appreciate methodologic variation in SLIT.

1815 Non-Allergic Rhinitis: Insights into the Pathophysiology, Classification and Clinical Management
Michael A. Kaliner, MD FAAAAI
Eli O. Meltzer, MD FAAAAI
Peabody, Celebration 5, Convention Level

Upon completion of this session, participants should be able to: Explore evidence for immunologic and neurogenic mechanisms in non-allergic rhinitis; discuss new approaches to phenotyping chronic nonallergic rhinitis subtypes using validated instruments; review current treatment options for non-allergic rhinitis and discuss new study designs for future non-allergic rhinitis clinical trials.

Allied Health Wine and Cheese Reception

5:00 to 6:00 pm
Peabody, Orchid Room, Recreation Level
All allied health members and guests are invited to attend this reception for an evening of networking with other allied health professionals.

International Assembly Business Meeting and Reception

5:15 to 7:15 pm
Convention Center, S330CD, Level III
All international members and delegates are invited to attend this business meeting and reception.
Upon completion of this session, participants should be able to:

- Recognize current state of understanding of regulatory T cells.
- Identify markers/cytokines distinguishing types of regulatory T cells.
- Discuss the functional capacity and limitations of regulatory T cells.
- Describe the implication for treatment given the varied immunopathologic and phenotypic expressions.

2002 Clinical Management of Asthma in the Older Adult

Upon completion of this session, participants should be able to:

- Explain how asthma symptoms and spirometry may differ in older adults compared to younger populations.
- Identify unique factors associated with poor asthma control and quality of life in older adults.
- Discuss the optimal pharmacologic and non-pharmacologic management strategies for older adults with asthma.

2003 Patients with Antibody Deficiency: Non-Infectious Complications

Upon completion of this session, participants should be able to:

- Identify the complications which occur in patients with primary antibody disorders.
- Describe clinical elements and laboratory tests for surveillance of these non-infectious complications.
- Appreciate therapeutic approaches to non-infectious complications in primary immunodeficiency.

2004 An Update on Regulatory T Cells

Upon completion of this session, participants should be able to:

- Describe regulatory T cell subsets, including markers/cytokines distinguishing types of regulatory T cells.
- Describe the current evidence of regulatory T cells in allergic diseases and treatments, such as asthma and eczema.
- Appreciate the functional capacity and limitations of regulatory T cells.

2005 The Role of the Allergist/Immunologist at the Policy Table

Upon completion of this session, participants should be able to:

- Recognize the current state and national trends in healthcare reform.
- Appreciate the importance of representing our patients as well as our specialty in this changing healthcare climate.
- Describe the current literature detailing the value added by allergy/immunology in the overall health management of our patients.
- Develop strategies for effective representation and delivery of supporting data for the importance of our continued role in the changing healthcare model.

2006 Environmental Biodiversity and the Impact on Environmental Allergens

Upon completion of this session, participants should be able to:

- Discuss biodiversity as it pertains to changes in aerobiology and environmental patterns.
- Discuss awareness of global pollen patterns.
- Discuss awareness of clinical trends associated with increased duration, intensity, and allergenicity of environmental allergens.
- Develop strategies for adaptation of these patterns, including becoming a resource for the development of public policy.
- Appreciate the importance of representing our patients as well as our specialty in this changing healthcare climate.

2007 Problem-Based Learning: The Practical Aspects of Beta Lactam Allergies

Upon completion of this session, participants should be able to:

- Discuss the evaluation and management of patients with other beta lactam allergies.
- Describe the risks for allergies against multiple and related antibiotics.

2008 Exercise-Induced Anaphylaxis and Food-Dependent Exercise-Induced Anaphylaxis

Upon completion of this session, participants should be able to:

- Review the most common clinical presentations of EIA and typical foods that can trigger FD-EIA.
- Learn about recent publications relevant to EIA and FD-EIA.
- Increase understanding of treatment options for EIA and FD-EIA.

2009 Marketing Your Practice on the Web

Upon completion of this session, participants should be able to:

- Discuss strategies for optimizing listings on healthcare rating websites.
- Discuss use of practice website to enhance/improve patient care.

2010 How to Successfully Submit an IRB Proposal

Upon completion of this session, participants should be able to:

- Identify appropriate tools for developing and maintaining a practice website.
- Implement social media and search engine optimization to market a practice.
- Discuss strategies for optimizing listings on healthcare rating websites.
- Discuss use of practice website to enhance/improve patient care.

2011 Immunotherapy: Transitioning from Fellowship to Practice

Upon completion of this session, participants should be able to:

- Identify EMRs available to assist with immunotherapy.
- Develop office staff skills in immunotherapy.
- Describe the regulatory issues in starting an immunotherapy program.
Upon completion of this session, participants should be able to:

- Identify the unique applications of the guidelines in the private practice and identify practical approaches for implementation.

- Discuss the compliance requirements for allergen extract preparation according to the USP chapter 797 and Immunotherapy Practice Parameter Guidelines third edition update; Discuss the practical applications of the guidelines in the private practice and identify practical approaches for implementation of the guidelines.

Allied Health Workshop

**2021: Immunotherapy Guidelines: Third Edition and USP 797 Compliance**

6:45 to 8:00 am

*Peabody, Bayhill 19, Lobby Level*

- Credit: 1.25 CME / 1.50 CE
- Cheryl Koff Bernstein, RN BSN CCRC
- Linda Cox, MD FAAAAI

Upon completion of this session, participants should be able to:

- Describe the compliance requirements for allergen extract preparation according to the USP chapter 797 and Immunotherapy Practice Parameter Guidelines third edition update; Discuss the practical applications of the guidelines in the private practice and identify practical approaches for implementation of the guidelines.

Allied Health Workshop

**2022: Educating Teens: Sneezes, Wheezes and Triggers, Too**

6:45 to 8:00 am

*Peabody, Bayhill 17 & 18, Lobby Level*

- Credit: 1.25 CME / 1.50 CE
- Moderator: Dee Maliam, RN AE-C
- Giselle Mosnaim, MD MS FAAAAI
- Kathleen Kelly Shanovich, BSN MS CPNP

Upon completion of this session, participants should be able to:

- Identify the unique learning modalities of the adolescent patient: Engage in mechanisms to create change and positive outcomes in the adolescent population; Identify the allied health professional’s role with this population in the clinical setting.

Presidential Plenary

**2011: Next Generation Science**

8:15 to 9:45 am

*Convention Center, South Hall A1, Level I*

- Credit: 1.50 CME / 1.80 CE
- Moderators: Charlotte Cunningham-Rundles, MD PhD FAAAAI
- Dennis K. Ledford, MD FAAAAI

8:25 A Mutation in the Human Uncoordinated 119 Gene Impairs TCR Signaling and is Associated with CD4 Lymphopenia

Magdalena M. Gorska, MD PhD

8:45 Delayed Food Challenge Reactions Correspond Temporally to the Appearance of CD63+ Basophils in Subjects with IgE to alpha-Gal

Scott P. Commins, MD PhD

9:05 Rapid Induction Of Tolerance To Peanut By Antigen-coupled Cell Transfer

Paul J. Bryce, PhD

9:25 Increased FcεRI Expression on Basophils at Birth Predicts Subsequent Allergic Sensitization

Daniel J. Jackson, MD

Upon completion of this session, participants should be able to:

- Discuss high-quality scientific research undertaken by junior faculty in the field of allergy/immunology.

Medical Administrator Workshop

**2011: Practice Management: What Do I Need to Know?**

9:00 to 10:15 am

*Peabody, Bayhill 23 & 24, Lobby Level*

- Credit: 1.25 CME / 1.50 CE
- Jeanette Booker

Upon completion of this session, participants should be able to:

- State what responsibilities fall to the office manager/administrator; Recognize the positives and negatives of good practice management; Identify resources available to achieve the goals of more efficient practice management and more effective total patient care.
SATURDAY • MARCH 3, 2012

Posters

9:45 to 10:45 am
Convention Center, South Hall A2, Level I
Posters on display from 7:00 am to 6:00 pm. Authors present from 9:45 to 10:45 am.
Credit: No CME / No CE
Refer to pages 75-128 for abstracts and authors.

2201 Diagnosis and Monitoring in Asthma Management
2202 Immune Cells
2203 Biologic Therapy, Immunoglobulin Replacement
2204 Bioaerosols
2205 Urban Allergen and Pollutant Exposures
2206 Food Allergy I–Diagnosis and Treatment
2207 Food Allergy Related Issues/Immune Skin Disease
2208 A Focus on Asthma
2209 Rhinosinusitis: Mechanisms and Therapy
2210 Immunotherapy
2211 Allergic Inflammation
2212 Innate Immunity
2213 Allied Health Poster Session

Hands-On Workshop

2251 Anaphylaxis Simulation
10:00 am to 3:00 pm
Convention Center, Exhibit and Resource Hall, Level I
Sessions limited to 3 small groups of 4 learners per hour.
Credit: 0.25 CME / 0.30 CE
Participate in a live simulation of treating a patient experiencing anaphylaxis, working with faculty and standardized patients from Florida International University. Space in these workshops is available on a first-come, first-served basis; participants must sign up onsite to complete this activity. This session is located in the training station within the Exhibit and Resource Hall.

Upon completion of this session, participants should be able to demonstrate appropriate clinical skills to be used when treating a patient at risk of, or experiencing, anaphylaxis.

Symposium

2303 Patients with Unusual Infections: When to Think Toll-Like Receptor Pathway Defects
10:45 am to 12:00 pm
Convention Center, S330AB, Level III
Credit: 1.25 CME / 1.50 CE
Moderator to be announced.

2304 Drug Allergy in the 21st Century
10:45 am to 12:00 pm
Convention Center, S310ABFE, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Mariana C. Castells, MD PhD FAAAAI

2305 Health Information Technology (HIT): Implications for Research and Clinical Care
10:45 am to 12:00 pm
Convention Center, S330GH, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Dan Dalan, MD FAAAAI

2306 Health Information Technology (HIT): What Has It Done for You Lately?
10:45 am to 12:00 pm
Convention Center, S330EF, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Santiago Quirce, MD PhD

11:05 Patterns of Cutaneous Eruptions in Drug Allergy
Neil Shear, MD

11:25 Role of Viral Infections in Drug Allergy
Tetsuo Shiohara, MD

11:45 Question & Answer
Upon completion of this session, participants should be able to: Discuss the role of TLR containing adaptors in TLR pathway signaling; Discuss TLR polymorphisms that are associated with susceptibility to fungal infections.

11:05 The Impact of HIT on the Allergy/Immunology Practice
Russell B. Leftwich, MD FAAAAI

11:25 EHRs in Comparative Effectiveness Research
Speaker to be announced.

11:45 Question & Answer
Upon completion of this session, participants should be able to: Explain recent trends and advances in health information technology (HIT) and medical informatics for research and patient care; Discuss the ramifications and challenges of EHRs, clinical decision support software, ASTHMA IQ and other clinical HIT for care of the allergy/immunology patient; Explain how comparative effectiveness research can leverage EHR and patient registry data in major chronic disease states such as asthma.
Symposium

2306 Dissecting Mechanisms of Oral Tolerance in Food Allergy
10:45 am to 12:00 pm
Convention Center, S320AB, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Wayne G. Shreffler, MD PhD FAAAAI

10:45 Epithelial Cell and Dendritic Cell Handling of Food Antigens at the Mucosa
M. Cecilia Berin, PhD

11:05 Induction of Tolerance with Baked Milk: Potential Mechanisms
Jennifer S. Kim, MD FAAAAI

11:25 T Cell Heterogeneity: The Role of Th2 Subsets and Tregs
Paul J. Bryce, PhD

11:45 Question & Answer

Upon completion of this session, participants should be able to: Explain the role of gastrointestinal dendritic cell subsets and T Cells in tolerance and allergic sensitization; Recognize novel approaches to the study of food allergen-specific T Cells and their relationship to clinical disease; Describe how immunotherapy alters the food allergen-specific T Cell response to promote clinical tolerance.

Symposium

2307 Factors Influencing Asthma Exacerbations in Children: Findings from the Childhood Asthma Research and Education Network
10:45 am to 12:00 pm
Convention Center, S310CDGH, Level III
Credit: 1.25 CME / 1.50 CE
Moderators: James P. Kiley, MD
Lynn M. Taussig, MD

10:45 Measuring Asthma Outcomes: Lessons Learned from CARE
Stanley J. Szefler, MD FAAAAI

11:05 The Effect of Oral Corticosteroids During Acute Lower Respiratory Tract Illnesses in Preschool Children
Avraham Beigelman, MD

11:25 Exacerbations and Loss of Lung Function
Ronina A. Covar, MD

11:45 Question & Answer

Upon completion of this session, participants should be able to: Identify factors which influence the expression of asthma exacerbations in children; Discuss the effect of oral corticosteroids treatment for acute lower respiratory tract illness in preschool children; Characterize the strengths and weaknesses of different measures of asthma outcomes in childhood asthma.

Symposium

2308 EAACI Symposium: Immunotherapy from Noon ‘til Dawn, from Bench to Bedside
10:45 am to 12:00 pm
Convention Center, S330CD, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Cezmi A. Akdis, MD FAAAAI

10:45 Mechanisms of Allergen-Specific Immunotherapy and Immune Tolerance to Allergens
Cezmi A. Akdis, MD FAAAAI

11:00 Results from Recent Large Scale Clinical Trials
Victoria Cardona, MD PhD

11:15 Novel Approaches to Allergen Immunotherapy
Marek Jutel, MD PhD

11:30 Recent Developments of Allergen Immunotherapy for Food Allergy
Maria Antonella Muraro, MD PhD

11:45 Question & Answer

Upon completion of this session, participants should be able to: Explain molecular mechanisms of immune tolerance to allergens and how they are regulated by allergen immunotherapy; Recall recent additions to the evidence base for immunotherapy based on large scale clinical trials; List novel developments in the area of oral immunotherapy for food allergy.

Medical Administrator Workshop

2311 Social Media for the Practicing Allergist: A No-Nonsense Guide
10:45 am to 12:00 pm
Peabody, Bayhill 17 & 18, Lobby Level
Credit: 1.25 CME / 1.50 CE
Moderator: Jeanette Booker
Sakina S. Bajowala, MD

Upon completion of this session, participants should be able to: Explain how the utilization of social media in allergy and immunology practices can lead to improved patient education and satisfaction; Create a step-wise plan for the implementation and maintenance of a social media strategy; Identify and implement processes designed to protect PHI and prevent HIPAA violations when using healthcare social media.

Clinical Research Workshop

2312 Research Subject Recruitment, Remuneration and Retention
10:45 am to 12:00 pm
Peabody, Bayhill 21, Lobby Level
Credit: 1.25 CME / 1.50 CE
Kim E. Mudd, RN MSN CCRP
Kathy L. Pinzone, RN AE-C CCRC

Upon completion of this session, participants should be able to: Discuss the process of developing a research project recruitment, remuneration and retention plan; Identify the regulatory issues involved with vulnerable populations; Explain the ethics and issues of research in minority populations.

Allied Health Symposium

2313 Primer on IgE: Applications for Clinical Practice with a Focus on Immunotherapy and Omalizumab
10:45 am to 12:00 pm
Peabody, Bayhill 23 & 24, Lobby Level
Credit: 1.25 CME / 1.50 CE
Moderator: Jeanette L. Arnold, MSN RN C-FNP

11:10 What is IgE?
Thomas B. Casale, MD FAAAAI

11:35 IgE in Asthma and Allergy
Jeanette L. Arnold, MSN RN C-FNP

10:45 The Future of IgE
Debra A. Sedlak, MSN CPNP

Upon completion of this session, participants should be able to: Discuss the discovery of immunoglobulins and their role in asthma and allergy; Identify standard anti-IgE therapies; Describe other potential therapies.
2502 An Update in Asthma Therapeutics Since the Last NHLBI Executive Summary
Timothy J. Craig, DO FAAAAI
Michael B. Fogg, MD FAAAAI
Peabody, Celebration 2, Convention Level
Upon completion of this session, participants should be able to: Explore new paradigms to treat asthma; Discuss stepping up and stepping down therapies; Explore alternatives to LABAs.

2503 Problem-Based Learning: Immunodeficiency Evaluation
Meredith Lee Heltzer, MD
E. Richard Stiehm, MD FAAAAI
Peabody, Celebration 3, Convention Level
Upon completion of this session, participants should be able to: Describe current diagnostic tests, including genetic, for CGD; Identify current antifungals and outcomes of bone marrow transplantation; Explain the predictive value of certain objective laboratory and clinical values in CGD.

2504 Advances in the Diagnosis and Management of Chronic Granulomatous Disease
L. Celine Hanson, MD FAAAAI
Elena E. Perez, MD PhD
Peabody, Celebration 4, Convention Level
Upon completion of this session, participants should be able to: Describe recent advances in characterizing the microbiome of the airway and gastrointestinal mucosa; Discuss the evidence for microbial influences on asthma and allergy; Discuss the therapeutic implications of manipulating the microbiome for the prevention and/or treatment of asthma and allergic diseases.

2505 An Iota About Our Microbiota
Jayant M. Pinto, MD
Erika Von Mutius, MD MSc
Peabody, Celebration 5, Convention Level
Upon completion of this session, participants should be able to: Discuss the interactions of allergic sensitization and viral respiratory infections in asthma; Discuss the evidence for a role for IgE and its receptors in modulating host responses to respiratory virus infections; Examine whether targeting IgE might be a useful strategy in the management of virus-induced asthma exacerbations.

2506 Role of IgE in Virus-Induced Asthma
William W. Busse, MD FAAAAI
Michelle A. Gill, MD PhD
Peabody, Celebration 6, Convention Level
Upon completion of this session, participants should be able to: Discuss the interactions of allergic sensitization and viral respiratory infections in asthma; Discuss the evidence for a role for IgE and its receptors in modulating host responses to respiratory virus infections; Examine whether targeting IgE might be a useful strategy in the management of virus-induced asthma exacerbations.

2507 Experimental Approaches to the Study of Food Allergy
M. Cecilia Berin, PhD
Madham Masilamani, PhD
Peabody, Celebration 7, Convention Level
Upon completion of this session, participants should be able to: Explain the utility and limitations of current animal models of IgE-mediated food allergy; Describe how the human gastrointestinal mucosa can be modeled using a variety of in vitro approaches; Appreciate how newer technologies such as iPScells may apply to these questions in the future.

2508 Diagnosis and Management of Mastocytosis
Cem Akin, MD PhD FAAAAI
Benjamin P. Soule, MD
Peabody, Celebration 8, Convention Level
Upon completion of this session, participants should be able to: Recognize a patient with a potential clonal mast cell disorder; Apply the diagnostic criteria for mastocytosis; Determine when to refer the patient to a hematologist for a marrow examination.
2509 There's an App for That: iPhone/iPad, Android and Web Tools for Clinical Practice
Linda D. Green, MD FAAAAI
Melinda M. Rathkopf, MD FAAAAI
Peabody, Celebration 9, Convention Level
Upon completion of this session, participants should be able to: Discuss novel applications of the iPhone/iPad, Android and other smart devices in daily practice; Present use case scenarios of web tools for improving patient care, education and outreach; Navigate and find features of the new AAAAI website.

2510 Addressing Complementary and Alternative Medicine (CAM) Within a Traditional Allergy Practice
Gailen D. Marshall Jr., MD PhD FAAAAI
Julie Wang, MD FAAAAI
Peabody, Celebration 10, Convention Level
Upon completion of this session, participants should be able to: Identify some of the more common CAM practices that may be considered by allergy patients; Describe the proposed mechanisms through which common CAM therapies may produce effects; Identify possible risks, benefits and interactions associated with CAM therapies; Describe paradigms of shared medical decision making and apply them appropriately.

2511 Eustachian Tube Obstruction in Allergy
Sigrid Payne DaVeiga, MD
David P. Skoner, MD
Peabody, Celebration 11, Convention Level
Upon completion of this session, participants should be able to: Describe the presentation, pathophysiology and complications of Eustachian tube dysfunction; Explain how to manage Eustachian tube dysfunction; Discuss the role of allergy/allergic rhinitis in this condition.

2512 Problem-Based Learning: Immunotherapy Dose Adjustment Issues That the Practice Parameters Did Not Solve
David W. Hauswirth, MD FAAAAI
Désirée E.S. Larenas Linnemann, MD FAAAAI
Peabody, Celebration 12, Convention Level
Upon completion of this session, participants should be able to: Discuss how to dose in special cases (e.g. after missed doses, local or systemic reactions, in pregnancy, AIDS and cancer); Learn dosing of AIT during build-up and maintenance; Discuss issues concerning dosing of AIT with non-standardized extracts.

2513 Airway Epithelium as the Interplay Between Innate and Th2 Immunity
Zoulfia Allakhverdi, PhD FAAAAI
Angela Haczku, MD PhD FAAAAI
Peabody, Celebration 13, Convention Level
Upon completion of this session, participants should be able to: Discuss the role of epithelial cell-derived cytokines/immune modulators in chronic airway inflammation; Discuss the role of epithelial cell-derived cytokines/immune modulators in the innate immune and Th2 responses; Explain the direct role of epithelial cells to both initiating and resolving the inflammatory response.

2514 Inflammaging and Late Onset Asthma
Paula J. Busse, MD FAAAAA
Sameer K. Mathur, MD PhD
Peabody, Celebration 14, Convention Level
Upon completion of this session, participants should be able to: Explain the mechanisms of inflamming; Discuss cellular and molecular mechanisms of inflamming; Describe how inflamming contributes to asthma in elderly patients.

2515 How Certain Medications Might Affect the Efficacy and Safety of Immunotherapy
Robert E. Colman, MD FAAAAI
Aidan A. Long, MD FAAAAA
Peabody, Celebration 15, Convention Level
Upon completion of this session, participants should be able to: Discuss controlled trials showing the effect of corticosteroids, antileukotrienes and vitamin D on the clinical and immunological benefits of SCT; Update the discussion on the actual data on beta-blockers affecting SCT safety; Update the discussion on the actual data on ACE inhibitors affecting SCT safety.

State-of-the-Art

2521 Safety of LABA/ICS Dynamic Dosing
12:30 to 1:30 pm
Convention Center, S310ABF, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Jordan Orange, MD PhD FAAAAI
Badru A. Chowdhury, MD PhD FAAAAA
Paul M. O’Byrne, MD FAAAAI
Upon completion of this session, participants should be able to: List reasons for concern regarding dynamic dosing of combination therapy; Discuss the pros and cons of this form of dosing; Highlight unmet needs in our present asthma armamentarium.

State-of-the-Art

2522 Reducing the Genome to Explain Congenital Susceptibility to Infection: Unusual Phenotypes and Primary Immunodeficiency
12:30 to 1:30 pm
Convention Center, S320AB, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Jennifer M. Puck, MD
Badru A. Chowdhury, MD PhD FAAAAI
A Molecular and Clinical Perspective in the Evolving Understanding of Primary Immunodeficiency
Jennifer M. Puck, MD
Upon completion of this session, participants should be able to: Identify how genomic advances are being successfully applied in complicated primary immunodeficiency phenotypes where there have not previously been clear leads; Describe new genetic immune deficient infectious susceptibility phenotypes that have been discovered as a result of advanced technologies; Review what unexpected immunology has been provided by taking these intellectual quantum leaps.

State-of-the-Art

2523 Fungal Diseases of the Lower Airways: A Fresh Look at an Old Problem
12:30 to 1:30 pm
Convention Center, S330CD, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Richard W. Weber, MD FAAAAI
12:30 Epidemiology of Fungal Sensitivity and Asthma
Robert K. Bush, MD FAAAAI
12:50 Redefining Allergic Bronchopulmonary Aspergillosis
Leslie C. Grammer, MD FAAAAA
1:10 Mold in the Workplace: Unrecognized Causes of Occupational Respiratory Disease
Karín A. Pacheco, MD MSPH FAAAAA
Upon completion of this session, participants should be able to: Identify the epidemiology of fungal sensitivity and its role in pulmonary disease; Expand a new approach to a better understanding of ABPA, including controversies in diagnosis; Recognize the role mold exposure plays in occupational lung disease.
State-of-the-Art

2524 Hypersensitivity to Drugs and Rapid Desensitization in the 21st Century: A True Niche for the Allergy Specialist
12:30 to 1:30 pm
Convention Center, S330AB, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: David A. Khan, MD FAAAAI
Mariana C. Castells, MD PhD FAAAAI

Upon completion of this session, participants should be able to: Identify the new presentation of ADR for monoclonals, chemotherapeutics and antibiotics amenable to rapid desensitization in the 21st century; Recognize the populations at risk and review the most useful protocols; Evaluate the safety and efficacy of rapid desensitizations in the context of quality of life parameters.

State-of-the-Art

2525 So You Suspect Your Patient is Non-Adherent: Now What?
12:30 to 1:30 pm
Convention Center, S330EF, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Giselle Mosnaim, MD MS FAAAAI

Upon completion of this session, participants should be able to: Discuss the causes of poor adherence; Identify tools to diagnose adherence status; Review strategies to promote adherence.

State-of-the-Art

2526 State of Sublingual Immunotherapy (SLIT) in the United States
12:30 to 1:30 pm
Convention Center, S310CDGH, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Fuad M. Baroody, MD FAAAAI

Upon completion of this session, participants should be able to: Identify the immunological changes after sublingual immunotherapy; Describe the status of clinical trials in the U.S. using SLIT.

State-of-the-Art

2527 Th2 Immunity and Potential Therapies
12:30 to 1:30 pm
Convention Center, S320CD, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Susan M. MacDonald, MD FAAAAI

Upon completion of this session, participants should be able to: Learn the role that the innate immune system plays in Th2 responses; Discuss the potential mechanisms of the pathogenesis of allergic asthma.

Oral Abstract

2601 Asthma Highlights
2:00 to 3:15 pm
Convention Center, S320EF, Level III
Credit: 1.25 CME / 1.50 CE
Moderators: Faoud Terrence Ishmael, MD PhD
Mark Sands, MD FAAAAI

2:00 Elevated Cord Blood Soluble CD14 Levels Predict Wheezing in the First Year of Life
Yu-Lin Huang, MD

2:15 Improvements In Quality Of Life Measures In A Structured Exercise Program For Persistent Asthma
Susan M. Pollart, MD MS

2:30 Real-world Effectiveness Of Asthma Step-up Options: Matched Comparison Of Extraline Hydrofluoroalkane-beclometasone AND Inhaled Corticosteroid / Long-Acting Beta-Agonist
David B. Price, MA

2:45 Alternaria Sensitization is Associated with Increased Airway Hyperresponsiveness and Sinusitis in Children with Severe Asthma
Jennifer Shih, MD

3:00 Disconnect Between Sputum Neutrophilia and Indices of Mucosal Inflammation in Severe Asthma
Joseph R. Arron, MD PhD

Oral Abstract

2602 Immunogenetics
2:00 to 3:15 pm
Convention Center, S320AB, Level II
Credit: 1.25 CME / 1.50 CE
Moderators: Kathleen C. Barnes, PhD FAAAAI
Michael O’Daines, MD

2:00 Co-associations Between IL10 Genetic Variants, IL10 Production And Helminth Infection In A Tropical Population Of Brazil With High Prevalence Of Asthma
Camila A. Figueiredo, PhD

2:15 Glucocorticoid Receptor Translational Isoforms Contribute to Distinct Glucocorticoid Responses of Neutrophils and Eosinophils
Joy Hsu, MD

2:30 Epigenetic Biomarkers of Established Allergic Disease in Peripheral Blood Mononuclear Cells
Michelle L. North, PhD

2:45 Genetic Polymorphisms of Transforming Growth Factor-β Signaling Pathway and Kawasaki Disease in the Taiwanese population
Ho-Chang C. Kuo, MD

3:00 The German Mouse Clinic (gmc): A Systemic Phenotyping Platform To Uncover New Models For Allergic Diseases
Juan A. Aguilar-Pimentel
Oral Abstract

**2603** Healthy Homes: Do They Make a Difference in Disease?
2:00 to 3:15 pm  
Convention Center, S330GH, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderators: Peter Heymann, MD  
Wanda Phipatanakul, MD MS FAAAAI  
2:00 Exposure to Indoor Allergens in Urban Elementary Schools and Homes of Children with Asthma  
Perdita Pernaul, MD  
2:15 Reduction in Dust Allergen Exposure through Healthy Homes Education  
Freddy Pacheco, MS  
2:30 Neither Dust Mite nor Cat Allergen Exposure Is Associated with Lung Function or Asthma Morbidity in Sensitized Baltimore City Children  
Sharon K. Ahluwalia, MD  
2:45 Among Middle-income Children In NYC, Neighborhood Reports Of Mouse Sightings Were Associated With Sensitization To Mouse  
Medina S. Jackson-Browne, MS  
3:00 Indoor Airborne Spore Levels Before and After Healthy Homes Education and Remediation  
Minati G. Dhar, PhD

**2604** Food Allergy
2:00 to 3:15 pm  
Convention Center, S230CD, Level II  
Credit: 1.25 CME / 1.50 CE  
Moderator: Antonella M. Muraro, PhD  
2:00 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Egg Oral Immunotherapy in Children: An Analysis of Clinical Tolerance  
Stacie M. Jones, MD  
2:15 Peanut Challenge Outcomes Following Sublingual Immunotherapy (SLIT) Correlate With Increased Peanut-Specific Salivary IgA  
Michael D. Kulis, PhD  
2:30 Plasma from Subjects on Peanut Oral Immunotherapy (OIT) Suppresses ex vivo Basophil Activation in Peanut-Allergic Subjects  
Caitlin Burk  
2:45 Sublingual Immunotherapy for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Multicenter Trial (CoFAR)  
David Mark Fleisher, MD FAAAAI  
3:00 Development of Clinical Tolerance after Peanut OIT  
A. Wesley Burks, MD FAAAAI

**2605** Determinants of Asthma Treatment Choices
2:00 to 3:15 pm  
Convention Center, S331CD, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderator: Giselle Mosnaim, MD MS FAAAAI  
2:00 Differences in Asthma Controller Medication Adherence by Age and Gender  
Leslie J. Hinyard, PhD MSW  
2:15 Survey of Asthma Management and Referral Preferences by Primary Care Pediatricians at a Pediatric Training Hospital.  
Nabeel Farooqui, MD  
2:30 The Comparison of Asthma Control Judgment Based on Japanese Guidelines for Asthma, GINA, EPR3, and ACT  
Hiroyuki Nagase, MD PhD  
2:45 Combined Corticosteroid Use in Patients with Asthma, Allergic Rhinitis, and Atopic Dermatitis  
Min Jung Lee, MD  
3:00 Depressive Symptoms in African American and Caucasian Women Participating in Telephone-Based Asthma Management Programs  
Georgiana Sanders, MD

**2606** Rhinosinusitis Mechanisms and Management
2:00 to 3:15 pm  
Convention Center, S320GH, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderators: Seong H. Cho, MD  
Martin Wagenmann, MD FAAAAI  
2:00 Differential Regional Expression Of Innate Immune Antimicrobial Proteins In Sinonasal Mucosa.  
Sudarshan Seethadri, PhD  
2:15 STAT3 and NF-kb Regulate S100A7 Expression in Human Bronchial Epithelial Cells  
Kathryn E. Hulse, PhD  
2:30 Clinical Characteristics of Patients with Chronic Rhinosinusitis and Specific Antibody Deficiency  
Sara Kashani  
2:45 Omalizumab Is Effective In Allergic And Non-allergic Patients With Nasal Polyps And Asthma.  
Philippe Gevaert, MD PhD  
3:00 IL-21 is Increased in Nasal Polyposis and after Stimulation with Staphylococcus Aureus Enterotoxins  
Lien Calus, MD
Oral Abstract

2607 Cytokines Initiating Allergic Responses
2:00 to 3:15 pm
Convention Center, S230EF, Level II
Credit: 1.25 CME / 1.50 CE
Moderators: Yui-Hsi Wang, PhD
Judith A. Woodfolk, MBChB PhD FAAAAI
2:00 The Interaction Between Ara h 1 and TSLP Selectively Expands Skin-Homing Th2 Cells in Peanut-Sensitized Children
Julia A. Wisniewski, MD
2:15 Allergen Induces Dual Upregulation of TSLP Receptor on Circulating Basophils and Dendritic Cells in Atopic Dermatitis
Rachana Agrawal, PhD
2:30 IL-33 Mediates Both Innate and Adaptive Th2-type Responses Induced by Proteases in the Airway
Kenichiro Hara, MD
2:45 Roles for IL-33 and TSLP in Chronic Eosinophilic Airway Inflammation Induced by Airborne Allergen Exposure
Koji Iijima, PhD
3:00 Role of Thymic Stromal Lymphopoietin (TSLP) in Chronic Rhinosinusitis
Atsushi Kato, PhD

Oral Abstract

2608 Drug Allergy
2:00 to 3:15 pm
Convention Center, S319, Level III
Credit: 1.25 CME / 1.50 CE
Moderators: Aleena Banerji, MD
Roland Solensky, MD FAAAAI
2:00 Influenza Vaccine Administration in Egg Allergic Children
Fatima S. Khan, MD
2:15 Experience With Carboplatin Desensitization: A Case Series
Adam Udegraft, DO
2:30 Nasal Inflammatory Mediators In Non-steroidal Anti-inflammatory Drugs (nsaids) Cross-intolerant Subjects After Lysine Nasal Challenge
Immaculada Dona, MD PhD
2:45 Anaphylaxis as a Potential Cause of Death in Heroin Users
Ziaoying Zhou, PhD
3:00 Beta Blocker Pretreatment before Coronary CT Angiography does not Increase the Rate of Contrast Reactions
Carl B. Lauter, MD

Clinical Research Symposium

2621 Food Allergy Research Update
2:00 to 3:15 pm
Peabody, Bayhill 17 & 18, Lobby Level
Credit: 1.25 CME / 1.50 CE
Moderator: Kim E. Mudd, RN MSN CCRP
2:00 Food Allergy Treatment: Research Update
Satya Narisety, MD
2:20 Safety and Protocol Implementation
Pamela H. Steele, MSN CPNP AE-C
2:40 Research Participant Recruitment and Retention
Sally A. Noone, RN MSN CCRC
3:00 Question & Answer
Upon completion of this session, participants should be able to: Describe current research approaches to food immunotherapy; Discuss implications of current research on the future of food allergy treatment; Discuss safety, regulatory issues and research protocol implementation.

Allied Health Workshop

2622 Problem-Based Learning: Improving Asthma Self-Management in Diverse Populations
2:00 to 3:15 pm
Peabody, Bayhill 20, Lobby Level
Credit: 1.25 CME / 1.50 CE
Moderator: Antonina G. Evans, BSPharm AE-C
Marciarose Winston, MSN CPNP AE-C
Upon completion of this session, participants should be able to: Discuss the importance of asking probing questions when evaluating a patient’s adherence to an asthma management plan; Identify the barriers to adherence and proper asthma self-management in a diverse patient population; Develop solutions to improve adherence and asthma self-management skills.

Allied Health Workshop

2623 Eosinophilic Esophagitis: Care and Controversies
2:00 to 3:15 pm
Peabody, Bayhill 19, Lobby Level
Credit: 1.25 CME / 1.50 CE
Moderator: Carrie L. Vibbert, RN BSN
Mary E. Bollinger, DO FAAAAI
Marion E. Groetch, MS RD
Upon completion of this session, participants should be able to: Describe the pathophysiology and the diagnostic process of eosinophilic esophagitis; Discuss the utility and limitations of food allergy and testing to determine implicated food in EoE; Participate in the interdisciplinary management of EoE.

Allied Health Workshop

2624 Primary Immune Deficiency: Laboratory Evaluation and Management Strategies
2:00 to 3:15 pm
Peabody, Bayhill 21, Lobby Level
Credit: 1.25 CME / 1.50 CE
Moderator: Donna W. Mitchell, RN MSN NP
Magee L. DeFelice, MD
Thomas A. Fleisher, MD FAAAAI
M. Elizabeth M. Younger, CRNP PhD
Upon completion of this session, participants should be able to: Identify indications for flow cytometry, functional antibody testing and cellular function tests; Develop appropriate management plans for subtypes of primary immune deficiency.
### Allied Health Workshop

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>2625</td>
<td>Spirometry: Hands-On Training</td>
<td>2:00 to 3:15 pm</td>
<td>Peabody, Bayhill 22, Lobby Level</td>
<td>Pre-registration and ticket required. Fee: $20. Credit: 1.25 CME / 1.50 CE. Participants must bring their spirometer. Moderator: MaryKay Bosard, BS RRT AE-C. Free to Allied Health Professionals. Please pre-register and bring your ticket. MaryKay Bosard, BS RRT AE-C. Maureen George, PhD RN AE-C. Concettina Tolomeo, DNP APRN FNP-BC AE-C. Upon completion of this session, participants should be able to: Demonstrate appropriate spirometry techniques.</td>
</tr>
</tbody>
</table>

### Panel Discussion Workshop

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>2802</td>
<td>Methacholine vs. Mannitol Challenge in Evaluation of Asthma</td>
<td>4:45 to 6:00 pm</td>
<td>Convention Center, S331CD, Level III</td>
<td>Credit: 1.25 CME / 1.50 CE. Participants must bring their spirometer. Free to Allied Health Professionals. Please pre-register and bring your ticket. MaryKay Bosard, BS RRT AE-C. Maureen George, PhD RN AE-C. Concettina Tolomeo, DNP APRN FNP-BC AE-C. Upon completion of this session, participants should be able to: Describe how and when to apply these tests to diagnose asthma; Discuss appropriate treatment and a strategy to withdraw treatment in those who are well controlled; Review how the tests can be used to assess new treatments for asthma.</td>
</tr>
</tbody>
</table>

### Keynote

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>2701</td>
<td>Hard Knocks: Communicating Science to the Public</td>
<td>3:30 to 4:30 pm</td>
<td>Convention Center, South Hall A1, Level I</td>
<td>Credit: 1.00 CME / 1.20 CE. Free to Allied Health Professionals. Please pre-register and bring your ticket. Moderator: Jonathan M. Spengler, MD PhD FAAAAI. Free to Allied Health Professionals. Please pre-register and bring your ticket. Paul A. Offit, MD. Chief of the Division of Infectious Diseases and the Director of the Vaccine Education Center at the Children's Hospital of Philadelphia; Maurie R. Hillman Professor of Vaccinology and a Professor of Pediatrics at the University of Pennsylvania School of Medicine. Upon completion of this session, participants should be able to: Discuss the optimal approaches for communicating medical information to patients and the public; Discuss various approaches to deal with medical misinformation; List examples of medical misinformation and potential harm from misinformation.</td>
</tr>
</tbody>
</table>

### Hands-On Workshop

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>2801</td>
<td>Achieving Part IV MOC Credit Using the ASTHMA IQ Module</td>
<td>4:45 to 6:00 pm</td>
<td>Convention Center, S331AB, Level III</td>
<td>Credit: 1.25 CME / 1.50 CE. Free to Allied Health Professionals. Please pre-register and bring your ticket. Free to Allied Health Professionals. Please pre-register and bring your ticket. Moderator: Stuart L. Abramson, MD PhD FAAAAI. Free to Allied Health Professionals. Please pre-register and bring your ticket. Upon completion of this session, participants should be able to: Assess baseline practice gaps in asthma management in one’s individual practice; Prepare a plan to address practice gaps using ASTHMA IQ; Demonstrate use of the ASTHMA IQ module to complete Part IV MOC credit.</td>
</tr>
<tr>
<td>2803</td>
<td>New Insights into Diagnosis and Treatment of Angioedema</td>
<td>4:45 to 6:00 pm</td>
<td>Convention Center, S330EF, Level III</td>
<td>Credit: 1.25 CME / 1.50 CE. Free to Allied Health Professionals. Please pre-register and bring your ticket. Free to Allied Health Professionals. Please pre-register and bring your ticket. Moderator: Allen P. Kaplan, MD FAAAAI. Free to Allied Health Professionals. Please pre-register and bring your ticket. Upon completion of this session, participants should be able to: Discuss the optimal approaches for communicating medical information to patients and the public; Discuss various approaches to deal with medical misinformation; List examples of medical misinformation and potential harm from misinformation.</td>
</tr>
<tr>
<td>2804</td>
<td>New Immunological Insights from the Study of Primary Immunodeficiency Disease</td>
<td>4:45 to 6:00 pm</td>
<td>Convention Center, S320GH, Level III</td>
<td>Credit: 1.25 CME / 1.50 CE. Free to Allied Health Professionals. Please pre-register and bring your ticket. Free to Allied Health Professionals. Please pre-register and bring your ticket. Moderator: Jordan Orange, MD PhD FAAAAI. Free to Allied Health Professionals. Please pre-register and bring your ticket. Upon completion of this session, participants should be able to: Evaluate in detail the indications and efficacy of the new generation HAE treatments for acute attacks and preventive therapy; Discuss the use of molecular diagnosis of angioedema in routine clinical practice; Describe knowledge of clinical presentation and therapy of patients with non-hereditary angioedema.</td>
</tr>
</tbody>
</table>

### Q & A Workshop

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>2802</td>
<td>Methacholine vs. Mannitol Challenge in Evaluation of Asthma</td>
<td>4:45 to 6:00 pm</td>
<td>Convention Center, S331CD, Level III</td>
<td>Credit: 1.25 CME / 1.50 CE. Free to Allied Health Professionals. Please pre-register and bring your ticket. Free to Allied Health Professionals. Please pre-register and bring your ticket. Moderator: Donald W. Cockcroft, MD FAAAAI. Free to Allied Health Professionals. Please pre-register and bring your ticket. Upon completion of this session, participants should be able to: Describe how and when to apply these tests to diagnose asthma; Discuss appropriate treatment and a strategy to withdraw treatment in those who are well controlled; Review how the tests can be used to assess new treatments for asthma.</td>
</tr>
<tr>
<td>2803</td>
<td>New Insights into Diagnosis and Treatment of Angioedema</td>
<td>4:45 to 6:00 pm</td>
<td>Convention Center, S330EF, Level III</td>
<td>Credit: 1.25 CME / 1.50 CE. Free to Allied Health Professionals. Please pre-register and bring your ticket. Free to Allied Health Professionals. Please pre-register and bring your ticket. Moderator: Allen P. Kaplan, MD FAAAAI. Free to Allied Health Professionals. Please pre-register and bring your ticket. Upon completion of this session, participants should be able to: Discuss the optimal approaches for communicating medical information to patients and the public; Discuss various approaches to deal with medical misinformation; List examples of medical misinformation and potential harm from misinformation.</td>
</tr>
<tr>
<td>2804</td>
<td>New Immunological Insights from the Study of Primary Immunodeficiency Disease</td>
<td>4:45 to 6:00 pm</td>
<td>Convention Center, S320GH, Level III</td>
<td>Credit: 1.25 CME / 1.50 CE. Free to Allied Health Professionals. Please pre-register and bring your ticket. Free to Allied Health Professionals. Please pre-register and bring your ticket. Moderator: Jordan Orange, MD PhD FAAAAI. Free to Allied Health Professionals. Please pre-register and bring your ticket. Upon completion of this session, participants should be able to: Evaluate in detail the indications and efficacy of the new generation HAE treatments for acute attacks and preventive therapy; Discuss the use of molecular diagnosis of angioedema in routine clinical practice; Describe knowledge of clinical presentation and therapy of patients with non-hereditary angioedema.</td>
</tr>
</tbody>
</table>
Q & A Workshop 2805  Hot Topics in Pediatric Allergy and Immunology
4:45 to 6:00 pm
Convention Center, S310ABFE, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Elizabeth Matsui, MD
4:45  Allergic Respiratory Disease
Bradley E. Chippis, MD FAAAAI
5:00  Food and Drug Allergies
Jennifer S. Kim, MD FAAAAI
5:15  Immunologic Disorders
Vivian P. Hernandez-Trujillo, MD FAAAAI
5:30  Question & Answer

Upon completion of this session, participants should be able to: Describe the latest developments in pediatric allergy and immunology; Discuss how these might impact the care of pediatric patients with respiratory allergic disease, food and drug allergy and immunologic disorders.

Q & A Workshop 2806  Home Inspections for Indoor Molds
4:45 to 6:00 pm
Convention Center, S330AB, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Rosa M. Codina-Overcash, PhD FAAAAI
4:45  Air Sampling Techniques
Charles S. Barnes, PhD
5:00  Interpretation
Karin A. Pacheco, MD MSPH FAAAAI
5:15  Indications and Overview
Robert L. Jacobs, MD
5:30  Question & Answer

Upon completion of this session, participants should be able to: Review the components of a proper home inspection; Describe the air sampling methods and laboratory analysis; Interpret the mold report.

Year-in-Review Workshop 2807  Occupational Disease: What the Allergist Should Know
4:45 to 6:00 pm
Convention Center, S320AB, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Jill A. Poole, MD FAAAAI
4:45  Occupational: Asthma, Rhinitis and Hypersensitivity Pneumonitis
Mark S. Dykewicz, MD FAAAAI
5:00  Work-Exacerbated Asthma
Susan M. Tarlo, MBBS FAAAAI
5:15  Occupational Dermatologic Disease: Differential Diagnosis and Patch Testing
D. Linn Holness, MD
5:30  Question & Answer

Upon completion of this session, participants should be able to: Identify recently described key occupational exposures; Explain the respiratory and cutaneous diseases caused by occupational exposures; Describe how to better assess and treat patients.

Q & A Workshop 2808  Eosinophilic Esophagitis: the Allergist, the Gastroenterologist and the Pathologist: How to Build a Winning Team in Your Community
4:45 to 6:00 pm
Convention Center, S230CD, Level II
Credit: 1.25 CME / 1.50 CE
Moderator: Fred (Dan) McDaniel Atkins, MD FAAAAI
4:45  The Allergist
Mark Holtrech, MD FAAAAI
5:00  The Gastroenterologist
Amir F. Kagalwalla, MD
5:15  The Pathologist
Nina Taveyan, MD
5:30  Question & Answer

Upon completion of this session, participants should be able to: Demonstrate the knowledge to begin or improve cooperative communication and interaction with gastroenterologists and pathologists in the community; Demonstrate the ability to discuss with the pathologist specific histological findings characteristic of eosinophilic esophagitis.

Q & A Workshop 2809  Oral Food Challenges in the Office vs. Research Setting
4:45 to 6:00 pm
Convention Center, S320EF, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Stacie M. Jones, MD
4:45  Choosing the Right Challenge for the Right Patient
Anna H. Nowak-Wegrzyn, MD FAAAAI
5:00  Selecting and Preparing the Challenge Food
Carina Venter, PhD RD
5:15  Conducting and Interpreting Blinded vs. Open Food Challenges
David Mark Fleischer, MD FAAAAI
5:30  Question & Answer

Upon completion of this session, participants should be able to: Identify which patients should be referred for which type of oral food challenge (open vs. single-blind vs. double-blind placebo-controlled); Review the differences between each protocol; Interpret observed results in aiding diagnosis of food allergy.
BYOP Workshop

2810 Insect Allergy: Difficult Cases and New Hymenoptera Guidelines
4:45 to 6:00 pm
Convention Center, S330CD, Level III
Pre-registration and ticket required. No fee.
Credit: 1.25 CME / 1.50 CE
Moderator: Theodore M. Freeman, MD FAAAAI
4:45 Cross-Reactivity in Venom Allergy: In Vivo and In Vitro Tests
James M. Tracy, DO FAAAAI
5:00 When to Stop Immunotherapy
David B.K. Golden, MD FAAAAI
5:15 Imported Fire Ant Stings: A Rising Problem?
Michael S. Tankersley, MD FAAAAI
5:30 Question & Answer

Upon completion of this session, participants should be able to: Explain cross-reactivity among various species and new tools to address this issue in the clinic; Discuss the rising prevalence of fire ant stings and how this phenomenon might impact practice; Review the unique aspects of various hymenoptera.

Hands-On Workshop

2811 EMR Roundtable: What Are Other Allergists Using?
4:45 to 6:00 pm
Convention Center, S230GH, Level II
Pre-registration and ticket required. Fee: $50.
Credit: 1.25 CME / 1.50 CE
Moderators: Vesselin Dimov, MD Melinda M. Rathkopf, MD FAAAAI
GE Centricity
A. Sean McKnight, MD FAAAAI
Allscripts
Melinda M. Rathkopf, MD FAAAAI
Epic
Vesselin Dimov, MD
Meditab-IMS
Dan Dulan, MD FAAAAA
NextGen
Robert Anolik, MD FAAAAA
ModuleMD
Ira Finegold, MD FAAAAA
eClinical Works
Hugh H. Windom, MD FAAAAA
Rosch
Nathaniel D. Hare, MD
AmericanEHR Partners
Russell B. Leftwich, MD FAAAAA
Open Discussion Table
Tao Le, MD MHS FAAAAA
5:45 Question & Answer

Upon completion of this session, participants should be able to: Discuss the challenges allergists face in EMR selection; Discuss tips on EMR implementation specific for the allergist; Review specific EMRs with allergists currently using them in practice.

Q & A Workshop

2812 Update from the U.S. Food and Drug Administration (FDA)
4:45 to 6:00 pm
Convention Center, S310CDGH, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: F. Estelle R. Simons, MD FAAAAA
4:45 Year-in-Review at the FDA
Badrul A. Chowdhury, MD PhD FAAAAA
5:00 Food Allergen Labeling
Stefano Luccioli, MD FAAAAA
5:15 Epinephrine and the Treatment of Anaphylaxis
Susan Lee Limb, MD FAAAAA
5:30 Question & Answer

Upon completion of this session, participants should be able to: Recognize recent issues of scientific importance at FDA and their regulatory implications; Identify aspects of allergen labeling in food product labels; Explore the regulatory history of epinephrine for the treatment of anaphylaxis and identify approved epinephrine products.

Q & A Workshop

2813 JCAAI: The Allergist and Healthcare in 2012: What Can YOU Do About It?
4:45 to 6:00 pm
Convention Center, S230AB, Level II
Credit: 1.25 CME / 1.50 CE
Programmed by the AAAAI and JCAAI. Funded through an educational grant from Robert J. Becker, MD, Joint Council of Allergy, Asthma & Immunology Memorial Lectureship Fund.
Moderator: Richard W. Honsinger, MD MACP FAAAAA
4:45 Health Care Reform and Your Practice
Donald W. Aaronson, MD FAAAAA
5:00 News You Can Use: Legal/ Coding Updates
Gary N. Gross, MD FAAAAA
5:15 Health Care is Local: Affecting Allergy Care in Your Neighborhood
James L. Sublett, MD FAAAAA
5:30 Question & Answer

Upon completion of this session, participants should be able to: Adjust their practice formats to new practice forms suggested in the Affordable Care Act passed in 2010; Participate in activities which are required in order to receive federal incentive payments; Describe how to affect local healthcare delivery issues.

Q & A Workshop

2814 Introductory Rhinolaryngoscopy
4:45 to 6:00 pm
Convention Center, S319, Level III
Pre-registration and ticket required. Fee: $50.
Credit: 1.25 CME / 1.50 CE
Moderator: Jerald W. Koepke, MD FAAAAA
5:45 Question & Answer

Upon completion of this session, participants should be able to: Discuss the advantages of being skilled in rhinolaryngoscopy; Perform rhinolaryngoscopy; Identify normal and abnormal variations in the upper airway anatomy, as well as upper airway pathology only visible with a rhinoscope.
Q & A Workshop ✴️

2815 Chronic Rhinosinusitis in Children  
4:45 to 6:00 pm  
Convention Center, S320CD, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderator: Martin Wagenmann, MD FAAAAI  
4:45 Pathophysiology of Pediatric Rhinosinusitis  
Daniel L. Hamilos, MD FAAAAI  
5:00 Medical Workup and Management of Pediatric Rhinosinusitis  
Melanie M. Makhija, MD  
5:15 Surgical Management Options in Pediatric Rhinosinusitis  
Fuad M. Baroody, MD FAAAAI  
5:30 Question & Answer  
Upon completion of this session, participants should be able to: Discuss the pathophysiology of chronic rhinosinusitis in pediatric patients; Describe medical treatment options; Review available surgical treatment modalities.

Q & A Workshop ✳️

2816 Tolerance Beyond Regulatory T Cells  
4:45 to 6:00 pm  
Convention Center, S230EF, Level II  
Credit: 1.25 CME / 1.50 CE  
Moderator: Anne Marie Singh, MD  
4:45 B Cells That Control T Cells  
Thomas Tedder, MD  
5:00 Natural Killer Cells That Don’t Kill  
Mübeccel Akdis, MD PhD  
5:15 Myeloid-Derived Suppressor Cells  
Dmitry I. Gabrilovich, MD PhD  
5:30 Question & Answer  
Upon completion of this session, participants should be able to: Describe how B cells can provide regulatory control; Discuss how NK cells are capable of performing regulatory functions; Demonstrate understanding of how myeloid derived suppressor cells function.

Q & A Workshop ✳️

2817 The Greatness of Granulocytes  
4:45 to 6:00 pm  
Convention Center, S330GH, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderator: Monica Vasudev, MD  
4:45 Neutrophils in the Modulation of the Immune Response  
Mitchell H. Grayson, MD FAAAAI  
5:00 Basophils as Antigen Presenting Cells  
John T. Schroeder, PhD  
5:15 Eosinophils Driving the Immune Response  
Peter F. Weller, MD FAAAAI  
5:30 Question & Answer  
Upon completion of this session, participants should be able to: Describe how neutrophils can drive a pro-atopic immune response; Describe how basophils can function as antigen presenting cells; Discuss how eosinophils are able to initiate and modulate an immune response.

Clinical Research Workshop ✳️

2821 Research Project Monitoring: Do You Have an Internal Monitoring Plan?  
4:45 to 6:00 pm  
Peabody, Bayhill 22, Lobby Level  
Credit: 1.25 CME / 1.50 CE  
Moderator: Sarah K. Knorr, RN MPH CCRP  
Upon completion of this session, participants should be able to: Discuss the regulatory issues concerning research project monitoring; Discuss the process of developing an internal monitoring plan; Demonstrate existing monitoring plans.

Allied Health Workshop ✴️

2822 Nursing Pro/Con: Clinical Considerations of Immune Replacement: IVIG vs. SCIG: Does One Therapy Fit All?  
4:45 to 6:00 pm  
Peabody, Bayhill 19, Lobby Level  
Credit: 1.25 CME / 1.50 CE  
Moderator: Sheelagh M. Stewart, MPH RN  
Upon completion of this session, participants should be able to: Describe the process to make appropriate selection of delivery method of immune replacement (risks, advantages, patient management).

Allied Health Workshop ✳️

2823 The Asthma Journey: Mapping Successful Travels  
4:45 to 6:00 pm  
Peabody, Bayhill 17 & 18, Lobby Level  
Credit: 1.25 CME / 1.50 CE  
Moderator: Jennifer Darr, MSW LCSW  
Melissa T. Korenblat-Hanin, ACSW LCSW  
Upon completion of this session, participants should be able to: Demonstrate the importance of utilizing a biopsychosocial methodology in the assessment and treatment of asthma; Discuss and explore strategies and techniques in successful asthma management; Identify patient centered approaches that maximize adherence and asthma control.

Allied Health Workshop ✴️

2824 Problem-Based Learning: Shifting Control: The Food Allergic Child Starts School  
4:45 to 6:00 pm  
Peabody, Bayhill 20, Lobby Level  
Credit: 1.25 CME / 1.50 CE  
Karen L. Gregory, DNP APRN-BC CNS RRT AE-C  
Dee Mallam, RN AE-C  
Upon completion of this session, participants should be able to: Recognize issues and concerns of a parent/guardian of a food-allergic child; Review evidence-based information regarding exposure of offending food allergens; Discuss school management of food allergies, including current state and federal laws.
**Allied Health Workshop**

**2825** Using Desktop Publishing to Create Patient Education Material for Children and Adults

- **4:45 to 6:00 pm**
- **Peabody, Bayhill 21, Lobby Level**
- **Credit:** 1.25 CME / 1.50 CE
- **Moderator:** Maureen George, PhD RN AE-C
- **Concettina Tolomeo, DNP APRN FNP-BC AE-C**

Upon completion of this session, participants should be able to: Describe Microsoft Publisher; Implement suitable formatting of patient education materials; Use adult learning principles in the implementation of key components of patient education materials; Identify AAAAI resources for patient education.

**New Allergist/Immunologist Assembly Business Meeting**

- **4:45 to 6:15 pm**
- **Peabody, Peabody Grand Ballroom Q, Convention Level**
- All new allergy/immunology specialists are invited to attend this business meeting and reception.

**Chrysalis Reception**

- **6:00 to 7:00 pm**
- **Peabody, Bayhill 25 & 26, Lobby Level**
- Chrysalis participants are encouraged to attend this closing reception along with their FIT mentors.

**Allergy, Asthma & Immunology Education and Research Trust Event “The Big Splash”**

- **7:00 to 10:00 pm**
- **Peabody, Terrace Pool, Recreation Level**
- All AAAAI members, delegates and guests are invited to attend this Saturday evening event. The Big Splash for ARTrust™ will take place at the Peabody Terrace Poolside. Admission by ticket only. See page 12 for more details.
3001 Induced Sputum Cell Counts in Practice and Research
Stephen C. Lazarus, MD
Parameswaran K. Nair, MD
Peabody, Celebration 1, Convention Level

Upon completion of this session, participants should be able to: Discuss how to establish a reliable clinical or research service; Describe when measurements are needed; Explain how cell counts help in practice and research.

3002 Chest Pain and Death in Sports
Jack M. Becker, MD
William Silvers, MD FAAAAI
Peabody, Celebration 2, Convention Level

Upon completion of this session, participants should be able to: Identify the worrisome signs and symptoms indicating cardiac disease; Review what is known about asthma death and the athlete and what if anything can be done to effect a change; Describe what is benign chest pain and how to make the diagnosis.

3003 Recurrent Infections in Pediatrics: Allergies or Immunodeficiency?
Jason W. Caldwell, DO
Laurence E. Cheng, MD PhD
Peabody, Celebration 3, Convention Level

Upon completion of this session, participants should be able to: Describe the factors that increase the risk of recurrent infections; Describe the workup of patients to determine if a clinically significant immune defect is present; Explain the “red flags” for rare vs. common presentations of routine infectious presentations to the allergy office.

3004 Understanding Autoimmunity in Immunodeficiencies
Troy R. Torgerson, MD PhD
Jolan E. Walter, MD PhD
Peabody, Celebration 4, Convention Level

Upon completion of this session, participants should be able to: Review immunodeficiencies with high incidence of autoimmunity and presence of autoantibodies; Describe the clinical implications of autoantibodies in primary immunodeficiencies; Identify the mechanistic underpinnings of autoantibody generation in primary immunodeficiency.

3005 Fungal Diseases of the Lower Airway: Report from the Task Force
Paul A. Greenberger, MD FAAAAI
Alan P. Knutsen, MD FAAAAI
Peabody, Celebration 5, Convention Level

Upon completion of this session, participants should be able to: Identify the characteristics and distinctions between different fungal pulmonary diseases; Describe and implement appropriate diagnostic approaches to fungal lung disease; Discuss environmental and pharmacologic therapeutic approaches.

3006 The Impact of Environmental Factors on the Progression of Atopic Diseases
David Elakayam, MD
Wanda Phisutanukul, MD MS FAAAAI
Peabody, Celebration 6, Convention Level

Upon completion of this session, participants should be able to: Describe evidence of the benefit of implementing prevention strategies that are effective in reducing atopy; Identify environmental allergens/host factors/endotoxin that may increase risk for the development of atopy; Develop strategies for implementation of prevention strategies with at-risk populations.
3014 Use of Cultured Mast Cells and Mast Cell Lines in the Study of Allergic Inflammation  
Larry Borish, MD FAAAAI  
David E. LaRosa, MD  
Peabody, Celebration 14, Convention Level  
Upon completion of this session, participants should be able to: Identify current, optimal culture methods for human CD34+ - derived mast cells; Describe LAD2, LUVA and related functional human mast cell lines and the MTA or licensing processes for obtaining cells; Describe how mast cell lines and cultured mast cells can aid the study of allergic disease.

3015 Vitamin D in Allergic and Immune Disorders  
Audreesh Banerjee, MD  
Marianne Frieri, MD PhD FAAAAI  
Peabody, Celebration 15, Convention Level  
Upon completion of this session, participants should be able to: Discuss the results of the NHANES survey related to Vitamin D; Explain the role of Vitamin D on various allergic and immune conditions, the science of the immune response, findings in asthmatic children and steroid resistance; Discuss the importance of both the clinical and basic science of Vitamin D.

Allied Health Workshop  
3021 Up in the Air: What You and Your Patients Need to Know about Outdoor Air Quality  
6:45 to 8:00 am  
Peabody, Bayhill 17 & 18, Lobby Level  
Credit: 1.25 CME / 1.50 CE  
Moderator: Maureen George, PhD RN AE-C  
Wade G. Hill, PhD APRN  
Kim Knowlton, PhD  
Upon completion of this session, participants should be able to: Contrast differences between ozone and particle pollution; Teach patients how to interpret air quality alerts in urban and rural areas; Identify critical components of asthma self management in response to the air quality index.

Allied Health Advanced Workshop  
3022 What You Need to Know about Adverse Drug Reactions  
6:45 to 8:00 am  
Peabody, Bayhill 19, Lobby Level  
Credit: 1.25 CME / 1.50 CE  
Moderator: Kristin E. Kloos Olson, RN  
Antonina G. Evans, BSPharm AE-C  
Miguel A. Park, MD  
Upon completion of this session, participants should be able to: Discuss the key components of the drug allergy history; Identify the diagnostic tests and work-up for drug allergies; Discuss the treatment options for drug allergies.

Allied Health Seminars  
3041 Practical Nutrition Advice for Patients and Families with Multiple Food Allergies  
G. Lynn Christie, MS RD  
Wendy Elverson, RD LDN  
Peabody, Bayhill 20, Lobby Level  
Upon completion of this session, participants should be able to: Discuss common nutrition issues in patients with food allergies; Discuss common substitutions for food allergens; Discuss practical tips for patients with food allergies.
Posters

7:00 am to 5:30 pm
Convention Center, South Hall A2, Level I
Posters on display from 7:00 am to 5:30 pm. Authors present from 9:45 to 10:45 am.
Credit: No CME / No CE
Refer to pages 75-128 for abstracts and authors.

3201 Asthma Therapeutics and Management
3202 Immunogenetics and Immunophenotyping
3203 Immune Deficiency
3204 Novel Allergens and Extracts: New Ways to Measure Sensitization
3205 Measuring Allergen Exposures
3206 EGID/Immunologic GI Disorders
3207 Drug Allergy
3208 Atopic Disease
3209 Mechanisms of Allergic Rhinitis
3210 Mechanisms of Immunotherapy
3211 Eosinophils
3212 Mast Cells, Basophils and IgE

Symposium

3301 New Approaches to Asthma Diagnosis and Treatment
10:45 am to 12:00 pm
Convention Center, S310CDGH, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Monica Kraft, MD
10:45 Update on Asthma Phenotypes
Sally E. Wenzel, MD FAAAAI
11:05 What is an Asthma Endotype?
Paul A. Greenberger, MD FAAAAI
11:25 Personalized Asthma Treatment
Parameswaran K. Nair, MD
11:45 Question & Answer
Upon completion of this session, participants should be able to: Discuss the difference between severe refractory asthma and difficult asthma; Explain why personalized treatment is important and how is it optimized; Evaluate which biologics show promise for improvement in treatment.

Symposium

3302 Demystifying Aspirin-Exacerbated Respiratory Disease
10:45 am to 12:00 pm
Convention Center, S320CD, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Mariana C. Castells, MD PhD FAAAAI
10:45 Understanding Mediators in Aspirin Reactions: The Role of COX1-COX2
Joshua A. Boyce, MD FAAAAI
11:05 Evidence for Platelets as Effectors in Human Asthma
Tanya M. Laidlaw, MD
11:25 Aspirin Reactions and Desensitizations: Safety and Outcomes
Katherine M. Woessner, MD FAAAAI
11:45 Question & Answer
Upon completion of this session, participants should be able to: Describe the role of mediators in aspirin reactions; Explain the role of platelets as effector cells in asthma; Discuss the role of aspirin desensitization in patients with AERD.

Symposium

3303 Innate Effectors of Allergic Responses
10:45 am to 12:00 pm
Convention Center, S330EF, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Larry Borish, MD FAAAAI
10:45 Epithelial Cell-Dendritic Cell Interactions in the Airway Mucosa
Hirohito Kita, MD
11:05 Innate Effector Mechanisms in Food Allergy
Paul J. Bryce, PhD
11:25 Nuocytes and the Expanding World of Innate Lymphoid Cells
Andrew McKenzie, PhD
11:45 Question & Answer
Upon completion of this session, participants should be able to: Describe the role of the epithelium in conditioning adaptive immune responses and its potential as a target for therapeutics in asthma; Explain the role of epithelial cell-derived cytokines; Define the newly described family of innate lymphoid cells and their relevance to allergic pulmonary inflammation.

Symposium

3304 Bacteria and Viruses: Fighting Dirty
10:45 am to 12:00 pm
Convention Center, S330AB, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Nikolaos G. Papadopoulos, MD FAAAAI
10:45 Bacteria and Microbiome in Early Life and Asthma
Hans Bisgaard, MD
11:05 Clinical Evidence for Defective Responses to Infection among Asthmatic Individuals
Tina V. Hartert, MD MPH
11:25 Viral Suppression of Antibacterial Immune Response
Jay K. Kolls, MD
11:45 Question & Answer
Upon completion of this session, participants should be able to: Discuss the evidence for deficient innate and acquired immunity which may account for impaired responses to respiratory pathogens; Describe the clinical evidence for susceptibility to the pathogenic effects of respiratory tract infections among asthmatic individuals; Describe mechanisms for viral modulation of IL-17 responses.

Symposium

3305 Epithelial Breakdown and Susceptibility to Disease: Immunological Insights
10:45 am to 12:00 pm
Convention Center, S330AB, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: John W. Steinke, PhD FAAAAI
10:45 Breakdown of Skin Epithelium and Development of Atopic Dermatitis
Michael D. Howell, PhD
11:05 Apoptosis of Lung Epithelium and Induction of Inflammation
Kodi S. Ravichandran, MD
11:25 Airway Epithelium and Induction of the Innate and Adaptive Immune Response
Atsushi Kato, PhD
11:45 Question & Answer
Upon completion of this session, participants should be able to: Describe how breakdowns in the epithelial layer can lead to disease and inflammation; Explain how apoptosis can fuel inflammatory responses; Identify specific features of the sinus epithelium relevant to inducing innate immunity.
Symposium  

3306  Molecular Diagnosis: Potential Tools for the Practicing Allergist  
10:45 am to 12:00 pm  
Convention Center, S330CD, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderator: Jörg Kleine-Tebbe, MD FAAAAI  
10:45  Multiplex and Singleplex Systems: Improving Diagnosis of Cross-Reactivity for Inhalant Allergens  
Ronald Van Ree, PhD FAAAAI  
11:05  Food Allergy Protein Families: Skin Testing and IgE Molecular Diagnosis to Predict Risk  
Montserrat Fernández-Rivas, MD PhD  
11:25  Allergenic Molecules in Hymenoptera Venom Hypersensitivity: Improved Differentiation and Higher Analytical Sensitivity  
Markus W. Ollert, MD  
11:45  Question & Answer  
Upon completion of this session, participants should be able to: Recognize new findings regarding allergenic molecules and how they will affect our interpretation of diagnostic workup, cross-reactivity and multisensitizations to inhalants; Describe which protein families harbor the most important allergens, the diagnostic value of food components and how they will lead to improved diagnostic answers and advice to the patient; Identify how components from bee and wasp venom will facilitate definitive answers in case of presumed double sensitizations and enhance analytical sensitivity.

Symposium  

3307  World Allergy Forum: Food Allergy: Pathogenesis and Prevention  
10:45 am to 12:00 pm  
Programmed by the AAAAI and WAO. Funded through an educational grant from Novartis.  
Convention Center, S310ABFE, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderators: Dennis K. Ledford, MD FAAAAI  
Ruby U. Pawankar, MD PhD FAAAAI  
10:45  Prenatal Events and Development of Food Allergies  
Susan L. Prescott, MD PhD  
11:05  Early Dietary Exposures and Feeding Practices  
Scott H. Sicherer, MD FAAAAI  
11:25  Food Allergy and Atopic Eczema  
Gideon Lack, MD  
11:45  Question & Answer  
Upon completion of this session, participants should be able to: Describe the genetic and environmental events which predispose individuals to food allergy; Identify the possible dietary and environmental interventions to prevent food sensitization; Recognize when food allergy is implicated in a patient with atopic eczema.

Allied Health Symposium  

3311  Asthma and Obesity: Should We Do More?  
10:45 am to 12:00 pm  
Peabody, Bayhill 17 & 18, Lobby Level  
Credit: 1.25 CME / 1.50 CE  
Moderator: Maureen George, PhD RN AE-C  
10:45  Is There a Link Between Asthma and Obesity?  
Peyton A. Eggleston, MD FAAAAI  
11:15  Manage Across the Ages: Is the Focus That Different?  
Christine W. Wagner, CPNP CFNP AE-C  
11:45  Question & Answer  
Upon completion of this session, participants should be able to: Describe the impact of obesity on asthma management; Identify effects of obesity on commonly prescribed asthma medications; Develop an educational intervention for the obese asthma patient.

Allied Health Symposium  

3312  IVIG and Other Options  
10:45 am to 12:00 pm  
Peabody, Bayhill 21, Lobby Level  
Credit: 1.25 CME / 1.50 CE  
Moderator: M. Elizabeth M. Younger, CRNP PhD  
10:45  When to Use IVIG  
Mark Ballow, MD FAAAAI  
11:05  Practical Aspects of SubQ vs. IVIG  
M. Elizabeth M. Younger, CRNP PhD  
11:25  Non-Standard Uses of IVIG  
Stephen J. McGeady, MD FAAAAI  
11:45  Question & Answer  
Upon completion of this session, participants should be able to: Discuss when to use IVIG; Explain the practical differences between SubQ and IVIG; Identify the non-standard uses of IVIG.

Allied Health Workshop  

3313  Practical Behavioral and Management Tips for Atopic Dermatitis: Case Studies from the Trenches  
10:45 am to 12:00 pm  
Peabody, Bayhill 19, Lobby Level  
Credit: 1.25 CME / 1.50 CE  
Moderator: Lynda C. Schneider, MD FAAAAI  
Jennifer S. LeBovidge, PhD  
Karol G. Timmons, RN MS CPNP  
11:45  Question & Answer  
Upon completion of this session, participants should be able to: Describe management and treatment of recalcitrant atopic dermatitis; Describe tips for patient education for atopic dermatitis; Discuss behavioral management for atopic dermatitis.

Allied Health Workshop  

3314  The ABCs of Vitamin D and Asthma  
10:45 am to 12:00 pm  
Peabody, Bayhill 20, Lobby Level  
Credit: 1.25 CME / 1.50 CE  
Moderator: Karen S. Rance, DNP RN CPNP AE-C  
Nicolette De Jong, PhD  
Karen L. Gregory, DNP APRN-BC CNS RRT AE-C  
Karen S. Rance, DNP RN CPNP AE-C  
Upon completion of this session, participants should be able to: Describe the link between Vitamin D deficiency and asthma; Describe when and how to screen patients for Vitamin D deficiency; Educate Vitamin D deficient patients to best improve their asthma outcomes.
Upon completion of this session, participants should be able to: Describe how to educate patients about the process of quitting smoking, including patients who are resistant to quit; Discuss evidence based use of smoking cessation medications; Describe nicotine dependence and nicotine withdrawal.

3501 Mechanisms of Corticosteroid Insensitivity in Asthma
Elena Goleva, PhD
Pia J. Hauk, MD
Peabody, Celebration 1, Convention Level
Upon completion of this session, participants should be able to: Explain glucocorticoid receptor function on the cellular level; Describe basic mechanisms that result in corticosteroid insensitivity in asthma; Explore alternative therapies in steroid insensitive patients.

3502 Pulmonary Function Testing in Infants
Howard Eigen, MD
Robert S. Tepper, MD
Peabody, Celebration 2, Convention Level
Upon completion of this session, participants should be able to: Identify different pulmonary function techniques for use with infants; Discuss the reliability and predictive value of infant pulmonary function testing; Review which infants need pulmonary function testing.

3503 Elevated IgE and Infections: Is it a Primary Immunodeficiency?
Alexandro Freeman, MD
Bodo Grimbacher, MD
Peabody, Celebration 3, Convention Level
Upon completion of this session, participants should be able to: Identify diagnostic elements of primary immunodeficiencies with elevated IgE; Review the Hyper IgE syndromes; Appreciate the "red-flags" that suggest IgE is resulting from an inherent immunological defect and not atopy.

3504 What’s New in Testing for Primary Immunodeficiency Disorders?
Roshini S. Abraham, PhD FAAAAI
Harry R. Hill, MD
Peabody, Celebration 4, Convention Level
Upon completion of this session, participants should be able to: Review the laboratory tests used to work up patients with recurrent infection, including a description of the assays; Describe the clinical value of these tests and interpretation of the results; Appreciate how newer technologies are being applied to diagnostic laboratories for primary immunodeficiency.

3505 Universal Newborn Screening for T Cell Deficiencies: Achievements and Surprising Findings
Lisa J. Kobranski, MD MPH FAAAAI
Jennifer M. Puck, MD
Peabody, Celebration 5, Convention Level
Upon completion of this session, participants should be able to: Outline the rationale for universal newborn screening for SCID; Review contrasting findings in different states; Appreciate the technology used to screen for SCID.

3506 Problem-Based Learning: How to Inform Your Patients about Home Indoor Air Quality (Healthy Homes)
Kevin Kennedy, MD CEIS
Jay M. Portnoy, MD FAAAAI
Peabody, Celebration 6, Convention Level
Upon completion of this session, participants should be able to: Discuss the house as a system; Describe air quality and house systems; Outline methods to keep a home dry and properly ventilated.

3507 Let’s Take the Myth-story Out of Mold
James J. Anderson, MILT
Peter J. Plyn, PhD
Peabody, Celebration 7, Convention Level
Upon completion of this session, participants should be able to: Provide evidence that the risk of mold is often overstated; Learn the proven risk presented by mold; Explore challenges of workplace mold investigations.

3508 Hereditary Angioedema: Home Therapy
Marc A. Riedl, MD
Lanny J. Rosenwasser, MD FAAAAI
Peabody, Celebration 8, Convention Level
Upon completion of this session, participants should be able to: Explain the need for starting treatment early in treating HAE attacks; Discuss the practical concerns and hurdles for in-home therapy; Review the clinical experience and guidelines.

3509 Difficult Cases in Anaphylaxis: Biphasic and Protracted Anaphylaxis
Terri F. Brown-Whitehorn, MD
Frank J. Twarog, MD PhD FAAAAI
Peabody, Celebration 9, Convention Level
Upon completion of this session, participants should be able to: Describe cases of multiphasic and protracted anaphylaxis; Review risk factors related to protracted reactions; Discuss proper treatment and current recommendations for patients with biphasic anaphylaxis.

3510 The Adolescent Patient and Asthma
Andrea J. Apt, MD MA MSc FAAAAI
David R. Naimi, DO
Peabody, Celebration 10, Convention Level
Upon completion of this session, participants should be able to: Identify the barriers to self-management in adolescents with asthma; Describe adolescent development and how beliefs and attitudes may impact asthma self-management; Describe ways to effectively communicate to the adolescent patient with asthma, including technology.

3511 Electronic Health Records: Selection and Implementation
Dan Dalan, MD FAAAAI
David L. Patterson, MD FAAAAI
Peabody, Celebration 11, Convention Level
Upon completion of this session, participants should be able to: Discuss how to select an EHR; Discuss implementation of an EHR; List the key variables in an EHR that need to be matched to a practice.

3512 Immunotherapy Niche Uses
Jonathan A. Bernstein, MD FAAAAI
Brian P. Vickery, MD
Peabody, Celebration 12, Convention Level
Upon completion of this session, participants should be able to: Discuss niche uses for IT including atopic dermatitis and food sublingual immunotherapy; Discuss the reimbursement environment as it applies to alternative uses of IT; Appreciate variables in IT preparation as they apply to alternative uses.
3513  The Child with Chronic Cough
Alan B. Goldsobel, MD FAAAAI
Jason E. Knuffman, MD
Peabody, Celebration 13, Convention Level

Upon completion of this session, participants should be able to: Review the diagnosis and treatment of chronic cough in children; Identify the differential diagnosis of chronic cough; Discuss treatment strategies in patients with chronic cough.

3514  Office-Based Assessment of Patients with Suspected Monoclonal Mast Cell Disorders
Melody C. Carter, MD
Arnold Kirshenbaum, MD FAAAAI
Peabody, Celebration 14, Convention Level

Upon completion of this session, participants should be able to: Discuss clonal and non-clonal mast cell activation disorders; Describe recommendations for conducting office based evaluation and when to refer for bone marrow biopsy; Examine the impact of these disorders and associated symptoms with the upcoming new ICD-10-CM system.

3515  Management of Children and Adult Patients with Atopic Dermatitis
Mark Boguniewicz, MD FAAAAI
Dagmar Simon, MD
Peabody, Celebration 15, Convention Level

Upon completion of this session, participants should be able to: Describe the presentation, pathophysiology and complications of atopic dermatitis; Discuss the management of these patients, including their education; Discuss possible therapeutic consequences due to new insights into the pathogenesis of atopic dermatitis.

Pro/Con Debate

3522  Rhinovirus is More Important than RSV in Asthma Inception
12:30 to 1:30 pm
Convention Center, S320AB, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Giovanni Piedimonte, MD
Pro
Robert F. Lemanske Jr., MD FAAAAI
Con
Tina V. Hartert, MD MPH

Upon completion of this session, participants should be able to: Discuss the role of early life viral wheezing illnesses in the development of asthma; Evaluate the evidence for a causative role for RSV wheezing illnesses in the development of asthma; Evaluate the evidence for a causative role for rhinovirus wheezing illnesses in the development of asthma.

3523  The Atopy Patch Test is a Clinically Useful Tool for Diagnostic Workup of Atopic Dermatitis
12:30 to 1:30 pm
Convention Center, S320CD, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Lisa A. Beck, MD FAAAAI
Pro
Andreas Wollenberg, MD FAAAAI
Con
Luz S. Fonacier, MD FAAAAI

Upon completion of this session, participants should be able to: Discuss the immunobiology of the Atopy Patch Test; Discuss the advantages and limitations of the Atopy Patch Test; Explain the key requirements for performing an Atopy Patch Test in a clinical setting.

3524  Functional Endoscopic Sinus Surgery Offers Advantage Over Medical Management of Chronic Rhinosinusitis
12:30 to 1:30 pm
Convention Center, S330AB, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Daniel L. Hamilos, MD FAAAAI
Pro
Robert C. Kern, MD
Con
Raymond G. Slavin, MD MS FAAAAI

Upon completion of this session, participants should be able to: Identify clinical scenarios in which medical treatment of CRS is preferred; Define clinical scenarios in which surgical treatment of CRS is preferred.
Symposium

3525 Future Funding of Graduate Medical Education in Allergy/Immunology
12:30 to 1:30 pm
Convention Center, S330CD, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Lawrence B. Schwartz, MD PhD FAAAAI
Atul Grover, MD PhD

Upon completion of this session, participants should be able to: Discuss how AAAAI can influence support for graduate medical education; Discuss how federal funding for graduate medical education occurs; Identify the advocates in Washington, DC for GME.

Symposium

3526 FDA's Review of the Efficacy and Safety of Non-Standardized Allergen Extracts
12:30 to 1:30 pm
Convention Center, S310CDGH, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Jay E. Slater, MD

12:30 FDA's Efficacy Review of Non-Standardized Allergen Extracts
Ronald L. Rabin, MD FAAAAI
12:55 Efficacy and Safety of Non-Standardized Allergen Extracts Used in the U.S.
Jay E. Slater, MD
1:15 Question & Answer

Upon completion of this session, participants should be able to: Explain the evidence for the safety and efficacy of U.S. licensed nonstandardized allergen extracts; Discuss the implications of the FDA assessments for the use of nonstandardized extracts in allergy practice.

Symposium

3527 The Regional Advocacy Discussion and Response Initiative (RADAR): Training the Practicing Allergist
12:30 to 1:30 pm
Convention Center, S330EF, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Sharon B. Markovics, MD FAAAAI

12:30 RADAR Initiative: Description and Goals
James M. Tracy, DO FAAAAI
12:50 RADAR Mechanics Overview
J. Allen Meadows, MD
1:10 JCAAI Integration
James L. Sublett, MD FAAAAI

Upon completion of this session, participants should be able to: Discuss and apply advocacy techniques; Identify resources available for plan implementation; Develop a repository of information that would be nationally available; Establish bi-directional communication skills with both professional and advocacy organizations.

Symposium

3528 Developmental Origins of Asthma in the First 1,000 Days of Life: How and When Should Primary Prevention of Asthma Begin?
12:30 to 1:30 pm
Convention Center, S330GH, Level III
Credit: 1.00 CME / 1.20 CE
Moderators: David P. Huston, MD FAAAAI
William J. Martin II, MD

12:30 Allergen Sensitization: A Target for Asthma Intervention in the First 1,000 Days
James E. Gern, MD FAAAAI

Upon completion of this session, participants should be able to: Examine the evidence for the role of allergens during the first 1,000 days of life on the development of asthma and the feasibility of designing an effective intervention; Examine the evidence for the role of microbiome during the first 1,000 days of life on the development of asthma and the feasibility of designing an effective intervention.

Oral Abstract

3601 Asthma Therapeutics: What's Below the Surface?
2:00 to 3:15 pm
Convention Center, S330EF, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: David Broide

2:00 Body Mass and Corticosteroid Response in Childhood Asthma
Rolando A. Nunez, MD

2:15 Steroid Requirements and Immune Associations With Vitamin D Are Stronger in Children Than Adults With Asthma
Donald Y. M. Leung, MD PhD

2:30 Ganoderic Acid C Isolated From Ganoderma Lucidum Suppress Lps-induced Macrophage Tnf-α Production By Down-regulating Mapk, Nf-kappab And Ap-1 Signaling Pathways
Changda Liu, PhD

2:45 Methoxyphenols Exhibit Anti-inflammatory Effects on Airway Epithelial Cells by Acting Post-transcriptionally
Fouad Terrence Ishmael, MD PhD

3:00 Asthma Control And Disordered Microbial Communities In The Lower Airways Of Patients With Poorly Controlled Asthma
Elena Goleva, PhD
### Oral Abstract

#### 3602 Immunophenotyping

2:00 to 3:15 pm  
**Convention Center, S230AB, Level II**  
Credit: 1.25 CME / 1.50 CE  
Moderator: Francisco J. Espinosa-Rosales, MD

#### 2:00 TH IL-17 Immunophenotyping Reference for Children

**Katherine A. Gonzaga, MD**

**2:15** Ex Vivo Identification and Phenotyping of Allergen-Specific T Helper Cells In Human Peripheral Blood based on CD154 Expression

**Karen A. Smith, MSc**

#### 2:30 Calculated Globulin (CG): A Viable Tool for the Identification of Patients with Potential Antibody Deficiency

**Stephen Jolles, MB ChB MRCP FRCPath**

#### 2:45 TH2A Cells As a Unique TH2 Cell Subset in Allergic Individuals: Steps Toward a T Cell Biomarker For Allergy

**Erik R.G. Wambre, PhD**

#### 3:00 A Central B Cell Tolerance Defect In Group Ia CVID Patients

**Neil Romberg, MD**

### Oral Abstract

#### 3603 Biological Dust Exposures and Atopic & Allergic Diseases

2:00 to 3:15 pm  
**Convention Center, S330GH, Level III**  
Credit: 1.25 CME / 1.50 CE  
Moderators: Neil Alexis, PhD  
Martin D. Chapman, PhD FAAAAI

#### 2:00 Enhanced Organic Dust Induced Airway Inflammation in Protein Kinase C Epsilon Deficient Mice is Associated with Dysregulation of Nitric Oxide

**Jill A. Poole, MD FAAAAI**

#### 2:15 Cigarette Smoke Exposure and its Effect on Bronchial Responsiveness and Response to Fluticasone Propionate, Salmeterol and their Combination

**Kiran Sapkota, MS Pharm.**

#### 2:30 The Prevalence of Asthma, Hay Fever and Allergic Sensitization in Amish Children

**Mark Holbreich, MD FAAAAI**

#### 2:45 Influence of Rural and Urban Dietary and Lifestyle Patterns in Atopic Diseases in a Colombian African-descent Population

**Javier A. Marrugo, MD**

#### 3:00 Vitamin E Reduces Airway Granulocyte Recruitment after Inhaled Endotoxin Challenge in Normal Volunteers

**Michelle L. Hernandez, MD**

### Oral Abstract

#### 3604 Anaphylaxis

2:00 to 3:15 pm  
**Convention Center, S230GH, Level II**  
Credit: 1.25 CME / 1.50 CE  
Moderators: Paul J. Bryce, PhD  
Scott P. Commins, MD PhD

#### 2:00 Maternal Low Dose Peanut and Cholera Toxin Subunit B Induces Oral Tolerance Associated with An Increased Number of T Regulatory Cells

**Ying Song, MD**

#### 2:15 SHIP-1 Is Critical in Regulation of Severe Anaphylaxis

**Sun Young Oh, PhD**

#### 2:30 Development of a Dendrimeric Structure containing ole 1 and CpG to Modulate an Allergic Response in an Experimental Model

**Ana B. Blazquez, PhD**

#### 2:45 Isolation and Identification of Compounds in Rubia cordifolia L. (Qian Cao) that Inhibit Human B cell IgE production

**Vincent Chan**

#### 3:00 Anaphylaxis in America - Results from a National Telephone Survey

**John Boyle, PhD**

### Oral Abstract

#### 3605 Management of Food Allergies

2:00 to 3:15 pm  
**Convention Center, S331AB, Level III**  
Credit: 1.25 CME / 1.50 CE  
Moderator: Andrew G. Weinstein, MD FAAAAI

#### 2:00 Food Allergy and Increased Asthma Morbidity in a School Inner-city Asthma Study

**James Friedlander, MD**

#### 2:15 Outcome Rather Than the Type of Diagnostic Intervention Predicts Improvement in Health-Related Quality of Life Score Among Children With Food Allergy Between 0-12 Years

**Linda Kirste, BSc RD**

#### 2:30 Bullying and Teasing In Children With Food Allergy: A Survey of Pediatric Patients In Urban Jackson, Mississippi Outpatient Allergy and Immunology Clinics

**Annette E. Morris, MD**

#### 2:45 Novel Use of a Social Network for Families with Food Allergic Children

**Tao Le, MD MHS FAAAAI**

#### 3:00 Food Allergy Attitudes and Beliefs among School Nurses in an Urban Public School District

**Hermant P. Sharma, MD**
Oral Abstract

3606 Treatment of Allergic Rhinitis
2:00 to 3:15 pm
Convention Center, S230CD, Level II
Moderator: Sam Friedlander, MD
Comparing the Effect of Intranasal Fluticasone Furoate (FF) to Intraocular Olopatadine (OLO) on the Ocular Response to Nasal Allergen Challenge (NAC).
Marcy DeTineo, BSN

2:15 Long-term Safety Study of MP29-02 (Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate) in Subjects with Chronic Allergic or Non-allergic Rhinitis
William E. Berger

2:30 MP29-02 (Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate) in the Treatment of Ocular Symptoms of Seasonal Allergic Rhinitis (SAR)
Paul Ratner, MD

2:45 The Addition of Vitamin D (VitD) to an Intranasal Steroid (INS) Improves Control of Symptoms in Seasonal Allergic Rhinitis (SAR).
Fuad M. Baroody, MD FAAAAI

3:00 Ocular Safety of Fluticasone furoate Nasal Spray in Subjects with Perennial Allergic Rhinitis
S. D. Miller, MD

3607 Regulation of Allergic Inflammation
2:00 to 3:15 pm
Convention Center, S230EF, Level II
Moderator: Joshua A. Boyce, MD FAAAAI

2:00 Allergen Specific IL-10 Producing T regulatory Cells Are Upregulated in Children Who Have Acquired Tolerance to Egg
Anna B. Fishbein, MD

2:15 IL-4, But Not IL-2, Induces Th2 Cells To Resist The IL-27 Counterregulation By Downregulating Stat1 Phosphorylation
Zhihong Chen, MD PhD

2:30 Increased Number of Regulatory T Cells in Skin Draining Lymph Nodes Suppress Priming Towards New Antigens
Subhashree Mahapatra, MSc

2:45 IgE Cross-Linking Downregulates Expression of Glycolytic Genes in Human Plasmacytoid Dendritic Cells
Gagan Bajwa, MSc

3:00 Increased Platelet Adherence to Leukocytes Results in Cysteinyl Leukotriene (cysLT) Overproduction in Aspirin Exacerbated Respiratory Disease (AERD)
Tanya M. Laidlaw, MD

Interest Section Forum

3701 ADT Interest Section Forum
3:30 to 5:30 pm
Convention Center, S320CD, Level III
Moderator: John Oppenheimer, MD FAAAAI
Business Meeting
Maintenance and Reliever
Stephen P. Peters, MD PhD FAAAAI
Break
Once Daily or As Needed Therapy

5:15 Question & Answer
Upon completion of this session, participants should be able to: Describe the impact of poor adherence on asthma care; Describe options for dynamic dosing (stepping up and down) in the care of asthmatic patients.

3702 BCI Interest Section Forum
3:30 to 5:30 pm
Convention Center, S320AB, Level III
Moderator: Jordan Orange, MD PhD FAAAAI
Announcements and Recognitions
Committee Acknowledgements and Committee Reports
Genetics of the Most Common Antibody Deficiencies
Bodo Grimbacher, MD
AMPC Future Planning and Venues for New Business
Upon completion of this session, participants should be able to: Identify new human defects that were discovered due to a comprehensive knowledge of basic T Cell biology; Identify newer human immune defects that interfere with anti-viral defense; Compare the interplay between genetic influence and microbiome as reflected in immune deviation and host defense; Appreciate insights into microbiome interaction and immune output as derived from immune genetic disease.
Interest Section Forum

3703  EORD Interest Section Forum
3:30 to 5:30 pm
Convention Center, S330CD, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Karin A. Pacheco, MD MSPH FAAAAI
3:30  Climate Change and Our Environment: The Impact on Allergic Diseases
Estelle Levetin, PhD FAAAAI
4:00  How Our Changing Ecosystem Affects Respiratory Disease and the Allergist
Gennaro D'Amato, MD FAAAAI
4:30  Question & Answer
4:45  Business Meeting
Upon completion of this session, participants should be able to: Identify the influence of climate change on pollen and mold spore levels, distribution and allergenicity; Develop insights into the effects of changing aerobiology on upper and lower respiratory disease prevalence and severity; Address the global nature of our changing environment and how it affects our patients and our practice of medicine.

Interest Section Forum

3704  FADDA Interest Section Forum
3:30 to 5:30 pm
Convention Center, S310ABFE, Level III
Credit: 1.50 CME / 1.80 CE
Moderator: Mariana C. Castells, MD PhD FAAAAI
3:30  Angioedema
Bruce L. Zuraw, MD
4:00  FADDA Committee Reports
4:15  Stinging Insect Hypersensitivity
David B.K. Golden, MD FAAAAI
4:45  FADDA Awards and Updates
Mariana C. Castells, MD PhD FAAAAI
5:00  Food Allergy Guidelines
A. Wesley Burks, MD FAAAAI
Upon completion of this session, participants should be able to: Describe the new 2011 practice parameters on angioedema and stinging insect hypersensitivity, as well as the new food allergy guidelines; Evaluate the indications and outcomes of the new drugs for HAE including kallikrein and bradykinin inhibitors and recognize the new presentations of HAE and their treatment; Evaluate the safety and outcomes for insect IT and potential new treatments, including anti-IgE as well as the new treatments for food allergy including anti-IgE and tolerization; Recognize the new criteria and indications for food immunotherapy and desensitizations, as well as the indications for insect immunotherapy.

Interest Section Forum

3705  HEDQ Interest Section Forum
3:30 to 5:30 pm
Convention Center, S330EF, Level III
Credit: 1.75 CME / 2.00 CE
Moderator: Andrew G. Weinstein, MD FAAAAI
3:30  Accountable Care Organizations: The Vision, Evolving Trends and Future Realities
Jonathan Niloff, MD
4:30  Business Meeting
4:50  Accountable Care and Chronic Disease Management: Allergy Case Study
Daniel G. Steinberg, MD FAAAAI
5:15  Question & Answer
Upon completion of this session, participants should be able to: Discuss the national trends driving ACO development; Describe the mechanics of how ACOs are being developed; Identify potential areas where ACO development impacts chronic disease management, allergy/asthma patients and the physicians who care for them.

Interest Section Forum

3706  IRSOC Interest Section Forum
3:30 to 5:30 pm
Convention Center, S310CDGH, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Fuad M. Baroody, MD FAAAAI
3:30  Rhinosinusitis and Ocular Allergy Committee Report
Sergio Bonini, MD
3:50  Phenotyping Chronic Rhinosinusitis
Claus Bachert, MD PhD
4:10  Genotyping Chronic Rhinosinusitis
Martin Desrosiers, MD
4:30  Tying it all Together and a Path for Future Discovery
Larry Borish, MD FAAAAI
4:50  Immunotherapy, Allergen Standardization and Allergy Diagnostics Committee Report
Désirée E.S. Larenas Linnemann, MD FAAAAI
5:10  Cough Committee Report
Arvind Madaan, MD FAAAAI
Upon completion of this session, participants should be able to: Identify different inflammatory phenotypes of chronic rhinosinusitis; Describe the different approaches to genotyping chronic rhinosinusitis; Explain how these two approaches might influence potential therapy of the disease.
**Interest Section Forum**

3707  **MAAI Interest Section Forum**
3:30 to 5:30 pm  
Convention Center, S330AB, Level III  
Credit: 1.50 CME / 1.80 CE  
Moderator: Susan M. MacDonald, MD FAAAAI

3:30  **Business Meeting**

4:00  **Role of Macrophages in the Regulation of Th2 Responses**  
Thomas A. Wynn, PhD

4:30  **Dendritic Cell-Basophil Cooperation in the Th2 Response to Cysteine Proteases**  
Bali Pulendran, PhD

5:00  **Effect of Anti-IgE Treatment on Dendritic Cell Response**  
John T. Schroeder, PhD

Upon completion of this session, participants should be able to: Discuss the state-of-the-art as to whether basophils can act as antigen presenting cells and are more potent than dendritic cells; Describe the cooperation between dendritic cells and basophils; Discuss the contribution of IgE levels to antigen presentation by dendritic cells.

**Featured Poster Session and Reception**

5:30 to 7:30 pm  
Convention Center, S210, Level II  
All Annual Meeting delegates and their guests are invited to attend this event. No fee and no pre-registration required.  
Credit: No CME / No CE

Featured Posters are the highest quality abstracts submitted for presentation at the Annual Meeting. These posters will be displayed throughout the meeting in the second floor lobby of the Convention Center. During the Featured Poster Session and Reception on Sunday evening, authors will be present with their posters to discuss their research. Take this opportunity to talk with these authors and network with other meeting delegates.

3801  **ADT Featured Poster Session**

3802  **BCI Featured Poster Session**

3803  **EORD Featured Poster Session**

3804  **FADDA Featured Poster Session**

3805  **HEDQ Featured Poster Session**

3806  **IRSOC Featured Poster Session**

3807  **MAAI Featured Poster Session**

3811  **Allied Health Featured Poster Session**

**Dinner Symposiums**

3901  **Office Anaphylaxis: Risk Factors, Treatment and Guidelines**
7:30 to 9:30 pm  
Peabody, Peabody Grand Ballroom PQ, Convention Level  
Credit: 1.50 CME / 1.80 CE  
Programmed by the AAAAI. Funded through an educational grant from Dey Pharma L.P.  
Moderator: Vivian P. Hernandez-Trujillo, MD FAAAAI

3902  **New Insights into Asthma Therapy**
7:30 to 9:30 pm  
Peabody, Peabody Grand Ballroom R, Convention Level  
Credit: 1.50 CME / 1.80 CE  
Programmed by the AAAAI. Funded through an educational grant from Teva Respiratory.  
Moderator: Leslie Hendeles, PharmD

Upon completion of this session, participants should be able to: Describe which patients are at risk of anaphylaxis within the office setting and recognize that a variety of presentations exist; List supplies that are needed to manage anaphylaxis in an office setting; Describe current evidence-based guidelines for the treatment of anaphylaxis (WAO guidelines/Practice Parameters).
Seminars

7:00 to 8:00 am
Pre-registration and ticket required. Fee: $40. Continental breakfast included. Sessions and meals limited to 30 people.
Credit: 1.00 CME / 1.20 CE

4006 Pesticides, Herbicides and Other VOCs in Indoor Environments as Causes of Allergies and Asthma: What is Real?
John R. Cohn, MD FAAAAI
Ronald A. Simon, MD FAAAAI
Peabody, Celebration 6, Convention Level
Upon completion of this session, participants should be able to: Develop improved understanding of the characteristics of unrelated chemicals that may be involved in inducing development of allergic disease and which may become increasingly important if predicted scenarios of climate change come to pass; Explain the role and mechanism of volatile organic compounds in causing allergic disease; Explain the epidemiologic evidence linking pesticides and herbicides with allergic disease, including asthma and their underlying mechanisms.

4007 Evaluation of an Index Case of Work-Related Asthma
Leslie C. Grammer, MD FAAAAI
Hae-Sim Park, MD FAAAAI
Peabody, Celebration 7, Convention Level
Upon completion of this session, participants should be able to: Identify the key steps in the investigation of work-related asthma to ensure better diagnosis and management of their patients; Discuss how to work with public authorities in evaluation; Appreciate how to protect the patient medically and legally during an evaluation.

4008 Problem-Based Learning: A Child with Recurrent Anaphylaxis
Amal H. Assa’ad, MD FAAAAI
Michelle B. Lierl, MD FAAAAI
Peabody, Celebration 8, Convention Level
Upon completion of this session, participants should be able to: Explain the causes of anaphylaxis in pediatric patients; Describe the diagnostic evaluation for this condition; Design a treatment plan for a child with anaphylactic food allergy.

4009 Allergic Reactions to Vaccines
Amanda Cox, MD
John M. Kelso, MD FAAAAI
Peabody, Celebration 9, Convention Level
Upon completion of this session, participants should be able to: Review allergies which present a risk of reaction to certain vaccines; Describe the current data on the safety of the influenza vaccination for egg-allergic individuals; Discuss approaches to testing or appropriate administration of vaccines where there is a concern about vaccine allergy.

4010 Adherence Management for Adults with Asthma
Cynthia S. Rand, PhD
Daniel A. Searing, MD
Peabody, Celebration 10, Convention Level
Upon completion of this session, participants should be able to: Determine the many reasons why adult asthma patients do not follow asthma management recommendations; Discuss proven patient-centered communication strategies to promote patient adherence; Determine how to use technology to accurately diagnose and maintain patient adherence.

4011 Getting Ready for ICD-10: Cracking the Code
Marshall P. Grodofsky, MD FAAAAI
Stephen A. Imbeau, MD FAAAAI
Peabody, Celebration 11, Convention Level
Upon completion of this session, participants should be able to: Discuss basics in coding, contrasting ICD-10 with ICD-9-CM; Describe the impact of ICD-10 on billing and coding; Identify strategies for implementing ICD-10 in clinical practice.
4012 Are We Ready to Use Parasites to Treat Allergic Diseases?
Luisa Karla P. Arruda, MD FAAAAI
Philip J. Cooper, PhD
Peabody, Celebration 12, Convention Level

Upon completion of this session, participants should be able to: Evaluate critically the data available on treatment of allergic diseases with parasites; Discuss the mechanisms by which parasites may down regulate allergic responses; Discuss parasite molecules with potential immunomodulatory effects.

4013 Problem-Based Learning: Rhinitis and Aging
Jayant M. Pinto, MD
Raymond G. Slavin, MD MS FAAAAI
Peabody, Celebration 13, Convention Level

Upon completion of this session, participants should be able to: Review pathophysiology of the nose during the aging process; Identify treatment of rhinitis in the elderly; Distinguish the difference in rhinitis between adults and the elderly.

4014 Surrogate Markers of Mast Cell Activation
Joshua A. Boyce, MD FAAAAI
Melody C. Carter, MD
Peabody, Celebration 14, Convention Level

Upon completion of this session, participants should be able to: Identify mast cell mediators and associated functions; Discuss utilization of mast cell markers as a diagnostic tool; Examine use of serum tryptase in clinical evaluation and as a management tool in children.

4015 Pediatric Asthma: Mechanisms, Management by the New Guidelines and Early Intervention
Ronina A. Covar, MD
Lynn M. Taussig, MD
Peabody, Celebration 15, Convention Level

Upon completion of this session, participants should be able to: Discuss the latest information about predisposing risk factors including new genetic and epigenetic studies; Discuss the latest guidelines on diagnostic criteria (NAEPP); Relate the pros and cons for the use of a diagnostic tool; Examine use of serum tryptase in clinical evaluation and as a management tool in children.

12:15 Luncheon Discussion of Difficult Cases
Margaret R. Dodds, RN MS CPNP
Carla M. Duff, CPNP MSN CCRP
Debbie Manning, RN
Stephen J. McGeady, MD FAAAAI
Jordan Orange, MD PhD FAAAAI

1:30 Infusion Pumps for Therapy
William R. Blouin, ARNP
Carla M. Duff, RN BSN CCRP

2:15 Administration Devices for SCIG
Margaret R. Dodds, RN MS CPNP
Debra A. Sedlak, MSN CPNP

Plenary

4101 Anaphylaxis in the New Millennium
8:15 to 9:45 am
Convention Center, South Hall A1, Level I
Credit: 1.50 CME / 1.80 CE
Moderator: Vivian P. Hernandez-Trujillo, MD FAAAAI

8:15 Pathophysiology of Anaphylaxis: New Concepts
Stephen J. Galli, MD

8:45 Clinical Aspects of Mast Cell Dysfunction
Dean D. Metcalfe, MD FAAAAI

9:15 Risk Factors for Severe and Fatal Anaphylaxis
F. Estelle R. Simons, MD FAAAAI

Posters

7:00 am to 6:00 pm
Convention Center, South Hall A2, Level I
Posters on display from 7:00 am to 6:00 pm. Authors present from 9:45 to 10:45 am.
Credit: No CME / No CE
Refer to pages 75-128 for abstracts and authors.

4201 Asthma Epidemiology and Environmental Influences
4202 Immune Deficiency
4203 Dendritic Cells, Pattern Recognition Receptors and Signaling
4204 Infections and Allergic Disease
4205 Epidemiology of Sensitization, Asthma and Occupational Asthma
4206 Food Allergy II
4207 Anaphylaxis
4208 Provider Knowledge and Training
4209 Treatment of Allergic Rhinitis/Conjunctivitis
4210 Immunotherapy Outcomes
4211 T Cells
4212 Cytokines and Chemokines
Symposium  4301  Macrophages: More than an Alternative in Airway Diseases
10:45 am to 12:00 pm
Convention Center, S230GH, Level II
Credit: 1.25 CME / 1.50 CE
Moderator: Joshua A. Boyce, MD FAAAAI
10:45 Regulatory Myeloid Cells Influence DCs to Temper Allergic Airway Inflammation
Anuradha Ray, PhD
11:05 Macrophages: The Neglected Effector Cell of Allergic Inflammation
Barbara Balestrieri, MD
11:25 Macrophages and Chronic Inflammation
Thomas A. Wynn, PhD
11:45 Question & Answer

Upon completion of this session, participants should be able to: Explain the contribution of macrophages to the development and progression of pulmonary inflammation; Recognize the critical role of macrophages in allergic pulmonary inflammation; Describe the interplay of macrophages, dendritic cells and T Cells in airway diseases.

Symposium  4302  What’s New in Indoor Mold: An Update on Health Effects and Exposure Assessment
10:45 am to 12:00 pm
Convention Center, S330AB, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: W. Elliott Horner, PhD LEED AP FAAAAI
10:45 World Health Organization Guidelines for Indoor Air Quality
Jay M. Portnoy, MD FAAAAI
11:05 What is New in Exposure Assessment for Indoor Mold and Remediation
Brett J. Green, PhD
11:25 Indoor Mold and Asthma Onset
Tina Reponen, PhD
11:45 Question & Answer

Upon completion of this session, participants should be able to: Describe recent research on the health effects of indoor mold exposure; Assess the status and value of new exposure assessment tools under development; Translate practical preventive steps for avoidance into patient management; Identify the role of mold in asthma onset or morbidity.

Symposium  4303  Mast Cell Activation Syndromes
10:45 am to 12:00 pm
Convention Center, S330CD, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Cem Akin, MD PhD FAAAAI
10:45 Mast Cell Activation Syndrome: Symptoms and Presentation
Mariana C. Castells, MD PhD FAAAAI
11:05 Differentiating Idiopathic Anaphylaxis from Mast Cell Clonal Disorder
Phillip L. Lieberman, MD FAAAAI
11:25 Mast Cell Surface Markers for Activation and Clonality
Dean D. Metcalfe, MD FAAAAI
11:45 Question & Answer

Upon completion of this session, participants should be able to: Describe the symptoms of mast cell activation; Review the differential diagnosis of mast cell activation disorders; Recognize the different management issues in mast cell activation syndromes.

Symposium  4304  Epigenetics and Immunologic Disease
10:45 am to 12:00 pm
Convention Center, S330EF, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Malcolm N. Blumenthal, MD FAAAAI
10:45 How Epigenetics Contributes to Asthma and Allergy
Shuk-Mei Ho, PhD
11:05 The Role of Epigenetics in Host Defense
Hao Shen, MD
11:25 Epigenetics, Autoimmunity and Auto Inflammation
Wesley Brooks, PhD MBA
11:45 Question & Answer

Upon completion of this session, participants should be able to: Discuss the triggers and modulators of allergy; Describe epigenetics and what role it has in the phenotypes of allergy; Explain the role of targeted epigenetic therapy in the treatment of allergy.

Symposium  4305  Novel Treatment of Food Allergy
10:45 am to 12:00 pm
Convention Center, S310ABFE, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: J. Andrew Bird, MD
10:45 Oral Desensitization in Patients with Peanut Allergy
A. Wesley Burks, MD FAAAAI
11:05 Oral Desensitization Enabled with Omalizumab for Food Allergy
Kari C. Nadeau, MD PhD FAAAAI
11:25 Traditional Chinese Medicine as Therapy for Food Allergy
Julie Wang, MD FAAAAI
11:45 Question & Answer

Upon completion of this session, participants should be able to: Discuss the recent clinical and immunological outcomes in oral food immunotherapy; Discuss the role of anti-IgE therapy in concert with oral food immunotherapy; Describe recent clinical and immunological outcomes with traditional Chinese medicine in food allergy.
MONDAY • MARCH 5, 2012

Symposium ▼

4306 Sneezy or Wheezy: Effect of Viral Diversity on Illness Severity
10:45 am to 12:00 pm
Convention Center, S320AB, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Robert F. Lemanske Jr., MD FAAAAI

10:45 Etiology of Viral Wheeze Determines Risk for Childhood Asthma
Tuomas Jartti, MD

11:05 HRV-C: Bad Actor or Just Another Rhinovirus?
E. Kathryn Miller, MD

11:25 RSV: A Role for Viral Genetic Diversity in Illness Severity?
Martin L. Moore, PhD

11:45 Question & Answer

Upon completion of this session, participants should be able to: Describe the evidence indicating that the identity of viruses causing early life wheezing episodes is a predictor of risk for developing childhood asthma; Discuss whether the recently discovered rhinovirus species, HRV-C, is more likely than other rhinoviruses to induce lower airway symptoms, leading to wheeze and exacerbations of asthma; Discuss the role that sequence diversity in viral virulence genes might play in determining the severity and clinical outcomes of RSV illnesses.

Symposium ▼

4307 Making Sense of Lymphocyte Development
10:45 am to 12:00 pm
Convention Center, S230EF, Level II
Credit: 1.25 CME / 1.50 CE
Moderator: Christine M. Seroogy, MD FAAAAI

10:45 Sorting out T Cell Development
M. Louise Markert, MD PhD FAAAAI

11:05 B Cell Differentiation and Control
Hans D. Ochs, MD

11:25 Birth of a Killer: NK Cell Development
Jeffrey Miller, MD

11:45 Question & Answer

Upon completion of this session, participants should be able to: Describe the factors driving T, B and NK cell lymphocyte development; Describe the transcription factors regulating progression along the phylogeny of developing lymphocytes; Explain the anatomic compartmentalization of lymphocytic development through stages of terminal maturation.

Symposium ▼

4308 New Trends in Immunotherapy
10:45 am to 12:00 pm
Convention Center, S320CD, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Désirée E.S. Larenas Linnemann, MD FAAAAI

10:45 Intralymphatic and Epicutaneous Immunotherapy
Thomas M. Kuendig, MD

11:05 The Dust Mite Story: How Do SCIT and SLIT Differ? Which is Better?
Stephen R. Durham, MA MD

11:25 New Molecules for Immunotherapy: Peptides and Modified Molecules Under Investigation
Mark Larche, PhD

11:45 Question & Answer

Upon completion of this session, participants should be able to: Discuss mechanisms and clinical aspects of intralymphatic and transcutaneous immunotherapy; Describe the current knowledge of immunologic changes associated with house dust mite specific immunotherapy, including the efficacy and safety of SCIT and SLIT with house dust mites; Comment on the safety and efficacy of peptide immunotherapy and other forms of immunotherapy that are under investigation.

AAAAI Business Meeting

12:30 to 1:30 pm
Convention Center, S310CDGH, Level III
All AAAAI Fellows and members are invited to attend this annual business meeting. Box lunches included. No Fee. No pre-registration required.

Oral Abstract

4601 Update in Asthma Therapeutics and Monitoring
2:00 to 3:15 pm
Convention Center, S330EF, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Riccardo Polosa, MD PhD FAAAAI

2:00 Early Non-Respiratory Symptom Patterns Precede Loss of Asthma Control in Children
Lisanne Newton, MD

2:15 Adverse Reaction Preparedness for Allergen Immunotherapy in the Primary Care Setting
Vinitha Reddy, MD

2:30 Clinical Efficacy and Safety of Combined Mometasone Furoate and Formoterol in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Edward Kerwin, MD

2:45 ASHMI (Antiallhma Simplified Herbal Medicine Intervention) is a Potent Inhibitor of Interferon-α Production from Human Dendritic Cells by Increasing Pro-inflammatory Cytokines
Jody R. Tversky, MD

3:00 Efficacy and Safety of AMG 853 in Asthma: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
William W. Busse, MD FAAAAI
Oral Abstract 4602  
**Immunoglobulin and Biological Therapy**  
2:00 to 3:15 pm  
Convention Center, S230EF, Level II  
Credit: 1.25 CME / 1.50 CE  
Moderator: Vincent R. Bonagura, MD  
2:00  
The Sialylated Fraction Of IVIg Suppresses Th2-driven Airway Inflammation Via The Induction Of Tolerogenic Dendritic Cells  
Amir Hessein Massoud, MD  
2:15  
The Effect Of Anti-IL-5 Therapy on Esophageal Mastocytosis in Pediatric Eosinophilic Esophagitis  
Iris M. Otani, MD  
2:30  
Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients With Primary Immunodeficiency Disease (PIDD)  
Isaac Melamed  
2:45  
A Scoring System to Guide Decisions on Immunoglobulin Replacement Treatment in Hypogammaglobulinemia  
Shradha Agarwal, MD  
3:00  
Long-term Safety And Efficacy Of Mepolizumab For The Treatment Of Hypereosinophilic Syndrome  
Amy D. Klion, MD  

Oral Abstract 4603  
**The Effect of Pollution on Allergic Disease**  
2:00 to 3:15 pm  
Convention Center, S230GH, Level II  
Credit: 1.25 CME / 1.50 CE  
Moderators: Christopher Chang, MD PhD FAAAAI  
Rachel Miller, MD FAAAAI  
2:00  
Postnatal Ozone Exposure Enhances House Dust Mite Induced Airway Hyperresponsiveness Without Increasing Inflammation  
Keisa Gabehart, PhD  
2:15  
Frequent Allergy Symptoms Among Children Living Near The World Trade Center Associated With Elevated Peripheral Airways Resistance  
Yi Feng Chen  
2:30  
Annual New York City Trends Of Ambient Fine Particulate Matter, Black Carbon And Ambient Metals Implicated In Airway Disease  
Fei Li Kuang, MD PhD  
2:45  
Relationship Between Environmental Phenols And Aeroallergen And Food Allergies In The US: Results From The National Health And Nutrition Examination Survey 2005-2006  
Natalia Vernon, MD  
3:00  
Distance From A Heavily Trafficked Highway Is Implicated In The Presence Of Allergic Rhinconjunctivitis And Asthma In Adults  
Maria-Anna Vastardi, MD  

Oral Abstract 4604  
**Genetic and Other Mechanisms of Atopic and Skin Diseases**  
2:00 to 3:15 pm  
Convention Center, S330AB, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderators: Luz S. Fonacier, MD FAAAAI  
Pia J. Hauk, MD  
2:00  
Effect of Th2 and Th17 Cytokines on Human Epidermal Tight Junctions  
Anna De Benedetto, MD  
2:15  
The Association Between HLA B7 Alleles and Human Atopic Dermatitis Complicated by Eczema Herpeticum  
Rasika A. Mathias, PhD  
2:30  
C3a Receptor (C3aR) is Important for Viral Containment in Mice Inoculated with Vaccinia Virus (VV) at Sites of Allergic Skin Inflammation  
Lalit Kumar, PhD  
2:45  
Staphylococcus Aureus Alpha-Toxin Augments Viral Load In Keratinocytes  
Lianghua Bin, PhD  
3:00  
Genetic Variants Associated with Asthma and Related Phenotypes are Also Risk Factors for Food Allergy  
Candelaria Vergara, MD PhD  

Oral Abstract 4605  
**New Insights into Allergy and Asthma Assessment**  
2:00 to 3:15 pm  
Convention Center, S331AB, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderators: Peter J. Crietupa, MD  
Harvey L. Leo, MD  
2:00  
Reliability, Validity, and Responsiveness of the Asthma Control Questionnaire among Pediatric Patients.  
Jessica M. Nguyen, MD  
2:15  
A Retrospective Analysis of Anti-Allergy Drug Efficacy tested in an Environmental Exposure Chamber (EEC) Model compared to that observed in the Traditional Allergy Field Trials demonstrates the clinical relevance of allergen exposure models.  
Anne Marie Salapatek, MD  
2:30  
Online Allergy Surveys - is There an App For That? A Quantitative and Qualitative Study of Allergic Rhinitis Patients During a Pollen Season  
Dan Dalan, MD FAAAAI  
2:45  
A Personalized Care Platform: Incorporating Structured Data In Allergy Clinical Care  
Jianfeng Meng, MD MPH MS  
3:00  
The First Phase of Instrument Development: The Conventional and Alternative Management (CAM) for Asthma Questionnaire  
Maureen George, PhD RN AE-C
### Oral Abstract

**4606 Mechanisms of Rhinitis**  
2:00 to 3:15 pm  
Convention Center, S330CD, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderators: Mark C. Glau, MD PhD FAAAAI  
Brian A. Smart, MD FAAAAI  
2:00 Local Allergic Rhinitis is Highly Prevalent in a Population Attended for the Evaluation of Rhinitis  
Carmen Rodon Segovia, MD PhD  
2:15 Interleukin-35 Suppresses Allergen-specific Th2 Response in Patients with Grass pollen induced Seasonal Allergic Rhinitis  
Daniela Achkova, MSc  
2:30 Effects of Repetitive Allergen Challenge on Expression of TGF-β, Activin-A and Its Receptor ALK4 in Nasal Mucosa of Allergic Rhinitis  
Huifen Wu, MD  
2:45 Basophils In Peripheral Blood can be Sensitized in Local Allergic Rhinitis  
Enrique Gomez  
3:00 Evaluation of Thymic Stromal Lymphopoietin (TSLP) and its Receptor in Adults with Allergic Rhinitis Following Controlled Allergen Challenge in the Environmental Exposure Unit (EEU).  
Tahira Batool, MD

**4607 Myeloid Cells in Allergic Inflammation**  
2:00 to 3:15 pm  
Convention Center, S230CD, Level II  
Credit: 1.25 CME / 1.50 CE  
Moderator: Francesca Levi-Schaffer, PhD FAAAAI  
2:00 Group V sPLA2 is Required in Alternative Activated Macrophages for the Development of Allergic Pulmonary Inflammation  
Shin Ohta, MD PhD  
2:15 Thioredoxin is Positively Associated with Eosinophils in Induced Sputum from Patients with Asthma  
Joel M. Hartman, MD  
2:30 Histamine is Necessary for IL-4-driven Eosinophilic Allergic Responses  
Julie A. Swartzendruber, BA  
2:45 Hypoxia Regulates Activation/Inhibitory Receptors on Eosinophils.  
Aron H. Nissim Ben Efraim, MSc  
3:00 Mechanisms Involved In IL-5 Enhancement Of Siglec-8-induced Eosinophil Apoptosis: Role For Reactive Oxygen Species (ROS)-enhanced MEK/ERK Activation  
Gen Kano, MD PhD

### Late Breaking Oral Abstract Session

**4611 Basic/Translational Sciences**  
2:00 to 3:15 pm  
Convention Center, S329, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderators to be announced.  
2:00 IFN-α Destabilizes Human CD4+ T Helper Type 2 (Th2) Cells By Disrupting the Th2-Specific Transcription Program  
Jonathan Huber  
2:15 Association of Gene Variant in IL12B Gene with Atopic Dermatitis Complicated by Eczema Herpeticum (ADEH)  
P.S. Gao, MD PhD  
2:30 IL-25 Down-regulates Epidermal Barrier Proteins and Enhances Viral Replication  
Byung Eui Kim, MD  
2:45 Paired Immunoglobulin-like Receptor B Is Required For Allergic Eosinophilic Airway Inflammation  
Ariel Munitz, PhD  
3:00 Ragweed Pollen Lipid is an Immunoadjuvant of the Humoral and Cellular Immune Response in BALB/c Mice  
Mehran Eftekh Bazhir, PhD

### Cutting-Edge Research Keynote

**4701 Understanding Disease Mechanisms: Past, Present and Future**  
3:30 to 4:30 pm  
Convention Center, South Hall A1, Level I  
Credit: 1.00 CME / 1.20 CE  
Moderator: Ray Stokes Peebles, Jr., MD FAAAAI  
3:30 Two Hundred Years of Reporting Medical News  
Jeffrey M. Drazen, MD FAAAAI  
4:00 The Antibody Paradox  
Jeffrey V. Ravetch, MD PhD  
Upon completion of this session, participants should be able to: Discuss the evolution of understanding the mechanisms and treatment of asthma; Describe mechanisms for antibodies to provoke disease, and induce tolerance.

### Q & A Workshop

**4801 Asthma in the Elderly**  
4:45 to 6:00 pm  
Convention Center, S230CD, Level II  
Credit: 1.25 CME / 1.50 CE  
Moderator: Monroe J. King, DO FAAAAI  
4:45 Asthma in the Elderly  
Paula J. Busse, MD FAAAAI  
5:00 Non-Allergic Rhinitis and Asthma  
Sharmilee M. Nyenhuis, MD  
5:15 Allergic Rhinitis and Asthma  
Joram S. Seggev, MD FAAAAI  
5:30 Question & Answer  
Upon completion of this session, participants should be able to: Describe the aging of the U.S. population and problems associated with it; Evaluate elderly patients for co-morbidities that may complicate the management of asthma or mimic the disease; Formulate a comprehensive management plan.
Q & A Workshop

4802 Tools and Resources for Scientists in Allergy Research
4:45 to 6:00 pm
Convention Center, S330AB, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Judith A. Woodfolk, MBChB PhD FAAAAI

4:45 Approaches to Molecular Modeling of Allergens
Anna Pomès, PhD FAAAAI

5:00 The Immune Epitope Database: Navigation and Applications
Alessandro Sette, PhD

5:15 Class II MHC/Peptide Tetramers: Insights into Allergen-Specific T Cells
William W. Kwok, PhD

5:30 Question & Answer

Upon completion of this session, participants should be able to: Describe how molecular modeling of allergens is performed and how it can be used to advance our knowledge of allergen structure and function; Review how the Immune Epitope Database can be used for allergen epitope discovery; Describe how Class II MHC/peptide tetramers can be used to identify allergen-specific T Cells and to identify relevant applications.

Q & A Workshop

4803 Shaping Immunologic Responses with Environmental Exposures
4:45 to 6:00 pm
Convention Center, S320CD, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: R. Stokes Peckles Jr., MD FAAAAI

4:45 Interactions Between the Innate and Adaptive Immune Systems that Impact the Development of Allergen Sensitization
Harald E. Renz, MD

5:00 The Impact of the Farming Environment on Neonatal Immune Responses
Erika Von Mutius, MD MSc

5:15 The Impact of Environmental Exposures on Pulmonary Dendritic Cell Function
Mitchell H. Grayson, MD FAAAAI

5:30 Question & Answer

Upon completion of this session, participants should be able to: Describe the interplay between the innate and adaptive immune system; Explain how in utero maternal exposures can modulate neonatal immune responses and how this relates to the development of allergic disease; Discuss how mucosal dendritic cells are impacted by environmental exposures and the effect on immune responses.

Panel Discussion Workshop

4804 Opportunities for Improving Immunoglobulin Therapy
4:45 to 6:00 pm
Convention Center, S310CDGH, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Marc A. Riedl, MD
W.A. Carrock Sewell, MD PhD FAAAAI
Erwin W. Gelfand, MD FAAAAI
Mark R. Stein, MD FAAAAI

Upon completion of this session, participants should be able to: Review the variables underlying effective and optimal IVIG therapy and if there are strategies that can allow improved outcomes; Discuss the innovations being applied to the method for administering SCIG and whether or not they present any value in improving care; Discuss how interpretation of patient-specific data can or cannot be used to guide optimization of therapy.

Panel Discussion Workshop

4805 Writing and Publishing a Manuscript: A Roadmap for the Allergist/Immunologist
4:45 to 6:00 pm
Convention Center, S230EF, Level II
Credit: 1.25 CME / 1.50 CE
Moderator: Michael H. Clayton, MD FAAAAI
Richard W. Honsinger, MD FAAAAI
James T. Li, MD PhD FAAAAI
Richard F. Lockey, MD FAAAAI

Upon completion of this session, participants should be able to: Discuss writing an article: formulating a concept, reviewing the literature and telling the story; Identify nuances in publishing a case report: determining the uniqueness, single case vs. case series and constructing the message; Discuss getting it published: the manuscript, authorship and choosing the right journal.

Problem-Based Learning Workshop

4806 Optimal Treatment of Hereditary Angioedema
4:45 to 6:00 pm
Convention Center, S320EF, Level III
Pre-registration and ticket required. Fee: $50.
Credit: 1.25 CME / 1.50 CE
Moderator: Timothy J. Craig, DO FAAAAI
Bruce L. Zuraw, MD

Upon completion of this session, participants should be able to: Describe risks and benefits of treatment options for exacerbations of HAE; Describe treatment options for HAE prophylaxis.

Problem-Based Learning Workshop

4807 Atopic Dermatitis
4:45 to 6:00 pm
Convention Center, S320GH, Level III
Pre-registration and ticket required. Fee: $50.
Credit: 1.25 CME / 1.50 CE
Moderator: Lynda C. Schneider, MD FAAAAI
Vivian P. Hernandez-Trujillo, MD FAAAAI

Upon completion of this session, participants should be able to: Identify triggers of atopic dermatitis; Develop a treatment plan for atopic dermatitis; Design an action plan to treat worsening of atopic dermatitis.

Problem-Based Learning Workshop

4808 The Intricacy of Penicillin Allergy Testing and Cross-Reactivity with Cephalosporin Allergy
4:45 to 6:00 pm
Convention Center, S310AB, Level II
Pre-registration and ticket required. Fee: $50.
Credit: 1.25 CME / 1.50 CE
Moderator: Eric M. Macy, MD FAAAAI
Miguel A. Park, MD

Upon completion of this session, participants should be able to: Discuss the different components of the penicillin skin test; Discuss how the different components of the penicillin skin test affect the negative predictive value; Discuss the role of oral challenges to penicillin and/or amoxicillin in the evaluation of penicillin allergy.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Location</th>
<th>Presenter(s)</th>
<th>Credit Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:45</td>
<td>Prevention of Food Allergy in Children</td>
<td>Convention Center, S310ABFE, Level III</td>
<td>Sani L. Bahna, MD DrPH FAAAAI</td>
<td>1.25 CME / 1.50 CE</td>
</tr>
<tr>
<td>5:00</td>
<td>Maternal Dietary Interventions</td>
<td></td>
<td>Gideon Lack, MD</td>
<td></td>
</tr>
<tr>
<td>5:15</td>
<td>Breastfeeding, Formula Feeding and Formula Options</td>
<td></td>
<td>Marion E. Groetch, MS RD</td>
<td></td>
</tr>
<tr>
<td>5:30</td>
<td>Question &amp; Answer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:45</td>
<td>ABAI Maintenance of Certification (MOC) and Beyond</td>
<td>Convention Center, S330CD, Level III</td>
<td>Mary Beth Fasano, MD MBA FAAAAI</td>
<td>1.25 CME / 1.50 CE</td>
</tr>
<tr>
<td>5:00</td>
<td>The Six Core Competencies</td>
<td></td>
<td>John M. James, MD FAAAAI</td>
<td></td>
</tr>
<tr>
<td>5:15</td>
<td>Evaluating Residents and Medical Students</td>
<td></td>
<td>Stephen I. Wasserman, MD FAAAAI</td>
<td></td>
</tr>
<tr>
<td>5:30</td>
<td>Question &amp; Answer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:45</td>
<td>Using Information Technology to Maximize Outcomes and Reimbursement</td>
<td>Convention Center, S330EF, Level III</td>
<td>David J. Shulan, MD FAAAAI</td>
<td>1.25 CME / 1.50 CE</td>
</tr>
<tr>
<td>5:00</td>
<td>Proving I Should be Paid for My Performance</td>
<td></td>
<td>Todd A. Mahr, MD FAAAAI</td>
<td></td>
</tr>
<tr>
<td>5:15</td>
<td>Questions to Consider When Determining the Optimal Software to Evaluate Patient Outcomes</td>
<td></td>
<td>Richard L. Wasserman, MD PhD FAAAAI</td>
<td></td>
</tr>
<tr>
<td>5:30</td>
<td>Question &amp; Answer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:45</td>
<td>The Child with Chronic Vomiting and Diarrhea</td>
<td>Convention Center, S331AB, Level III</td>
<td>Scott H. Sicherer, MD FAAAAI</td>
<td>1.25 CME / 1.50 CE</td>
</tr>
<tr>
<td>5:00</td>
<td>Panel Discussion Workshop</td>
<td></td>
<td>Marion E. Groetch, MS RD</td>
<td></td>
</tr>
<tr>
<td>5:15</td>
<td>Question &amp; Answer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:45</td>
<td>Teaching Residents and Students in the Clinical Practice</td>
<td>Convention Center, S329, Level III</td>
<td>Mark H. Moss, MD</td>
<td>1.25 CME / 1.50 CE</td>
</tr>
<tr>
<td>5:00</td>
<td>The Six Core Competencies</td>
<td></td>
<td>John M. James, MD FAAAAI</td>
<td></td>
</tr>
<tr>
<td>5:15</td>
<td>Evaluating Residents and Medical Students</td>
<td></td>
<td>Jeffrey R. Stokes, MD FAAAAI</td>
<td></td>
</tr>
<tr>
<td>5:30</td>
<td>Question &amp; Answer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:45</td>
<td>Hands-On Rhinolaryngoscopy</td>
<td>Convention Center, S331CD, Level III</td>
<td>Allen D. Adinoff, MD FAAAAI</td>
<td>1.25 CME / 1.50 CE</td>
</tr>
<tr>
<td>5:00</td>
<td>Hands-On Rhinolaryngoscopy</td>
<td></td>
<td>Jerald W. Koepke, MD FAAAAI</td>
<td></td>
</tr>
<tr>
<td>5:15</td>
<td>Questions to Consider When Determining the Optimal Software to Evaluate Patient Outcomes</td>
<td></td>
<td>Nathan Segall, MD</td>
<td></td>
</tr>
<tr>
<td>5:30</td>
<td>Question &amp; Answer</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Upon completion of this session, participants should be able to: Review available data for maternal dietary interventions during pregnancy/lactation; Discuss available dietary interventions for infants/young children with food allergies or at risk of developing food allergies; Discuss ideal timing of introduction of solids and allergenic foods into the infant/child diet.

Upon completion of this session, participants should be able to: Discuss how to successfully report their MOC activities to the ABAI; Discuss the mechanics of the four major components of the ABAI MOC program (i.e. Parts I – IV), with an emphasis on Part IV modules; Identify current issues of MOC that are pertinent to all ABAI diplomates including future initiatives and programs.

Upon completion of this session, participants should be able to: Identify the six core competencies of postgraduate medical training; Describe resources to enhance teaching of trainees in the office setting; Discuss qualities of a clinical rotation that lend value to a medical training program.

Upon completion of this session, participants should be able to: Demonstrate the initial skills needed to perform a comprehensive upper airway examination with a fiber optic endoscope; Discuss information regarding the upper airway anatomy learned in the didactic session.
Q & A Workshop

4815 CNS Consequences of Allergic Rhinitis in Children and Adults: Sleep Disturbance, Behavioral Problems and Migraine Headache
4:45 to 6:00 pm
Convention Center, S230GH, Level II
Credit: 1.25 CME / 1.50 CE
Moderators: Lyndon E. Mansfield, MD FAAAAI
Eli O. Meltzer, MD FAAAAI
5:00 Overview of the CNS Consequences of Allergic Rhinitis
Mark S. Dykewicz, MD FAAAAI
5:15 ADHD, Sleep Apnea and Allergic Rhinitis in Children
Bernard Silverman, MD FAAAAI
5:30 Question & Answer

Upon completion of this session, participants should be able to: Identify the associations and theories of causality among allergic rhinitis, adenotonsillar hypertrophy and sleep obstruction; Explore the association and theories of causality between allergic rhinitis and migraine headache; Identify the demonstrated effects and possible benefits of intranasal corticosteroids and other allergic rhinitis treatment.

Hands-On Workshop

4816 Skin Testing: How to Get the Right Swing
4:45 to 6:00 pm
Convention Center, S330GH, Level III
Pre-registration and ticket required. Fee: $50.
Credit: 1.25 CME / 1.50 CE
Moderator: Kaiser G. Lim, MD FAAAAI
Minor Details That Can Improve Your Skin Prick Testing Accuracy
John Oppenheimer, MD FAAAAI
Extracts and Devices
Désirée E.S. Larenas Linnemann, MD FAAAAI
Documentation of Skin Test Results
Warner W. Carr, MD FAAAAI
Hands-On Instruction

Upon completion of this session, participants should be able to: Demonstrate proper technique for skin testing; Review for and take a proficiency test; Experiment with different SPT devices (mono and multitest).

Q & A Workshop

4817 Beyond Th2 Cells and Mediators of Allergic Inflammation
4:45 to 6:00 pm
Convention Center, S320AB, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Larry Borish, MD FAAAAI
4:45 Allergic Inflammation Regulating Th17 Immunity
Dawn C. Newcomb, PhD
5:00 IL9, Th9 Cells and Allergic Inflammation
Clare M. Lloyd, PhD
5:15 Complement in Allergic Inflammation
Marsha A. Wills-Karp, PhD
5:30 Question & Answer

Upon completion of this session, participants should be able to: Define how Th17 cells modulate allergic inflammatory disorders such as asthma; Describe the role of IL9 and Th9 cells in allergic inflammation; Discuss how complement plays a critical role in allergic inflammatory response.

Seminars

4821 How to Advise Patients on Home Pest Control, Indoor Contaminants and Clean and Safe Indoor Environments
4:45 to 5:45 pm
Pre-registration and ticket required. Fee: $40. Refreshments included.
Sessions and refreshments limited to 30 people.
Credit: 1.00 CME / 1.20 CE
Peabody, Celebration 1, Convention Level
Kevin Kennedy
Elizabeth Matsui, MD

Upon completion of this session, participants should be able to: Describe pest management practices consistent with a healthy home; Explain integrated pest management; Discuss chemical contamination in the home environment.

4822 Oral Immunotherapy for Food Allergy: Contrasting Practices in the U.S. and in Europe
4:45 to 5:45 pm
Pre-registration and ticket required. Fee: $40. Refreshments included.
Credit: 1.00 CME / 1.20 CE
Peabody, Celebration 2, Convention Level
Giovanni Battista Pajno, MD FAAAAI
Rushani W. Saltzman, MD

Upon completion of this session, participants should be able to: Discuss the right patients for the right OIT; Describe food allergens which are worth OIT; Review food allergies which are worth active treatment.

4823 Using Technology in Teaching and Medical Education
4:45 to 5:45 pm
Pre-registration and ticket required. Fee: $40. Refreshments included.
Credit: 1.00 CME / 1.20 CE
Peabody, Celebration 3, Convention Level
Adrian Casillas, MD FAAAAI
Tao Le, MD MHS FAAAAI

Upon completion of this session, participants should be able to: Describe low cost learning technologies such as webinars, online video and social media; Discuss best use case scenarios for low cost learning technologies; Explain advanced PowerPoint techniques and presentation alternatives to PowerPoint.

4824 Use of Pneumococcal Vaccination in Immunodeficiency Diagnosis and Management
4:45 to 5:45 pm
Pre-registration and ticket required. Fee: $40. Refreshments included.
Credit: 1.00 CME / 1.20 CE
Peabody, Celebration 4, Convention Level
Francisco A. Bonilla, MD PhD FAAAAI
Kenneth Paris, MD MPH

Upon completion of this session, participants should be able to: Use and interpret pneumococcal immunization in evaluation of patients with possible primary immunodeficiency disorders.

4825 Advanced Therapeutics: Managing the Severe and Refractory Eczema Patient
4:45 to 5:45 pm
Pre-registration and ticket required. Fee: $40. Refreshments included.
Credit: 1.00 CME / 1.20 CE
Peabody, Celebration 5, Convention Level
Jennifer S. Kim, MD FAAAAI
Peter Lio, MD

Upon completion of this session, participants should be able to: Identify common pitfalls in the treatment of eczema, with special emphasis on compliance; Describe the rationale for an extended therapeutic ladder for patients refractory to standard treatments; Evaluate treatments and interventions that have been shown to be of no benefit in the disease.
<table>
<thead>
<tr>
<th>Seminar ID</th>
<th>Seminar Title</th>
<th>Facilitator(s)</th>
<th>Convention Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>5001</td>
<td>Eosinophilic Esophagitis: Practical Aspects of Assessing Immediate and Delayed Food Hypersensitivity</td>
<td>Mark Holbreich, MD FAAAAI; Amir F. Kagalwalla, MD</td>
<td>Peabody, Celebration 1, Convention Level</td>
</tr>
<tr>
<td>5002</td>
<td>Outpatient Evaluation of Patients with Multiple Drug Allergy Syndrome</td>
<td>David A. Khan, MD FAAAAI; Roland Solensky, MD FAAAAI</td>
<td>Peabody, Celebration 2, Convention Level</td>
</tr>
<tr>
<td>5003</td>
<td>How to Safely Do Drug Challenges in the Office: A Practical Approach</td>
<td>Eric M. Macy, MD FAAAAI; Stephen A. Tilles, MD FAAAAI</td>
<td>Peabody, Celebration 3, Convention Level</td>
</tr>
<tr>
<td>5004</td>
<td>Dermatology for the Allergist</td>
<td>Vincent S. Beltrani, MD FAAAAA; Peter Lio, MD</td>
<td>Peabody, Celebration 4, Convention Level</td>
</tr>
<tr>
<td>5005</td>
<td>Food Protein-Induced Enterocolitis Syndrome (FPIES): Diagnosis and Management</td>
<td>Jonathan M. Spergel, MD PhD FAAAAA; Robert A. Wood, MD FAAAAI</td>
<td>Peabody, Celebration 5, Convention Level</td>
</tr>
<tr>
<td>5006</td>
<td>Rush/Cluster Immunotherapy: Pearls and Protocols</td>
<td>Linda Cox, MD FAAAAI; Joseph T. Inglefield III, MD</td>
<td>Peabody, Celebration 6, Convention Level</td>
</tr>
<tr>
<td>5007</td>
<td>Laryngoscopy for VCD and GERD</td>
<td>Allen D. Adinoff, MD FAAAAA; Corinna S. Bowser, MD FAAAAA</td>
<td>Peabody, Celebration 7, Convention Level</td>
</tr>
<tr>
<td>5008</td>
<td>Hypereosinophilic Disorders: Diagnosis and Treatment of Difficult Cases</td>
<td>Carla M. Davis, MD; Amy D. Klion, MD</td>
<td>Peabody, Celebration 8, Convention Level</td>
</tr>
<tr>
<td>5009</td>
<td>Advanced Coding for Allergists</td>
<td>Noga Askarian, MD FAAAAA; Stephen A. Imbeau, MD FAAAAA</td>
<td>Peabody, Celebration 9, Convention Level</td>
</tr>
<tr>
<td>5010</td>
<td>Perioperative Anaphylaxis: Anesthetics, Antibiotics, Latex and Others</td>
<td>Gordon L. Sussman, MD FAAAAA; Kristen K. Volkman, MD</td>
<td>Peabody, Celebration 10, Convention Level</td>
</tr>
</tbody>
</table>

**New! EDUCA TIONAL GAMES FOR KIDS**

Innovative website tools in the Member Resource Center
Plenary

5101 Immunology at the Epithelial Frontier
8:15 to 9:45 am
Convention Center, South Hall A1, Level I
Credit: 1.50 CME / 1.80 CE
Moderator: Steve Ziegler, PhD

8:15 Allergen Interactions with Epithelial Surfaces
Marsha A. Wills-Karp, PhD
8:15 Epithelial Cells Determine Balance Between Tolerance and Immunity
David Artis, PhD
8:15 Epithelial Barrier Recovery: A New Frontier in the Management of Allergic Diseases
Lisa A. Beck, MD FAAAAI

Upon completion of this session, participants should be able to: Discuss how the expression of pattern recognition receptors (Toll-like receptors, NOD1) expressed on the epithelium distinguishes between commensal and pathogenic microbes to maintain tolerance vs. induction of a protective immune response to pathogens; Explain how the release of Th2-promoting cytokines such as TSLP, IL-25 and IL-33 from bronchial epithelial cells contributes to the pathogenesis of asthma and atopic dermatitis; Describe evidence for epithelial cells acting as antigen presenting cells; Describe how epithelial cells play an active role in the initiation, regulation and resolution of immune responses; Discuss the evidence for epithelial barrier disruption in allergic diseases, biological consequences of this disruption and potential repair mechanisms.

Symposium

5302 Lessons from the Inner City Environment on the Immunologic Basis and Treatment of Allergy and Asthma
10:45 am to 12:00 pm
Convention Center, S320AB, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: William W. Busse, MD FAAAAI

10:45 Immunologic Effects of Cockroach Sublingual Immunotherapy
Robert A. Wood, MD FAAAAI
11:05 Insights into the Management of Asthma in Urban Children
Stephen Teach, MD
11:25 Risk Factors for Early Wheezing
James E. Gern, MD FAAAAI
11:45 Question & Answer

Upon completion of this session, participants should be able to: Describe which urban environmental exposures affect the development of recurrent wheeze in early life; Compare immunologic effects of cockroach sublingual immunotherapy to those reported for other antigens; Discuss the evidence base for the treatment of asthma in children from poor urban environments.

Symposium

5303 Silencing is Golden: microRNA Regulation of Immunity
10:45 am to 12:00 pm
Convention Center, S320CD, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Ivan K. Chinn, MD

10:45 Physiologic and Pathologic Roles for microRNA in Immune Development and Function
Carl Novina, MD PhD
11:05 The Biology of microRNA Accessory Proteins
Rachel Jane Senturia, PhD
11:25 Diagnostic and Therapeutic Potential of microRNA in Allergic Disease
Paul S. Foster, PhD
11:45 Question & Answer

Upon completion of this session, participants should be able to: Discuss the role of microRNAs in the development and function of immune cells; Recognize the role of accessory proteins in processing microRNAs; Discuss potential therapeutic uses of microRNA technology.
Symposium

5304 Biomarkers for Monitoring Allergen Immunotherapy Induced Tolerance
10:45 am to 12:00 pm
Convention Center, S310CGH, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Mohamed Shamji, BSc MSc PhD

10:45 Serum and Local Biomarkers for Monitoring Allergen Immunotherapy
Stephen R. Durham, MD MD

11:05 Use of IgG4 Arrays in Monitoring Allergen Immunotherapy: Are They Any Good?
Robert G. Hamilton, PhD D.ABMLI FAAAAI

11:25 Cellular Assays for Monitoring Allergen Immunotherapy
Wayne G. Shreffler, MD PhD FAAAAI

11:45 Question & Answer
Upon completion of this session, participants should be able to: Discuss which serum biomarkers can be used for monitoring allergen immunotherapy and their clinical uses; Describe the use of IgG4 arrays in monitoring allergen immunotherapy; Evaluate which cellular assays are being studied to monitor AIT.

Symposium

5305 Genetics of Food Allergy: Into the Future
10:45 am to 12:00 pm
Convention Center, S310ABFE, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: A. Wesley Burks, MD FAAAAI

10:45 Peanut Allergy and Loss-of-Function Variants in the Filaggrin Gene
Sara Brown, MBChB

11:05 Eosinophilic Esophagitis and Variants of TSLP/TSLP Receptor
Antonella Cianferoni, MD PhD

11:25 Mechanistic and Clinical Insights from a Novel Food Allergy Related Syndrome
Pamela A. Guerrero, MD PhD

11:45 Question & Answer
Upon completion of this session, participants should be able to: Describe the link between peanut allergy and loss-of-function variants in the Filaggrin gene; Explain the relationship between variants of TSLP/TSLP receptor and eosinophilic esophagitis; Discuss how identification of a new link between a rare syndrome and food allergy could provide new insight into the genetics of food allergy.

Symposium

5306 Beyond Necrosis and Apoptosis: Spectrum of Cell Death
10:45 am to 12:00 pm
Convention Center, S330CD, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Nives Zimmermann, MD FAAAAI

10:45 Interplay of Autophagy with Apoptosis and Necrosis in T Cell Homeostasis
Craig Walsh, MD MD

11:05 Role and Mechanism of Necroptosis in Homeostasis
John W. Eild, PhD

11:25 Mechanism of NETosis: Neutrophil Cell Death Following Extrusion of DNA Traps
Arturo Zychlinsky, PhD

11:45 Question & Answer
Upon completion of this session, participants should be able to: Explain the role and mechanism of necroptosis in cell death and how it relates to immune cell homeostasis; Describe the role and mechanism of autophagy in cell death and how it relates to immune cell homeostasis; Discuss the role and mechanism of NETosis in cell death and how it relates to immune cell homeostasis.

Symposium

5307 What You Need to Know About STATs
10:45 am to 12:00 pm
Convention Center, S330AB, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Gurjit K. Khurana Hershey, MD PhD FAAAAI

10:45 Mechanisms of STAT-induced CD4+ T Cell Differentiation
John J. O’Shea Jr., MD

11:05 STAT Defects in the Pathogenesis of Primary Immunodeficiency Diseases
Joshua D. Milner, MD

11:25 STAT Genetic Susceptibility Loci for Autoimmunity
John B. Harley, MD PhD

11:45 Question & Answer
Upon completion of this session, participants should be able to: Discuss how STAT molecules impact the differentiation of CD4+ T cells; Identify STAT defects that result in specific primary immunodeficiency diseases; Discuss polymorphisms in STAT genes that are associated with susceptibility to autoimmune diseases.

Pro/Con Debate

5501 Skin Testing is Required in Choosing an Elimination Diet in Eosinophilic Esophagitis
12:30 to 1:30 pm
Convention Center, S330AB, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Wayne G. Shreffler, MD PhD FAAAAI

Pro
Katrina J. Allen, MD PhD

Con
Mirna Chehade, MD

Upon completion of this session, participants should be able to: Describe the difference in approach to EoE between allergist/immunologists and gastroenterologists; Explain evidence of the effectiveness of various protocols for dietary elimination; Review prognostic implications for sub-phenotypes of EoE for both children and adults dependent on response to dietary elimination.
TUESDAY • MARCH 6, 2012

**Pro/Con Debate ▽**

**5502** Immunotherapy Works via Regulatory T Cells
12:30 to 1:30 pm
Convention Center, S310CDGH, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Dorothy S. Cheung, MD FAAAAI

Pro
Carsten B. Schmidt-Weber, PhD

Con
Thomas A.E. Platts-Mills, MD PhD FAAAAI

Upon completion of this session, participants should be able to: Describe the data supporting a primary role for regulatory T Cells in driving the efficacy of immunotherapy; Define the various alternative explanations for how immunotherapy is an effective therapy in allergic disease; Discuss how the various potential mechanisms operative in immunotherapy interact to provide effective treatment.

**Pro/Con Debate ▽**

**5503** Subcutaneous Immunoglobulin is the Preferred Mode of Therapy for Primary Immunodeficiency
12:30 to 1:30 pm
Convention Center, S320AB, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Christine M. Seroogy, MD FAAAAI

Pro
Ralph Shapiro, MD

Con
Erwin W. Gelfand, MD FAAAAI

Upon completion of this session, participants should be able to: Describe an overview of both routes of administration of gammaglobulin; Discuss clinical considerations when choosing which route of administration of IgG replacement will benefit the patient; Describe the options for IgG replacement.

**Pro/Con Debate ▽**

**5504** Use of Probiotics Can Prevent and Treat Allergic Diseases
12:30 to 1:30 pm
Convention Center, S330CD, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Anna H. Nowak-Wegrzyn, MD FAAAAI

Pro
Liam O’Mahony, MD

Con
Susan L. Prescott, MD PhD

Upon completion of this session, participants should be able to: Explain the importance of bacterial flora for normal development of the immune system; Describe the evidence for the use of probiotics in prevention of allergic diseases; Review the evidence for the use of probiotics in treatment of allergic diseases.

**Symposium ▽**

**5505** Evidence-Based Approach to Asthma Step Down: ICS or LABA
12:45 to 1:45 pm
Convention Center, S310ABFE, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Christine A. Sorkness, PharmD

12:45 LABAs: The Good, Bad and Ugly
Thomas B. Casale, MD FAAAAI

1:05 Drop the LABA or Decrease the ICS? Evidence Based Approach to Step-Down Care
Jan Brozek, MD

1:25 Balancing the FDA and EPR3 Recommendations on LABA Use
Monica Kraft, MD

Upon completion of this session, participants should be able to: Review the data and controversy surrounding LABA safety; Discuss the evidence for the most appropriate approach to step down care in a well controlled asthma patient on ICS/LABA combination; Explore how best to use LABAs in clinical asthma care.

**Pro/Con Debate ▽**

**5506** Acetaminophen (Paracetamol) Causes Wheezing and Asthma in Children
12:45 to 1:45 pm
Convention Center, S330EF, Level III
Credit: 1.00 CME / 1.20 CE
Moderator: Ronald A. Simon, MD FAAAAI

Pro
Dennis R. Ownby, MD FAAAAI

Con
Christine Cole Johnson, PhD MPH FAAAAI

Upon completion of this session, participants should be able to: Describe experimental evidence linking acetaminophen use to childhood wheezing illnesses and asthma; Discuss potential confounding effects of concurrent illnesses.

**Oral Abstract ▽**

**5601** Novel Mechanisms in Asthma Therapeutics
2:00 to 3:15 pm
Convention Center, S330CD, Level III
Credit: 1.25 CME / 1.50 CE
Moderators: Timothy Craig, DO FAAAAI
Heather K. Lenman, MD

2:00 Suppression of Allergic Airway Inflammation by Low Dose, Intranasally Administered Der p 1 Derived Peptides, in a Murine Model of House Dust Mite Allergy
Daniel M. Moldaver, BSc

2:15 A Comparison of the Local and Systemic Effects of AZD3199, an Inhaled Ultra-long-acting β2-adrenoceptor Agonist (uLABA), With Formoterol in Patients With Asthma
Leif Bjerman, MD

2:30 Selective Blockade of Pulmonary Epithelial Stat3 for the Treatment of Asthma
Sege De Golovine, MD

2:45 Maternal Asthm Therapy Reduces Offspring Susceptibility To Developing Airway Inflammation In A Murine Model
Kamal D. Srivastava, PhD

3:00 Myeloid Derived Suppressor Cells Attenuate Murine Allergic Airway Inflammation
Qingdong Guan, MSc
Oral Abstract

5602 Cellular Mechanisms of Allergy
2:00 to 3:15 pm
Convention Center, S230GH, Level II
Credit: 1.25 CME / 1.50 CE
Moderator: Lisa R. Forbes, MD
2:00 Expression of the Regulatory Protein Caveolin-1 is reduced in Asthma
Sonia N. Bains, MD
2:15 Mechanical Skin Injury Induces TLR4/MyD88 Dependent IL-23 Expression In Epidermal Keratinocytes
Juhan Yoon, PhD
2:30 Human Dendritic Cells Stimulated with a Novel Peanut Protein Express High Levels of RALDH2 and Induce RA-Sensitive Genes in Naïve T Cells
Bert Ruiter, PhD
2:45 Interaction With Myd88-dependent CD8-CD11c+ Cells Mediates Rapid Induction Of Antigen-specific IgE-suppressive Gamma Delta T Cells
Yafei Huang, PhD
3:00 Combined Blockade Of The Histamine H1 and H4 Receptor Suppresses Peanut-Induced Diarrhea And Intestinal Inflammation By Regulating Dendritic Cell Function
Meiqin Wang, MD PhD

Oral Abstract

5603 Viral Bronchiolitis and Asthma in Children
2:00 to 3:15 pm
Convention Center, S330EF, Level III
Credit: 1.25 CME / 1.50 CE
Moderators: Pedro Avila, MD FAAAAI
Jeffrey G. Demain, MD FAAAAI
2:00 Upregulation Of Glucocorticoids Beta Receptors In Severe RSV Bronchiolitis In Infants.
Patricia V. Diaz, MD PhD
2:15 Sequence Analysis of a Cloned Human Rhinovirus Designed For Use in Human Inoculation Studies
Kazuyuki Nakagome, MD PhD
2:30 Risk of Childhood Asthma Following Infant Bronchiolitis During RSV Season
Kristina M. James, MD
2:45 Clinical Factors and Response to Albuterol in Wheezing Infants with Bronchiolitis & Respiratory Failure
Christopher L. Carroll, MD
3:00 Bacterial Detection In The Fall Is Associated With Increased Viral Respiratory Infections
Kristen M. Kloepper, MD

Oral Abstract

5604 Mechanisms of EGID
2:00 to 3:15 pm
Convention Center, S330CD, Level III
Credit: 1.25 CME / 1.50 CE
Moderators: Juan Pablo Abonia, MD
Antonella Ciaferoni, MD PhD
2:00 Proton-sensing Receptor GPR65 Regulates Allergic Gastrointestinal Eosinophilia
Xiang Zhu, PhD
Eileen S. Alexander, MD
2:30 Interleukin (II)-15 Overexpression In The Esophagus Promotes IgE Associated Experimental EoE
Priya Rajavelu, PhD
2:45 Increased CD3+CD69+ T-Cells and CD40+ Eosinophils in the Esophageal Tissue of Eosinophilic Esophagitis
Minou Le-Carlson, MD
3:00 Dietary Therapy and Topical Corticosteroids Can Reverse Esophageal Fibrosis in Patients with Eosinophilic Esophagitis
Jay Lieberman, MD

Oral Abstract

5605 Treatment of Immunodeficiency and Angioedema
2:00 to 3:15 pm
Convention Center, S330GH, Level III
Credit: 1.25 CME / 1.50 CE
Moderators: Marcus S. Shaker, MD MS FAAAAI FAAP
John M. Weiler, MD FAAAAI
2:00 Preferences for Immunoglobulin Treatment Administration Attributes by Patients and Parents
Ateesha Mohamed, MA
2:15 Financial Impact of Late Diagnosis of Severe Combined Immunodeficiency: Why It is Fiscally Sound for States to Invest in the Implementation of Newborn Screening
Catherine Kubiak, MD
2:30 Tolerability of Subcutaneous Immunoglobulin (SCIG) in Patients Receiving Antiplatelet (AP) and Anticoagulant (AC) Therapy
John Kuryan, MD
2:45 Discrepancies Between Guidelines and International Practice in the Treatment of Hereditary Angioedema: Results from a World Allergy Organization Survey of Physicians
Melanie C. Dispenza, PhD
3:00 Cost of Treating Hereditary Angioedema with Newly Available Medications in Five Different Settings
Ajay Bhasin
Oral Abstract

5606  Immunotherapy
2:00 to 3:15 pm
Convention Center, S230CD, Level II
Credit: 1.25 CME / 1.50 CE
Moderator: David Hauswirth, MD FAAAAI
2:00  How Molecular Diagnosis Can Change Allergen-specific Immunotherapy Prescription In A Complex Area Of Pollen Sensitization (madrid, Spain).
Maria Eulalia Landivar Encalada, MD
2:15  Rapid Induction Of Tolerance To Peanut By Antigen-coupled Cell Transfer
Chia-Lin Hsu, MS
2:30  Bispecific Antibody-induced Allergen-specific Regulatory T cells (Tregs) Suppress Der-P-1-induced Airway Inflammation
Bellur S. Prabhakar, PhD
2:45  Long-term Safety Of A 300IR Sublingual Tablet Of 5-grass-pollen Allergen Extract In Adults With Grass-pollen-induced Allergic Rhinconjunctivitis
Alain Didier, MD
3:00  Ragweed Allergy Immunotherapy Tablet Reduces Nasal and Ocular Symptoms of Allergic Rhinoconjunctivitis Over the Peak Ragweed Pollen Season in North America
Gary Berman, MD

Oral Abstract

5607  Mechanism of Allergic Sensitization
2:00 to 3:15 pm
Convention Center, S230EF, Level II
Credit: 1.25 CME / 1.50 CE
Moderator: Nives Zimmerman, MD FAAAAI
2:00  Age-related Differences in Antigen Sensitization and the Allergic Airway Responses in Acute and Resolved Viral Respiratory Infection
Janette Birmingham, MS
2:15  Diesel Exhaust Particles Induce Cysteine Oxidation and S-Glutathionylation in House Dust Mite Induced Murine Asthma
Gerald B. Lee, MD
2:30  The Gut Mucosa Microenvironment Affects Allergic Sensitization vs tolerance to Food proteins
Karine Adel-Patient, PhD
2:45  Rhinovirus Matures Dendritic Cells (DCs) and Primes Them for Antigen Presentation
John W. Steinke, PhD FAAAAI
3:00  Leukocyte Ig-like Receptor LILRB4 (LILRB4) Downregulates Key Events in the Migration of Antigen (Ag)-bearing Lung Dendritic Cells in Th2 Inflammation
Laura B. Fanning, MD

Late Breaking Oral Abstract

5611  Clinical Sciences
2:00 to 3:15 pm
Convention Center, S331CD, Level III
Credit: 1.25 CME / 1.50 CE
Moderators to be announced.
2:00  Findings From Year 3 Of The National AAAAI/ACAII Surveillance Study: Clinical Practices Related To Subcutaneous Immunotherapy (SCIT) Administration And The Risk Of Systemic Reactions (SRS)
Molly E.G. Epstein, MD MS
2:15  Prevalence of Eczema and Food Allergy is Associated with Latitude in Australia
Nicholas J. Osborne, PhD
2:30  Bacterial Lipopolysaccharide Triggers Dose-Dependent, Distinct Airway Inflammation in Childhood Asthma
Pia J. Hauk, MD
2:45  Novel Rituximab Desensitization Protocol Increases Safety of Drug Desensitization
Caroline L. Sokol, MD PhD
3:00  Can Novel Histologic Biomarkers Predict Correct Diagnosis And Treatment Response In Patients With Matched Esophageal Eosinophilia?
Srividiya Sridhara, MD

Problem-Based Learning Workshop

5701  The Child with Chronic Cough
3:30 to 4:45 pm
Convention Center, S331AB, Level III
Pre-registration and ticket required. Fee: $50.
Credit: 1.25 CME / 1.50 CE
Mary Beth Fasano, MD FAAAAI
Alan B. Goldsobel, MD FAAAAI
Upon completion of this session, participants should be able to: Determine the etiology of chronic cough at various ages; Define appropriate diagnostic tests; Evaluate appropriate therapeutic interventions for each diagnosis.

Panel Discussion Workshop

5702  Asthma and COPD: Similarities and Differences
3:30 to 4:45 pm
Convention Center, S330AB, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Sally E. Wenzel, MD FAAAAI
Eugene R. Bleecker, MD
Monica Kraft, MD
Ian D. Pavord, MD
Upon completion of this session, participants should be able to: Compare and contrast asthma and COPD; Define how asthma and COPD are assessed.
### Q & A Workshop

#### 5703 Diesel Exhaust Exposure and Children's Health
- **Time:** 3:30 to 4:45 pm
- **Location:** Convention Center, S330CD, Level III
- **Credit:** 1.25 CME / 1.50 CE
- **Moderator:** Andrew M. Smith, MD

- **3:30** New Insights from the Cincinnati Birth Cohort
  - David I. Bernstein, MD FAAAAI
- **3:45** Immunologic Mechanisms
  - Gurjit K. Khurana Hershey, MD PhD FAAAAI
- **4:00** Diesel Exhaust and Allergen Interactions
  - David Diaz Sanchez, PhD

- **4:15** Question & Answer

Upon completion of this session, participants should be able to: Discuss the most recent findings regarding the association between diesel exposure and wheezing in young children; Describe the interaction with DEP and allergens; Review the immunologic mechanisms by which diesel exposure promotes wheezing in young children.

#### 5704 Innate Immunity and Allergic Disease: Evidence and Controversies
- **Time:** 3:30 to 4:45 pm
- **Location:** Convention Center, S230CD, Level II
- **Credit:** 1.25 CME / 1.50 CE
- **Moderator:** Dale T. Umetsu, MD PhD FAAAAI

- **3:30** NK in Atopic Diseases: What is the Evidence?
  - Gunnur Deniz, MD
- **3:45** iNKT and Lipid Allergens: Their Role in Environmental and Food Allergies
  - Antonella Cianferoni, MD PhD
- **4:00** Macrophages: Which Role Do They Play in Asthma?
  - Mitchell H. Grayson, MD FAAAAI

- **4:15** Question & Answer

Upon completion of this session, participants should be able to: Describe the biology of NK, iNKT and macrophages; Describe the role of NK, iNKT and macrophages in allergic inflammation; Discuss the role macrophages play in asthma.

#### Panel Discussion Workshop

#### 5705 Mechanisms of Virus/Allergen Interactions
- **Time:** 3:30 to 4:45 pm
- **Location:** Convention Center, S230GH, Level II
- **Credit:** 1.25 CME / 1.50 CE
- **Moderator:** Peter W. Heymann, MD

- Pedro Avila, MD FAAAAI
- Michael Edwards, PhD
- Daniel J. Jackson, MD
- Nikolaos G. Papadopoulos, MD FAAAAI

Upon completion of this session, participants should be able to: Describe three potential mechanisms for virus/allergen interactions; Discuss the role of reducing IgE-mediated inflammation on viral outcomes in patients with asthma; Explain the three risk factors for virus-induced exacerbations of asthma.

### Q & A Workshop

#### 5706 Eosinophilic Esophagitis: Treatment Options
- **Time:** 3:30 to 4:45 pm
- **Location:** Convention Center, S230AB, Level II
- **Credit:** 1.25 CME / 1.50 CE
- **Moderator:** Neal Jain, MD FAAAAI

- **3:30** Dietary Elimination in EE Patients
  - Mirna Chehade, MD
- **3:45** Food Reintroduction
  - Katrina J. Allen, MD PhD
- **4:00** When Dietary Elimination is Not Enough: Prognosis
  - Jonathan M. Spergel, MD PhD FAAAAI

- **4:15** Question & Answer

Upon completion of this session, participants should be able to: Appreciate the complexity of food avoidance as a part of long-term therapy and highlight the evidence of the effectiveness of various protocols of dietary elimination; Gain insight into the methods used to reintroduce foods into the diet in EoE patients; Demonstrate what to do when dietary elimination is not enough.

#### 5707 Alternate Models of Anaphylaxis
- **Time:** 3:30 to 4:45 pm
- **Location:** Convention Center, S320CD, Level III
- **Credit:** 1.25 CME / 1.50 CE
- **Moderator:** Phillip L. Lieberman, MD FAAAAI

- **3:30** IgE and Non-IgE Mediated Models of Anaphylaxis
  - Fred D. Finkelman, MD
- **3:45** Anaphylaxis to Parasites
  - Thomas Nutman, MD
- **4:00** Anaphylaxis to Mammalian Meat After Tick Bites
  - Thomas A.E. Platts-Mills, MD PhD FAAAAI

- **4:15** Question & Answer

Upon completion of this session, participants should be able to: Explain the paradigm of IgE and non-IgE mediated anaphylaxis; Describe the relevance of invasive and ectoparasites in anaphylaxis.

#### 5708 Asthma Therapies and the FDA: Black Box Warning
- **Time:** 3:30 to 4:45 pm
- **Location:** Convention Center, S310ABFE, Level III
- **Credit:** 1.25 CME / 1.50 CE
- **Moderator:** Stephen A. Tilles, MD FAAAAI

- **3:30** The LABAs
  - Malcolm R. Sears, MD FAAAAI
- **3:45** Leukotriene Modifiers
  - Jay M. Portnoy, MD FAAAAI
- **4:00** Omalizumab and the FDA
  - William W. Busse, MD FAAAAI

- **4:15** Question & Answer

Upon completion of this session, participants should be able to: Discuss FDA labeling requirements for omalizumab; Discuss FDA warnings for montelukast; Discuss FDA warnings for LABAs.
Q & A Workshop

5709 Fundamentals of Clinical Research Studies: Principles and Processes
3:30 to 4:45 pm
Convention Center, S31CD, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Mary M. Kote, MD
3:30 Principles of Good Clinical Practice in Conducting Clinical Research Studies
Mary M. Kote, MD
3:45 Understanding the Basics in Managing Clinical Research Studies
Mark H. Moss, MD
4:00 Investigator and Study Site Responsibilities and Liability in Clinical Trials
Christine A. Sorkness, PharmD
4:15 Question & Answer
Upon completion of this session, participants should be able to: Describe the activities associated with conducting responsible clinical research studies and reporting the results; Describe the responsibilities of various members of the clinical research team and understand the concepts of institutional review, informed consent and financial disclosure; Develop knowledge about concepts and functions associated with insuring overall quality and ethics of clinical research studies.

Panel Discussion Workshop

5710 Is your Office Providing Optimal Allergen Immunotherapy?
3:30 to 4:45 pm
Convention Center, S310CDGH, Level III
Credit: 1.25 CME / 1.50 CE
Moderators: Richard F. Lockey, MD FAAAAI
Mark S. La Shell, MD
Bryan L. Martin, DO FAAAAI
Michael S. Tankersley, MD FAAAAI
Upon completion of this session, participants should be able to: Discuss the selection criteria one uses to select which patients might be the best candidates for immunotherapy, taking into account probability of success vs. risk of adverse events; Describe methods to improve clinic logistics, such as electronic records, tracking of stock vials and clinic supplies; Compare techniques for vial preparation used in one’s office/ clinic with the new guidelines on vials.

Q & A Workshop

5711 Experimental Models of Allergic Rhinitis: What is Their Clinical Relevance?
3:30 to 4:45 pm
Convention Center, S330EF, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Fuad M. Baroody, MD FAAAAI
3:30 Experimental Allergen Challenge Techniques in Allergic Rhinitis
Martin Wagenmann, MD FAAAAI
3:45 Utility of Environmental Exposure Units in Allergic Rhinitis
Anne K. Ellis, MD
4:00 Clinical Relevance of Allergen Challenges in the Therapy of Allergic Rhinitis
Alkis Togias, MD FAAAAI
4:15 Question & Answer
Upon completion of this session, participants should be able to: Describe the most commonly used methods of experimental nasal allergen challenge for the investigation of allergic rhinitis; Describe the methodology utilized in Environmental Exposure Unit type studies of allergic rhinitis; Identify the clinical relevance of both models with respect to the natural history/treatment of allergic rhinitis.

Q & A Workshop

5712 Anaphylaxis and Mastocytosis: The Spectrum of Clonal and Non-Clonal Systemic Mast Cell Activation
3:30 to 4:45 pm
Convention Center, S320AB, Level III
Credit: 1.25 CME / 1.50 CE
Moderator: Luis Escrivan, MD PhD FAAAAI
3:30 Mast Cell Activation and Signaling Pathways
Dean D. Metcalfe, MD FAAAAI
3:45 Immune Deficiency in Urticaria: New Molecular Understanding
Joshua D. Milner, MD
4:00 Mast Cell Mediators: Release and Systemic Consequences in Anaphylaxis and Mastocytosis
Melody C. Carter, MD
4:15 Question & Answer
Upon completion of this session, participants should be able to: Recognize the mechanisms and pathways through which mast cells get activated; Describe the genetic basis of mast cell disorders; Describe the clinical features and treatment of mast cell disorders.

BYOP Workshop

5714 Difficult Situations in Practice Management
3:30 to 4:45 pm
Convention Center, S330GH, Level III
Pre-registration and ticket required. No fee.
Credit: 1.25 CME / 1.50 CE
Moderator: Weily Soong, MD
Contracts
David A. Brown, MD
Adhuna C. Mathuria, MD
Hiring and Firing
Marshall P. Grodofsky, MD FAAAAI
Vinay Mehta, MD
Marketing
Paul M. Carter, MD, MHCM FAAAAI
Stanley M. Finehan, MD MBA FAAAAI
Upon completion of this session, participants should be able to: Identify and address difficult situations regarding employment and partnership contracts; Evaluate difficult situations in hiring and firing; Investigate difficult situations in marketing.
Scientific Abstract Sessions

Presidential Plenary

Next Generation Science

2101
Session Time: Saturday, March 3, 2012, 8:15 AM - 9:45 AM
1 A Mutation in the Human Uncoordinated 119 Gene Impairs TCR Signaling and is Associated with CD4 Lymphopenia
M. M. Gorska1,2, R. Alam1,2;
1National Jewish Health, Denver, CO, 2University of Colorado Denver, Aurora, CO.
2 Delayed Food Challenge Reactions Correspond Temporally to the Appearance of CD63+ Basophils in Subjects with IgE to alpha-Gal
S. Mozzicato1, H. R. James1, M. H. Land2, S. L. Pochan1, L. J. Workman1, T. A. E. Platts-Mills1, S. P. Commins1;
1University of Virginia, Charlottesville, VA, 2Duke University, Durham, NC.
3 Rapid Induction Of Tolerance To Peanut By Antigen-coupled Cell Transfer
C. Hsu, C. B. Smarr, A. J. Byrne, S. D. Miller, P. J. Bryce;
Northwestern University, Chicago, IL.
4 Increased FcεRI Expression on Basophils at Birth Predicts Subsequent Allergic Sensitization
D. J. Jackson, M. D. Evans, S. Sahu, R. E. Gangnon, J. E. Gern, R. F. Lemanske, Jr.;
University of Wisconsin School of Medicine and Public Health, Madison, WI.

Poster Session

Diagnostic and Monitoring in Asthma Management

2201
Session Time: Saturday, March 3, 2012, 9:45 AM - 10:45 AM
5 Bronchial Hyperresponsiveness in Sportschildren; Different methods to reach a diagnosis
Fundacion Jimenez Diaz, Madrid, Spain.
6 Probable Asthma Is Associated With Reduced Lung Function Among Recurrent Wheezing Infants
G. F. Wandalsen, F. C. Lanza, A. Dela Bianca, C. L. Cruz, D. Sole;
Federal University of Sao Paulo, Sao Paulo - SP, BRAZIL.
7 Mannitol Bronchoprovocation in the Evaluation of Airway Reactivity in a High-Risk Pediatric Cohort
A. Y. Okupa, D. J. Jackson, C. A. Sorkness, V. P. Rajamanickam, T. J. Kang, I. A. Awoyinka, E. L. Anderson, R. F. Lemanske, Jr;
University of Wisconsin, Madison, WI.
8 Comparison Between Methacholine And Mannitol Tests For The Study Of Bronchial Hyperresponsiveness In Asthma Induced By Exercise In Pediatric Athletes
M. Andregnette, M. Fernandez Nieto, L. Arochena, M. Garcia Del Potro, E. Aguado, J. Sastre;
Fundacion Jimenez Diaz, Madrid, Spain.
9 Association between Atopy and Bronchial Hyperresponsiveness in Preschool children with Recurrent Wheezing
J. Lee, D. Suh, Y. Koh;
Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.
10 Is Methacholine Challenge Sufficient To Rule Out Bronchial Hyperresponsiveness In Patients With Suspected Asthma?
La Paz Hospital, Madrid, SPAIN.
11 Mannitol Challenge for Diagnosis of Exercise-Induced Bronchoconstriction: Experience in Practice
C. C. Randolph1,2, C. Kaplan1, M. Randolph1, S. Asevica1;
1Center for Allergy, Asthma & Immunology, Waterbury, CT, 2Yale Univ Medical Center, New Haven, CT.
12 Exercise-Induced Bronchoconstriction in Thai Pediatric Asthma: Prevalence and Risk Factors
U. Yinsuwan;
Queen Sirikit National Institute of Child Health, Bangkok, THAILAND.
13 Usefulness Of Impulse Oscillometry In Children With Eosinophilic Bronchitis
Y. Kim1, K. Kim1, J. Baek1, H. Park1, H. Lee2, M. Sohn3, K. Kim1;
1Department of Pediatrics and Institute of Allergy, Severance Bio medical Science Institute, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF; 2Kwandong University College of Medicine, Goyang, KOREA, REPUBLIC OF.
14 Eucapnic Voluntary Hyperventilation Screen for Bronchospasm Risk During a SCUBA Dive
R. R. Rosenthal;
Johns Hopkins School of Medicine, Baltimore, MD.
15 BMI Does Not Correlate with PFTs in Asthma Screening
L. A. Wiens;
BreatheAmerica, Tulsa, OK.
16 Patterns of Aeroallergen Sensitization and Development of Spumus Eosinophilia and Airway Hyperresponsiveness
S. Kim1,2, W. Song1,2, T. Kim3, S. Lee2, H. Kang2, H. Park2, S. Kim4, Y. Chang1,2, S. Cho5, K. Min3;
1Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF; 2Department of Internal Medicine, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF.
17 Pitfalls In The Diagnosis Of Allergic Bronchopulmonary Aspergillosis In Patients With Asthma In Real Clinical Practice
S. Lee, M. Park, K. Kim, Y. Nam, H. Lee, I. Jeong, S. Park, S. Um, C. Son;
Dong-A University, Busan, KOREA, REPUBLIC OF.
18 A rare case of Allergic Bronchopulmonary Mycosis secondary to Penicillium
K. Zakarian, S. Min, P. Huynh, L. Scott;
LAC-USC, Los Angeles, CA.
19 Genetics of Asthma Exacerbations: A Candidate Gene and Genome-Wide Association Study
H. G. Ortega, L. Huang, B. Koshy, S. Sinnett, M. Mosteller, W. Anderson;
GlaxoSmithKline, Research Triangle Park, NC.
20 Changes in Prevalence with Different Definitions of a “Positiv e” Skin Test
J. Wildfire1, S. Arbes1, P. Gergen2;
1Rho, Inc, Chapel Hill, NC, 2National Institute of Allergy and Infectious Diseases, Bethesda, MD.

21 Cord Blood Proliferative Response As A Predictive Factor For Atopic Dermatitis At 6 Months of Age
1Inje University Sanggye Paik Hospital, Seoul, KOREA, REPUBLIC OF, 2University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, 3Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF, 4Inje University Haeundae Paik Hospital, Busan, KOREA, REPUBLIC OF, 5Sanggyeunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF, 6Inje University Seoul Paik Hospital, Seoul, KOREA, REPUBLIC OF, 7College of Medicine, Korea University, Seoul, KOREA, REPUBLIC OF, 8Hallym University College of Medicine, Seoul, KOREA, REPUBLIC OF, 9Ajou University School of Medicine, Suwon, KOREA, REPUBLIC OF, 10National Health Insurance Corporation Ilsan Hospital, Ilsan, KOREA, REPUBLIC OF, 11Yonsei University, Seoul, KOREA, REPUBLIC OF, 12CHA University School of Medicine, Seoul, KOREA, REPUBLIC OF.

22 Allergic Airways Responses Are Associated With A Late-phase Systemic Inflammatory Response In An Environmental Allergen Challenge Model
E. N. Torjusen1, S. Biswal2, M. Ong3, B. Thomas, S. Noel4, G. Diette5, P. Breysee6, E. Matsui7, B. Kim12, S. Hong12;
1University of Wisconsin, Madison, WI, 2Department of Pediatrics, Presbyterian Scottsdale Healthcare, Scottsdale, AZ, 3Department of Pediatrics, Purcellville, VA, 4Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, 5Department of Pediatrics, Children’s National Medical Center, Washington, DC, 6Department of Pediatrics, Oregon Health and Science University, Portland, OR, 7Department of Pediatrics, University of Toronto, Toronto, ON.

23 Real Time Pcr Detection Of Aspergillus Fumigatus, Aspergillus Flavus And Aspergillus Niger Based On Polyclonal Synthese Gene
1Indiana University School of Medicine, Indianapolis, IN, 2University of Maryland Medical Center, Baltimore, MD, 3University of Virginia, Charlottesville, VA, 4Milwaukee Children’s Hospital, Milwaukee, WI, 5Medical College of Wisconsin, Milwaukee, WI.

24 Asthma Phenotypes in School-aged Children from the Population Study: Cluster Analysis
J. Kwon1, J. Seo2, H. Kim3, B. Kim4, H. Kim5, S. Lee6, K. Park8, S. Hong9;
1Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF, 2Department of Pediatrics, Asan Medical Center, Seoul, KOREA, REPUBLIC OF, 3Department of Pediatrics, Haeundae Paik Hospital, Inje University College of Medicine, Busan, KOREA, REPUBLIC OF, 4Department of Pediatrics, Hallym University Sacred Heart Hospital, Suwon, KOREA, REPUBLIC OF, 5Department of Pediatrics, Presbyterian Medical Center, Jeonju, KOREA, REPUBLIC OF.

25 Ectoparasite Induced Elevations of alpha-gal Specific IgE are Associated with Increased Total Serum IgE and Cat Sensitization but not with Asthma
1University of Virginia, Charlottesville, VA, 2University of Maryland Medical Center, Baltimore, MD, 3University of South Florida, Tampa, FL.

26 Helicobacter Pylori, A Protective Agent For Asthma Or Not?
C. Camacho1, J. Santiago, V. Velazquez2, M. Gonzalez, A. Sepulveda, J. Ramos;
1Hospital Episcopal San Lucas, Ponce, PR, 2Hospital Episcopal San Lucas, Ponce, PR.

27 The Role of Atopy as a Predictor of Childhood Atopic Asthma
S. Abbott, R. Green, C. Els;
University of Pretoria, Pretoria, SOUTH AFRICA.

28 Assessment of Repeated Measures of Fractional Exhaled Nitric Oxide in Clinically Stable Persistent Asthma
A. Elizalde1, R. J. Khan, S. Chirnhattanapitik, M. J. Dorsey;
1University of South Florida, Saint Petersburg, FL.

29 Identification of Vocal Cord Dysfunction by Methacholine Laryngoscopy Reduces Inhaled Corticosteroid and Rescue Inhaler Use in Children and Adults
J. S. Tam1, N. L. Hartog2, K. Divine3, M. Dasgupta4, R. K. Hoffman1, M. Vasudev5;
1Medical College of Wisconsin, Milwaukee, WI, 2University of Iowa, Iowa City, IA.

30 Asthma In The Elderly: The Role Of Exhaled Nitric Oxide Measurements
M. Colombo1, B. Wong2, R. A. Panettieri, Jr.3, A. S. Rohr1;
1Asthma, Allergy and Immunology Specialists, Bryn Mawr, PA, 2Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, 3Pulmonary, Allergy and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA.

31 Intratropium Normalizes FEV1 Following Methacholine Challenge in Patients Diagnosed with Vocal Cord Dysfunction
Medical College of Wisconsin, Milwaukee, WI.

32 Gastroesophageal Reflux in Patients with Chronic Cough
R. Agondo1, J. Kalil, P. Giavani-Bianchi;
1University of Sao Paulo, Sao Paulo, BRAZIL.

33 Development and Preliminary Validation of the Asthma Intensity Manifestations Score (AIMS) Derived from Asthma Control Test, FEV1, Exhaled Nitric Oxide, and Step Therapy Assessments
M. Schatz, R. Zeiger, F. Zhang, W. Chen;
Kaiser Permanente, San Diego, CA.

34 The Role Of Induced Sputum Cytology In Clinical Monitoring Of Childhood Asthma
Z. Tamay1, B. Kucukemre Aydin2, G. Kilic3, A. Suleyman4, F. Aydin5, D. Yilmazbayan6, N. Gul7;
1Istanbul University, Istanbul Medical Faculty, Department of Pediatric Allergy, Istanbul, TURKEY, 2Istanbul University, Istanbul Medical Faculty, Department of Pediatrics, Istanbul, TURKEY, 3Bursa Dortcelik Cocuk Hastanesi, Bursa, TURKEY, 4Istanbul University, Istanbul Medical Faculty, Department of Pediatrics, Istanbul, TURKEY, 5Istanbul University, Istanbul Medical Faculty, Department of Pathology, Istanbul, TURKEY.

35 A Retrospective Analysis of Distinguishing Features Between Asthma and Vocal Cord Dysfunction
R. S. Traister1, E. Whitman, W. C. Anderson, D. P. Landsittel, M. Fajt, A. A. Petrov;
University of Pittsburgh Medical Center, Pittsburgh, PA.

36 Phenotypes of Rhinitis and Difficult Asthma
J. Cuy3YMAI_scientificsectionJCuy36January2012JCuy31:32am

37 Sprouty2 is a Novel Regulator of T cell Activation and Differentiation
L. Guo1, C. Chen1, M. Gorska1,2, R. Alam1,2;
1Transylvania University Brasov, Faculty of Medicine, Brasov, ROMANIA, 2SC Theramed SRL, Brasov, ROMANIA.

Poster Session
Immune Cells

Session Time: Saturday, March 3, 2012, 9:45 AM - 10:45 AM

2202 Sprouty2 is a Novel Regulator of T cell Activation and Differentiation
L. Guo1, C. Chen1, M. Gorska1,2, R. Alam1,2;
**Stat5b (Signal Transducer and Activator of Transcription 5b), Not Stat5a, Is a Critical Modulator of Human Treg Development and Function**

J. Jenks, S. Seki, J. Huang, R. Nath, M. Madmedov, V. Hwa, R. Rosenfeld, K. C. Nadeau; Stanford University School of Medicine, Stanford, CA.

Hyperthermia enhances Th1 differentiation and downregulates FOX3 expression in Tregs

D. Q. Tran, J. M. Bull; University of Texas Medical School at Houston, Houston, TX.

**Critical Role Of T Follicular-helper Cells In B Cell Autoimmunity During Lymphopenia**

M. Imamura1, T. Kanzaki1, K. Kawahata1, L. Akahira1, K. Michishita1, T. Eri1, M. Dohi1, T. Tokuhisa2, K. Yamamoto1;

the University of Tokyo, Tokyo, JAPAN, 

1Chiba University, Chiba, JAPAN.

Per a 10 Protease Activity Induces Th2 Polarization That Is Amplified By Allergic Status

N. Araoa1, C. Goel1, N. Kala2, B. S. Dwarkanath2, S. N. Gaur3; 

1Institute of Genomics and Integrative Biology, Delhi, INDIA, 

2Institute of Nuclear Medicine and Allied Sciences, Delhi, INDIA, 

Vallabhba Patell chest Institute, Delhi, INDIA.

IgE and Atopy Are Associated With Phosphorylated P38 MAPK Expression By CD4 and CD8 T Lymphocytes

J. I. Silverberg1, H. G. Durkin2, R. Joks3;

1St Lukes-Roosevelt Hospital Center, New York, NY, 

2State University of New York Downstate Medical Center, Brooklyn, NY.

Regulatory T cell regulation by STAT5B

T. Kanai, S. Seki, J. Jenks, K. Nadeau;

Stanford University, stanford, CA.

The Effect Of Phototherapy On Lymphocyte Subsets In Newborn Infants

R. A. A. ELFeky1, M. A. Abdel Fattah1, D. M. Gafaar1, H. M. Afifi2;

1Pediatric Department Ain Shams University, Cairo, EGYPT, 

2Clinical Pathology Department,Ain Shams University, Cairo, EGYPT.

CD27 Developing B Cells are Common in Human Fetal Liver

L. M. McWilliams, K. Y. Su, X. Liang, S. Floyd, J. Amos, M. Moody, G. Kelsoe, M. Kuraoka;

Duke University Medical Center, Durham, NC.

Intravenous Immunoglobulins Suppress Antibody-Dependent Effector Functions of Human Peripheral Blood Cells

S. Bunk, A. Trbic, A. M. Winkler, A. Weber, H. P. Schwarz, B. M. Reipert, C. Hermann;

Baxter BioScience, Vienna, AUSTRIA.

Physiologic DNA Breaks Activate Non-canonical NFkB Signaling in Developing B Cells

A. A. Trott, J. J. Bednarski, B. P. Sleckman;

Washington University School of Medicine, St. Louis, MO.

Phenotypic Characterization Of Immune Cells Isolated From Adenoids And Tonsils Of Children With Adenoid And Tonsil Hypertrophy

L. P. Titov1, A. M. Dashkevich1, V. L. Chekan2, L. M. DuBuske3;

1Research Institute for Epidemiology and Microbiology, Minsk, BELARUS, 

2Republica Scientific-and-Practical Center for Epidemiology and Microbiology, Minsk, BELARUS, 

3Immunology Research Institute of New England, Gardner, MA.

B Cell Phenotype in Patients with Common Variable Immunodeficiency (CVID) and its Relation to their Clinical Characteristics

A. M. Kahn1, G. Luque1, G. Gatti2, M. Maccioni2, J. J. Garcia1, E. Cuestas1, A. Basquin2, B. Ricci1, V. E. Rivero3;

1Hospital Privado, Cordoba, ARGENTINA, 

2Centro de Investigaciones en Bioquimica Clinica e Immunologia (CIBICI-CONICET), 

Facultad de Ciencias Quimicas, Universidad Nacional de Cordoba, Cordoba, ARGENTINA.

Altered Frequency And Composition Of Cultured Natural Killer Cells From Food Allergic Subjects

A. Bhatt, L. Ford, M. Masilamani, H. Sampson;

Mount Sinai Medical Center, New York, NY.

**Poster Session**

**Biologic Therapy, Immunoglobulin Replacement**

**Biologic Therapy, Immunoglobulin Replacement**

**Biologic Therapy, Immunoglobulin Replacement**

Glycine vs. L-Proline Stabilization of IGIV Solution: 18-Month Follow-up Data to Support Equally Effective Stabilization

A. K. Sun1, Y. Wu1, G. Pot1, E. Vandamme1, W. Teschner1, H. P. Schwarz2;

1Baxter Healthcare Corporation, Los Angeles, CA, 

2Baxter Healthcare Corporation, Westlake Village, CA.

Home Care Use of Intravenous and Subcutaneous Immunoglobulin for Primary Immunodeficiency in the United States F. Huang, C. Cunningham-Rundles;

Mount Sinai School of Medicine, New York, NY.

Factors Affecting Infusion of High (20%) vs Lower Concentration (16%) SCIg in Primary Immunodeficiency Disorders

Z. Panahloo1, S. Jolles2;

1CSL Behring Ltd, Haywards Heath, UNITED KINGDOM, 

2University Hospital of Wales, Cardiff, UNITED KINGDOM.

Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (Ighy) in a Subset of Patients with Primary Immunodeficiency Disease (PIDD)

M. Stein1, R. L. Wasserman1, I. Melamed2, J. Puck3, S. Gupta3, W. Eng3, H. Leib3, D. Gelmont3, R. I. Schiff, on behalf of IGSC, 10% rHuPH20 Study Group4;

1IMMUNOe, Centennial, CO, 

2Dallas Allergy Immunology, Dallas, TX, 

3Allergy Associates of the Palm Beaches, North Palm Beach, FL, 

4University of California, San Francisco, CA, 

5University of California, Irvine, CA, 

6Baxter BioScience, Vienna, AUSTRIA, 

7Baxter BioScience, Westlake Village, CA.

Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (Ighy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD)

R. L. Wasserman1, I. Melamed2, M. Stein3, J. Puck4, S. Gupta5, W. Eng6, H. Leib6, D. Gelmont7, R. I. Schiff on behalf of IGSC, 10% rHuPH20 Study Group8;

1Dallas Allergy Immunology, Dallas, TX, 

2Allergy Associates of the Palm Beaches, North Palm Beach, FL, 

3University of California, San Francisco, CA, 

4University of California, Irvine, CA, 

5Baxter BioScience, Vienna, AUSTRIA, 

6Baxter BioScience, Westlake Village, CA.

Subcutaneous Hizentra® (20%) Is Better Tolerated And Shares Similar Efficacy Compared To Subcutaneous Vivaglobin® (16%)

D. Nguyen, M. Dorsey, T. Alberdi, C. Duff, J. Sleasman;

University of South Florida/All Children’s Hospital, St. Petersburg, FL.
SATURDAY

58 Targeting IL-18 by Employing a Recombinant IL-18 Peptide-based Vaccine Ameliorates TNBS-induced Murine Acute and Chronic Colitis
S. Moreno, Q. Guan, C. Weiss, Q. Gefei, C. Bernstein, Z. Peng; University of Manitoba, Winnipeg, MB, CANADA.

59 In Patients With Hereditary Angioedema, Self-administration Of Intravenous C1 Esterase Inhibitor Decreases The Number Of Days Spent In An Emergency Room
C. Rizk1, S. Santschi2, S. McDermid2, J. Kaspar1, W. H. Yang1; 1University of Ottawa, Ottawa, ON, CANADA, 2Yang Medicine, Ottawa, ON, CANADA.

60 IgG Trough Levels are Poor Predictors of Infectious Outcomes in Pediatric Patients on Immunoglobulin Replacement
M. Mahendra1, S. McGhee2; 1UCLA, Westwood, CA, 2Stanford University, Palo Alto, CA.

61 Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Two Infants with Immunodeficiency
J. L. Gallagher, N. C. Patel; Carolinas Medical Center, Charlotte, NC.

62 Desensitization Approach Using High-Concentration Subcutaneous Immunoglobulin in a Bruton’s-Like Patient With a Previous Anaphylactic Reaction to Intravenous Immunoglobulin
T. Prince, M. Gettys; The Allergy Asthma and Sinus Center, Maryville, TN.

63 Immunoglobulin Replacement Therapy: A 20 Year Review and Current Update
M. Saeedian1, I. Randhawa2; 1UCLA, Los Angeles, CA, 2UC Irvine, Miller Children’s Hospital, Irvine, CA.

Poster Session

Bioaerosols

2204 Session Time: Saturday, March 3, 2012, 9:45 AM - 10:45 AM

64 Exposure to Smaller-Sized Fungal Fragments in Homes with a Childhood Asthmatic
S. Seo1, Y. Cho1, J. Choi1, Y. Yoo2, D. Kim3, J. Choung2; 1Korea University, Seoul, KOREA, REPUBLIC OF, 2Korea University Medical Center, Seoul, KOREA, REPUBLIC OF, 3Department of Public Administration, North Carolina Central University, Durham, NC.

65 Effect of meteorological parameters on airborne fungal spore counts: Sixteen Year Study (1995-2010) in Sarasota, FL

66 Profiling of Endotoxin Induced Immune Regulatory Network in Ovalbumin Sensitized Mice
S. Kumar, E. Kettleson, M. T. Borchers, J. Chakrabarti, T. Repo nen, S. A. Grinshpun, A. Adhikari; University of Cincinnati, Cincinnati, OH.

67 Airborne Fungus Diversity and Concentrations in Inner City Elementary Schools
S. N. Bax1, W. J. Sheehan1, P. Permaul1, J. M. Gaffin1, D. Rao1, C. Fu1, C. Rogers4, M. Mullenberg5, E. B. Hoffman1, D. R. Gold6, W. Phitapanakul1; 1Children’s Hospital Boston, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Channing Laboratory, Boston, MA, 4University of Massachusetts, Amherst, MA, 5Harvard School of Public Health, Boston, MA, 6Brigham and Women’s Hospital, Boston, MA.

68 Evaluation Of The Proinflammatory Activity Of Basidiomycetes And Spore-bearing Tissues From The Mushroom Chlorophy lum Molybdites Using Human Whole Blood
F. E. Rivera-Mariani, T. Hartung, P. N. Breyssse; Johns Hopkins University, School of Public Health, Baltimore, MD.

69 Inactivation of Stachybotrys Antigen by Mold Remediation Chemicals
A. Dixit, B. R. Tumala; Saint Louis University School of Medicine, St. Louis, MO.

70 Differences of Indoor Endotoxin Levels from South Florida versus Latin American Bedrooms of Hispanic/Latino Children
M. J. Lanz1, B. Eifaw2, R. Harbeck2, A. H. Liu3; 1AAADRS, Coral Gables, FL, 2National Jewish Health, Denver, CO.

71 Metagenomic Analysis Of Bacteria And Bacteria-derived Nanovesicles Collected From Indoor Dust
Y. Kim1, Y. Jee1, Y. Gho1, Y. Kim1; 1POSTECH, Pohang/Gyangbuk, KOREA, REPUBLIC OF, 2Dankook University College of Medicine, Cheonan, KOREA, REPUBLIC OF.

Urban Allergen and Pollutant Exposures

2205 Session Time: Saturday, March 3, 2012, 9:45 AM - 10:45 AM

72 Ambient Air Pollution and Allergic Sensitization: Results from the National Health and Examination Survey (NHANES) 2005-2006
C. Weir1, K. Yeatts1, W. Vizueta1, S. London2, P. M. Salo2, R. Jar anillo1, D. Zeldin4; 1Univ of North Carolina Chapel Hill, Chapel Hill, NC, 2National Institute of Environmental Health Sciences, Research Triangle Park, NC, 3SRA International Inc., Durham, NC, 4National Institute of Environmental Health Sciences, Durham, NC.

73 Time Trends In Residential Indoor Polycyclic Aromatic Hydrocarbon Exposures Among Inner City Children
S. Hasan1, K. H. Jung2, S. Hsu2, K. Moors3, B. Yan3, P. L. Kinney4, S. Chilrud5, R. Whyatt1, D. Camann1, F. P. Perera1, R. L. Miller1; 1Department of Medicine, Columbia Presbyterian Medical Center, New York, NY, 2Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, College of Physicians and Surgeons, New York, NY, 3Lamont-Doherty Earth Observatory, Columbia University, New York, NY, 4Columbia Center for Children's Environmental Health, Mailman School of Public Health, Columbia University, New York, NY, 5Chemistry and Chemical Engineering Division, Southwest Research Institute, San Antonio, TX.

74 Urban Heat And Humidity Indices And The Preferential Deposition Of Airborne Pollen
P. K. Van de Water1, L. Bunderson1, J. Luvall1, E. Levetin3; 1California State University Fresno, Fresno, CA, 2University of Tulsa, Tulsa, OK, 3Marshall Space Flight Center, Huntsville, AL.

75 Risks Factors for Exercise-Induced Wheeze Among Asthmatics in NYC Include Neighborhood Asthma Prevalence and Differ by Serotype
T. Mainardi1, A. Cornell2, L. Acosta1, I. Goldstein4, A. Rundle4, R. Mellins1, L. Hoeper1, F. Perera1, J. Jacobson1, R. Miller1, M. Perzanowski1;
Seasonal Variation of Pollen and Spore Counts Does Not Influence Severity of Sleep Apnea
S. Cajigal, V. Krishnan;
MetroHealth Medical Center, Cleveland, OH.

\[\text{Poster Session}\]

\textbf{Food Allergy I-Diagnosis and Treatment}

\textbf{2206}
Session Time: Saturday, March 3, 2012, 9:45 AM - 10:45 AM

\textbf{77} The Role Of Skin Prick Testing And Specific IgE To Boiled Versus Unheated Cow Milk In Cow Milk Allergic Children
J. C. Hong, A. P. Knutsen;
Saint Louis University, Saint Louis, MO.

\textbf{78} Characterization Of Immunologic Parameters In Children With Variable Milk Protein Tolerance
A. H. Nowak-Wegrzyn, E. Strong, M. Groetch, H. A. Sampson;
Mt. Sinai School of Medicine, New York, NY.

\textbf{79} Case-specific Regulatory T Cells and Effector T Cells in Patients with Variable Milk Protein Tolerance
J. D. Kattan, A. Nowak-Wegrzyn, M. Musliamani, A. O. Bhatt, H. A. Sampson;
Mount Sinai School of Medicine, New York, NY.

\textbf{80} Predicting Food Challenge Outcomes for Baked Milk: Role of Specific IgE and Skin Prick Testing
L. M. Bartnikas, W. J. Sheehan, L. C. Schneider, W. Pipatanakul;
Children’s Hospital Boston, Boston, MA.

\textbf{81} Risk Factors for Persistence of IgE-Mediated Cow’s Milk Allergy
A. Elizur\(^1\), N. Rajukan\(^1\), M. R. Goldberg\(^1\), M. Leshno\(^1\), A. Cohen\(^1\), Y. Katz\(^1\);
\(^1\)Allergy and Immunology Institute, Asaf Harofeh Medical Center, Sackler School of Medicine, Tel Aviv University, Zerifin, ISRAEL, \(^2\)Department of Pediatrics, Asaf harofeh Medical Center, Zerifin, ISRAEL, \(^3\)Faculty of Management, Tel Aviv University, Tel Aviv, ISRAEL.

\textbf{82} Role Of Egg-white-specific Iga And Iga2 Levels In Egg Allergy: A Longitudinal Cohort Study
G. N. Konstantinou, A. Nowak-Wegrzyn, L. Bardina, S. H. Sichrer, H. Sampson;
Elliot and Roslyn Jaffe Food Allergy Institute, Division of Allergy and Immunology, Department of Pediatrics, Mount Sinai School of Medicine, New York, NY.

\textbf{83} Ovalbumin and Ovomucoid IgE/IgG4 Epitopes in Patients Ingesting Baked Egg Products by Peptide Microarray Immunoassay
Mount Sinai School of Medicine, New York, NY.

\textbf{84} Identifying Characteristics in Egg-Allergic Subjects to Predict Heated Egg Tolerance: A Retrospective Review
N. U. Swamy\(^1\), M. Crain\(^1\), J. A. Bird\(^1\);
\(^1\)UT Southwestern Medical Center, Dallas, TX, \(^2\)Children's Medical Center, Dallas, TX.

\textbf{85} Association To Other Food Allergies And Persistence Of IgE-mediated Hen’s Egg Allergy
F. J. Ruano, N. Blanca-Lopez, M. Gacimartin, M. Vazquez de Lara Torre, E. Seoane, G. Canto;
Hospital Infanta Leonor, Madrid, Spain.

\textbf{86} Baked Egg Food Challenges - Clinical Outcomes And Determination Of Negative And Positive Predictive Values For Skin Test To Baked Egg And Ovomucoid
Children’s Hospital at Westmead, Westmead, Sydney, AUSTRALIA.

\textbf{87} Development of a National Guideline for the Diagnosis of Cow’s Milk Allergy (CMA) in The Netherlands
B. J. Vlieg-Boerstra\(^1\), C. Wensing\(^1\), Y. Meijer\(^1\), T. Kuijpers\(^1\), H. Silvius\(^1\), M. Luning\(^1\), E. de Vries\(^2\), T. Hendriks\(^3\), C. M. F. Kneepkens\(^4\), A. B. Sprinkelman\(^5\);
\(^1\)Emma Children’s Hospital, Academic Medical Center, Amsterdam, NETHERLANDS, \(^2\)Baby Health Clinic, Lisse, NETHERLANDS, \(^3\)Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, NETHERLANDS, \(^4\)Dutch Institute for Healthcare Improvement CBO, Utrecht, NETHERLANDS, \(^5\)General Practice Bosbuizen, Leiden, NETHERLANDS, \(^6\)Dutch College of General Practitioners, Utrecht, NETHERLANDS, \(^7\)Jeroen Bosch Hospital, ’s-Hertogenbosch, NETHERLANDS, \(^8\)Catharina Hospital, Eindhoven, NETHERLANDS, \(^9\)VU Medical Center, Amsterdam, NETHERLANDS.

\textbf{88} Predicting Positive Food Challenges at the Introduction of Nuts in Sensitised Children
S. W. Ludman\(^1\), P. Ballabeni\(^1\), M. Hofer\(^1\), P. A. Eigenmann\(^1\), J. Wassenberg\(^1\);
\(^1\)Division of Allergology, Immunology and Rheumatology, Department of Pediatrics, University Hospital, Lausanne, SWITZERLAND, \(^2\)Institute of Social and Preventive Medicine, University Hospital, Lausanne, SWITZERLAND, \(^3\)Paediatric Allergology, University Hospitals, Geneva, SWITZERLAND.

\textbf{89} The Prevalence of Clinical Cross-reactivity of Non-peanut Legumes to Peanut in Patients with Persistent Peanut Allergy
D. L. Neuman-Sunshine\(^1\), J. A. Eckman\(^2\), C. A. Keet\(^1\), E. C. Matsui\(^1\), R. D. Peng\(^1\), P. J. Lenehan\(^1\), R. A. Wood\(^1\);
\(^1\)The Johns Hopkins University School of Medicine, Department of Medicine, Division of Allergy and Immunology, Baltimore, MD, \(^2\)University of Cincinnati, Department of Internal Medicine, Division of Immunology, Cincinnati, OH, \(^3\)The Johns Hopkins University School of Medicine, Department of Pediatrics, Division of Allergy and Immunology, Baltimore, MD, \(^4\)The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

\textbf{90} Evaluation of Oral Food Challenges With Hazelnut And Actual Reinroduction Of Hazelnut In The Diet After Negative OFC
N. W. De Jong\(^1\), N. Tizirkan\(^1\), H. F. J. Savelkoul\(^2\), R. Gerth van Wijk\(^1\);
\(^1\)ErasmusMC, Rotterdam, NETHERLANDS, \(^2\)Wageningen University, Wageningen, NETHERLANDS.

\textbf{91} Milk And Egg Allergy In Adulthood
Hospital General Universitario Gregorio Maranon, Madrid, SPAIN.

\textbf{92} Cellular and Serologic Profiling of Adults with Peanut Allergen Sensitization
Johns Hopkins Hospital, Baltimore, MD.
93 The Effects of CCR9+ and CD103+ Dendritic Cells on Regulatory T-cells in Food Allergy
M. A. Garcia, K. Nadeau;
Stanford University, Stanford, CA.

94 Relationship of Cytokine and Regulatory Gene Expression to the Outcomes of Milk and Egg Allergy in an Atopic Cohort (COFAR2)
S. H. Sicherrerr1, D. Stablein2, R. A. Wood3, A. W. Burks4, A. H. Liu5, S. M. Jones6, D. M. Fleischer7, L. Mayer1, R. Lindblad8, A. Grishin9, H. A. Sampson1, 2, for the Consortium of Food Allergy Research1.

95 Oral Immunotherapy for Egg Allergy Clinical and Immunologic Results
G. B. Pajno, L. Caminiti, D. Vita, G. Crisafulli;
University of Messina, Messina, ITALY.

96 Milk Oral Immunotherapy: A Single-Center Pilot Study of Safety and Efficacy
R. W. Saltzman1, M. Kelleher1, T. Brown-Whitehorn1, J. Fiedler1, J. Corry1, L. Gobe1, E. Dudek2, A. Cianferoni1,2, J. Spergel1,2; 1Children’s Hospital of Philadelphia, Philadelphia, PA, 2The Children’s Hospital of Philadelphia Research Institute, Philadelphia, PA.

97 Milk Oral Desensitization: Role of Invariant Natural Killer T Cells (iNKTs)
F. Saretta1, R. W. Saltzman2, V. Abraham3, E. Dudek2, J. Spergel2, A. Cianferoni2; 1University of Udiine, Pediatric Department, Udine, ITALY, 2The Children’s Hospital of Philadelphia, Division of Allergy and Immunology, Philadelphia, PA.

98 Clinical Follow-Up After An Oral Induction Tolerance Protocol with Cow Milk: 4 Years Later
M. Reche Frutos, T. Valbuena, A. Padial, C. Pascual; Hospital Infantia Sofia, San Sebastian de los Reyes, SPAIN.

99 Rush Oral Immunotherapy For Wheat-induced Anaphylaxis In Japan
T. Utsunomiya, T. Imai, K. Ogura, M. Goto, K. Iikura, Y. Koike, K. Otani, S. Sato, A. Shukuya, M. Ebisawa; Sagamihara National Hospital, Sagamihara, JAPAN.

100 Baked Proteins In The Management Of Cow’s Milk And Egg Allergic Children, Less Than 2 Years Of Age: Are Infants At Increased Risk Of Breakthrough Reactions?
M. I. Kidon1,2, M. Deutch1, M. Yaron1, A. Goren1, A. Siedletzki1, S. Steinberg1, A. Reshef2; 1Sheba Medical Center, Tel Hashomer, ISRAEL, 2Children’s Health Center, “Clalit” Health Services, Rishon Lezion, ISRAEL.

101 Induction of Regulatory T Cells After Peanut Sublingual Immunotherapy
E. Kim1, M. Kulis2, B. Vickery2, A. Burks2; 1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Duke University Medical Center, Durham, NC.

102 A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual versus Oral Immunotherapy for the Treatment of Peanut Allergy
S. D. Nariset1, C. Keet1, P. Guerriero1, J. Schroeder2, R. Hamilton2, R. A. Wood1; 1Department of Pediatrics, Division of Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Medicine, Division of Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, MD.

103 Early Intervention with Oral Immunotherapy is a Promising Strategy for the Treatment of Peanut Allergy
B. P. Vickery, P. Steele, J. Kamilaris, A. Edie, M. Kulis, A. Burks; Duke University, Durham, NC.

104 A Phase 1 Study of Heat/Phenol Killed, E. coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the Treatment of Peanut Allergy
R. Wood1, D. Stablein2, A. Henning3, R. Lindblad4, S. Sicherrerr5; 1Johns Hopkins University, Baltimore, MD, 2Emmes Corporation, Rockville, MD, 3Mount Sinai School of Medicine, New York, NY.

105 Peanut Oral Immunotherapy and Omalizumab Treatment for Peanut Allergy
M. Henson, A. Edie, P. Steele, J. Kamilaris, M. Kulis, A. Thyagarajan, B. P. Vickery, A. W. Burks; Duke University School of Medicine, Durham, NC.

106 Measurement of the Eliciting Dose Threshold at Baseline is Useful for Establishing the Starting Dose in Peanut Oral Immunotherapy (OIT)
J. A. Bird1, A. Clark2, M. G. Crain2, A. Arneson2; 1UT Southwestern Medical Center, Dallas, TX, 2Children’s Medical Center, Dallas, TX.

107 A Prospective, Randomized, Case Controlled Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associatd with Peanut Desensitization in Children with Peanut Allergies
N. Berlin1, S. Maclachlan1, N. Leader1, D. Penn2, G. Sussman3,4; 1Gordon Sussman Clinical Research Inc., Toronto, ON, CANADA, 2Mast Cell Pharmaceuticals Inc., Raleigh, NC, 3University of Toronto, Toronto, ON, CANADA.

108 Oral Food Immunotherapy: Protective Doses Reached Within Two Months
M. B. Levy, M. R. Goldberg, M. L. Stein, A. Elizur, L. Nachshon, Y. Katz; Assaf Harofe Medical Center, Zrifin, ISRAEL.

109 Classification, Prevalence and Outcomes of Non-IgE Mediated Reactions to Oral Food Immunotherapy
M. L. Stein1, M. B. Levy1, M. R. Goldberg1, G. Hermann2, E. Broide1, A. Elizur1, L. Nachshon1, Y. Katz1; 1Allergy and Clinical Immunology Institute, Assaf-Harofeh Medical Center, Zrifin, ISRAEL, 2Pathology Institute, Assaf-Harofeh Medical Center, Zrifin, ISRAEL, Gastroenterology Institute, Assaf-Harofeh Medical Center, Zrifin, ISRAEL.

110 Participation in Peanut Oral Immunotherapy Improves Quality of Life
J. S. Kamilaris, P. H. Steele, M. D. Kulis, A. H. Edie, B. P. Vickery, A. W. Burks; Duke University Medical Center, Durham, NC.

111 Food Allergy Quality of Life (FAQOL) Is Improved For Food Oral Immunotherapy (OIT) Treated Patients and Their Families
A. R. Hauge, R. L. Wasserman, R. W. Sugerman; DallasAllergyImmunology, Dallas, TX.

112 The Effects of Peanut Oral Immunotherapy on Food Allergy Related Quality of Life

113 Patient and Parent Perspectives on Quality of Life during Participation in a Study of Rapid Oral Desensitization with Omalizumab Therapy in Patients with Milk Allergy
J. S. LeBovidge1, S. Haskell1, I. Borras1, E. Hoyte2, D. T. Umesu1, K. C. Nadeau2, L. C. Schneider1; 1Children’s Hospital Boston, Boston, MA, 2Stanford Medical School, Stanford, CA.

114 Effect of A Reaction During Oral Food Challenges (OFC) on Food-specific IgE levels (sIgE)
Y. Hui, J. A. Lieberman, S. H. Sicherrerr; Mt. Sinai School of Medicine, New York, NY.
115 Biphasic Reactions in Children Undergoing Oral Food Challenges  
Children’s Hospital of Philadelphia, Philadelphia, PA.

116 Clinical Protocols For Allergen Threshold Studies: Does One Stand Above The Rest?  
B. Remington, J. L. Baumert, S. L. Taylor;  
University of Nebraska, Lincoln, NE.

**Poster Session**

**Food Allergy Related Issues/Immune Skin Disease**

2207  
Session Time: Saturday, March 3, 2012, 9:45 AM - 10:45 AM

117 Hen’s Egg White Hypersensitivity among a group of Egyptian Allergic Children  
D. H. El-Ghoneimey1, S. M. Reda1, E. A. Mohammed1, A. E. Shehab2;  
1Department of Pediatric Allergy and Immunology, Ain Shams University, Cairo, EGYPT, 2Department of Clinical Pathology, Ain Shams University, Cairo, EGYPT.

118 Outcomes Of Pediatric Oral Food Challenges In A Singapore Hospital  
M. M. Tan;  
National University Hospital, Singapore, SINGAPORE.

119 Oral Food Challenge Outcomes in a Tertiary Care Allergy Center  
E. M. Abrams, N. Cisneros, A. B. Becker;  
University of Manitoba, Winnipeg, MB, CANADA.

120 Bullying of Food-Allergic Youth: Results from a Parent and Child Survey  
M. Ambrose1, R. Annunziato2, N. Ravid, K. Chuang, C. Mullarkey1, E. Shemesh1, S. H. Sicherer2;  
1Mt. Sinai School of Medicine, New York, NY, 2Fordham University, New York, NY.

121 Administration Of Influenza Vaccine To Pediatric Patients With Egg Anaphylaxis  
I. Fung, J. M. Spergel;  
Children’s Hospital of Philadelphia, Philadelphia, PA.

122 Parental Perceptions of Anaphylaxis in Children with Egg Allergy  
L. E. Howe, M. J. Greenhawt, G. Sanders;  
University of Michigan, ANN ARBOR, MI.

123 Dietary Advice and Accidental Exposures to Egg in Allergic Children  
C. A. Filion, L. Paradis, A. Des Roches;  
University of Montreal, Montreal, QC, CANADA.

124 Geographical Variability In The Ltp Recognition In A Large Sample Of Rosacea Allergy Patients  
1Plant Biotechnology and Genomics Institute, UPM-INIA, Pozuelo de Alarcon (Madrid), SPAIN, 2Departamento de Evolucion Molecular, Centro de Astrobiologia (INTA-CSIC), Torrejon de Ardoz, Madrid, SPAIN, 3Unidad d’Alergia. Servei Pneumologia i Alergia Respiratoria. Hospital Clinic, Unitat d´Alergia. Servei de Pneumologia. Hospital Clinic. Universitat de Barcelona, Institut d’Investigacions Biomdiques August Pi i Sunyer (IDIBAPS), Barcelon, SPAIN, 4Servicio de Allergia, Hospital Universitario de la Princesa, Instituto de Investigacion Sanitaria Princesa (IP), Madrid, SPAIN, 5Hospital Universitario de Gran Canaria Dr. Negrn, Las Palmas de Gran Canaria, SPAIN, 6Unidad Servicio de Alergia, Fundacion Jimnez Diaz, Madrid, SPAIN, 7Allergy Section, General University Hospital, Miguel Hernandez University, Elche, SPAIN, 8Unidad de Alergologa, Complejo Hospitalario, Ourense, SPAIN, 9Servicio de Alergia, Hospital de Basurto, Bilbao, SPAIN, 10Departamento de Bioquimica y Biologa Molecular I, Facultad de Quimicas, Universidad Complutense, Madrid, SPAIN, 11Research Laboratory, Fundacion IMABIS-Carlos Haya Hospital; Hospital Civil, Malaga, SPAIN.

125 In Vivo And In Vitro Studies On The Sensitisation To A Panel Of Allergens In A Large Rosacea Allergic Group Of Patients  
I. Garcia-Nunez1, A. Aranda2, A. Blazquez3, M. Torres2, M. Galindo1, M. Sanz4, M. Blanca5;  
1Hospital Universitario Carlos Haya, Malaga, SPAIN, 2Clinica Universitaria de Navarra, Pamplona, SPAIN.

126 Co-sensitization Between Specific IgE to nAct d 2 and rAlt a 1  
O. M. Calderon;  
La Paz University Hospital, Madrid, SPAIN.

127 Assessing Specialists’ Opinion Related to Prescribing Auto-injectable Epinephrine In An Unusual Case of Peanut Sensitivity with Oral Allergy  
J. R. Parkerson, D. K. Ledford;  
University of South Florida, Tampa, FL.

128 Reaction To Soymilk But Not Other Soy Products In Gly m 4 Sensitized Birch Pollen-Allergic Patients  
R. Q. Chaudhry1, R. Bigelsen2, A. Wolff3;  
1University of Medicine and Dentistry of New Jersey, Newark, NJ, 2Tulane University, New Orleans, LA.

129 Gastrointestinal food allergies in children with Ehlers Danlos type 3 syndrome  
Great Ormond Street Hospital for Children, London, UNITED KINGDOM.

130 Food Protein-induced Enterocolitis Syndrome (FPIES): Our Experience  
M. Ruiz Garcia;  
Fundacion Jimenez Diaz, Madrid, SPAIN.

131 The Acquisition of Food Allergy in Children after Liver Transplantation  
National Center for Child Health and Development, Tokyo, JAPAN.

132 Atopic Dermatitis And Assessment Of Food Tolerance By Oral Food Challenges  
Medical College of Wisconsin, Milwaukee, WI.

133 Frequency of Sensitization to Egg and Cow’s Milk in Children with Atopic Dermatitis and Associated Factors  
N. P. M. Rubini, F. L. B. Limongi, B. O. Figueiredo, N. A. Costa, N. S. Santos, N. M. Almeida, F. S. Sion, C. Moraes-de-Sa;  
Federal University of Rio de Janeiro State, Rio de Janeiro, BRAZIL.

T. Mucci1, S. Axelrod1, M. Michelis2, S. Lighvani3, M. Aquino1, M. Davis-Lorton1, L. Fonacier1;  
1Great Ormond Street Hospital for Children, London, UNITED KINGDOM.
135 Skin Immunity Is Regulated By Histamine Receptors Through Dendritic Cell Number And Function
T. A. Kamdar, A. Byrne, P. Bryce;
Northwestern University Feinberg School of Medicine, Chicago, IL.

136 Role of Mast Cells in the Development of Atopic Dermatitis Induced by IL-13
M. OH1, Z. Zhu1, J. Yu1, T. Zheng1;
1Johns Hopkins University, Baltimore, MD, 2Asan Medical Center, Ulsan University, College of Medicine, Seoul, KOREA, REPUBLIC OF.

137 Involvement of Human Histamine N-methyltransferase Gene Polymorphisms in Susceptibility to Atopic Dermatitis in Korean Children
H. S. Lee1, S. H. Kim2, K. W. Kim1, H. B. Park1, Y. H. Kim1, H. M. Jee1, H. S. Park2, M. H. Sohn1, K. E. Kim1;
1Department of Pediatrics and Institute of Allergy, Severance Biomedical Science Institute, BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF; 2Department of Allergy and Rhenumatology, Ajou University School of Medicine, Suwon, KOREA, REPUBLIC OF; 3Department of Pediatrics, CHA University School of Medicine, Seongnam, KOREA, REPUBLIC OF.

138 The Association of Polymorphisms in the Interleukin 33 (IL-33) and Interleukin 1 Receptor-like 1 (IL1RL1) Genes with Risk of Atopic Dermatitis
L. Gao1, D. Taylor1, N. M. Rafaela1, M. Campbell1, R. Lewis1, C. V. Ribera1, A. L. Beck1, R. A. Mathias1, D. Y. Leung1, K. C. Barnes1;
1Johns Hopkins School of Medicine, Baltimore, MD, 2University of Rochester Medical Center, Rochester, NY, 3National Jewish Health, Denver, CO.

139 TL1R4 Deficiency Exacerbates Allergen-Induced Atopic Dermatitis
E. B. BRANDT1, A. M. Gibson, S. Bass, M. Lindsey, G. K. Khurana Hershey;
Cincinnati Children’s Hospital Medical center, Cincinnati, OH.

140 In Silico Analyses Reveal Putative Regulatory Elements Upstream of the Thynnical Stromal Lymphopoiethen Receptor Gene M. J. Romeo, J. A. Woodfolk;
University of Virginia, Charlottesville, VA.

141 Filaggrin Deficiency Impairs Viral Containment in Mice Cutaneously Inoculated with Vaccinia Virus (VV)
R. S. Geha, M. K. Oyoshi;
Children’s Hospital Boston, Boston, MA.

142 Sequencing Of The Fig2 Gene In Patients With Atopic Dermatitis And Eczema Herpeticum In A Population Of European Descent
N. M. Rafaela1, D. Y. Leung2, L. Beck3, R. Lewis1, L. Huang1, P. Gao1, M. Boguniewicz4, T. Hata4, L. Schneider5, J. Hanlin6, R. Gallo7, L. Gao1, R. Mathias1, K. C. Barnes1;
1Johns Hopkins School of Medicine, Baltimore, MD, 2Department of Pediatrics, National Jewish Health, Denver, CO, 3Department of Dermatology, University of Rochester Medical Center, Rochester, NY, 4Division of Dermatology, University of California, San Diego, CA, 5Division of Immunology, Children’s Hospital Boston, Boston, MA, 6Department of Dermatology, Oregon Health & Science University, Portland, OR.

143 Relevance of Patch Test Results to the Clinical Diagnosis of Allergic Contact Dermatitis - Need for Standardization
H. Morissette1, B. McGoeo2, M. Michielis;
Hackensack University Medical Center, Hackensack, NJ.

144 Systemic Tolerability of Intermittent Topical Corticosteroid Therapy Using Salivary Cortisol Measurements in Infants With Atopic Dermatitis
T. Fukui1, S. Sano1, I. Nomura2, M. Narita3, T. Taguchi1, T. Ogata1, K. Matsumoto3, Y. Ohyoa;
1Hamamatsu University School of Medicine, Shizuoka, JAPAN, 2National Center for Child Health and Development, Tokyo, JAPAN, 3National Research Institute for Child Health and Development, Tokyo, JAPAN.

145 Factors Determining The Effectiveness Of Oral Cyclosporine In Children With Severe Atopic Dermatitis (AD)
P. D. Arkwright, D. R. Beaumont;
University of Manchester, Manchester, UNITED KINGDOM.

146 Omalizumab - One Year Experience In The Treatment Of Severe Atopic Dermatitis
A. M. Mendes, A. C. C. Costa, S. Luz, E. Pedro, M. Pereira-Barbosa;
Santa Maria Hospital, Lisbon, PORTUGAL.

147 A Case Series Of Severe Atopic Dermatitis Treated By Anti-ige Therapy: A Paediatric Perspective
J. Lacombe Barrios1, L. Paradis2, A. Hatami1, J. Paradis3, A. Des Roches1;
1Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, CANADA, 2Centre Hospitalier de l’Universite de Montreal, Montreal, QC, CANADA.

148 MRSA Skin Colonization Is Associated With Higher Total IgE in Young Children With Atopic Dermatitis
J. Abbott, D. C. Everett, D. Y. Leung;
National Jewish Health, Denver, CO.

149 Bifidobacterium in Gut Microbiota for Infants with and without Eczema
G. Yap1, K. Chee1, P. Hong1, M. Aw2, L. Shek1, K. Chua1, X. Zhang1, D. Leow1, B. Lee1;
1National University of Singapore, Singapore, SINGAPORE, 2University of Illinois, Urbana-Champaign, IL, 3Singapore Clinical Research Institute, Singapore, SINGAPORE.

150 Relationship of Serum 25-hydroxyvitamin D Levels with the Severity of Atopic Dermatitis in Children
J. Shim, M. Kim, Y. Kim, J. Shim, D. Kim, H. Jung, M. Park; Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF.

151 Nutritional Status and Bone Metabolism in Children With Atopic Dermatitis
School of Medicine - University of Sao Paulo, Sao Paulo, BRAZIL.

152 Dietary Intervention With Specific Non-digestible Oligosaccharide Mixtures Is Effective During Induction Of Murine Cow’S Milk Allergy But Not Suitable As Treatment In The Same Allergic Disease Model
P. V. Jeurink1,2, J. Kerperien1, T. M. D. Wehkamp1,2, E. C. A. M. van Esch1,2, A. Rijniers1,2, G. A. Hofman1, L. E. M. Willemsen2, J. Kerren2,1, L. M. J. Knippels1,2;
1Danone Research - Centre of Specialised Nutrition, Wageningen, NETHERLANDS, 2Utrecht Institute of Pharmaceutical Sciences, Utrecht, NETHERLANDS.

153 Different Timings of Prenatal or Postnatal Tobacco Smoke Exposure have Different Effects on The Development of Atopic Eczema/Dermatitis Syndrome (AEDS) during Infancy
M. Shinohara1,2, H. Saito3, K. Matsumoto4;
1National Shimosizu Hospital, Department of Pediatric Allergy and Clinical Research, 934-5 Shikawatashi, Yotsukaido-City, Chiba, JAPAN, 2Kochi University, Department of Pediatrics, Kochi, JAPAN, 3National Research Institute for Child Health and Development, Department of Allergy & Immunology, 2-10-1 Okura Setagaya-ku Tokyo,157-8535 Japan, JAPAN, 4National Research Institute for Child Health and Development, Department of Allergy & Immunology, -10-1 Okura Setagaya-ku Tokyo,157-8535 Japan, JAPAN.
A Focus on Asthma

Poster Session

154 Asthma and Physical Activity in Adolescents: A Cross Sectional Analysis
A. L. Leyton, A. P. Baptist; University of Michigan, Ann Arbor, MI.

155 Correlates of Asthma Deaths at a Children’s hospital with a Multidisciplinary Team (MDT) Asthma Program for High Risk Asthmatics.
S. Z. Faghihi1,2, P. Abghari1,2, K. Dhekney1,2, S. Marzec2, E. Secord1,2; 1Children’s Hospital Of Michigan, Detroit, MI, 2Wayne State University, Detroit, MI.

156 Reducing Health Disparities For Asthma With a School Based Asthma Education Program
S. E. Monforte, M. Gleason, L. Covar, L. Cicuttio, S. J. Szefler; National Jewish Health, Denver, CO.

157 Relationship Of Canister Weight To The Amount Of Medication Actuated From Metered-dose Inhalers
S. sahajarupat; 1Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Hatyai, THAILAND.

158 Asthma and Risk of the Novel 2009 H1N1 Influenza Infection in Children: A Population-Based Case-Control Study
C. F. Santillan Salas1, S. Mehra1, E. J. Park1, B. D. Lahr1, B. P. Yawn2, Y. J. Juhn2; 1Mayo Clinic Rochester, Rochester, MN, 2Olmsted Medical Center, Rochester, MN.

159 Prevalence Of The Correct Technique Of Using An Inhaler Among Asthmatic Patients Reporting In Tertiary Care Hospitals Of Rawalpindi, Pakistan

160 Risk of Hospitalization in Thai Children with Acute Asthma
P. Kulalert, P. Sangsupawanich; Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine,Prince of Songkla University, Hatyai, THAILAND.

161 Metered-Dose Inhaler Spacers: A Double Edged Sword?
J. L. Mutnick; Stevens Community Medical Center, Morris, MN.

162 Fluticasone- propionate/Salmeterol is Associated with a Higher Likelihood of Achieving an Optimal Controller-to-Total Asthma Medication Ratio Compared to Inhaled Corticosteroid Alone
R. H. Stanford1, A. D'Souza2, A. Dhama2, M. Shah2; 1GlaxoSmithKline, Research Triangle Park, NC, 2Xcenda, Palm Harbor, FL.

A Focus on Asthma

Poster Session

Rhinosinusitis: Mechanisms and Therapy

2209 Session Time: Saturday, March 3, 2012, 9:45 AM - 10:45 AM

163 Mast Cells with a Unique Phenotype Are Highly Elevated in Chronic Rhinosinusitis with Nasal Polyps
T. Takabayashi1,2, A. Kato1, A. T. Peter1, L. A. Suh1, R. Carter1, J. Norton1, L. C. Grammer1, B. K. Tan1, R. K. Chandra2, D. B. Conley1, R. C. Kern1, S. Fujieda1, R. P. Schleimer1; 1The Division of Allergy and Immunology Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 2The Division of Otorhinolaryngology Head and Neck Surgery, Department of Sensory and Locomotor Medicine, University of Fukui, Fukui, JAPAN.

164 Age-related Reduction Of S100A8/A9 In Chronic Rhinosinusitis Is Associated With Increased Production Of Soluble gp30
S. H. Lee1, K. Hulse1, J. Siebert1, J. Norton1, D. B. Conley2, R. Chandra2, R. C. Kern1, S. Hong1,3, R. P. Schleimer1, S. H. Cho1; 1Division of Allergy-Immunology, Department of Medicine, Northwestern Feinberg School of Medicine, Chicago, IL, 3Department of Otolaryngology, Feinberg School of Medicine Northwestern University, Chicago, IL.

165 Elevated Expression of mRNA for CCL2, CCL19, CCR7 and CXCR3 in Chronic Rhinosinusitis with Nasal Polyposis

166 Vitamin D Modulates Immune Defense Molecules in Patients with Chronic Rhinosinusitis
S. Watanabe1, X. Jiang2, S. Sharma3, J. Lane3, M. DeTineo2, T. Muninopasa2, M. Bashir4, N. Joyner1, F. M. Baroody1, R. M. Naclerio1,2, J. M. Pinto5; 1Showa University School of Medicine, Tokyo, JAPAN, 2University of Chicago, Chicago, IL, 3University of Michigan, Ann Arbor, MI.

167 Efficacy of Mometasone Furoate Nasal Spray in Relieving Congestion in Patients With Nasal Polyps With or Without Eosinophilia
C. B. Small1, P. Stryszak2, A. Teper2; 1New York Medical College, Valhalla, NY, 2Merck Research Laboratories, Kenilworth, NJ.

168 Efficacy Of Gentamicin Nasal Irrigation In Chronic Rhinosinusitis
S. Saitama Medical University Hospital, Saitama, JAPAN.

169 Impacts of Sinus Surgery on Lower Airway Disease
R. Kagoya1, M. Shinogami1, H. Mouri1, S. Suzuki2, W. Nakanishi2, H. Yoshinami3; 1Tokyo Metropolitan Police Hospital, Tokyo, JAPAN, 2University of Tokyo, Tokyo, JAPAN, 3Saitama Medical University Hospital, Saitama, JAPAN.

170 Eleven Year Follow Up of an African-American Adolescent with Destructive Sinus Disease and Intermittent Asthma Diagnosed with Allergic Fungal Sinusitis (AFS) and Incidentally Found to have Allergic Bronchopulmonary Mycosis (ABPM)
A. G. Hall, A. E. Morris, G. D. Marshall, Jr.; University of Mississippi Medical Center, Jackson, MS.

171 The Adenoid Inflammation of Children with Rhinosinusitis and Alternaria Hypersensitivity
S. Shin1, K. Lee1, S. Kim1, J. Cho1, H. Park2; 1Kyung Hee University, Seoul, KOREA, REPUBLIC OF, 2Ajou University, Suwon, KOREA, REPUBLIC OF.

172 The Examination of the Association Between the Chronic Rhinosinusitis and the Inflammation of the Lower Respiratory Airway by Using the Exhaled Nitric Oxide(NO) and the Respiratory Function Test
H. Yoshinami; Saitama Medical University, Saitama, JAPAN.
**Poster Session**

**Immunotherapy**

2210 Session Time: Saturday, March 3, 2012, 9:45 AM - 10:45 AM

173 Absence Of IgE Neosensitization In House Dust Mite Allergic Patients Following Sublingual Immunotherapy

P. Moingeon; Stallergenes SA, Antony, FRANCE.

174 Improvement In Quality Of Life With Administration Of A 300 IR Sublingual Tablet Of 5-grass Pollen Allergen Extract In Adults With Grass Pollen-induced Allergic Rhinoconjunctivitis

F. Horak¹, A. Didier², M. Worm³, H. Malling⁴, K. Abiteboul⁵, A. Montagut⁶, R. K. Zeldin⁷;

¹Allergy Centre Vienna, Vienna, AUSTRIA, ²Rueguil-Larrey Hospital, Toulouse, FRANCE, ³Allergie-Centrum-Charit, Klinik fr Dermatologie, Venerologie und Allergologie, Berlin, GERMANY, ⁴National University Hospital, Copenhagen, DENMARK, ⁵Stallergenes, Antony, FRANCE.

175 Characteristics of Systemic Reactions to Inhalant Allergen Immunotherapy (SRIT) in the University of Michigan Health System (UMHS)

J. L. Baldwin, K. Samuels, C. L. Holland, J. Postma; University of Michigan Allergy Immunology Specialty Clinic, Ann Arbor, MI.

176 A Us Study Of 5-grass Pollen Allergen Extract In Adults With Grass Pollen-induced Allergic Rhinoconjunctivitis - Results Of Secondary Efficacy Assessments

L. Cox¹, T. B. Casale², A. Nayak³, P. Creticos⁴, A. Montagut⁵, R. K. Zeldin⁶;

¹Nova Southeastern University School of Osteopathic Medicine, Davie, FL, ²Division of Allergy and Immunology, Department of Medicine, Creighton University - Allergy & Asthma, Omaha, NE, ³Sneeze, Wheeze and Itch Associates, Normal, IL, ⁴Johns Hopkins University, baltimore, MD, ⁵Stallergenes, Antony, FRANCE.

177 Post-treatment, Long-term Efficacy Of A 300IR Sublingual Tablet Of 5-grass Pollen Allergen Extract In Adults With Grass Pollen-induced Allergic Rhinoconjunctivitis: The Relationship With Disease Severity

M. Worm¹, A. Didier², F. Horak³, H. Malling⁴, S. Soulie⁵, R. K. Zeldin⁶;

¹Allergie-Centrum-Charit, Klinik fr Dermatologie, Berlin, GERMANY, ²Rueguil-Larrey Hospital, Toulouse, FRANCE, ³Allergy Centre Vienna, Vienna, AUSTRIA, ⁴National University Hospital, Copenhagen, DENMARK, ⁵Stallergenes, Antony, FRANCE.

178 Comparative Efficacy and Tolerability of Subcutaneous and Sublingual Allergen Specific Immunotherapy

A. Blaziene¹, A. Chomiciene², L. M. DuBuske³;

¹Vilnius University, Center of Pulmonology and Allergology, Vilnius, LITHUANIA, ²Immunology Research Institute of New England, Gardner, MA.

179 Grass Pollen Immunotherapy In Children: Safety Aspects

M. I. Garciamartin, M. Vazquez De La Torre Gaspar, F. Ruano Perez, N. Blanca Lopez, E. Seoane Reula, M. De Diego, M. Canto Diez;

Hospital Infanta Leonor, Madrid, Madrid, Spain.

180 Dose-related Effects of Ragweed Allergy Immunotherapy Tablet on Nasal and Ocular Symptoms of Allergic Rhinoconjunctivitis During the Peak Ragweed Pollen Seasons in Europe and North America

J. Maloney¹, H. Nolte¹, K. Nekam², P. Creticos³, G. Berman⁴, A. Kaur⁵, J. Hebert⁶;

¹Merck Research Laboratories, Kenilworth, NJ, ²Hospital of the Haytiller Brothers of St John of God, Budapest, HUNGARY, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Allergy & Asthma Specialists, Minneapolis, MN, ⁵Centre de Recherche Appliquee en Allergie de Quebec, Quebec, QC, CANADA.

**Poster Session**

**Allergic Inflammation**

2211 Session Time: Saturday, March 3, 2012, 9:45 AM - 10:45 AM

181 Controlled Allergen Exposure in the Environmental Exposure Chamber (EEC) Results in a Late Phase Inflammatory Response Evidenced by Increased Eosinophils in the Upper Airways of Allergic Patients

N. Camuso, S. Zafar, N. Najera, A. Liac, G. Aguirre, A. Salapatek; Cetero Research, Mississauga, ON, CANADA.

182 Mold and House Dust Mite Allergens Activate and Sensitize Sensory Neurons Innervating Airways

M. J. Patil¹, M. A. Henry², A. N. Akopian³;

¹Pharmacology Dept, Gradate School, UTHSCSA, San Antonio, TX, ²Dental School, UTHSCSA, San Antonio, TX.

183 Peripheral Blood Mononuclear cells from Patients with Bronchial Asthma show impaired regulatory responses to Rhinovirus in vitro

K. Ikura;

Sagamihara National Hospital, Kanagawa, JAPAN.

184 Pharmacological Characterization of TASP0412098, A Selective CRTH2 (Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells) Antagonist

M. Kawanishi¹, K. Watanabe¹, Y. Asakura¹, A. Oka¹, T. Naruse¹, R. Nishikawa¹, T. Takayama¹, T. Koami², D. Wakasugi³, M. Kawamura², A. Takaoka¹, S. Tokita¹;

¹Molecular Function and Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama-shi, Saitama, JAPAN, ²Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama-shi, Saitama, JAPAN.

185 Pro-inflammatory Effect Of Dexamethasone In Human Airway Fibroblasts

W. Manuyakorn¹,², D. Davies¹, P. Howarth¹;

¹Faculty of Medicine, University of Southampton, Southampton, UNITED KINGDOM, ²Faculty of Medicine, Ramathobodi Hospital, Mahidol University, Bangkok, THAILAND.

186 Characterization of a Novel, Potent and Selective Small Molecule Spleen Tyrosine Kinase (SYK) Inhibitor in In Vitro and In Vivo Models of Asthma

M. A. Crackower¹, L. Y. Moy¹, Y. Jia², H. Yu¹, S. Vincent¹, J. R. Miller¹, G. Lieber³, X. Fernandez³, M. Canigà³, M. Gil¹, A. Wilhelm³, H. Houseyar¹, A. Northrup¹, R. Chapman¹, W. M. Abraham¹, N. Kelly¹, E. Hickey², T. Miller¹;

¹Merck Research Labs, Boston, MA, ²Merck Research Labs, Kenilworth, NJ, ³Mount Sinai Medical Center, Miami Beach, FL.

187 Increased Expression of Importin a3 (KPNA4) and Decreased VDR in the Lung of OVA-Sensitized and Challenged Mice

T. Agrawal, G. K. Gupta, M. Kim, D. K. Agrawal; Creighton University, Omaha, NE.

188 Similarities And Differences Between Lung Ligands For Mouse Siglec-f And Human Siglec-8

T. Kiwamoto¹, H. J. Na¹, M. E. Brummet¹, D. F. Smith², B. S. Bochner³;

¹Mount Sinai Medical Center, Miami Beach, FL, ²Columbia University, New York, NY, ³National Jewish Medical Center, Denver, CO.
198 Relationship Between Leptin Bronchial Hyperresponsiveness To Manitol And Urinary Leukotriene E4/exhaled Nitric Oxide Ratio In Asthmatic Children
H. Baek1, J. Oh2, H. Lee2;
1Hallym University Gangdong Sacred Heart Hospital, Seoul, KOREA, REPUBLIC OF; 2Hanyang University College of Medicine, Seoul, KOREA, REPUBLIC OF.

199 Silymarin Reduces OVA-induced Allergic Airway Inflammation
D. C. Newcomb1, M. G. Boswell1, M. M. Huckabee1, J. S. Markowitz2, T. V. Hartert1, R. S. Peebles1, Jr1;
1Vanderbilt University Medical Center, Nashville, TN, 2University of Florida, Gainesville, FL.

200 Preventive Effects of Challenge With Ragweed Pollen Extract (RWPE) In Allergic Rhinitis
D. C. Newcomb1, J. L. Parks, IV, W. C. Spear;
University of Texas Medical Branch, Galveston, TX.

201 Influence of Maternal Allergen Exposure in the Development of Allergic Airway Disease in the Offspring: Effects of Antigen and Timing of Exposure
J. Yang1, K. Gabehart1, K. A. Correll, A. George, M. L. Collins, E. W. Gelfand, A. Dakhama;
National Jewish Health, Denver, CO.

202 Effect of Prenatal Cigarette Smoke Exposure on the Development of Allergic Airway Disease in Mice
K. A. Correll1, K. Gabehart1, J. Yang, A. George, M. L. Collins, A. Dakhama;
National Jewish Health, Denver, CO.

203 The Single Nucleotide Polymorphism, CRTh2-6373G>A, is Associated with Allergic Asthma and Increased Expression of CRTh2
L. Cameron1, E. Campos Alberto1, E. MacLean1, C. Davidson1, D. Brenner2, A. El-Sohemy2, H. Viagofski3;
1University of Alberta, Edmonton, AB, CANADA, 2University of Toronto, Toronto, ON, CANADA.

204 Transglutaminase 2 Knock-out Protects Against Airway Inflammation And Tissue Remodeling In Ova-specific Allergic Asthma In Mice
G. Hong1, B. Park1, J. Park2, S. Kim3, J. Ro4;
1sungkyunkwan university of medicine, suwon, KOREA, REPUBLIC OF, 2Department of Internal Medicine, Yonsei University College of Medicine, Division of Allergy and Immunology, seoul, KOREA, REPUBLIC OF, 3Cancer Cell and Molecular Biology Branch, Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, KOREA, REPUBLIC OF.

---

Poster Session

Innate Immunity

2212 Session Time: Saturday, March 3, 2012, 9:45 AM - 10:45 AM

205 Diesel Exhaust Alters Nasal Innate Immune Mechanisms in Allergic Rhinitics
C. V. E. Chehrazi1, B. J. Horton, H. Zhou, T. Noah, D. Diaz-Sanchez, I. Jaspers;
University of North Carolina, Chapel Hill, NC.

206 Silica Crystals Cause Cellular Injury in TLR3-Activated Human Bronchial Epithelial Cells
H. Unno1, K. Futamura, R. Kojima, H. Morita, H. Saito, K. Matsusoto, A. Matsuda;
National Research Institute for Child Health & Development, Tokyo, JAPAN.

207 Alternaria Induces Stat-6 Dependent Acute Airway Eosinophilia And Epithelial Fizz1 Expression That Promotes Airway Fibrosis And Epithelial Thickness
N. Khorram1, K. Sugimoto2, D. Sheppard2, P. Rosenthal1, J. Cho1, A. Tham1, M. Miller1, B. Zaraw1, M. Croft1, D. H. Broide1, T. A. Doherty1;
1University of California, San Diego, La Jolla, CA, 2University of British Columbia, Vancouver, BC, CANADA.
208 Chemokines, Soluble Receptors and Mediators of Cord Blood Mononuclear Cells and Atopic Sensitization at 2 Years of Age in At Risk Infants Participating in a Probiotic Supplementation Clinical Trial

P. Quah, C. Huang, P. Shek, M. Aw, K. Chua, B. Lee, I. Kuo; National University of Singapore, Singapore, SINGAPORE.

209 Gene-Environment Interaction Between Early Life Exposure and CD14, TLR4, IL13 in Development of Allergic Diseases or Atopy

J. Seo, H. Kim, M. Kang, Y. Kim, J. Kwon, B. Kim, K. Park, S. Lee, S. Hong; 1Department of Pediatrics, Childhood Asthma Asthma Center, Research Center for Standardization of Allergic Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF; 2Asan Institute for Life Sciences, University of Ulsan, Seoul, KOREA, REPUBLIC OF; 3Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF; 4Department of Pediatrics, Inje University Haeundae Paik Hospital, Pusan, KOREA, REPUBLIC OF; 5Department of Pediatrics, Presbyterian Medical Center, Jeonju, KOREA, REPUBLIC OF; 6Department of Pediatrics, Hallym Sacred Heart Hospital, Hallym University College of Medicine, Anyang, KOREA, REPUBLIC OF.

210 Exogenous Interferons Reduce Rhinovirus Replication in Human Bronchial Epithelial Cells

K. Fischer, T. Toll-Like Receptors in Human Bronchial Epithelial Cells

University of Wisconsin School of Medicine and Public Health, Madison, WI.

211 Transforming Growth Factor-β Regulates the Expression of Toll-Like Receptors in Human Bronchial Epithelial Cells

K. Fischer 1, R. Gaurav 2, D. K. Agrawal 3; 1Center for Clinical & Translational Science, and Department of Microbiology & Immunology, Creighton University School of Medicine, Omaha, NE; 2Center for Clinical & Translational Science, and Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, NE.

212 Enhancer of Zeste Homolog 2 induces Pulmonary Artery Smooth Muscle Cell Proliferation and Migration

S. A. Aljubran, R. Cox, P. Tamarapu Parthasarathy, G. KR, S. M. Mohapatra, R. Lockey, N. Kollipudi; University Of South Florida, Tampa, FL.

213 Differential recruitment of CD49d+ Neutrophils by Toll-like Receptor Agonists

D. S. Cheung, E. J. Buell, D. A. Hunter, S. J. Temple, M. H. Grayson; Medical College of Wisconsin, Milwaukee, WI.

Poster Session

Allied Health Poster Session

2213 Session Time: Saturday, March 3, 2012, 9:45 AM - 10:45 AM

214 Participant Survey Results From the Starting Hizentra Administration With Resources and Education (SHARE) Program

E. Murphy 1, P. Riley 1, A. Zampelli 1, C. Duff 2; 1CSL Behring, LLC, King of Prussia, PA, 2University of South Florida, Tampa, FL.

215 Factors Associated with Daily Stress and Asthma Stress in Caregivers of Children with Asthma

C. L. Vibbert 1, A. Buza 2, M. Donithan 2, M. E. Bollinger 1; 1University of Maryland, Baltimore, MD; 2Johns Hopkins University, Baltimore, MD.

216 Increase in Food Protein consumed during Milk and Egg Open Food Challenges are not associated with increase in failures

S. A. Lowe 1, J. E. Conner 2, L. A. Crandall 1, C. M. Lee 1, M. B. Ho 3, M. B. Feuling 3, C. L. Sova 3, M. Vasudev 3; 1Medical College of Wisconsin, Milwaukee, WI, 2Children’s Hospital of Wisconsin, Milwaukee, WI.

217 Churg-Strauss syndrome: The Clinical Features and Long-term Prognosis of 47 Patients

C. Lee 1, B. Lee 1, J. Lee 3, D. Choi 4; 1Samsung medical center, Sungkyunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF; 2Center for Health Promotion, Samsung Medical Center, Seoul, KOREA, REPUBLIC OF.

218 Food Allergy Educational Needs of Allergy Dietitians in the UK

C. Venter 1, R. Meyer 2, L. Reeves 3; 1The David Hide Asthma and Allergy Research Center, Isle of Wight, UNITED KINGDOM, 2Great Ormond Street Hospital, London, UNITED KINGDOM, 3Oxford Health NHS Foundation Trust, Oxford, UNITED KINGDOM.

219 Role of Preventive Anti-histamine Medications for Local Reactions with Conventional Aeroallergen Subcutaneous Immunotherapy (SCIT)

S. Golubski, T. Gobel, R. Gutra, L. Pien; Cleveland clinic, cleveland, OH.

220 Response to State Epinephrine IM (epi IM) Dose vs. BMI and WAO Systemic Reaction Grading in the Incidence of Systemic Reactions (SRs) to Prick (P) and Intraderal (ID) Skin Tests

D. Shearer; Univ So. Fla, Tampa, FL.

221 Temporal Changes In Lung Function In A Mouse Worker Population

B. M. Thomas 1, C. Aloe 1, J. Curtin-Brownan 1, R. D. Peng 2, P. A. Eggleston 1, W. G. Sheffler 3, K. A. Hagberg 4, M. Krevans 4, R. Korstanje 4, E. C. Matsui 1, S. A. Lowe 1, J. E. Conner 2, L. A. Crandall 1, C. M. Lee 1, M. B. Ho 4, M. B. Feuling 4, C. L. Sova 4, M. Vasudev 4; 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 3Massachusetts General Hospital, Boston, MA, 4The Jackson Laboratory, Bar Harbor, ME.

222 Clinical Utility of Anergy Panel Testing in Conjunction with Purified Protein Derivative (PPD) Tuberculin Skin Testing (TST) for Detection of Latent Tuberculosis Infection (LTBI) in Pre-lung Transplant Patients

K. Caruso, R. Guta, L. Pien; Cleveland Clinic, Cleveland, OH.

223 Development of Standards of Care for Immunoglobulin Re- Replacement Therapy

C. M. Duff 1, W. Blouin 2, D. Sedlak 3; 1I. D. F. Nurse Advisory Committee; 1University of South Florida, St. Petersburg, FL, 2Miami Children’s Hospital, Miami, FL, 3Duke University Medical Center, Durham, NC, 4Immune Deficiency Foundation, Townsend, MD.

224 The Newport News Healthy Homes Initiative: Targetting A Hard To Reach Low Income Asthmatic Population

J. C. Taylor-Fishwick 1, W. G. Shreffler 2; 1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2University of South Florida, St. Petersburg, FL.

225 Indoor Allergens in the Rocky Mountains: Dust Collection and Analysis in the Arid North

E. C. Weiler; University of Montana, Missoula, MT.

226 Effects of Asian Dust and Spherical Particles Exposure on Human Health and Allergic Symptom

R. T. Kishikawa 1, T. Iwasaki 2, T. Ichinose 1, Y. Okuno 3, K. Arashidani 1, M. Nishikawa 1, T. Shimoda 1, T. Iwanaga 1; 1University Of South Florida, Tampa, FL.
Oral Abstract Session

Asthma Highlights

2601 Session Time: Saturday, March 3, 2012, 2:00 PM - 3:15 PM

Elevated Cord Blood Soluble CD14 Levels Predict Wheezing in the First Year of Life
Y. Huang, K. Yeh, J. Huang
1Chang Gung Memorial Hospital at Keelung, Keelung City, TAIWAN, 2Chang Gung Memorial Hospital at Linkou and Chang Gung University, Taoyuan, TAIWAN.

236 Improvements In Quality Of Life Measures In A Structured Exercise Program For Persistent Asthma
S. M. Pollart, K. S. Elward, T. A. E. Platts-Mills; University of Virginia, Charlottesville, VA.

Real-world Effectiveness Of Asthma Step-up Options: Matched Comparison Of Extrafine Hydrofluoroalkane-beclomethasone AND Inhaled Corticosteroid / Long-Acting Beta-Agonist
1University of Aberdeen, Aberdeen, UNITED KINGDOM, 2Research in Real Life, Cambridge, UNITED KINGDOM, 3National Jewish Health, Denver, CO, 4London Chest Hospital, Barts and the London NHS Trust, London, UNITED KINGDOM, 5Hopital de l’Hotel-Dieu, Paris, FRANCE, 6Teva Pharmaceuticals, Horsham, PA, 7Washington Hospital Center and George Washington University School of Medicine, Washington, DC.

233 Alternaria Sensitization Is Associated With Increased Airway Hyperresponsiveness and Sinusitis in Children with Severe Asthma
J. Shih, A. Fitzpatrick; Emory University, Atlanta, GA.
Oral Abstract Session

Healthy Homes - Do they make a difference in disease?

2603  
Session Time: Saturday, March 3, 2012, 2:00 PM - 3:15 PM

240 Exposure to Indoor Allergens in Urban Elementary Schools and Homes of Children with Asthma

P. Permaul1, E. Hoffman2, C. Fu3, W. Sheehan4, S. Baxi5, J. Gaffin6, J. Lane6, A. Bailey1, D. Gold1, W. Phipatanakul4, 1Division of Pediatric Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 2Department of Biostatistics, Harvard School of Public Health, Boston, MA, 3Channing Laboratory, Brigham and Women’s Hospital, Boston, MA, 4Division of Allergy and Immunology, Children’s Hospital Boston, MA, 5Division of Pulmonary, Children’s Hospital Boston, MA, 6Facilities Management, Boston, MA.

241 Reduction in Dust Allergen Exposure through Healthy Homes Education

F. Pacheco, M. G. Dhar, C. S. Barnes, C. Childrens Mercy Center for Environmental Health; Children’s Mercy Hospital, Kansas City, MO.

242 Neither Dust Mite nor Cat Allergen Exposure Is Associated with Lung Function or Asthma Morbidity in Sensitized Baltimore City Children

S. K. Abluwalla, P. Broysse, G. Diette, E. Matsui; Johns Hopkins University, Baltimore, MD.

243 Among Middle-income Children In NYC, Neighborhood Reports Of Mouse Sightings Were Associated With Sensitization To Mouse


244 Indoor Airborne Spore Levels Before and After Healthy Homes Education and Remediation

M. G. Dhar, F. Pacheco, C. Barnes, C. Childrens Mercy Center for Environmental Health; Children’s Mercy Hospital, Kansas City, MO.

Oral Abstract Session

Food Allergy

2604  
Session Time: Saturday, March 3, 2012, 2:00 PM - 3:15 PM

245 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Egg Oral Immunotherapy in Children: An Analysis of Clinical Tolerance

1University of Arkansas for Medical Sciences and Arkansas Children’s Hospital, Little Rock, AR, 2Duke University Medical Center, Durham, NC, 3Johns Hopkins University Medical Center, Baltimore, MD, 4National Jewish Health, Denver, CO, 5Mount Sinai School of Medicine, New York, NY, 6The EMMES Corporation, Rockville, MD, 7Massachusetts General Hospital, Harvard Medical School, Boston, MA, 8National Institutes of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD.

246 Peanut Challenge Outcomes Following Sublingual Immunotherapy (SLIT) Correlate With Increased Peanut-Specific Salivary IgA

D. M. Fleischer1, R. A. Wood2, S. M. Jones3, S. H. Sicherer4, A. H. Liu5, D. Stablein6, A. Henning7, L. Mayer8, R. Lindblad9, H. A. Sampson10, A. W. Burks11; 1National Jewish Health, Denver, CO, 2Johns Hopkins University Medical Center, Baltimore, MD, 3University of Arkansas for Medical Sciences and Children’s Hospital, Little Rock, AR, 4Mount Sinai School of Medicine, New York, NY, 5The EMMES Corporation, Rockville, MD, 6Duke University Medical Center, Durham, NC.

249 Development of Clinical Tolerance after Peanut OIT

A. W. Burks1, B. P. Vickery2, A. M. Scurluck2, P. Steele3, J. Kamilarios3, L. Mayer4, S. M. Jones5; 1Duke University Medical Center, Durham, NC, 2University of Arkansas for Medical Sciences, Little Rock, AR.

Determinants of Asthma Treatment Choices

2605  
Session Time: Saturday, March 3, 2012, 2:00 PM - 3:15 PM

250 Differences in Asthma Controller Medication Adherence by Age and Gender

L. J. Hinyard1, C. Geremak1, J. Temprano2; 
1Children’s Mercy Hospital, Kansas City, MO, 2Duke University Medical Center, Durham, NC.
Oral Abstract Session

Rhinovirus Mechanisms and Management
2606
Session Time: Saturday, March 3, 2012,
2:00 PM - 3:15 PM

255 Differential Regional Expression Of Innate Immune Antimicrobial Proteins In Sinonasal Mucosa
S. Seshadri1, M. Rosati1, D. C. Lin1, R. Carter2, J. Norton3, A. Kato1, L. Suh1, A. T. Peters1, R. Chandra2, K. E. Harris1, H. Chu1, D. B. Conley2, B. Tan2, L. C. Grammer1, R. C. Kern2, R. P. Schleimer1; 1Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Department of Medicine, National Jewish Health, Denver, CO.

256 STAT3 and NF-kB Regulate S100A7 Expression in Human Bronchial Epithelial Cells
K. E. Hulse1, R. Singh1, K. Chaung1, J. Norton1, K. Harris1, D. Conley2, R. Chandra2, R. Kern2, A. Peters1, L. Grammer1, B. Tan1, R. Carter2, S. Seshadri1, L. Suh1, A. Kato1, R. Schleimer1; 1Northwestern University Department of Medicine, Chicago, IL, 2Northwestern University Department of Otolaryngology, Chicago, IL.

257 Clinical Characteristics of Patients with Chronic Rhinosinusitis and Specific Antibody Deficiency
S. Kashani1, L. C. Grammer2, R. P. Schleimer2, T. F. Carr3, A. T. Peters2; 1Northwestern University, Evanston, IL, 2Northwestern University Feinberg School of Medicine, Chicago, IL, 3The University of Arizona College of Medicine, Tucson, AZ.

258 Omalizumab Is Effective In Allergic And Non-allergic Patients With Nasal Polyposis And Asthma
P. Gevaert, L. Calus, T. Van Zele, K. Blomme, N. De Ruyck, W. Bauters, P. Hellings, D. De Bacquer, G. Brusselle, P. Van Cauwenberge, C. Bachert; Ghent University, Gent, BELGIUM.

IL-21 Is Increased in Nasal Polyposis and after Stimulation with Staphylococcus Aureus Enterotoxins
L. Calus1, I. Derycke1, N. De ruyck1, G. Holtappels1, M. Dullaers2, B. Lambrecht2, C. Bachert1, P. Gevaert1; 1Upper airways research laboratory, Ghent, BELGIUM, 2Laboratory of Immunoregulation and Mucosal Immunology, Ghent, BELGIUM.

Oral Abstract Session

Cytokines Initiating Allergic Responses
2607
Session Time: Saturday, March 3, 2012,
2:00 PM - 3:15 PM

260 The Interaction Between Ara h 1 and TSLP Selectively Expands Skin-Homing Th2 Cells in Peanut-Sensitized Children
J. A. Wisniewski, M. D. Yu, S. P. Commins, J. A. Woodfolk; University of Virginia, Charlottesville, VA.

261 Allergen Induces Dual Upregulation of TSLP Receptor on Circulating Basophils and Dendritic Cells in Atopic Dermatitis
R. Agrawal, P. W. Wright, J. A. Woodfolk; University of Virginia, Charlottesville, VA.

262 IL-33 Mediates Both Innate and Adaptive Th2-type Responses Induced by Proteases in the Airway
K. Harai1,2, K. Iijima1, T. Kobayashi1, G. Kephart1, H. Kita1; 1Mayo Clinic, Rochester, MN, 2Department of Medicine and Biological Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, JAPAN.

263 Roles for IL-33 and TSLP in Chronic Eosinophilic Airway Inflammation Induced by Airborne Allergen Exposure
K. Iijima, T. Kobayashi, K. Harai, G. M. Kephart, H. Kita; Mayo Clinic, Rochester, MN.

264 Role of Thymic Stromal Lymphopoietin (TSLP) in Chronic Rhinosinusitis
A. Kato1, J. A. Poposki1, D. R. Nagarkar1, B. K. Tan2, M. R. Comeaux1, A. L. Budelsky2, L. Suh1, J. Norton1, K. E. Harris1, A. T. Peters2, L. C. Grammer1, R. K. Chandra1, D. B. Conley2, R. C. Kern2, R. P. Schleimer1; 1Allergy-Immunology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Department of Inflammation Research, Amgen Inc., Seattle, WA.

Oral Abstract Session

Drug Allergy
2608
Session Time: Saturday, March 3, 2012,
2:00 PM - 3:15 PM

265 Influenza Vaccine Administration in Egg Allergic Children
F. S. Khan1, F. S. Virani1,2, C. T. Furukawa1,2, L. C. Altman1,2, P. V. Williams1,2, M. S. Kennedy1,2, J. W. Becker1,3, M. V. Lasley1,2;
M. E. Weiss1,2, S. A. Tilles1,2, A. J. Tatum1,2, J. C. Walker1,2, T. N. Tran1,2, D. R. Naimi1,2, A. Y. Park1,2, N. J. Attaway1,2, J. D. Sprenger1,2, D. Frazier2, T. Chinn2, L. Higgins2;
1University of Washington, Seattle, WA, 2Northwest Asthma and Allergy Center, Inc, Seattle, WA, 3The Polyclinic, Seattle, WA.

266 Experience With Carboplatin Desensitization: A Case Series

A. Updegraff1, D. Bestul1, D. Doshi1;
1William Beaumont Beaumont Hospital, Department of Internal Medicine and Pediatrics, Royal Oak, MI, 2William Beaumont Beaumont Hospital, Department of Pharmacology, Royal Oak, MI, 3William Beaumont Beaumont Hospital, Department of Internal Medicine and Pediatrics, Division of Allergy and Immunology, Oakland University William Beaumont School of Medicine, Royal Oak, MI.

267 Nasal Inflammatory Mediators In Non-steroidal Anti-inflammatory Drugs (nsaids) Cross-intolerant Subjects After Lysine Nasal Challenge

I. Dona1, P. Campo1, M. Sanak2, J. Cornejo2, A. Correa2, N. Blanca-Lopez3, M. Salas4, M. Sanchez2, G. Canto4, M. Blanca1;
1Allergy Department, Hospital Carlos Haya, Malaga, SPAIN, 2Molecular Biology, Dept. of Medicine, UJ CM, Krakow, POLAND, 3Allergy Laboratory, F. IMABIS, Malaga, SPAIN, 4Allergy Department, Hospital Infanta Leonor, Madrid, SPAIN.

268 Anaphylaxis as a Potential Cause of Death in Heroin Users

X. Zhou1, M. White1, L. Lau1, S. Williams1, A. C. Bateman2, E. Abu3, A. F. Walls4;
1University of Southampton, Southampton, UNITED KINGDOM, 2Southampton University Hospitals NHS Trust, Southampton, UNITED KINGDOM.

269 Beta Blocker Pretreatment before Coronary CT Angiography does not Increase the Rate of Contrast Reactions

C. B. Lauter1, G. L. Raff1, K. M. Chinnaiyan, A. Abidov1, William Beaumont Hospital, Royal Oak, MI.

Poster Session

Asthma Therapeutics and Management

3201 Session Time: Sunday, March 4, 2012, 9:45 AM - 10:45 AM

270 Impact on Anti-Endotoxin Immunity of Allergen Specific Immunotherapy and Probiotics in Asthmatic Patients

V. A. Beloglazov1, L. K. Znamenska1, Y. A. Biysuk1, L. M. Dubuske2;
1Crimea State Medical University, Simferopol, UKRAINE, 2ImmunoResearch Institute of New England, Gardner, MA.

271 Use Of Omalizumab To Treat A Nine-year Old, With Steroid-dependent, Allergic Asthma, Adrenal Insufficiency And Vertebral Compression Fractures Due To Steroid-induced Severe Osteoporosis

S. Santucci1, A. Ring1, C. Rizk2, I. MacLuskey2, J. Karsh2, W. H. Yang1;
1Yang Medicine, Ottawa, ON, CANADA, 2University of Ottawa, Ottawa, ON, CANADA.

272 Overturning The Conventional Notion Of Bronchial Asthma Treatment

Y. Shimoide;
Yoshiteru Shimoide Clinic of Internal Medicine, Kagoshima City, JAPAN.

273 Reductions In Oral Corticosteroid Use In Patients With Allergic (IgE- Mediated) Asthma Receiving Omalizumab

G. Braunstahl1, R. Maykut2, M. Figliomeni3, C. Chen4, G. Peachey5;
1St. Francisca Gasthuis, Rotterdam, NETHERLANDS, 2Novartis Pharma AG, Basel, SWITZERLAND, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4Novartis Pharmaceuticals UK Limited, Horsman, West Sussex, UNITED KINGDOM.

274 Impact of Omalizumab on Emergency-Department Visits, Hospitalizations and Corticosteroid Use in Patients with Uncontrolled Asthma Using High-Dose Inhaled Corticosteroids

M. Lafeuille1, J. Dean1, J. Zhang2, M. S. Duhl3, B. Gorsh7, P. Lefvre1;
1Groupe d’analyse, Ltee, Montreal, QC, CANADA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, 3Analysis Group, Inc., Boston, MA.

275 Characterization and Predictors of Asthma Exacerbations in Patients on Steps 4, 5 And 6 Therapy in the TENOR Cohort

W. Calhoun1, T. Haselkorn2, D. R. Mink3, D. P. Miller1, A. Dorenbaum1, R. Zeiger1;
1University of Texas Medical Branch, Galveston, TX, 2Genentech, South San Francisco, CA, 3ICON Late Phase & Outcomes Research, San Francisco, CA, 4Genentech, Inc., South San Francisco, CA, 5Kaiser Permanente Southern California, San Diego, CA.

276 Predictive Factors for Therapeutic Response to Asthma Treatment with Montelukast or Fluticasone in a Randomized Controlled Trial with Asthmatic Smokers

D. Price1, L. Bjerman2, T. A. Popov3, S. Lu4, R. Petrovic4, K. Vandormael1, A. Meltl1, J. D. Strus4, P. G. Polos4, G. Philips1;
1University of Aberdeen, Cambridge, UNITED KINGDOM, 2Skane University Hospital, Lund, SWEDEN, 3Alexander’s University Hospital, Sofia, BULGARIA, 4Merck Sharp & Dohme Corp., Whitehouse Station, NJ.

277 Oral Corticosteroid Use Increases the Risk of Glucocorticoid-related Adverse Events in Asthmatics

J. L. Zazzali1, M. Broder2, E. Chang3;
1Genentech, Inc., South San Francisco, CA, 2Partnership for Health Analytic Research, Beverly Hills, CA.

278 Onset and Duration of Action of Mometasone Inhalation Powder Measured by Impulse Oscillometry (IOS) in Patients on Steps 4, 5 And 6 Therapy in the TENOR Cohort

J. Hong1, M. Kang2, H. Kim3, J. Seo1, Y. Kim2, J. Yu1, S. Hong1;
1Cushing Academy, Ashburnham, MA, 2Asian Institute for Life Science, Asian Medical Center, Seoul, KOREA, REPUBLIC OF, 3Childhood Asthma Atopy Center, Department of Pediatrics, Asian Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF.

280 Association Between The STIP1 Polymorphism And The Response To Inhaled Steroid In Children With Asthma

J. Hong1, M. Kang2, H. Kim3, J. Seo1, Y. Kim2, J. Yu1, S. Hong1;
1Cushing Academy, Ashburnham, MA, 2Asian Institute for Life Science, Asian Medical Center, Seoul, KOREA, REPUBLIC OF, 3Childhood Asthma Atopy Center, Department of Pediatrics, Asian Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF.

281 The Ability and Predictive Factors of Preschool Children to Use Swingshaler Device

P. Letchmanarangrit1, P. Rattanasukol, N. Suratannon, N. Voraphani, P. Chatchatee, J. Ngamphaiboon;
Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, THAILAND.

282 Comparative Sensitivity of Various Indices in Evaluating Improvement in Mild Persistent Asthma

A. G. Ayars1, S. Potter-Perigo2, T. N. Wight2, S. A. Tilles1, L. C. Altman1;
1University of Washington, Seattle, WA, 2Benaroya Research Institute, Seattle, WA, 3ASTHMA Inc, Seattle, WA.

283 Combined Mometasone Furoate and Formoterol in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD): Phase 3 Efficacy and Safety Study

284 Efficacy of Budesonide/Formoterol Pressurized Metered-Dose Inhale in Patients With Mild to Moderate Asthma With and Without Fixed Airflow Obstruction
B. E. Chips\textsuperscript{1,2}, D. P. Tashkin\textsuperscript{3}, T. Uryniak\textsuperscript{4}, S. Zhao\textsuperscript{3}, J. G. Zangrilli\textsuperscript{1};
\textsuperscript{1}Capital Allergy and Respiratory Dis. Ctr., Sacramento, CA, \textsuperscript{2}University of California, Los Angeles, Los Angeles, CA, \textsuperscript{3}AstraZeneca LP, Wilmington, DE.

285 Clinical Pharmacokinetics and Tolerability of AZD3199, a New Inhaled Ultra Long-acting β₂-adrenoceptor Agonist (uLABA) Bronchodilator
P. Kuna\textsuperscript{1}, J. Rosenborg\textsuperscript{2}, T. Bengtsson\textsuperscript{3}, C. Junop\textsuperscript{4}, L. Bjerner\textsuperscript{2};
Barlucchini University Hospital, Medical University of Lodz, Lodz, POLAND, \textsuperscript{3}AstraZeneca Rd&D, Molndal, SWEDEN, \textsuperscript{4}University Hospital, Lund, SWEDEN.

286 Long-term Cardiovascular Safety, as Evaluated by Electrocardiographic Monitoring, of Budesonide/Formoterol Pressurized Metered-Dose Inhaler in African-American Patients With Moderate to Severe Asthma
R. W. Brown\textsuperscript{1}, C. D. O’Brien\textsuperscript{2}, U. J. Martin\textsuperscript{3}, T. Uryniak\textsuperscript{4}, K. L. Lampl\textsuperscript{5};
\textsuperscript{1}Children’s Hospital of Michigan/University of Michigan School of Public Health, Ann Arbor, MI, \textsuperscript{2}AstraZeneca LP, Wilmington, DE.

287 Efficacy of Budesonide/Formoterol Pressurized Metered-Dose Inhaler in Patients With Moderate to Severe Asthma With and Without Fixed Airflow Obstruction
D. P. Tashkin\textsuperscript{1,2}, B. E. Chips\textsuperscript{3}, T. Uryniak\textsuperscript{1}, S. Zhao\textsuperscript{1}, J. G. Zangrilli\textsuperscript{1};
\textsuperscript{1}David Geffen School of Medicine at UCLA, Los Angeles, CA, \textsuperscript{2}Capital Allergy and Respiratory Disease Center,Sacramento, CA, \textsuperscript{3}AstraZeneca LP, Wilmington, DE.

288 Post-hoc Analysis Of Short-acting Beta-agonist Efficacy In Baseline Corticosteroid Users And Non-corticosteroid Users Following Treatment With Levalbuterol Metered-dose Inhaler, Racemic Albuterol Or Placebo In Asthma Patients Ages 4-11 Years
J. Walsh\textsuperscript{1}, D. Skoner\textsuperscript{2,3}, W. Berger\textsuperscript{4}, N. Wilson\textsuperscript{1};
\textsuperscript{1}Sunovion Pharmaceuticals Inc., Marlborough, MA, \textsuperscript{2}Allegheny General Hospital, Pittsburgh, PA, \textsuperscript{3}Drexel University College of Medicine,Philadelphia, PA, \textsuperscript{4}Allergy and Asthma Associates, Mission Viejo, CA.

289 The Relationship between Sales Data for Asthmatic Drugs and Asthma Events
A. Tanaka, K. Sugiyama, H. Hirata, T. Kakuta, M. Watanabe, M. Tatewaki, A. Takeda, M. Arima, Y. Fukushima, T. Fukuda; Dokkyo Medical University, Tochigi, JAPAN.

290 Clinical Usefulness of Asthma Clinical Pathway for Management of Acute Asthmatic Children in Pediatric Emergency Department
H. Kim, Y. Chun, J. Yoon, J. Kim, J. Lee;
The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF.

291 Gastroesophageal Reflux Is Associated With More Severe Acute Respiratory Illness In Infants
Vanderbilt University School of Medicine, Nashville, TN.

292 Flavonoid-Rich Alcoholic Extract of Leaves of Achyranthes Aspera Reduces Inflammation in a Murine Model of Ova-Induced Asthma
R. Kandasamy\textsuperscript{1}, G. R. Hellermann\textsuperscript{2}, S. S. Mohapatra\textsuperscript{2,3}, R. F. Lockey\textsuperscript{2,3};
Anna University of Technology, Tiruchirappalli, INDIA, \textsuperscript{2}Division of Allergy and Immunology-Joy McCann Culverhouse Airway Disease Center, Dept. of Internal Medicine and Nanomedicine Research Center, College of Medicine, Tampa, FL, \textsuperscript{3}James A. Haley, VA Hospital, Tampa, FL.

293 The effect of vitamin D Status on Pediatric Asthma in a University hospital, Thailand
W. Krobrakulchai;
Siriraj, bangkok, THAILAND.

294 History Of Asthma Maintenance Medication Use And Asthma Exacerbation Risk Factors Before Initiation Of Inhaled Corticosteroid/Long-acting β-agonist (ICS/LABA) Combination Therapy For Asthma: Comparison Of Budesonide/formoterol (BFC) And Fluticasone/salmeterol (ICS) In A US Commerically Insured Population
O. Tunceli\textsuperscript{1}, D. Kern\textsuperscript{1}, S. Ramachandran\textsuperscript{2}, N. Pethick\textsuperscript{2};
\textsuperscript{1}HealthCore, Wilmington, DE, \textsuperscript{2}AstraZeneca, Wilmington, DE.

295 Positive Correlation Between Serum IL-5 and TNF-alpha Levels and Churg-Strauss Syndrome Activity in Patients Successfully Treated with Montelukast
K. Lisichuk-Yakymovych\textsuperscript{1}, V. Chopyak\textsuperscript{1}, R. Pukalyak\textsuperscript{1}, L. M. DuBuske\textsuperscript{2};
\textsuperscript{1}Liviv National Medical University, Liviv, UKRAINE, \textsuperscript{2}Immunology Research Institute of New England, Gardner, MA.

Poster Session

Immunogenetics and Immunophenotyping

3202 Session Time: Sunday, March 4, 2012, 9:45 AM - 10:45 AM

296 Role of a Plasminogen Activator Inhibitor-1 4G/5G polymorphism in the development and clinical outcome of Idiopathic Sudden Sensorineural Hearing Loss
J. Kim\textsuperscript{1}, H. Chen\textsuperscript{1}, I. Kim\textsuperscript{1}, C. Yokose\textsuperscript{1}, C. Cai\textsuperscript{2}, S. Palma\textsuperscript{3}, M. Busi\textsuperscript{4}, A. Martin\textsuperscript{1}, T. J. Yoo\textsuperscript{2}, S. H. Cho\textsuperscript{1};
\textsuperscript{1}Northwestern University Feinberg School of Medicine, Chicago, IL, \textsuperscript{2}University of Tennessee College of Medicine, Memphis, TN, \textsuperscript{3}University of Modena, Modena, ITALY, \textsuperscript{4}University of Ferrara, Ferrara, ITALY.

297 Interferon-Gamma Gene Polymorphism In Patients With Allergy
O. O. Yanovich\textsuperscript{1}, L. V. Maslova\textsuperscript{1}, L. P. Titov\textsuperscript{1}, L. M. DuBuske\textsuperscript{2};
\textsuperscript{1}Research Institute for Epidemiology and Microbiology, Minsk, BELARUS, \textsuperscript{2}Immunology Research

298 Incidence of Immunodeficiency in Patients with 49-XXXXY Chromosomal Variation
M. D. Keller\textsuperscript{1}, C. Samango-Sprouse\textsuperscript{2}, T. Sadeghin\textsuperscript{1}, J. S. Orange\textsuperscript{1};
\textsuperscript{1}Children’s Hospital of Philadelphia, Philadelphia, PA, \textsuperscript{2}George Washington University of the Health Sciences, Washington, DC.

299 INTERLEUKIN 1 BETA +3953 C/T Gene Polymorphism In Patients With Asthma And Chronic Obstructive Pulmonary Disease In Venezuela
N. E. Lorocca;
Universidad Central de Venezuela, Caracas, VENEZUELA, BOLIVARIAN REPUBLIC OF.

300 Pregnancies in Women with Hereditary Angioedema due to Mutations in the F12 gene
E. Aygoren-Pursun\textsuperscript{1}, I. Martinez Saguer\textsuperscript{1}, G. Dewald\textsuperscript{2}, E. Rusicke\textsuperscript{1}, T. Klingebiel\textsuperscript{1}, W. Kreuz\textsuperscript{1};
301 Lack Of Associations Between Tnf-α Genetic Polymorphism -308g/a And Anti-tuberculosis Drug-induced Maculopapular Eruption

S. Kim, Y. Kim, H. Yoon, D. Shin, S. Park, Y. Kim, J. Park, Y. Jee

1Hanyang University College of Medicine, Seoul, KOREA, REPUBLIC OF; 2Eulji University School of Medicine, Seoul, KOREA, REPUBLIC OF; 3Dankook University College of Medicine, Cheonan, KOREA, REPUBLIC OF.

302 Reactivity Profile Of IgE, IgG1 And IgG4 To Dermatophagoides farinae Allergen Extract In Atopic And Non-atopic Patients Using Immunoproteomics Approach


1Federal University of Uberlandia, Uberlandia, BRAZIL; 2State University of Santa Cruz, Ilheus, BRESIL.

303 Blood Type Does Not Predict the Development of an IgE Response to Galactose-alpha-1,3-Galactose

N. D. Cresce, J. Posthumus, T. A. E. Platts-Mills, S. P. Commins; University of Virginia, Charlottesville, VA.

304 Classification of 26 Cases of Biopsy-proven Eosinophilic Myocarditis

R. I. Siles, S. DaVeiga, B. C. Schroer, F. H. Hisch

1Cleveland Clinic Foundation, Cleveland, OH; 2Children’s Hospital of Philadelphia, Philadelphia, PA.

305 Basophil Autoinducted Degranulation (BAD) Test, A New Variant Of Basophil Activation Test (BAT) As Reliable In Vitro Tool For The Diagnosis Of Chronic Autoimmune Urticaria (CAU)

M. Caruso, G. Tringali, C. Russo, R. Polosa

1University of Catania, Catania, ITALY; 2Istituto Ricerca Medica ed Ambientale (IRMA), Acireale (CT), ITALY.

306 Levels Of Inflammatory Cytokines And Chemokines In Bronchoalveolar Lavage Fluid In Patients With Idiopathic Interstitial Pneumonitis And Collagen Vascular Disease Associated Interstitial Pneumonitis

m. tatewaki

Dokky Medical University, Tochigi, JAPAN.

307 Terreysin, A Potential Biomarker of Exposure to Aspergillus terreus

A. P. Nayak, B. J. Green, D. H. Beezhold

1National Institute for Occupational Safety and Health, Morgantown, WV; 2West Virginia University, Morgantown, WV.

308 Type III Hereditary Angioedema: First Description of a Mutation in Factor XII Gene and Clinical Features in a Brazilian Family


1School of Medicine of Ribeirão Preto, Ribeirão Preto, BRAZIL; 2Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, BRAZIL; 3Joseph-Fourier University of Grenoble, Grenoble, FRANCE.

309 Parasite-related IgE Antibodies, Including IgE to Galactose-alpha-1,3-galactose, in Sera from Virginia and Ecuador


1University of Virginia, Charlottesville, VA; 2Futures Group International, Nairobi, KENYA; 3Universidad San Francisco de Quito, Cumbay, ECUADOR; 4Liverpool School of Tropical Medicine, Liverpool, UNITED KINGDOM.

310 Analysis Of 4,610 Patients With Elevated Serum Immunoglobulin E

R. Rokutanda, K. Yamaguchi, H. Shimizu, Y. Suyama, Y. Ohara, A. Takeda, M. Kishimoto, M. Okada; St.Luke’s International Hospital, Tokyo, Japan; Tokyo, JAPAN.
Cytokine Profile Shifts In Patients With Recurrent Herpes Simplex Of The Oral Mucosa And Lips
G. N. Drannik, A. I. Kurchenko, R. A. Rehuretska, L. M. Dubuske
1National Medical University, Kiev, UKRAINE, 2Immunology Research Institute of New England, Gardner, MA.

A Novel Severe Combined Immunodeficiency (SCID) Mutation in Three Mexican Siblings with additional de novo Duchenne Muscular Dystrophy (DMD) mutation
Bayelor College of Medicine- Texas Children’s Hospital, Houston, TX.

Role of IgM in Pulmonary Complications of Common Variable Immunodeficiency (CVID)
P. J. Maglione
Mount Sinai Medical Center, New York, NY.

The Medical Awareness Concerning Primary Immunodeficiency Diseases (PID) in the City of Sao Paulo, Brazil
1Federal University of Sao Paulo (UNIFESP), Sao Paulo, BRAZIL, 2Hospital Israelita Albert Einstein, Sao Paulo, BRAZIL, 3Hospital do Servidor Publico Municipal, Sao Paulo, BRAZIL, 4University of Sao Paulo, Sao Paulo, BRAZIL.

Vitamin D Levels and Respiratory Infections in Patients with Common Variable Immunodeficiency
J. Zheng, K. Gundling
1Kaiser Permanente Medical Group, Oakland, CA, 2University of California, San Francisco, San Francisco, CA.

Prolonged Klebsiella Sepsis and Meningitis in a Five Week Old Infant with an iKBKG Gene Mutation (NEMO)
S. S. Griffin, T. P. Atkinson
University of Alabama at Birmingham, Birmingham, AL.

Common Variable Immunodeficiency Presenting with Stenotrophomonas maltophilia Pneumonia
S. D. Dickson, R. H. Waibel
1Department of Allergy and Immunology, Wilford Hall Ambulatory Surgical Center, Lackland AFB, TX, 2Department of Medicine, San Antonio Military Medical Center, Fort Sam Houston, TX.

Correlation Between IgG, IgA, IgM and BMI or Race in a Large Pediatric Population
A. Mehta, G. Ramirez, G. Ye, S. McGeady, C. Chang
1Alfred I duPont Children’s Hospital, Wilmington, DE, 2Thomas Jefferson University, Philadelphia, PA, 3Nemours Children’s Health System, Orlando, FL.

Vitamin D Levels and Respiratory Infections in Patients with Common Variable Immunodeficiency Presenting in a Previously Healthy Child After Splenectomy for Autoimmune Cytopenias
C. Sokol, F. Bonilla, M. R. Murali, J. Walter
1Massachusetts General Hospital, Boston, MA, 2Children’s Hospital Boston, Boston, MA.

Griscelli Syndrome In A Newborn With Silver Hair And Seizures
S. Min, Z. Zakarian, S. Yano, P. Huyhn, MD, L. Scott
LAC+USC Medical Center, Los Angeles, CA.

Novel Allergens and Extracts: New Ways to Measure Sensitization
SUNDAY

High Resolution Crystal Structure of Peanut Allergen Ara H 5
Y. Zhang, Y. Wang
1US Dept of Agriculture, Albany, CA, 2Illinois Institute of Technology, Chicago, IL.

Radial Immunodiffusion (RID) to Sandwich ELISA for the Quantitation of Fel d 1 and Amb a 1 in Cat and Short Ragweed Pollen Allergenic Extracts
S. Huynh, S. Menzies, T. Khurana, T. Lin, L. Yan, N. deVore, J. E. Slater, R. L. Rabin
FDA, Bethesda, MD.

Validation by Patch Testing of a Blood Test for Nickel Sensitization
K. A. Pacheco, L. Barker, L. Shimame-More, V. Nagabhushanam
National Jewish Health, Denver, CO.

Discordance Between Skin Prick Test and Aeroallergen Specific IgE in Children Under the Age of Four
P. Parikh, D. Ferastaoroa, R. Nizari, Y. Pichardo, M. Chin, D. Serebriksy, G. deVo1
1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, NY, 2Jacobi Medical Center, Bronx, NY, NY.

Allergen Specificity Of 3 ScfV Antibodies Developed For A Multiplex Assay Of Blattella Germanica Extract Potency
T. Khurana, M. Collision, F. Chew, K. Jeong, J. Slater
1FDA, Bethesda, MD, 2National University of Singapore, Singapore, SINGAPORE, 3Institute of Tropical Medicine, Seoul, KOREA, 4DEMOCRATIC PEOPLE’S REPUBLIC OF.

IgE Against Bed Bug (Cimex lectularius) Allergens Are Common Among Adults Bitten By Red Bugs
1Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY, 2Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, 3Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ.

Assessment of Allergenicity of GMO Maize Pollen
H. Steimann
Food & Allergy Consulting & Testing Services, Milnerton, Cape Town, SOUTH AFRICA.
Poster Session

Measuring Allergen Exposures

3205
Session Time: Sunday, March 4, 2012, 9:45 AM - 10:45 AM

340 Development Of A System For Pollen Forecasting In Vinnitsa, Ukraine
V. Rodinkova1, L. M. DuBuske2.
1Vinnitsa National Pirogov Memorial Medical University, Vinnitsa, UKRAINE, 2Immunology Research Institute of New England, Gardner, MA.

341 Airborne Exposures To Allergen And Particles With And Without Carpeting
B. Mitchell, A. Southey, M. Fox, G. Hughes, T. Yeomans; Airmid Healthgroup Ltd., Dublin, IRELAND.

342 Mouse and Cockroach Exposure in Rural Arkansas Delta Region Homes
A. T. Coleman1, M. Rettiganti1, S. Bai1,2, R. H. Brown1, T. T. Perry3.
1UAMS/Arkansas Children’s Hospital, Little Rock, AR, 2Ohio State, Columbus, OH.

343 The Relationship Between Indoor Particulate Matter and Home Ventilation
A. L. Humphrey, L. C. Gard, C. S. Barnes, C. E. Ciaccio; Children’s Mercy Hospital and Clinics, Kansas City, MO.

344 The Effects Of Wind Conditions On Ragweed Counts
S. C. Argo, C. S. Barnes, M. G. Dhar, J. M. Portnoy; Children’s Mercy Hospitals and Clinics/University of Missouri-Kansas City, Kansas City, MO.

345 Is Red-Berry Juniper an Overlooked Fall Allergen in the Southwest?
E. Levetin1, L. Bunderson1, P. Van de Water2, J. Luvall3.
1University of Tulsa, Tulsa, OK, 2California State University - Fresno, Fresno, CA, 3NASA Marshall Space Flight Center, Huntsville, AL.

346 Trends In Kansas City Tree Pollen: A 15 Year Perspective
N. Raje, C. S. Barnes, M. G. Dhar, J. M. Portnoy; Children’s Mercy Hospitals & Clinics/University of Missouri-Kansas City, Kansas City, MO.

347 Pilot Study on Inhaled Allergen filtration performance of newly developed intranasal filter
J. Lee, J. Sohn, C. Hong, J. Park; Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF.

348 Collection and Detection of Airborne Cat Allergen, Fel d 1, with a Compact Ionic Capture Device
J. Gordon; Inspirotec Inc, Chicago, IL.

349 When Is It Safe To Go Outside? Nighttime Juniper Pollen Concentrations In Texas, Oklahoma, And New Mexico
L. D. Bunderson1, P. Van de Water2, J. Luvall3, E. Levetin1.
1The University of Tulsa, Tulsa, OK, 2California State University, Fresno, Fresno, CA, 3NASA, Huntsville, AL.

350 Falsely Ascribing Changes In Disease Patterns To Climate Change
R. J. Green, J. Cloete; University of Pretoria, Pretoria, SOUTH AFRICA.

351 A Recent Significant Increase In Ambrosia Pollen Abundance In Central Ukraine
O. Palamarchuk, V. Rodinkova, L. M. DuBuske.
1Vinnitsa National Pirogov Memorial Medical University, Vinnitsa, UKRAINE, 2Immunology Research Institute of New England, Gardner, MA.

Poster Session

EGID/Immunologic GI Disorders

3206
Session Time: Sunday, March 4, 2012, 9:45 AM - 10:45 AM

352 Identification Of Increased Oral Eosinophils In Patients With Eosinophilic Esophagitis (EE) Using Oral Rinse Analysis: Proof Of Concept
J. Ohayon; McMaster University, Hamilton, ON, CANADA.

353 Fecal Eosinophil-derived Neurotoxin Is Significantly Elevated In Non-ige Dependent Gastrointestinal Allergies, Especially In Subtypes Showing Bloody Stool
H. Morita1,2, I. Nomura1, T. Shoda1, H. Saito1, K. Matsumoto1.
1National Research Institute for Child Health and Development, Tokyo, JAPAN, 2Department of Pediatrics, Keio University School of Medicine, Tokyo, JAPAN.

354 Dynamics of Eosinophils in Non-IgE-mediated Gastrointestinal Food Allergies in Neonates and Infants, differences between 4 Clusters

355 Our 3-year Experience with Patch Testing for Eosinophilic Esophagitis
C. S. Bauer1,2, A. R. Lamba1, H. P. Zimmerman1, R. G. Hoffmann1, M. Dasgupta1, R. J. Noel1, M. B. Levy2, M. Vasudev1.
1Medical College of Wisconsin, Milwaukie, WI, 2Assaf Harofe Medical Center, Tzrifin, ISRAEL.

356 Food Extract Testing for Delayed-Type hypersensitivity in Eosinophilic Esophagitis
D. M. Robertson, J. L. Baldwin, M. J. Greenhawt; University of Michigan, Ann Arbor, MI.

357 Quantifying Allergic Sensitivities among Adults with Eosinophilic Esophagitis
1Nationwide Children’s Hospital, Columbus, OH, 2The Ohio State University Medical Center, Columbus, OH, 3University of Virginia Asthma and Allergic Diseases Center, Charlottesville, VA.

358 Evaluation of Skin Testing to Aeroallergens and Foods in the Management of Adults with Eosinophilic Esophagitis and Response to Comprehensive Therapy

359 Clinical and Laboratory Characteristics of Adults with Eosinophilic Esophagitis
M. A. Slack1, C. B. Cho1, R. Raveendran1, E. Erwin2, P. U. Ogbo2.
Poster Session

Drug Allergy

371 Utility of a Website-based Database of Drug Allergy Case Reports and Desensitization Protocols
T. W. Pun1, Z. Abdurrahman2, R. Warrington1, A. Noyek1;
1University of Manitoba, Winnipeg, MB, CANADA, 2McMaster University, Hamilton, ON, CANADA.

372 Outcomes Of Adult Provocation Tests In A Singapore Allergy Centre
M. Thalayasingam1, L. J. Davies2, G. Llanora1, I. Gerez1, H. Van Bever1,2, L. P. C. Shek1,2;
1National University Hospital, Singapore, SINGAPORE, 2National University of Singapore, Yong Loo Lin School of Medicine, Singapore, SINGAPORE.

373 Survey of Drug Allergy Testing, Challenge, and Desensitization Practice
J. H. Butterfield, C. Osie; Mayo Clinic, Rochester, MN.

374 Analysis Of Adverse Drug Reactions In Children
G. M. Park1, J. H. Seo2, H. Y. Kim3, Y. W. Hwang3, Y. S. Na1, Y. C. Song3, J. H. Yu3, S. J. Hong3;
1Childhood Asthma Atopy Center, Department of Pediatrics, Department of Pharmacy, Asan Medical Center, University of Ulsan College of Medicine, seoul, KOREA, REPUBLIC OF; 2Childhood Asthma Atopy Center, Research Center for Standardization of Allergic Diseases, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, seoul, KOREA, REPUBLIC OF; 3Department of Pharmacy, Asan Medical Center, University of Ulsan College of Medicine, seoul, KOREA, REPUBLIC OF.

375 A Survey of Current Physician Practice and Knowledge of Drug Allergy at a University Medical Center
J. Sturm, J. Temporano; Saint Louis University, St. Louis, MO.

376 Pediatric Patients with a History of Penicillin Allergy and a Positive Penicillin Skin Test May Not Be at an Increased Risk for Multiple Drug Allergies
V. A. Martin, M. A. Park; Mayo Clinic, Rochester, MN.

377 Multiple Drug Intolerance Syndrome: Prevalence, Clinical Characteristics, And Management
E. M. Macy1, N. J. Ho; 1SCPMG-Kaiser Permanente San Diego, San Diego, CA, 2Kaiser Permanente Healthcare Program - Department of Research and Evaluation, Pasadena, CA.

378 Characterization of Multiple Antibiotic Allergies in Adult and Pediatric Patients
P. B. M. Jhaveri, B. VanNostrand, F. Ishmael; Penn State Hershey Medical Center, Hershey, PA.

379 Immediate Hypersensitivity To Quinolones: Drug Photodegradation Influences The Specific Basophil Activation
C. Mayorga1, A. Aranda1, I. Andreu1, M. I. Montaez1, A. Ariza1, I. Doa, PhD1, N. Blanca-Lopez2, E. Nuin2, M. A. Miranda2, M. Blanca3, M. J. Torres1;
380 Immunologic Evaluation of Quinolone Hypersensitivity
Y. NAM;
1Department of Allergy & Clinical Immunology, Ajou University School of Medicine, Suwon, KOREA, REPUBLIC OF.

381 Allergy To Betalactams Is A Risk Factor For Anaphylaxis To Quinolones
M. J. Torres1, I. Dona1, I. Garcia1, F. Gomez1, M. Salas1, N. Blanca-Lopez2, M. D. Caamero1, G. Canto2, M. Blanca1;
1Carlos Haya Hospital, Malaga, SPAIN, 2Infanta Leonor Hospital, Madrid, SPAIN.

382 Skin Testing and Graded Challenges for Meropenem Hypersensitivity in Penicillin Allergic Subjects
Northwestern Univ. Feinberg School of Medicine, Chicago, IL.

383 The Potential of Using ELISPOT to Diagnose Cephalosporin-induced Maculopapular Exanthems
J. Klaewsongkram, B. Tanvarasethee, S. Buranapradditkun;
Chulalongkorn University, Bangkok, THAILAND.

384 Epidemiology of Betalactams Hypersensitivity in a Drug Allergy Unit
HOSPITAL CRUZ ROJA, MADRID, SPAIN.

385 Value Of Skin Testing Solely With Penicillin G In Children With a History Of Penicillin Allergy
CHU Sainte-Justine, Montreal, QC, CANADA.

386 Cross-Reactivity between Penicillins and Third-Generation Cephalosporins
Hospital General Universitario Gregorio Maranon, Madrid, SPAIN.

387 Cephalosporin Allergy: Cross-reactivity To Penicillin In Pediatric Patients
E. K. Ham, M. Park;
Mayo Clinic, Rochester, MN.

388 Safety and Effectiveness of Penicillin Allergy Evaluation in the Pre-Lung Transplant Patient Population
R. GUTTA, C. Radojicic;
Cleveland Clinic, Cleveland, OH.

389 Prevalence of Penicillin Allergy and Adverse Outcomes in Geriatric Inpatients at a Tertiary Care Hospital
N. Baman, B. VanNostrand, F. Ishmael;
Pennsylvania State University Milton S. Hershey Medical Center, Hershey, PA.

390 Carrier Molecules Displaying Dual Haptenic Presentation for in Vivo Testing to Determine IgE Antibody in Patients Allergic to Betalactams
M. I. Montanez1, A. J. Ruiz-Sanchez2, A. Ariza1, C. Mayorga1, E. Perez-Insfranosa1, J. L. Rodriguez-Bada1, M. D. Ruiz1, M. Blanca1, M. J. Torres1;
1Research Laboratory, IMABIS Foundation-Carlos Haya Hospital, Malaga, SPAIN, 2Organic Chemistry, Faculty of Science, University of Malaga, Malaga, SPAIN.

391 Tlr Expression On Monocyte-derived Dendritic Cells From Patients With Allergy To Betalactams
M. J. Sanchez-Quintero;
Fundacion IMABIS, Malaga, SPAIN.

392 Diagnosis in Hypersensitivity to Oxaliplatin
R. Madrigal-Burgaleta1, M. P. Berges-Gimeno1, D. Angel-Pereira1, G. V. Sanchez-Moreno1, L. Venemalm1, E. Alvarez-Cuesta1;
1Ramon y Cajal University Hospital, Madrid, SPAIN, 2Phadia AB, Upplasa, SWEDEN.

393 Use of Omalizumab to Achieve Successful Desensitization After Oxaliplatin Anaphylaxis
K. N. Cahuil1,2, P. Harrison1, M. de Asis1, M. Castells1,2;
1Brigham and Women’s Hospital, Boston, MA, 2Harvard Medical School, Boston, MA, 3Asthma and Allergy Consultants of Rockland/Bergan County, West Nyack, NY.

394 Hypersensitivity To Docetaxel: Retrospective Study And Desensitization Protocol
E. Syrigou, N. Makrilia, E. Kotteas, F. Psarras, K. N. Syrigos;
Oncology Unit, 3rd Dept of Medicine, Sotiria General Hospital, Athens School of Medicine, Athens, GREECE.

395 Safety of Aspirin Desensitization in Patients with a Cardiac Indication for Aspirin
K. L. McMullan, H. J. Wedner;
Washington University School of Medicine in St. Louis, St Louis, MO.

396 Value Of The Clinical History In The Diagnosis Of NSAID Hypersensitivity Reactions Induced By Cross-intolerance
N. Blanca-Lopez1, I. Dona2, M. Torres2, P. Campos2, C. Rondond2, M. L. Salas2, I. Garcia2, G. Canto1, M. Blanca2;
1Hospital Infanta Leonor, Madrid, SPAIN, 2Hospital Carlos Haya, Malaga, SPAIN, 3Hospital Infanta Leonor, Malaga, SPAIN.

397 Aspirin Allergy in a Community Teaching Hospital
D. E. Riester, J. A. Jones, J. A. Saryan;
Lahay Clinic, Burlington, MA.

398 Etoricoxib: A Probable Safe Alternative For NSAID Intolerant Patients In Asia
G. V. Llanora1, I. F. A.arez1, Y. K. Cheng2, L. P. C. Shek1,3;
1National University Hospital, Singapore, SINGAPORE, 2Gleneagles Hospital, Singapore, SINGAPORE, 3Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.

399 Desensitization to Liposomal Amphotericin B after Anaphylactic Reaction
L. Dhindsa-Castanedo, M. Narra;
Baylor College of Medicine, Houston, TX.

400 Anaphylactic Reaction After 6-methyl-prednisolone
A. Rosado, C. Vila, M. D. Alonso, E. G. Farias, M. Acosta, W. L. Almanzar, M. A. Tejedor;
Hospital Universitario Fundacion Alcorcon, MADRID, SPAIN.

401 Two Cases Of Rituximose-induced Lung Injury In Patients With Amyotrophic Lateral Sclerosis
Dokkyo Medical University, Tochigi, JAPAN.

402 Using Human Single Chain Variable Fragment (scFv) Antibodies for Identification of Potential Allergens of Neuprosora crassa
J. E. Slater1, T. Khurana1, M. Collison1, B. Haynes2, E. Cambier3,2;
1FDA/CBER/OVRR/DBPAP, Rockville, MD, 2Neugenesis Corporation, Burlingame, CA.

403 Allergy to General Anesthetics: Evaluation of Patients Profile in Asia
C. Irani, C. Saade, C. Dagher;
Hotel Dieu de France hospital, Beirut, LEBANON.

404 Retrospective Review of Adverse Reaction Profile of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
T. L. Mertz, A. N. Peric, F. T. Ishmael;
M.S. Hershey Penn State Medical Center, Hershey, PA.

405 Desensitization to Epoetin Alfa in a Patient with Anaphylaxis: a Case Report
C. J. Luna, N. Aziz, R. A. Rodby, M. C. Tobin;
Rush University Medical Center, Chicago, IL.
Clinical Characteristics of Severe Cutaneous Adverse Reactions in a tertiary hospital in Korea

M. Yang, Y. Kim, M. Kim, J. Jung, T. Kim, H. Kang, H. Park, S. Cho;
Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF.

Hypersensitivity Reactions To Monoclonal Antibodies: Desensitization Approach

Hospital General Universitario Gregorio Maranon, Madrid, SPAIN.

Poster Session

Atopic Disease

3208
Session Time: Sunday, March 4, 2012, 9:45 AM - 10:45 AM

1. C1-INH: Test Use Evaluation On In-Patient Adults

V. Yee1, C. Lauter2,3,1
1Wayne State University School of Medicine, Detroit, MI, 2William Beaumont Hospital, Royal Oak, MI, 3Oakland University William Beaumont School of Medicine, Royal Oak, MI.

Distribution of Allergic Sensitization by ISAC Microarray

J. C. Thompson1, P. B. Williams2, G. F. Kroeker3;
1Allergy Associates of La Crosse, Onalaska, WI, 2Mercy Hospitals and Clinics, Kansas City, MO.

Patterns of Intranasal Corticosteroid Use Among Individuals Diagnosed with Allergic Rhinitis: Evidence from a Large Claims Database

M. J. Lage1, G. N. Gross2, P. O. Buck3, M. Lepore3;
1HealthMetrics Outcomes Research, Groton, CT, 2Dallas Allergy and Asthma Center, Dallas, TX, 3Teva North America Branded Pharmaceuticals, Inc., Horsham, PA.

Comparison Of Patient Adherence To Intranasal Corticosteroids By Pressurized Metered-dose Inhaler Versus Aqueous Formulations

M. Lepore1, D. Lang2, L. Cox3, C. S. Hankin4, Z. Wang5, A. Bronstone4, P. O. Buck1;
1Teva North America Branded Pharmaceuticals, Inc., Horsham, PA, 2Cleveland Clinic, Cleveland, OH, 3Teva North America Branded Pharmaceuticals, Inc., Horsham, PA, 4BioMedEcon, Moss Beach, CA.

Evolution of Coverage of Allergy Concepts in Electronic Health Records

A. Yu, M. Ballow, A. Shvarts, H. Lehman;
Division of Allergy and Immunology, Women and Children’s Hospital of Buffalo, SUNY-University at Buffalo, Buffalo, NY.

Does Allergen-Specific Immunotherapy Reduce the Risk, Reverse, and/or Mitigate Asthma in Children with Allergic Rhinitis? The Pediatric IMproved Access to AllerGen-Specific ImmunoNothErapY - Asthma Incidence Rates Among Medicaid Enrollees (Pediatric-IMAGINE-AIRE) Study, Funded by the Joint Council of Allergy, Asthma and Immunology

C. S. Hankin1, L. Cox2, A. Bronstone1, Z. Wang1;
1BioMedEcon, Moss Beach, CA, 2Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, FL.

Poster Session

Mechanisms of Allergic Rhinitis

3209
Session Time: Sunday, March 4, 2012, 9:45 AM - 10:45 AM

Gene-Environment Interaction between TLR4 Gene and Mold Exposure in Infancy on the Development of Allergic Rhinitis in School-Aged Children

H. Kim1,2, J. Seo1,2, S. Lee3,2, M. Kang4, J. Kwon5,2, B. Kim6,2, Y. Song7,2, Y. Kim7, S. Hong7,2;
1Childhood Asthma Atopy Center, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, 2Research Center for Standardization of Allergic Diseases, Seoul, KOREA, REPUBLIC OF, 3Department of Pediatrics, Hallym Sacred Heart Hospital, Hallym University College of Medicine, Anyang, KOREA, REPUBLIC OF, 4Asan Institute for Life Sciences, Asan Medical Center, Seoul, KOREA, REPUBLIC OF, 5Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF, 6Department of Pediatrics, Inje University Haeundae Paik Hospital, Busan, KOREA, REPUBLIC OF, 7Childhood Asthma Atopy Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF.

Development of an In Vitro Fluoro-4 Calcium Assay for Assessing Selective TRPV1 Agonist Responses

B. P. Davis, U. Singh, L. Haar, K. W. Jones, J. A. Bernstein;
University of Cincinnati, Cincinnati, OH.

Differential TRPV1 Activation Responses to Rhinconjunctivitis Pharmacologic Agents Using an In Vitro Fluoro-4 Calcium Assay

U. Singh, L. Haar, W. Jones, J. Bernstein;
University of Cincinnati, Cincinnati, OH.

Abstracts AB273
423 Effects of Head-of-Bed Elevation in Supine Nasopharyngeal Reflex
D. R. Scott, R. A. Simon; Scripps Health, San Diego, CA.

424 Seasonal Local Allergic Rhinitis in Areas with High Exposure to Grass Pollen
F. de la Rosa1, N. Blanca-Lopez2, C. Rondon3, R. Herrera4, J. L. Rodriguez-Bada4, G. Canto5, F. Feo Bríto6, M. Blanca Gomez7; 1Allergy Service, General Hospital, Ciudad Real, SPAIN, 2Allergy Service, Infanta Leonor Hospital, Madrid, SPAIN, 3Allergy Service, Carlos Haya Hospital, Malaga, SPAIN, 4Research Laboratory, Carlos Haya Hospital-Fundacion IMABIS, Malaga, SPAIN.

425 Evidence of Local Allergic Rhinitis in Areas with High and Permanant Aeroallergens Exposure
D. Cruz Niesvaa1, C. Rondon2, L. Almeida Quintana1, A. Correa1, R. Castillo Sainz2, L. Melendez2, T. Carrillo Diaz1, M. Blanca2; 1Allergy Service, Dr. Negrin University Hospital, Gran Canaria, SPAIN, 2Allergy Service, Carlos Haya Hospital, Malaga, SPAIN, 3Research Laboratory, Carlos Haya Hospital-Fundacion IMABIS, Malaga, SPAIN.

426 Anti-Allergic Effects of So-Cheong-Ryang-Tong, A Traditional Korean Herbal Medicine, in An Allergic Rhinitis Mouse Model
D. Kim, J. Mo, C. Rhee, C. Lee; Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF.

427 Clinical Validation of Controlled Grass Pollen Challenge in the Environmental Exposure Unit (EEU)
A. K. Ellis1, L. M. Steacy2, T. Walker2; 1Queen’s University, Kingston, ON, CANADA, 2Kingston General Hospital, Kingston, ON, CANADA.

428 Does Presence of Nasal Congestion Influence Patient’s Choice of Delivery Interface for Continuous Positive Airway Pressure Therapy?
P. Bajaj1, C. Sheerer2, A. Donato2; 1Penn state Hershey Medical Centre, Hershey, PA, 2The Reading Hospital and Medical Center, west Reading, PA.

429 Nasal Symptoms Induced By A Standardized Nasal Challenge Test With Aqueous Pfeum Pratense Reflects Seasonal Nasal Symptoms In Grass Allergic Patients
K. Aasbjerg1, P. A. Wurtzen2, V. R. Vagtmann1, V. Backer1; 1Bispebjerg Hospital, Copenhagen, DENMARK, 2ALK-Abello, Hoersholm, DENMARK.

430 Using Objective Tools to Evaluate Pediatric Patients with Chronic Rhinitis
R. raveendran1,2,3; E. Clough-Paabo2, L. Borish, MD2, E. Erwin3; 1the Ohio State University Medical Center, Columbus, OH, 2 Nationwide Childrens Hospital, Columbus, OH, 3University of Virginia, Charlottesville, VA.

Poster Session

Mechanisms of Immunotherapy

3210
Session Time: Sunday, March 4, 2012, 9:45 AM - 10:45 AM

431 In Mice Sensitized to Milk, Epicutaneous Immunotherapy Prevents Further Sensitization to Peanut or House Dust Mite
L. Mondoulet1, V. Dioszeghy1, E. Pateux2, M. Ligouis1, V. Dhelft1, C. Dupont2, P. Benhamou1; 1DBV Technologies, Bagneux, FRANCE, 2Hopital Necker, Paris, FRANCE.

432 In Situ Imaging Of Honeybee (Apis Mellifera) Venom Components From Immunotherapy Preparations
U. Seppala1, S. Francese2, S. Turilli3, G. Monet3, M. Clench2, D. Barber2; 1Global Research, ALK-Abello, Horsholm, DENMARK, 2Sheffield Hallam University, Sheffield, UNITED KINGDOM, 3CISM, University of Florence, Florence, ITALY, 4Global Research, ALK-Abello, Madrid, SPAIN.

433 Protection from Oral Peanut-Induced Esophageal Lesions in Sensitized Mice treated by Epicutaneous Immunotherapy is Mediated by CD25+CD46+ Tregs
V. Dioszeghy1, L. Mondoulet1, V. Dhelft1, M. Ligouis1, E. Pateux2, C. Dupont2, P. Benhamou1; 1DBV-Technologies, Bagneux, FRANCE, 2Univrsite Paris descartes - Hopital Necker, Paris, FRANCE.

434 Bioavailability of IgG Administered by the Subcutaneous Route
M. Berger1, S. Jolles1, J. W. Sleasman1; 1CSL Behring LLC, King of Prussia, PA, 2University Hospital of Wales, Cardiff, UNIFIED KINGDOM, 3University of South Florida, St. Petersburg, FL.

435 Sublingual Allergen Immunotherapy: Mode Of Action And Its Relationship With The Safely Profile
M. A. Calderon1, E. R. Simons2, H. Malling3, R. F. Lockey4, P. Moingeon5, P. Demoly6; 1Section of Allergy and Clinical Immunology, Imperial College-NHLI, Royal Brompton, London, UNITED KINGDOM, 2Department of Pediatrics & Child Health, Department of Immunology, University of Manitoba, Winnipeg, QC, CANADA, 3Copenhagen University Hospital, Copenhagen, DENMARK, 4Division of Allergy & Immunology, University of South Florida College of Medicine, Tampa, FL, 5Stallergenes, Antony, FRANCE, 6Allergy Division, Pneumology Department, INSERM U657, Hopital Arnaud de Villeuneuve, University Hospital of Montpellier, Montpellier, FRANCE.

436 Anti-Inflammatory Activity Of Sublingual Immunoglobulins (SLIG) In A Preclinical Model Of Allergic Asthma
T. BATARD; Stallergenes SA, Antony, FRANCE.

437 The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Subjects with Allergic Rhinitis and Asthma
A. S. Rohr1, B. Wong2, R. A. Panettieri, Jr.1, M. Columbo2; 1Asthma, Allergy and Immunology Specialists, Bryn Mawr, PA, 2Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, 3Pulmonary, Allergy and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA.

438 Inhibition Of Human IgE-Allergen Interaction By Antibodies Of Rabbits Immunized With Depigmented-polymerized Allergen Extracts
V. Iraola, M. T. Gallego, T. Aranda, M. A. Lopez-Matas, M. Morales, R. Saez, C. Marquez, J. R. Leonor, J. Carnes; Laboratorios LETI, S.L.U., Tres Cantos, SPAIN.

439 Immunological Changes During Subcutaneous And Sublingual Grass Pollen Immunotherapy
P. A. Wurtzen1, K. Aasbjerg2, G. Grauert1, G. K. Koel1, M. Holse1, V. Backer1, V. R. Vagtmann1; 1ALK-Abello, Hoersholm, DENMARK, 2Bispebjerg Hospital, Copenhagen, DENMARK.

440 Induced-Tolerogenic Dendritic Cells That Promote Tolerance And De Novo Differentiation Of Regulatory T Cells
R. A. Maldonado1,2, L. C. Perdomo1,2, F. Vascotto1,2, L. Francisco2, A. T. Bauquert1, V. K. Kuchro1, A. H. Sharpe2, U. H. von Andrian3; 1Selecta Biosciences Inc, Watertown, MA, 2Harvard Medical School, Boston, MA, 3Center for Neurologic Diseases and Brigham and Womens Hospital, Boston, MA.
Poster Session

Eosinophils

3211 Session Time: Sunday, March 4, 2012, 9:45 AM - 10:45 AM

442 Modulation of Eosinophil Responsiveness to TSLP-Mediated Degranulation
E. B. Cook, J. L. Stahl, E. A. Schwantes, N. P. Barney, S. A. Mathur; University Wisconsin, Madison, WI.

443 Eosinophil Granular Proteins Specifically Major Basic Protein Damage Bronchial Epithelial Cells Infected with Respiratory Syncytial Virus
M. Kato1, T. Ishioka2, H. Kita3, K. Kozawa3, Y. Hayashi3, H. Kimura5;
1Department of Allergy and Immunology, Gunma Children’s Medical Center, Shibukawa, Gunma, JAPAN, 2Gunma Prefectural Institute of Public Health and Environmental Sciences, Maebashi, Gunma, JAPAN, 3Department of Internal Medicine, Mayo Clinic, Rochester, MN, 4Department of Hematology and Oncology, Gunma Children’s Medical Center, Shibukawa, Gunma, JAPAN, 5National Institute of Infectious Diseases, Musashimurayama, Tokyo, JAPAN.

444 Aspirin Activation of Eosinophils: Relevance to Aspirin-Exacerbated Respiratory Disease (AERD)
L. Borish, P. Huyett, L. Liu, J. A. Negri, S. Payne, J. W. Steinke; University of Virginia Practice, Charlottesville, VA.

445 Eosinophils Promote Epithelial To Mesenchymal Transition Of Bronchial Epithelial Cells
1Mie National Hospital, Tsu, JAPAN, 2Department of Immunology, Mie University School of Medicine, Tsu, JAPAN, 3Department of Pulmonary and Critical Care Medicine, Mie University School of Medicine, Tsu, JAPAN.

446 Extracellular Release of Endogenous ATP Mediates Eosinophil Recognition of Fungal Products and Degranulation Response
T. Soma1,2, T. Kobayashi1,2,3, S. Seno1, H. Kita2;
1Allergy Center, Saitama Medical University, Saitama, JAPAN, 2Division of Allergic Diseases, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN.

447 Analysis of Eosinophil, Mast Cell, and Basophil Siglec-8 Expression on Human Cell Lines and Hematologic Malignancies
A. N. Salicru1, H. Hermann2,3, S. Hudson1, J. Steinke1, L. Borish4, P. Valent2,3, B. S. Bochner1;
1Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, AUSTRIA, 3Ludwig Boltzmann Cluster Oncology, Vienna, AUSTRIA.

448 Cord Blood (CB) Eosinophil/Basophil (Eo/B) Progenitors Predict Respiratory Outcomes Until The Age Of Two
K. M. Weisse1,2, G. Herberth1, S. Roeder1, M. Borte1, D. Heroux2, J. A. Denburg2, I. Lehmann1;
1Helmholtz-Centre for Environmental Research Gmbh - UFZ, Department of Environmental Immunology, Leipzig, GERMANY, 2McMaster University, Division of Clinical Immunology and Allergy, Hamilton, ON, CANADA, 3Helmholtz-Centre for Environmental Research Gmbh - UFZ, Core Facility Studies, Leipzig, GERMANY, 4Children’s Hospital, Municipal Hospital St. Georg, Leipzig, GERMANY.

449 Mechanisms Of Tir-mediated Cord Blood Cd34+ Progenitor Cell Eosinophil Differentiation: Signaling And Autocrine Pathways
P. Reece, A. J. Baatjes, M. M. Cyr, R. Sehmi, J. A. Denburg; McMaster, Hamilton, ON, CANADA.

450 Differential Effect of TGF-β1 and Eotaxin on Novel CLC3 Ion-Channel Variants in Human Peripheral Blood Eosinophils
R. Gaurav, D. K. Agrawal;
Center for Clinical and Translational Science and Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, NE.

451 Identification of Suitable qPCR Reference Genes during IL-5 Induced Cord Blood Eosinophilopoiesis
J. Thiele, A. K. Ellis;
Queen’s University, Kingston, ON, CANADA.

452 Selective Glucocorticoid Receptor Modulator CpdA Overcomes GM-CSF-induced Resistance of Eosinophil to Glucocorticoid Treatment
K. Pazdrak1, Y. Moon2, C. Straub3, R. Maroto1, A. Kurosky4;
1Univ. of TX Medical Branch, Galveston, TX, 2University of Notre Dame, Notre Dame, IN.

453 Failure Of Hepoxilin A-3 To Chemoattract Eosinophils In An In-vitro Gradient Barrier System
Massachusetts General Hospital, Boston, MA.

454 Peripheral Blood Eosinophils Are Not Activated By Highly Purified Recombinant High Mobility Group Box 1 (HMGB1) Protein
The University of Texas Medical Branch, Galveston, TX.

455 Membrane Cholesterol Removal from Human Eosinophils Disrupts Cholesterol Rich Membrane Microdomains Resulting in Down Regulated MAP Kinase Signaling but not JAK/STAT Signaling
M. E. Burnham, M. E. Bates, P. J. Bertics; University of Wisconsin School of Medicine and Public Health, Madison, WI.

456 Inhibition of Eosinophil Differentiation in vitro by a PPARγ Agonist
S. G. Smith, M. Hill, A. J. Baatjes, K. Howie, R. M. Watson, R. Sehmi, G. M. Gauvreau; McMaster University, Hamilton, ON, CANADA.

Poster Session

Mast Cells, Basophils and IgE

3212 Session Time: Sunday, March 4, 2012, 9:45 AM - 10:45 AM

457 Mast Cell Phenotypes and Distribution in Nasal Polyps with Allergic Airway
E. E. Fouda1, S. Abdelgawad2, S. Said-Ahmed3, A. Ali3, E. Mohamed1;
1Al-azhar university allergy &Immunology center, Cairo, EGYPT, 2Faculty of medicine(girls),Al-azhar university, Cairo, EGYPT, 3Faculty of medicine(Girls),Al-azhar university, Cairo, EGYPT.

458 A Role for Mast Cell Chymase in Regulating Levels of Immunoglobulin E
Abstracts AB277

Asthma Therapeutics: What’s Below the Surface?

3601
Session Time: Sunday, March 4, 2012,
2:00 PM - 3:15 PM

482 Body Mass and Corticosteroid Response in Childhood Asthma
R. A. Nunez, L. P. Jackson, E. Goleva, D. Y. M. Leung, P. J. Hauk;
National Jewish Health, Denver, CO.

483 Steroid Requirements and Immune Associations With Vitamin D Are Stronger In Children Than Adults With Asthma
D. Y. Leung, D. A. Searing, L. P. Jackson, B. N. Richers, E. Goleva;
National Jewish Health, Denver, CO.

484 Ganoderic Acid C Isolated From Ganoderma Lucidum Suppress Lps-induced Macrophage Tnf-α Production By Down-regulating Mapk, Nf-kappab And Ap-1 Signaling Pathways
C. Liu, N. Yang, W. Folder, J. Cohn, R. Wang, X. Li;
Pediatric Allergy & Immunology, The Mount Sinai School of Medicine,
New York, NY.

485 Methoxyphenols Exhibit Anti-inflammatory Effects on Airway Epithelial Cells by Acting Post-transcriptionally
E. T. Ishmael, K. R. Houser, D. Johnson;
The Pennsylvania State University, Hershey, PA, State University of New York College at Geneseo, Geneseo, NY.

486 Asthma Control And Disordered Microbial Communities In The Lower Airways Of Patients With Poorly Controlled Asthma
National Jewish Health, Denver, CO, University of Colorado Denver,
Denver, CO.

Oral Abstract Session

Immunophenotyping

3602
Session Time: Sunday, March 4, 2012,
2:00 PM - 3:15 PM

487 TH IL-17 Immunophenotyping Reference for Children
Medical College of Wisconsin, Milwaukee, WI.

488 Ex Vivo Identification and Phenotyping of Allergen-Specific T Helper Cells In Human Peripheral Blood based on CD145 Expression
K. A. Smith, R. S. Rashid, A. J. Frew, F. Kern, M. D. Tarzi;
Brighton and Sussex Medical School, Brighton, UNITED KINGDOM,
Department of Respiratory Medicine, Royal Sussex County Hospital,
Brighton, UNITED KINGDOM.

489 Calculated Globulin (CG): A Viable Tool for the Identification of Patients with Potential Antibody Deficiency
S. Jolles, R. Borrell, M. Moody, C. Selwood, P. Williams, T. El-Shanawany;
University Hospital of Wales, Cardiff, UNITED KINGDOM.

490 Th2A Cells As A Unique Th2 Cell Subset In Allergic Individuals: Steps Toward a T Cell Biomarker For Allergy
Benaroya Research Institute, Seattle, WA, Virginia Mason Medical Center, Seattle, WA.

491 A Central B Cell Tolerance Defect In Group Ia CVID Patients
N. Romberg, Y. Ng, C. Cunningham-Rundles, E. Meffre;
Yale School of Medicine, New Haven, CT, Mount Sinai Medical Center, New York, NY.

Oral Abstract Session

Biological Dust Exposures and Atopic & Allergic Diseases

3603
Session Time: Sunday, March 4, 2012,
2:00 PM - 3:15 PM

492 Enhanced Organic Dust Induced Airway Inflammation in Protein Kinase C Epsilon Deficient Mice is Associated with Dysregulation of Nitric Oxide
J. A. Poole, A. Gleason, C. Bauer, W. W. West, D. J. Romberger, T. A. Wyatt;
UNMC, Omaha, NE.

493 Cigarette Smoke Exposure and its Effect on Bronchial Responsiveness and Response to Fluticasone Propionate, Salmeterol and their Combination
K. Sapkota, M. Sapkota, R. G. Towner;
Division of Asthma Allergy and Immunology and Department of pharmacology, Creighton University School of Medicine, Omaha,
NE, Department of pharmacology, Creighton University School of Medicine, Omaha, NE-68131, Omaha, NE, Division of Asthma Allergy and Immunology Creighton University School of Medicine, Omaha, NE-68131, Omaha, NE.

494 The Prevalence of Asthma, Hay Fever and Allergic Sensitization in Amish Children
M. Holbreich, J. Genuenit, J. Weber, C. Braun-Fahrlander, E. von Mutius;
Allergy and Asthma Consultants, Indianapolis, IN, Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, GERMANY, University Children’s Hospital, Munich, GERMANY, Swiss Tropical and Public Health Institute, Basel, SWITZERLAND.

495 Influence of Rural and Urban Dietary and Lifestyle Patterns in Atopic Diseases in a Colombian African-descent Population
J. A. Marrugo, J. R. Urrego, L. C. Fang, C. A. Munoz, L. C. Fang;
University of Cartagena, Cartagena, COLOMBIA, National University of Colombia, Bogota, COLOMBIA.
Vitamin E Reduces Airway Granulocyte Recruitment after Inhaled Endotoxin Challenge in Normal Volunteers
1UNC Chapel Hill, Chapel Hill, NC, 2Purdue University, West Lafayette, IN.

Oral Abstract Session

Anaphylaxis

3604
Session Time: Sunday, March 4, 2012, 2:00 PM - 3:15 PM

Maternal Low Dose Peanut and Cholera Toxin Subunit B Induces Oral Tolerance Associated with An Increased Number of T Regulatory Cells
Y. Song, H. Sampson, X. Li;
Mount Sinai School of Medicine, New York, NY.

SHIP-1 Is Critical in Regulation of Severe Anaphylaxis
S. Oh, F. Wu, T. Zheng, Z. Zhu;
Johns Hopkins Allergy and Asthma Center, Baltimore, MD.

Development of a Dendrimeric Structure containing ole e 1 and CpG to Modulate an Allergic Response in an Experimental Model
A. B. Blazquez, A. Aranda, M. Villalba, M. J. Torres, C. Mayorga, J. Rojo, M. Blanca;
1IMABIS Foundation-Carlos Haya Hospital, Malaga, SPAIN, 2Instituto de Investigaciones Quimicas, CSIC, Sevilla, SPAIN, 3Departamento de Bioquimica y Biologia Molecular I, Universidad Complutense, Madrid, SPAIN, 4Allergy Service, Carlos Haya Hospital, Malaga, SPAIN.

Isolation and Identification of Compounds in Rubia cordifolia L. (Qian Cao) that Inhibit Human B cell IgE production
V. Chan, C. Liu, S. Uzun, N. Yang, X. Li;
Mount Sinai School of Medicine, New York City, NY.

Anaphylaxis in America - Results from a National Telephone Survey
1Abt SRBI, Silver Spring, MD, 2Massachusetts General Hospital, Boston, MA, 3University of Tennessee College of Medicine, Germantown, TN, 4Mount Sinai School of Medicine, New York, NY, 5Virginia Commonwealth University, Richmond, VA, 6University of Manitoba, Winnipeg, MB, CANADA, 7University of Mississippi Medical Center, Jackson, MS, 8Asthma & Allergy Foundation of America, Landover, MD, 9Johns Hopkins University School of Medicine, Baltimore, MD.

Oral Abstract Session

Management of Food Allergies

3605
Session Time: Sunday, March 4, 2012, 2:00 PM - 3:15 PM

Food Allergy and Increased Asthma Morbidity in a School Inner-city Asthma Study
J. Friedlander, W. Sheehan, E. Hoffman, C. Fu, D. Gold, W. Phipatanakul;
1Children’s Hospital Boston, Boston, MA, 2Division of Respiratory Epidemiology, Channing Laboratory, Brigham and Women’s Hospital, Boston, MA, 3Department of Biostatistics, Harvard School of Public Health, Boston, MA.

Outcome Rather Than the Type of Diagnostic Intervention Predicts Improvement in Health-Related Quality of Life Score Among Children With Food Allergy Between 0-12 Years
L. Kirtse, T. K. Takaro, B. Kuzeljevic, T. Wong, E. S. Chan;
1Simon Fraser University, Burnaby, BC, CANADA, 2Child and Family Research Institute, Vancouver, BC, CANADA, 3Department of Pediatrics, Division of Allergy, University of British Columbia, Vancouver, BC, CANADA.

Bullying and Teasing In Children With Food Allergy: A Survey of Pediatric Patients In Urban Jackson, Mississippi Outpatient Allergy and Immunology Clinics
University of Mississippi Medical Center, Jackson, MS.

Novel Use of a Social Network for Families with Food Allergic Children
T. T. Le, S. V. Montandon, T. C. Gaslin;
1University of Louisville, Louisville, KY, 2The Center for Courageous Kids, Scottsville, KY.

Food Allergy Attitudes and Beliefs among School Nurses in an Urban Public School District
1Children’s National Medical Center, Washington, DC, 2Food Allergy and Anaphylaxis Network, Fairfax, VA.

Oral Abstract Session

Treatment of Allergic Rhinitis

3606
Session Time: Sunday, March 4, 2012, 2:00 PM - 3:15 PM

Comparing the Effect of Intranasal Fluticasone Furoate (FF) to Intracocular Olopatadine (OLO) on the Ocular Response to Nasal Allergen Challenge (NAC)
M. DeTineo, H. Logothetis, M. Bashir, J. M. Pinto, F. M. Baroody, R. M. Naclerio;
University of Chicago, Chicago, IL.

Long-term Safety Study of MP29-02 (Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate) in Subjects with Chronic Allergic or Non-allergic Rhinitis
1Allergy & Asthma Associates, Mission Viejo, CA, 2Allergy & Asthma Medical Group & Research Center, San Diego, CA, 3Medical Pharmacuticals, Somerset, NJ, 4IRL-Syneuxis Clinical Research Centre, Mumbai, INDIA.

MP29-02 (Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate) in the Treatment of Ocular Symptoms of Seasonal Allergic Rhinitis (SAR)
P. Ratner, E. O. Meltzer, W. Carr, D. Ginsberg;
1Sylvana Research Associates, San Antonio, TX, 2Allergy & Asthma Medical Group & Research Center, San Diego, CA, 3Allergy & Asthma Associates, Mission Viejo, CA, 4Meda Pharmaceuticals, Somerset, NJ.
The Addition of Vitamin D (VitD) to an Intranasal Steroid (INS) Improves Control of Symptoms in Seasonal Allergic Rhinitis (SAR)
F. M. Baroody, J. Lane, S. Watanabe, M. DeTineo, J. Pinto, R. M. Naclerio;
University of Chicago, Chicago, IL.

Ocular Safety of Fluticasone Furoate Nasal Spray in Subjects with Perennial Allergic Rhinitis
S. D. Miller, W. Wu, L. Sutton, L. Lee;
1Northeast Medical Research Associates, Dartmouth, MA, 2Glaxo-SmithKline, Research Triangle Park, NC.

Oral Abstract Session

Regulation of Allergic Inflammation
3607
Session Time: Sunday, March 4, 2012, 2:00 PM - 3:15 PM

Allergen Specific IL-10 Producing T-Regulatory Cells Are Upregulated in Children Who Have Acquired Tolerance to Egg
A. B. Fishbein1, K. A. Erickson2, C. Szychlinski1, M. J. Kwasny2, R. L. Fuleihan1, A. M. Singh1;
1Northwestern University Children’s Memorial Hospital, Chicago, IL, 2Northwestern University, Chicago, IL.

II-4, But Not II-2, Induces Th2 Cells To Resist The II-2 Counterregulation By Downregulating Stat1 Phosphorylation
Z. Chen1,2, S. Wang2, C. Bai2, F. Z. Chowdhury, J. D. Farrar, J. Sudderth, R. J. Deberardinis1;
1Zhongshan Hospital, Shanghai, CHINA, 2National Jewish Health, Denver, CO.

Increased Number of Regulatory T cells in Skin Draining Lymph Nodes Suppress Priming Towards New Antigens
S. Mahapatra1, E. Robinson2, C. Herrick2, M. Albrecht3, A. M. Dittrich1;
1Hannover Medical School, Hannover, GERMANY, 2Yale University School of Medicine, New Haven, CT.

IgE Cross-Linking Downregulates Expression of Glycolytic Genes in Human Plasmacytoid Dendritic Cells
G. Bajwa, F. Z. Chowdhury, J. D. Farrar, J. Sudderth, R. J. Deberardinis, M. A. Singh;
UT Southwestern Medical Center at Dallas, Dallas, TX.

Increased Platelet Adherence to Leukocytes Results in Cysteinyl Leukotriene (cysLT) Overproduction in Aspirin Exacerbated Respiratory Disease (AERD)
T. M. Laidlaw1, M. S. Kiddler1, N. Bhattacharyya1, G. L. Milne2, J. A. Boyce1;
1Brigham and Women’s Hospital, Boston, MA, 2Vanderbilt University Medical Center, Nashville, TN.

Featured Poster Session

BCI Featured Poster Session
3802
Session Time: Sunday, March 4, 2012, 5:30 PM - 7:30 PM

Different Forms of ADA and PNP Deficiency On Thymocytes Development
E. Grunewald, T. Papinazath, R. Somach, C. M. Roifman;
Hospital for Sick Children, Toronto, ON, CANADA.

Pioglitazone (pio), A Peroxisome Proliferator-activated Receptor (ppar)γ Agonist, Restores Efferocytosis Of Neutrophils In Chronic Granulomatous Disease (cgd) By Enhancing Oxidant Production And “Eat Me” Signaling
R. Fernandez-Boyanapalli, S. Frasch, D. L. Bratton;
National Jewish Health, Denver, CO.

Knockdown of Dock8 in Zebrafish Reveals a Role for Dock8 in Extra-Lymphoid Tissue Development
W. Chan, K. Dippolite, S. Lin, T. Chatterlia;
UCLA, Los Angeles, CA.

Elucidating the Role of IgM Memory B Cells in Common Variable Immunodeficiency
J. H. Park;
Mount Sinai Medical Center, New York, NY.

510 The Addition of Vitamin D (VitD) to an Intranasal Steroid (INS) Improves Control of Symptoms in Seasonal Allergic Rhinitis (SAR)
F. M. Baroody, J. Lane, S. Watanabe, M. DeTineo, J. Pinto, R. M. Naclerio;
University of Chicago, Chicago, IL.

511 Ocular Safety of Fluticasone Furoate Nasal Spray in Subjects with Perennial Allergic Rhinitis
S. D. Miller, W. Wu, L. Sutton, L. Lee;
1Northeast Medical Research Associates, Dartmouth, MA, 2Glaxo-SmithKline, Research Triangle Park, NC.

512 Allergen Specific IL-10 Producing T-Regulatory Cells Are Upregulated in Children Who Have Acquired Tolerance to Egg
A. B. Fishbein1, K. A. Erickson2, C. Szychlinski1, M. J. Kwasny2, R. L. Fuleihan1, A. M. Singh1;
1Northwestern University Children’s Memorial Hospital, Chicago, IL, 2Northwestern University, Chicago, IL.

513 II-4, But Not II-2, Induces Th2 Cells To Resist The II-2 Counterregulation By Downregulating Stat1 Phosphorylation
Z. Chen1,2, S. Wang2, C. Bai2, F. Z. Chowdhury, J. D. Farrar, J. Sudderth, R. J. Deberardinis1;
1Zhongshan Hospital, Shanghai, CHINA, 2National Jewish Health, Denver, CO.

514 Increased Number of Regulatory T cells in Skin Draining Lymph Nodes Suppress Priming Towards New Antigens
S. Mahapatra1, E. Robinson2, C. Herrick2, M. Albrecht3, A. M. Dittrich1;
1Hannover Medical School, Hannover, GERMANY, 2Yale University School of Medicine, New Haven, CT.

515 IgE Cross-Linking Downregulates Expression of Glycolytic Genes in Human Plasmacytoid Dendritic Cells
G. Bajwa, F. Z. Chowdhury, J. D. Farrar, J. Sudderth, R. J. Deberardinis, M. A. Singh;
UT Southwestern Medical Center at Dallas, Dallas, TX.

516 Increased Platelet Adherence to Leukocytes Results in Cysteinyl Leukotriene (cysLT) Overproduction in Aspirin Exacerbated Respiratory Disease (AERD)
T. M. Laidlaw1, M. S. Kiddler1, N. Bhattacharyya1, G. L. Milne2, J. A. Boyce1;
1Brigham and Women’s Hospital, Boston, MA, 2Vanderbilt University Medical Center, Nashville, TN.

Meta-analysis of Transcriptome Data using Pathway-based Approach Reveals Biologically Relevant Asthma Genes
T. M. Baye, S. Amirisetty, G. Khurana Hershey;
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

Gene-Environment Interaction between CD14/TLR4 Polymorphisms and Use of Antibiotics in Infancy increases the Risk of Allergic Diseases
K. Park1, H. Lee1, J. Seo3, H. Kim2, M. Kang3, J. Kwon4, Y. Song2, B. Kim3, S. Lee6, S. Hong5;
1Presbyterian Medical Center, Jeonju, KOREA, REPUBLIC OF, 2Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, 3Asan Institute for Life Sciences, University of Ulsan, Ulsan, KOREA, REPUBLIC OF, 4Seoul National University Bundang Hospital, Seoul, KOREA, REPUBLIC OF, 5Inje University Haemudea Paik Hospital, Busan, KOREA, REPUBLIC OF, 6Hallym Sacred Heart Hospital, Hallym University College of Medicine, Anyang, KOREA, REPUBLIC OF.

Exhaled Breath Condensate Formate Increases After Allergen Challenge In Human Atopic Asthamatics In Vivo
R. Greenwald1, A. Hoskins2, R. Dworski2;
1Emory University, Atlanta, GA, 2Vanderbilt University, Nashville, TN.

Characterization of Genetic Epidemiology for GWAS-identified Asthma Susceptibility Loci in Chinese by Next Generation Sequencing
T. F. Leung1, P. Law2, L. Y. Ts3, H. Y. Sy1, S. K. W. Tsu1;
2Department of Pediatrics, The Chinese University of Hong Kong, Hong Kong, HONG KONG, 3School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, HONG KONG.

520 Exhaled Breath Condensate Formate Increases After Allergen Challenge In Human Atopic Asthamatics In Vivo
R. Greenwald1, A. Hoskins2, R. Dworski2;
1Emory University, Atlanta, GA, 2Vanderbilt University, Nashville, TN.

521 Characterization of Genetic Epidemiology for GWAS-identified Asthma Susceptibility Loci in Chinese by Next Generation Sequencing
T. F. Leung1, P. Law2, L. Y. Ts3, H. Y. Sy1, S. K. W. Tsu1;
2Department of Pediatrics, The Chinese University of Hong Kong, Hong Kong, HONG KONG, 3School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, HONG KONG.

522 Simultaneous Detection of TRECs and KRECs in Newborn DNA Isolated From Dried Blood Spots (Guthrie Cards)
V. R. Bonagura1, J. DeVoti1, L. Massaro4, N. Sharifi1, J. Isabelle3, M. Caggana2;
1Feinstein Institute for Medical Research NS-LIJ Health System, Great Neck, NY, 2NYS Department of Health Wadsworth Center, Albany, NY.

523 Different Forms of ADA and PNP Deficiency On Thymocytes Development
E. Grunewald, T. Papinazath, R. Somach, C. M. Roifman; Hospital for Sick Children, Toronto, ON, CANADA.

524 Pioglitazone (pio), A Peroxisome Proliferator-activated Receptor (ppar)γ Agonist, Restores Efferocytosis Of Neutrophils In Chronic Granulomatous Disease (cgd) By Enhancing Oxidant Production And “Eat Me” Signaling
R. Fernandez-Boyanapalli, S. Frasch, D. L. Bratton; National Jewish Health, Denver, CO.

525 Knockdown of Dock8 in Zebrafish Reveals a Role for Dock8 in Extra-Lymphoid Tissue Development
W. Chan, K. Dippolite, S. Lin, T. Chatterlia; UCLA, Los Angeles, CA.

526 Elucidating the Role of IgM Memory B Cells in Common Variable Immunodeficiency
J. H. Park; Mount Sinai Medical Center, New York, NY.
Abstracts
AB280

527 Specific Induction Of CD203c Expression In Blood Basophils Differentiates Between CF patients With Aspergillus Colonization And Those With CF-ABPA
Y. Gernez, C. Everson, E. Mitsunaga, C. Dunn, L. Herzenberg, R. Tirouvanziam, R. Moss;
Stanford University, Stanford, CA.

528 Inflammatory Gene Expression Differentiates With Airway Neutrophil Response To Ozone
R. Fry1, H. Zhou2, B. Zou2, J. Rager1, J. Brickey1, J. Ting1, D. Ped- den5, N. Alexis6;
1Gillings School of Global Public Health, UNC Chapel Hill, Chapel Hill, NC, 2Dept for Env Med Asthma and Lung Biology, Chapel Hill, NC, 3Dept of Microbiology and Immunology, Chapel Hill, NC, 4Dept of Microbiology and Immunology, Lineberger Cancer Ctr., Chapel Hill, NC, 5Cntr for Env Med Asthma and Lung Biology, Chapel Hill, NC.

529 Functional Interaction of Cockroach Allergens and Mannose Receptor on Human Circulating Fibrocytes
Y. Tsai;
School of Medicine, Johns Hopkins University, Baltimore, MD.

530 Der p 2 Stimulate Inflammatory Responses from Lung Epithelial cells and Macrophages through the TLR2 and MAPK pathway
S. Tanyaratrisakul1, O. Jirapongsananuruk2, W. R. Thomas3, S. Piboonpopocaum3, D. R. Voelker1;
1Department of Medicine, Program in Cell Biology, National Jewish Health, Denver, CO, 2Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, THAILAND, 3Department of Pediatric, Mahidol University, Bangkok, THAILAND.

531 Transient Receptor Potential Melastatin 8 Mediates Airway Inflammation Of Toluene-diisocyanate Induced Asthma
J. Kim1, E. Yang2, H. Jin2, Y. Nam2, E. Hwang2, G. Choi3, Y. Ye2, H. Park2;
1Hallym University College of Medicine, Anyang, KOREA, REPUBLIC OF, 2Ajou University School of Medicine, Suwon, KOREA, REPUBLIC OF, 3Kosin University Gaspel Hospital, Pusan, KOREA, REPUBLIC OF.

532 Comparison of Sublingual Immunotherapy (SLIT) versus Oral Immunotherapy (OIT) in the Treatment of Peanut Allergy
S. J. Chin1, E. H. Kim1, M. D. Kilis1, P. Varshney1, P. Steele1, J. Kamilaris1, A. Hiegel2, S. K. Carlisle2, A. M. Scurlock2, P. B. Smith1, B. P. Vickery1, S. M. Jones2, A. W. Burks1;
1Duke University Medical Center, Durham, NC, 2University of Arkansas for Medical Sciences, Little Rock, AR.

533 Infants Who Develop Eczema at 12 Months Have a Deficient T Regulatory Cell Response to Microbial Stimuli at the Time of Birth
I. Ismail;
Murdoch Childrens Research Institute, Melbourne, AUSTRALIA.

534 Real-time Imaging Assessment of Blood Flow, Temperature and Skin Color on Patients with Cold-induced Urticaria: Correlation with Histamine and Tryptase Release
1Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 2Infrared Imaging and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 3Clinical Research Directorate/CMRP, SAIC-Frederick, NCI Frederick, Frederick, MD.

535 Vitamin D Insufficiency is Strongly Associated with Challenge-proven Infantile Food Allergy in the Healthhunts Population-based Study
1Murdoch Childrens Research Institute, Parkville, VICTORIA, AUSTRALIA, 2Royal Children’s Hospital, Parkville, AUSTRALIA, 3University of Melbourne, Parkville, VICTORIA, AUSTRALIA, 4European Centre for Environment and Human Health, Peninsula College of Medicine and Dentistry, University of Exeter, UNITED KINGDOM.

536 Genetic Variants In Cep68 In Patients With Hypersensitivity Reactions To Nsaids
J. A. Cornejo-Garcia1, M. C. Plaza-Seron2, C. Flores3, I. Dona1, N. Blanca-Lopez4, L. R. Jagemann1, J. J. Laguna3, J. Fernandez3, G. Canto1, M. Blanca3;
1Laboratorio de Investigacion, Fundacion IMABIS, Malaga, SPAIN, 2Unidad de Investigacion, Hospital Universitario N.S. de Candelaria, Tenerife, SPAIN, 3Servicio de Alergia, Hospital Carlos Haya, Malaga, SPAIN, 4Servicio de Alergia, Hospital Infa- nta Leonor, Madrid, SPAIN, 5Servicio de Alergia, Hospital Central de la Cruz Roja, Madrid, SPAIN, 6Servicio de Alergia, Hospital de Elche, Elche, Alicante, SPAIN.

Featured Poster Session
FADDa Featured Poster Session

3804
Session Time: Sunday, March 4, 2012, 5:30 PM - 7:30 PM

532 Comparison of Sublingual Immunotherapy (SLIT) versus Oral Immunotherapy (OIT) in the Treatment of Peanut Allergy
S. J. Chin1, E. H. Kim1, M. D. Kilis1, P. Varshney1, P. Steele1, J. Kamilaris1, A. Hiegel2, S. K. Carlisle2, A. M. Scurlock2, P. B. Smith1, B. P. Vickery1, S. M. Jones2, A. W. Burks1;
1Duke University Medical Center, Durham, NC, 2University of Arkansas for Medical Sciences, Little Rock, AR.

Featured Poster Session
HEDQ Featured Poster Session

3805
Session Time: Sunday, March 4, 2012, 5:30 PM - 7:30 PM

537 A Speech Recognition (SR) Reminder System Improves Adherence to ICS Among Pediatric Asthma Patients
P. J. Cvietusa1, D. J. Magid2, G. Goodrich2, N. Wagner3, R. Lowe4, H. Nuanes5, S. Shetterly2, C. Tacinas4, F. S. Wamboldt5, S. Xu2, B. G. Bender1;
1Department of Asthma, Allergy and Immunology at Kaiser Perma- nente, Highlands Ranch, CO, 2Institute For Health Research at Kaiser Permanente, Denver, CO, 3Department of Pediatrics, National Jewish Health, Denver, CO.
538 Short Message Service (SMS) For Asthma Management: A Pilot Study Utilizing Text Messaging To Promote Asthma Self-management
D. A. Searing, B. G. Bender; National Jewish Health, Denver, CO.

539 An Asthma Self-Management Intervention Can Improve Outcomes For Older Adults
J. A. Ross, N. M. Clark, A. Baptist; University of Michigan, Ann Arbor, MI.

540 Effects of Coping Skills Training in Low-Income Urban African-American Adolescents with Asthma
B. F. Velsor-Friedrich1, L. Milletello2, M. Richards1; 1Loyola University Chicago, Chicago, IL, 2Arizona State University, Phoenix, AZ.

539 Associations Between Self-Reported Adherence to Asthma Anti-Inflammatory Therapy and Child/Parent Attitudes and Behaviors Regarding Disease Management
A. G. Weinstein1, J. Laurencceau, J. Vok; 1Jefferson Medical College, Newark, DE.

541 IRSOC Featured Poster Session

542 Efficacy and Safety of a Novel Ragweed Allergy Immunotherapy Tablet (AIT) During Peak Season in North America
P. Creticos1, J. Maloney2, H. Nolte2, G. Berman3, A. Cheema3, A. Kaur3, J. Heben4; 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Merck Research Laboratories, Kenilworth, NJ, 3Allergy & Asthma Specialists, Minneapolis, MN, 4Alpha Medical Research, Mississauga, ON, CANADA.

543 Efficacy and Tolerability of a Novel Ragweed Allergen Immunotherapy Tablet During Peak Season in North American and European Patients
H. Nolte1, J. Maloney1, D. Bernstein2, R. Berkowitz3, K. Nekam4, A. Kaur5, N. Liu6, J. Heben7; 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Merck Research Laboratories, Kenilworth, NJ, 3University of Cincinnati College of Medicine, Cincinnati, OH, 4Rx Research, Woodstock, GA, 5Hospital of the Hospitalar Brothers of St John of God, Budapest, HUNGARY, 6Boys Town National Research Hospital, Boys Town, NE.

544 Timothy Grass Allergy Immunotherapy Tablets Reduce Nasal and Ocular Symptoms Associated With Allergic Rhinconjunctivitis During Grass Pollen Season in North American Children and Adults: 2 Randomized, Placebo-Controlled Trials
D. Skoner1, H. Nolte2, P. Creticos3, M. Blais4, J. Maloney2, H. Nelson5; 1Drexel University College of Medicine, Philadelphia, PA, 2Merck Research Laboratories, Kenilworth, NJ, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4University of Tennessee Health Science Center, Memphis, TN, 5National Jewish Medical & Research Center, Denver, CO.

545 Post-treatment, Long-term Clinical Efficacy Of A 300 IR Sublingual Tablet of 5-grass Pollen Allergen Extract In Adults With Grass Pollen-induced Allergic Rhinconjunctivitis
H. Malling1, A. Didier2, F. Horak3, M. Worm4, O. de Beaumont5, P. Rodriguez3, A. Montagut3, R. K. Zeldin2; 1National University Hospital, Copenhagen, DENMARK, 2Rangueil-Larrey Hospital, Respiratory Diseases Department, Toulouse, FRANCE, 3Allergy Centre Vienna West, Dptm. - Institute for Allergy Research, Vienna, AUSTRIA, 4Allergie-Centrum-Charit, Klinik fr Dermatologie, Venerologie und Allergologie, Berlin, GERMANY, 5Stallergenes, Antony, FRANCE.

546 Persistent Treatment Effect Achieved at One Year After 4 Doses of Fel d 1-Derived Peptide Immunotherapy in an Environmental Exposure Chamber (EEC) Model of Cat Allergy
R. P. Hafner1, J. Efthimiou1, A. Salapatek2, D. Patel2, M. Larche3; 1Circassia Ltd., Oxford, UNITED KINGDOM, 2Cetero Research, Mississauga, ON, CANADA, 3McMaster University, Hamilton, ON, CANADA.

Featured Poster Session

MAAI Featured Poster Session

3807 Session Time: Sunday, March 4, 2012, 5:30 PM - 7:30 PM

547 Eosinophil Derived LTC4 Acts Via CysLT2R to Promote Skin Thickening and Collagen Deposition in a Mouse Model of Allergic Skin Inflammation
M. K. Oyoshi1, R. He2, C. N. Lewis3, K. F. Austen7, Y. Kanaoka2, R. S. Geha1; 1Children’s Hospital Boston, Boston, MA, 2Brigham and Women’s Hospital, Boston, MA.

548 Exposure to IL-1-Family Cytokines Regulates Differential Development of Antigen-Specific Th2 Cells and T Follicular Helper (Thf) Cells in the Airway
T. Kobayashi, K. Iijima, H. Kita; Mayo Clinic Rochester, Rochester, MN.

549 Reduced Regulatory T Cells Due To Streptomycin Treatment Increases Mortality To Respiratory Viral Infection
L. E. Camarda, S. J. Zempl, M. A. Hayward, N. H. Salzman, M. H. Grayson; Medical College of Wisconsin, Milwaukee, WI.

550 Selective Deficiency Of Prostaglandin E2 Uncovers A Dominant Effector Role For Thromboxone A2 In Allergen-induced Pulmonary Inflammation And Vascular Remodeling
T. Liu1,2, C. Feng1,2, T. M. Laidlaw1,2, W. Xing1,2, S. Shen1,2, G. Milne4, J. A. Boyle2,3; 1Department of Medicine, Harvard Medical School, Boston, MA, 2Jeff and Penny Vinik Center for Allergic Disease Research, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 3Department of Medicine and Pediatrics, Harvard Medical School, Boston, MA, 4Department of Pharmacology, Vanderbilt University, Nashville, TN.

Vitamin D Inhibits Monocyte/macrophage Pro-inflammatory Cytokine Production by Targeting Mitogen-Activated Protein Kinase Phosphatase-1
Y. Zhang1, D. Y. Leung1, B. N. Richers1, Y. Liu2, L. K. Remigio1, D. W. Riches1, E. Goleva1; 1National Jewish Health, Denver, CO, 2The Ohio State University College of Medicine, Columbus, OH.

Featured Poster Session

MAAI Featured Poster Session

3807 Session Time: Sunday, March 4, 2012, 5:30 PM - 7:30 PM

547 Eosinophil Derived LTC4 Acts Via CysLT2R to Promote Skin Thickening and Collagen Deposition in a Mouse Model of Allergic Skin Inflammation
M. K. Oyoshi1, R. He2, C. N. Lewis3, K. F. Austen7, Y. Kanaoka2, R. S. Geha1; 1Children’s Hospital Boston, Boston, MA, 2Brigham and Women’s Hospital, Boston, MA.

548 Exposure to IL-1-Family Cytokines Regulates Differential Development of Antigen-Specific Th2 Cells and T Follicular Helper (Thf) Cells in the Airway
T. Kobayashi, K. Iijima, H. Kita; Mayo Clinic Rochester, Rochester, MN.

549 Reduced Regulatory T Cells Due To Streptomycin Treatment Increases Mortality To Respiratory Viral Infection
L. E. Camarda, S. J. Zempl, M. A. Hayward, N. H. Salzman, M. H. Grayson; Medical College of Wisconsin, Milwaukee, WI.

550 Selective Deficiency Of Prostaglandin E2 Uncovers A Dominant Effector Role For Thromboxone A2 In Allergen-induced Pulmonary Inflammation And Vascular Remodeling
T. Liu1,2, C. Feng1,2, T. M. Laidlaw1,2, W. Xing1,2, S. Shen1,2, G. Milne4, J. A. Boyle2,3; 1Department of Medicine, Harvard Medical School, Boston, MA, 2Jeff and Penny Vinik Center for Allergic Disease Research, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 3Department of Medicine and Pediatrics, Harvard Medical School, Boston, MA, 4Department of Pharmacology, Vanderbilt University, Nashville, TN.

Vitamin D Inhibits Monocyte/macrophage Pro-inflammatory Cytokine Production by Targeting Mitogen-Activated Protein Kinase Phosphatase-1
Y. Zhang1, D. Y. Leung1, B. N. Richers1, Y. Liu2, L. K. Remigio1, D. W. Riches1, E. Goleva1; 1National Jewish Health, Denver, CO, 2The Ohio State University College of Medicine, Columbus, OH.
Featured Poster Session

Allied Health Featured Poster Session

3811
Session Time: Sunday, March 4, 2012, 5:30 PM - 7:30 PM

552 Oral Food Challenge Tolerance Rates are higher in Patients with Asthma
C. M. Lee1, S. A. Lowe1, J. E. Conner1, L. A. Crandall1, M. B. Ho1, M. B. Feuling2, C. L. Sova2, M. Vasade1,
1Medical College of Wisconsin, Milwaukee, WI, 2Children’s Hospital of Wisconsin, Milwaukee, WI.

555 Omalizumab Improves Patient-Reported Outcomes In Patients With Allergic (IgE-mediated) Asthma
W. H. Yang1,2, P. Georgiou3, J. Canvin3, C. Chen3, G. Peachey3,
1Allergy & Asthma Research Centre, Ottawa, ON, CANADA, 2Novartis Horsham Research Centre, Horsham, UNITED KINGDOM,
3Novartis Pharmaceuticals, East Hanover, NJ.

554 Outcome Of Childhood Asthma Observational Follow-up Study In First 4 Years In Japan
A. Akasawa1, H. Watanabe2, K. Yoshida1, M. Furukawa1, T. Fuji-sawa3, M. Ebisawa1, H. Oda-jima3,
1Tokyo Metropolitan Children’s Medical Center, Tokyo, JAPAN, 2Kanagawa Hospital, Kanagawa, JAPAN, 3Mie Hospital, Mie, JAPAN,
4Sagamihara Hospital, Kanagawa, JAPAN, 5Fukuoka Hospital, Fukuoka, JAPAN.

553 The Predictors of Elderly Asthma Control
E. Hwang1, Y. Nam1, H. Jin1, Y. Shin1, Y. Ye1, D. Nahm1, H. Park1,
1University School of Medicine, Suwon, KOREA, REPUBLIC OF.

556 Trend of Asthma Comorbidities of Sleep Apnea, Obesity, and Gastroesophageal Reflux - A 5-year Population Survey
K. Yeh1,2, C. Yu1, J. Hong1, J. Huang1,2,
1Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, TAIWAN, 2Chang Gung University, Taoyuan, TAIWAN,
3Department of Computer Science and Information Engineering, National Central University, Taoyuan, TAIWAN.

International Study of Wheezing in Infants (EISL) - phase 3, Sao Paulo - SP, Brazil
C. S. Aranda1, E. O. Dantas1, J. A. Soares1, L. Fonzar1, A. C. Dela Bianca1, G. F. Wandslesen2, J. Malloff2, D. Sole2,
1Universidade Federal de Sao Paulo - UNIFESP, Sao Paulo, BRAZIL, 2Universidade de Santiago, Santiago, CHILE.

558 Obesity Is Associated With Nocturnal And Exercise-related Symptoms, But Not Asthma Severity In Urban Children With Asthma
K. D. Lu1, G. B. Dietle1, P. N. Breyssse2, J. Curtin-Brosnan1, C. Aloe1, E. C. Matsui1,
1Johns Hopkins School of Medicine, Baltimore, MD, 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

559 Effect of Statins in Asthmatic Patients with Hyperlipidemia
S. C. Christiansen1,2, M. Schatz1, S. Yang1, W. Chen1, B. L. Zuraw1,2,
1Southern California Kaiser Permanente Medical Grp, San Diego, CA, 2University of California San Diego, La Jolla, CA, 3San Diego VA Healthcare, San Diego, CA.

560 The Risk of Asthma in Late Preterm Infants
G. A. Matthews, B. D. Lahr, W. A. Carey, Y. J. Juhn1,
1Mayo Clinic, Rochester, MN.

Impact Of Rhinitis On Asthma In Japanese School Children
Y. Adachi2, Y. Okabe2, T. Itazawa1, K. Yoshida2, Y. Ohyaa, H. Oda-jima2, A. Akasawa2, T. Miyawaki1,
1Department of Pediatrics, University of Toyama, Toyama, JAPAN, 2Division of Allergy, Tokyo Metropolitan Children’s Hospital, To-kyo, JAPAN, 3Division of Allergy, National Center for Children Health and Development, Tokyo, JAPAN, 4Department of Pediatrics, Fukuoka National Hospital, Fukuoka, JAPAN.

562 Asthma and Risk of Herpes Zoster in Children: A Population-Based Case-Control Study
B. Kim1,2, S. Mehra1, B. Yawn1, R. Tower2, B. Lahr3, Y. Juhn3,
1Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN, 2Department of Pediatrics, Gustave D. Reese Asan Hospital, University of Ulsan College of Medicine, Gungneung-si, KOREA, REPUBLIC OF, 3Department of Research, Ohsmed Medical Center, Rochester, MN, 4Department of Health Sciences Research, Mayo Clinic, Rochester, MN.

563 Strains of Rhinovirus Associated with Asthma in Costa Rican Children
1University of Virginia, Charlottesville, VA, 2Center for Disease Control, Atlanta, GA, 3Hospital Nacional de Ninos, San Jose, COSTA RICA.

Gene-environment Interaction Between Tlr4 +8595c/t Polymorphism And Bronchiolitis May Influence The Development Of Asthma In Preschool Children
Y. Jung1,2, H. Kim1,2, J. Seo1,2, J. Kwong1, B. Kim1,2, S. Lee2,3, G. Jang2,6, D. Song2,8, W. Kim3,9, J. Shim1,10, M. Kang1,11, Y. Kim1,11, S. Hong1,2,
1Childhood Asthma Atopy Center, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, 2Research Center for Standardization of Allergic Diseases, Seoul, KOREA, REPUBLIC OF, 3Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF, 4Department of Pediatrics, Inje University Hae-undae Paik Hospital, Busan, KOREA, REPUBLIC OF, 5Department of Pediatrics, Inje University Sanggye Paik Hospital, Seoul, KOREA, REPUBLIC OF, 6Department of Pediatrics, Hallym Sacred Heart Hospital, Hallym University College of Medicine, Anyang, KOREA, REPUBLIC OF, 7Department of Pediatrics, National Health Insurance Corporation Ilsan Hospital, Il-san, KOREA, REPUBLIC OF, 8Department of Pediatrics, College of Medicine, Korea University, Seoul, KOREA, REPUBLIC OF, 9Department of Pediatrics, Inje University Seoul Paik Hospital, Seoul, KOREA, REPUBLIC OF, 10Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF, 11Asian Institute for Life Sciences, Asan Medical Center, Seoul, KOREA, REPUBLIC OF.

565 Adherence Estimator™ Scores and Relation to Asthma Control among Inner City Pediatric Patients
L. Yang, M. Kim, H. Lee, R. Joks,
1SUNY Downstate Medical Center, Brooklyn, NY.

566 Comparisons of Severe Asthma Characteristics from Two Pediatric Cohorts in the Severe Asthma Research Program (SARP)
S. B. Burka1, M. L. Fajt2, S. J. Aujla3, A. M. Fitzpatrick3, S. E.
567 Burden of Early Childhood Asthma in Children Born Preterm or With a History of Chronic Lung Disease
S. Dorris; Vanderbilt Medical Center, Nashville, TN.

568 Scuba Diving and Asthma: A 2011 Survey of AAAAI Members
D. M. Lang1, F. Twarog2; 1Cleveland Clinic, Cleveland, OH; 2Brigham and Women’s Hospital, Concord, MA.

569 Environmental Factors and Pediatric Emergency Visits for Acute Bronchospasm
V. VELAZQUEZ, B. DiGiorgi, N. Lopez, A. Pietri, J. Bracero; Hospital Episcopal San Lucas, Ponce, PR.

570 Obstructive Sleep Apnea, Sinusitis, Gastroesophageal Reflux and Severe Asthma Exacerbations
J. Temprano, C. Geremakis, L. Hinyard; Saint Louis University, St. Louis, MO.

571 Follow-up of Wheezing in Preschool Children from Sao Paulo and Maceio, Brazil: International Study of Wheezing in Infants - phase 2
A. C. C. Dela Bianca1, M. L. Medeiros2, G. F. Wandslen1, F. J. Soares2, J. Mallo1, D. Sole1; 1Universidade Federal de Sao Paulo - UNIFESP, Sao Paulo - SP, BRAZIL; 2State University of Health Sciences (UNCISAL), Maceio - AL, BRAZIL; 3Universidad do Chile, Santiago, CHILE.

572 Burden of Acute Pediatric Asthma Exacerbations in Gaborone, Botswana
K. M. Best1, A. P. Steenhoff2,3, S. Barenbaum2, L. Mazhani4, S. Kung2,4; 1Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA; 2University of Pittsburgh School of Medicine, Pittsburgh, PA; 3Emory University Department of Pediatrics, Atlanta, GA; 4Emory University School of Medicine, Atlanta, GA.

573 Evolving Prescription Trends in the Management of Childhood Wheeze in Singapore
J. Soh1, S. Xu2, Z. Tan2, Z. Ng2, W. Hing3, T. Wu3, Y. Chan2, B. Lee1; 1National University Health Systems, Singapore, SINGAPORE; 2Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE; 3Pharmacy, National University Health Systems, Singapore, Singapore, SINGAPORE.

574 Factors Related to Repeated Admission in Children with Asthma
S. Choi1, Y. Rha2; 1Kyung Hee University Gangdong Hospital, Seoul, KOREA, REPUBLIC OF; 2Kyung Hee University Hospital, Seoul, KOREA, REPUBLIC OF.

575 Exercise-Induced Bronchoconstriction among Adolescent Athletes: A Survey of Symptoms, Prevalence, and Performance Anxiety
J. C. Rabbat1, A. L. King2, J. R. Moy2, J. N. Moy3; 1Rush University Medical Center and John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; 2Rush University Medical Center, Chicago, IL.

576 Hypovitaminosis D is Very Frequent but not Associated with Asthma Control in a Low-Income Pediatric Population Seen in an Allergy and Immunology Clinic
F. Neagu; Rush University Medical Center, Chicago, IL.

577 Age-Dependent Interaction Between Atopy and Eosinophils in Asthma
S. J. Arbes, Jr1, A. Calatroni2, H. E. Mitchell1, P. J. Jergensen2; 1Rhô, Inc., Chapel Hill, NC; 2NIAID/NIH, Bethesda, MD.

578 Multiple Weather Related Changes Are Perceived as Common Triggers in Inner City Asthma Patients
E. E. Clarke, D. A. Khan; University of Texas Southwestern Medical Center, Dallas, TX.

579 Zingiber Cassumunar Inhibits No Through The Suppression Of NF-κB Pathway In Lps-stimulated Mouse Macrophages
O. P. S. Poochamkoon; Thammasat University, Prathum Tani, THAILAND.

580 Correlation of the Change of the Juniper Mini Quality of Life Questionnaire with Clinical Measurements in Asthma Patients from a Joint Commission Disease-Specific Practice
D. Menillo, R. Shah, B. McGoe, M. Michelis; Center for Allergy, Asthma & Immune Disorders, PA, Hackensack, NJ.

581 Daily Stressors as Antecedents of Nocturnal Asthma in Children
C. C. Horner, C. Dula, L. Bacharier, J. Garbutt, M. Krauss, R. Strunk; Washington University School of Medicine, Saint Louis, MO.

582 Do Asthma Symptoms Lag Behind Cold Symptoms in a Viral Illness?
D. McMahon, J. Germ, V. Rajamanickam; UWM Madison, Madison, WI.

583 Asthma Severity in Aspirin Exacerbated Respiratory Disease
K. S. Farmarn, D. D. Stevenson; Scripps Clinic, San Diego, CA.

Abstracts AB283

Poster Session

Imune Deficiency

4202
Session Time: Monday, March 5, 2012, 9:45 AM - 10:45 AM

584 DiGeorge Syndrome Immune Reconstitution and CMV Elimination by Bone Marrow Transplant
S. K. Chan1, R. Krance2, W. W. Stafford2, R. Lee1, D. K. Nguyen4, G. Harrison1, I. C. Hanson1; 1Texas Children’s Hospital, Baylor College of Medicine, Houston, TX; 2Drs. Childrens Hospital, Corpus Christi, TX; 3Texas Department of State Health Services, Austin, TX; 4Houston Allergy Asthma Associates, Houston, TX.

585 Genetic Defects of Griscelli Syndrome Type 2 in Saudi Arabia
H. Al-Mousa1, A. A. Al-Ghonaum1, H. Al-Dhekri1, S. Al-Mulsen1, B. Al-Saud1, R. Arnaut1, N. Aides1, S. Alhisi1, A. Hossari1; 1King Faisal Specialist Hospital and Research Center, Riyadh, SAUDI ARABIA; 2Alfaisal university, Riyadh, SAUDI ARABIA.

586 Histone-3-lysine-4 (H3K4) Methylation Defects in an Adult Female Kabuki Syndrome Patient with Pan-Hypogammaglobuline- mia
A. W. Lindsay1, J. Bernstein3, M. Wills-Karp1; 1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 2University of Cincinnati, College of Medicine, Division of Immunology Allergy & Rheumatology, Cincinnati, OH.

587 Development of Atopic Diseases in Patients with Primary Humoral Immunodeficiency
A. M. Jonge1, L. Heltner2, J. Fagin1; 1Cohen Children’s Medical Center of NY, Great Neck, NY; 2North Shore-Long Island Jewish Health System, Manhasset, NY.
588 A Scoring System to Determine the Need for Immunoglobulin Therapy in Patients with Humoral Immune Defects
E. S. Resnick, S. Taylor-Black, S. Agarwal, C. Cunningham-Rundles;
Mt. Sinai Medical Center, New York, NY.

589 Immune Abnormalities in Chronic Pain Syndrome (CPS) With Unknown Etiology
R. Khianey1, R. Shapiro2, L. Gang1, P. Kattouf3, H. Jyonouchi1; 1University of Medicine and Dentistry of New Jersey - New Jersey Medical School, Newark, NJ; 2Department of Physical Medicine - Columbia University Medical Center, New York, NY;

590 IgM Deficiency: A Retrospective Chart Review of Clinical and Immunologic Features
N. A. Mazer, A. Rubinstein; Albert Einstein College of Medicine- Montefiore Medical Center, Bronx, NY.

591 Primary Immunodeficiency in Microphagocytic Osteodysplastic Primordial Dwarfism Type III (MOPD III)
M. L. DeFelice, M. B. Bober, C. C. Chang, S. J. McGeady; Thomas Jefferson University/Alfred I. duPont Hospital for Children, Wilmington, DE.

592 Primary Immunodeficiency Presentations And 10 Warning Signs
M. L. Tierce, IV E. Secord; Wayne State University/Children’s Hospital of Michigan, Detroit, MI.

593 Prevalence of Malignancies in Various Primary Immune Deficiency States: A systematic review
D. M. George-Grandon, K. Osann, S. Gupta; UCI, Irvine, CA.

594 Phenotypic Comparison of B cells in Discordant Identical Twins with Common Variable Immune Deficiency and Recurrent Sinopulmonary Infection Patients
T. A. Hwanggo, E. Szymanska, C. R. Liu, M. G. Brand, E. E. Brown, H. Schroeder; University of Alabama at Birmingham, Birmingham, AL, AL.

595 Novel ZAP70 mutations causing Severe Combined Immunodeficiency Disease in Saudi Arabia
A. Hawwari1, O. Alsmadi1, H. Al-Dheki1, A. Al-Ghnaouim1, S. Al-Maheen1, B. Al-Saud1, R. Arnaut1, H. Al-Mousa1,2; 1King Faisal Specialist Hospital and Research Center, Riyadh, SAUDI ARABIA, 2Alfaisal university, Riyadh, SAUDI ARABIA.

596 Primary Immunodeficiency Diseases: A 20 Years Experience in a Tertiary University Hospital at Ramathibodi
O. Luecha, W. Kamchaisatan, S. Vilaiyuk, W. Manuyakorn, C. Saisakunporn, W. Teawsomboonkit, S. Benjaponpitak; Division of Pediatric Allergy/Immunology/Rheumatology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, THAILAND.

597 Is Common Variable Immune Deficiency Common In Cystic Fibrosis?
S. Jain1, R. Hopkins2, M. Kiernan; 1University of California, Irvine, CA, 2University of Iowa, Iowa City, IA.

598 Phenotypic Variations in Patients with Profound Mannose Binding Lectin Deficiency
M. Rasheed1, E. Visconti2, J. Shlobozerg1, A. Rubinstein1; 1Albert Einstein - Montefiore Medical Center, Bronx, NY; 2Seaview Avenue, Staten Island, NY.

599 C2 Deficiency Presenting as Pseudomonas Aeruginosa Bacteremia
S. Hasan, A. E. Hathaway, D. Q. Tran; University of Texas Health Science Center at Houston, Houston, TX.

600 Transient Hypereosinophilia and Markedly Elevated IgE as the Presenting Feature in DOCK8 (Dedicator of Cytokinesis 8) Deficiency
M. G. Gates, T. P. Atkinson; University of Alabama at Birmingham, Birmingham, AL.

601 Toll Like Receptor-3 (TLR3) Dysfunction in a Young Child with Recurrent Bacterial and Mucocutaneous HSV Infections
C. B. Cho1, D. W. Hauswirth1, P. J. Mustillo2; 1Nationwide Children’s Hospital, Columbus, OH, 2The Ohio State University Medical Center, Columbus, OH.

602 Classical Pyoderma Gangrenosum Associated with Abnormal Neutrophil Oxidative Burst
J. M. Bellak, M. C. Bell, S. R. Durrani, R. K. Viswanathan, J. E. Gern, C. M. Seroogy; University of Wisconsin-Madison, Madison, WI.

603 Common Variable Immunodeficiency (CVID) Presenting as Severe, Refractory Gastritis and Autoimmune Enteropathy in an Adolescent Male
C. Kuo, M. Garcia-Lloret; UCLA, Los Angeles, CA.

604 Is It Hyper Ige Syndrome Or Something Else? A Patient With Chromosome 1q4 Deletion
M. R. Yasharpour, N. Cac, G. Venkat, S. Gupta, L. Yel; University of California, Irvine, CA.

---

**Poster Session**

**Dendritic Cells Pattern Recognition Receptors and Signaling**

4203 Session Time: Monday, March 5, 2012, 9:45 AM - 10:45 AM

605 Analysis of the Expression of Toll-like Receptors 2 and 4 in Keratinocytes of Patients with Extensive Dermatophytosis due Trichophyton rubrum
P. R. Criado, C. B. Oliveira, C. Vasconcellos, N. Y. S. Valente, M. N. Sotto, F. Guedes Luiz, W. Belda Junior; Post-graduation Program in Science of Health, Sao Paulo University, School of Medicine., Sao Paulo, BRAZIL.

606 Respiratory Syncytial Virus (RSV)-Infected Elderly Mice Exhibit Impaired Expression and Activation of Pattern Recognition Receptors (PRR)
T. M. Wong, S. S. Mohapatra; University of South Florida, Tampa, FL.

607 GRK3 Deficiency Enhances Parathyroid Hormone (PTH) Receptor Function On Bone Marrow Mesenchymal Stem Cells And May Enhance Hematopoiesis
M. W. McGinnis, R. G. Timoshchenko, D. S. Serafin, N. Case, J. Rubin, T. K. Tarrant; University of North Carolina, Chapel Hill, NC.

608 Cytokine Profiles of Human Myeloid Dendritic Cell Subsets in Response to RSV and TLR Agonists
M. R. Gupta, D. Kolli, R. P. Garofolo; UTMB, Galveston, TX.

609 Prostaglandin I2 Receptor (IP) Signaling Inhibits Antigen Uptake but Induce the Ability of Migration on Immature Dendritic Cells
S. Toki1, K. Goleniewska1, G. A. FitzGerald2, R. S. Peebles, Jr.3; 1Vanderbilt University, Nashville, TN, 2University of Pennsylvania, Philadelphia, PA.
Inflammasome activates Alveolar Cell Permeability through Neuregulin-1-Human Epidermal Receptor-2 Signaling V. Rajanbanu, B. Huynh, P. Tamarapo Parthasarathy, N. Kollipudi; Nanomedicine Research Center and Division of Allergy and Immunology, College of Medicine, University of South Florida, Tampa, FL.

Innate Interferons and Plasmacytoid Dendritic Cells constrain Th2 Cytokine Responses to Rhinoviruses: a Regulatory Mechanism with Relevance to Asthma J. W. Upham 1,2, M. L. Carroll 3, J. G. Burel 3, A. L. Pritchard 1; 1University of Queensland, Brisbane, AUSTRALIA, 2Princess Alexandra Hospital, Brisbane, AUSTRALIA.

Remote Pulmonary Inflammation Following Renal Graft Engraftment In Rats D. Ma, H. Huang, H. Zhao; Imperial College London, London, UNITED KINGDOM.

Role of the NLRP3 Inflammasome in Vaccine Responses S. Wilson, S. Cassel, F. Sutterwala; The University of Iowa Hospitals & Clinics, Iowa City, IA.

Soybean Isoflavones Inhibit DC-SIGN Signaling: Implications for Allergenicity of DC-SIGN Binding Food Allergens M. Kamalakannan; Mount Sinai School of Medicine, New York, NY.

Th2 Cytokines Compromise The Function of TLR2 In Human Keratinocytes I. Kuo 1,2, A. DeBenedetto 1, T. Yoshida 1, L. Y. McGirt 3, D. Y. M. Leung 3, L. A. Beck 3; 1Department of Dermatology, University Of Rochester Medical Center, Rochester, NY, 2Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, 3Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD.

Type I And III IFN Expression Attenuated In Human Alternatively Activated Macrophages A. El Fiky, R. Perreault, R. L. Rabin; FDA/CBER, Bethesda, MD.

Characterization Of Plasmacytoid Dendritic Cells From Blood Of Patients With Systemic Lupus Erythematosus A. Y. Hancharou 1, K. A. Chyzh 2, L. P. Titov 1, N. F. Soroka 2, L. M. DuBuske 1; 1Research Institute for Epidemiology and Microbiology, Minsk, BELARUS, 2Belarusian State Medical University, Minsk, BELARUS.

Plasmacytoid Dendritic Cells From Blood Of Patients With Systemic Lupus Erythematosus A. Y. Hancharou 1, K. A. Chyzh 2, L. P. Titov 1, N. F. Soroka 2, L. M. DuBuske 1; 1Research Institute for Epidemiology and Microbiology, Minsk, BELARUS, 2Belarusian State Medical University, Minsk, BELARUS.

Human Rhinovirus Species Var By Season And Diagnosis In 21-year Prospective Pediatric Cohort J. E. (Linder) Jackson, D. Kraft, K. M. Edwards, J. V. Williams, E. Miller; Vanderbilt University, Nashville, TN.

Seasonal Asthma Exacerbation and Viral Association in a Pediatric Population Receiving ICS + LABA Therapy C. M. Prazma 1, B. A. Prillaman 3, J. E. Gern 2, D. A. Stempel 1; 1GlaxoSmithKline, Dutham, NC, 2University of Wisconsin-Madison, Madison, WI.

LDH/Caspase Ratio in Nasal-Wash Fluid as a Marker of Disease Severity in Bronchiolitis R. Mehta 1, K. Patel 2, A. Jewell 2, K. Jennings 3, M. Scheffler 4, L. Aideyan 2, R. Garofalo 1, P. Piedra 1,2; 1Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, 2Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, 3Department of Preventative Medicine and Community Health, University of Texas Medical Branch, Galveston, TX, 4Department of Pediatrics, Baylor College of Medicine, Houston, TX.

Asthma and Risk of Community-Associated Blood Stream Infection Due to Staphylococcus aureus: A Population-Based Case-Control Study J. Lee 1,2, H. Yang 1,2, W. Atouni 3, L. Baldour 3, B. Yawn 3, Y. Ju 3, S. Hong 3; 1Inje University Haeundae Paik Hospital, Busan, KOREA, 2Department of Pediatrics, Samsung Changwon Hospital, Changwon, KOREA, 3Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, 4Department of Pediatrics, Soonchunhyang University Hospital, Seoul, KOREA, 5Division of Infectious Diseases, Department of Internal Medicine, University of Kansas Medical Center, Kansas, KS.

Air Pollution And Environmental Tobacco Smoking During Infancy May Increase The Risk Of Bronchiolitis B. Kim 1, H. Kim 1, S. Lee 2, J. Kwon 1, J. Seo 3, H. Kim 5, J. Yu 4, S. Hong 3; 1Inje University Haeundae Paik Hospital, Busan, KOREA, 2Inje University Sanggye Paik Hospital, Busan, KOREA, 3Hallym University Medical Center, Seoul, KOREA, 4Seoul National University Bundang Hospital, Seoul, KOREA, 5Asan Medical Center, Seoul, KOREA.

Asthma and Severity of Blood Stream Infection Caused by Escherichia coli: A Population-Based Study H. J. Yang 1,2, J. Lee 1, L. M. Al-Hasan 3, M. N. Al-Hasan 3, B. P. Yawn 2; 1Soonchunhyang Univ Hospital, Seoul, KOREA, 2Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, 3Samsung Changwon Hospital, SungKyunKwan University, Changwon, KOREA, 4Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, MN.

Epidemiology of Sensitization, Asthma and Occupational Asthma

Poster Session

Infections and Allergic Disease

4204
Session Time: Monday, March 5, 2012, 9:45 AM - 10:45 AM

Live But Not Heat-Killed Staphylococcus aureus Induce Production Of TSLP And IL-33 In Skin Fibroblasts From Both Healthy Children And Those With Atopic Dermatitis S. Tan, J. L. Pennock, P. D. Arkwright; University of Manchester, Manchester, UNITED KINGDOM.

Human Rhinovirus Species Vary By Season And Diagnosis In 21-year Prospective Pediatric Cohort J. E. (Linder) Jackson, D. Kraft, K. M. Edwards, J. V. Williams, E. Miller; Vanderbilt University, Nashville, TN.

Seasonal Asthma Exacerbation and Viral Association in a Pediatric Population Receiving ICS + LABA Therapy C. M. Prazma 1, B. A. Prillaman 3, J. E. Gern 2, D. A. Stempel 1; 1GlaxoSmithKline, Dutham, NC, 2University of Wisconsin-Madison, Madison, WI.

Lactate Dehydrogenase/Caspase Ratio in Nasal Wash Fluid as a Marker of Disease Severity in Bronchiolitis R. Mehta 1, K. Patel 2, A. Jewell 2, K. Jennings 3, M. Scheffler 4, L. Aideyan 2, R. Garofalo 1, P. Piedra 1,2; 1Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, 2Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, 3Department of Preventative Medicine and Community Health, University of Texas Medical Branch, Galveston, TX, 4Department of Pediatrics, Baylor College of Medicine, Houston, TX.

Asthma and Risk of Community-Associated Blood Stream Infection Due to Staphylococcus aureus: A Population-Based Case-Control Study J. Lee 1,2, H. Yang 1,2, W. Atouni 3, L. Baldour 3, B. Yawn 3, Y. Ju 3, S. Hong 3; 1Inje University Haeundae Paik Hospital, Busan, KOREA, 2Department of Pediatrics, Samsung Changwon Hospital, Changwon, KOREA, 3Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, 4Department of Pediatrics, Soonchunhyang University Hospital, Seoul, KOREA, 5Division of Infectious Diseases, Department of Internal Medicine, University of Kansas Medical Center, Kansas, KS.

Air Pollution And Environmental Tobacco Smoking During Infancy May Increase The Risk Of Bronchiolitis B. Kim 1, H. Kim 1, S. Lee 2, J. Kwon 1, J. Seo 3, H. Kim 5, J. Yu 4, S. Hong 3; 1Inje University Haeundae Paik Hospital, Busan, KOREA, 2Inje University Sanggye Paik Hospital, Busan, KOREA, 3Hallym University Medical Center, Seoul, KOREA, 4Seoul National University Bundang Hospital, Seoul, KOREA, 5Asan Medical Center, Seoul, KOREA.

Asthma and Severity of Blood Stream Infection Caused by Escherichia coli: A Population-Based Study H. J. Yang 1,2, J. Lee 1, L. M. Al-Hasan 3, M. N. Al-Hasan 3, B. P. Yawn 2; 1Soonchunhyang Univ Hospital, Seoul, KOREA, 2Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, 3Samsung Changwon Hospital, SungKyunKwan University, Changwon, KOREA, 4Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, MN.

Epidemiology of Sensitization, Asthma and Occupational Asthma

Poster Session

Epidemiology of Sensitization, Asthma and Occupational Asthma

4205
Session Time: Monday, March 5, 2012, 9:45 AM - 10:45 AM

The Role of Seasonal Grass Pollen on Childhood Asthma Emergency Department Presentations
627 Bronchial Asthma in Urban Malagasy Children: The VAVANY-Study
P. T. Wolff1, L. Arison2, A. Rahasamikatra3, F. Raserisaona2, B. Niggemann4;
1Pediatric Practice, Pfullendorf, GERMANY, 2Clinique MM 24/24 Mptisabo Mikambana, Antananarivo, MADAGASCAR, 3German Red Cross Hospital Westend, Berlin, GERMANY.

628 Triclosan, a Common Ingredient in Household Products, is Associated With Allergic Sensitization
Johns Hopkins Hospital, Baltimore, MD.

629 Microarray Analysis of IgE Reactivity in Patients with Asthma and/or Rhinitis Allergic to Cockroach and Mites: Clinical Application
G. A. Bardin1, A. S. Moreno1, A. C. A. F. Santos1, K. S. Santos2, L. Arnada1;
1School of Medicine of Ribeirao Preto, Ribeirao Preto, BRAZIL, 2School of Medicine - University of Sao Paulo, Sao Paulo, BRAZIL.

630 Association Between Asthma-related Emergency Department Visits, and Tree Pollen Concentrations In The Bronx, 2001 - 2008
J. Toh1, S. Jariwala1, D. Rosenstreich1, K. Zou5;
1Albert Einstein School of Medicine, New York, NY, 2Southern Methodist University, Dallas, TX.

631 Specific IgE to Mite, Shrimp and Blo t 13 allergens in an Allergic Population From the Caribbean
L. Puerta1, J. I. Tudela2, M. Manera1, B. Cases2, S. Lafosse-Marin3, E. Fernandez-Caldas2, L. Caraballo1;
1Institute for Immunological Research, University of Cartagena, Cartagena, COLOMBIA, 2Inmunotek, Madrid, SPAIN, 3Cabinet de Allergologie, Fort de France, MARTINIQUE.

632 What causes Asthma and Allergy in School-going Children in Jaipur?
R. S. Rao, V. Singh, S. Singh;
SMS Medical college & hospital, Jaipur, INDIA.

633 Aerallergen Sensitivities In A Cohort of Patients Residing In Vietnam
T. Nguyen1, N. Ngoc Dung1, Q. Nguyen2, T. Craig3;
1ENT Hospital, Ho Chi Minh City, VIET NAM, 2Penn State, 500 University Dr, PA, 3Penn State, Hershey, PA.

634 Serum Cytokine Profiles In Trimellitic Anhydride Exposed Factory Workers
D. Ghosh, J. Bernstein;
University of Cincinnati College of Medicine, Cincinnati, OH.

635 Dug-Well Lung
S. Singh, B. B. Sharma, V. Singh, R. S. Rao;
SMS Medical college & hospital, Jaipur, INDIA.

636 Sensitization to Storage Mites, Wheat and Yeast Allergens in Cuban Bakers
M. Alvarez-Castello1, Y. Leyva1, R. L. Castro-Alamarales2, A. Labrada3, V. R. Meli4, H. Barata1;
1Calixto García University Hospital, Havana, CUBA, 2National Center of Bioproducts, Havana, CUBA, 3Diater Laboratorios, Buenos Aires, ARGENTINA.

637 Sensitization To Multiple Woods Caused By An IgE-mediated Mechanism
A. Aranda1, P. Campo2, A. Palacin3, M. Montanez1, R. Herrera2, G. Campos2, A. Diaz-Perales3, M. Blanca2;
1Allergy Laboratory, Fundacion IMABIS, Malaga, SPAIN, 2Allergy Department, Carlos Haya Hospital, Malaga, SPAIN, 3Biotechnology Dept, Politechnic University, Madrid, SPAIN.

638 A National Review of Tobacco Smoking Among Females and Males in Turkey
G. E. ERGOLU;
Beyzailem Vakif University, Istanbul, Turkey.

645 Exclusive Sensitization to Striped Catfish (Pangasianodon hypophthalmus) and Closely Related Fish Species
G. Seszek-Greinecker1, N. Balic2, W. Hemner1, I. Swoboda3;
1Floridsdorf Allergy Center, Vienna, AUSTRIA, 2Department of...
A Bioassay For Assessing Dose-Response Relationships In A Food Allergic Mouse Model
E. K. Kweyir-Afful1,2, O. T. Feye3, K. Williams3, S. Lucioli1, 2Office of Food Additive Safety, CFSAN, FDA, College Park, MD, 2Office of the Commissioner, Office of Science and Innovation, Silver Spring, MD, 3Office of Applied Research and Safety Assessment, CFSAN, FDA, Beltsville, MD.

Peanut plus Cholera Toxin Subunit B in vitro Effects on Induction of IL-10 in Human Peripheral Blood Mononuclear Cells from Subjects with Peanut Allergy
A. Tang, Y. Song, J. Wang, J. Ross, X. Li; Mount Sinai School of Medicine, New York, NY.

Nasal Immunization with Peanut Antigen and The Cationic Peanut plus Cholera Toxin Subunit B
J. Renaudin1,2, N. Abraham, A. W. Burks, H. F. Staats; Duke University, Durham, NC.

In vitro Digestion and Characterization of Proteins and Digestion-Resistant Peptides of Pecan
J. Spircic1, A. Knulst2, J. Nordlee1, S. Taylor1, J. Baumert1; 1University of Nebraska-Lincoln, Lincoln, NE, 2University Medical Center Utrecht, Utrecht, NETHERLANDS.

Modified Peanut Extracts are Hypoallergenic in Mediator Release Assay
R. Bencharitiwong1, H. P. van der Kleij2, S. J. Koppelman2, A. H. Nowak-Wegrzyn1; 1Mt. Sinai School of Medicine, New York, NY, 2Hal Allergy BV, Leiden, NETHERLANDS.

Recombinant Ara H 6 Expressed In Pichia Pastoris Preserves Effector Function And Is Useful To Assess Mutations
Y. Zhuang, S. Durrani, K. Otsu, S. C. Dreskin, X. Chen; University of Colorado Denver, Aurora, CO.

Identification of Maillard reaction induced chemical modifications on Ara h 1

Interest Of Specific IgE Measurement For Galactose-alpha-1,3-galactose In Unexplained Recurrent Urticaria With Angioedema, Predominantly Nocturnal : About 6 Cases
J. Renaudin1, S. Jacquenet2, C. Metz-Favre3, E. Baudouin4, F. Engel5, F. de Blay1, D. Moneret-Vautrin1; 1Department of Allergology, J Monnet Hospital, Epinal, FRANCE, 2Gencis SAS, Vandoeuvre les Nancy, FRANCE, 3Department of Pneumology, University Hospital, Strasbourg, FRANCE.

In the Pork-Cat Syndrome, Allergic Reactions to Pork Reflect IgE Antibodies to Cat Albumin that Cross-reacts with Other Albumins
J. Posthumus1, L. J. Workman1, H. R. James1, S. L. Pochan1, C. J. Lane2, D. C. McBride3, S. S. Eapen1, L. A. Matos3, S. P. Commins1, T. A. E. Platts-Mills1; 1University of Virginia, Charlottesville, VA, 2Allergy Partners of Lynchburg, Lynchburg, VA, 3Asthma and Allergy Center, Lynchburg, VA.

A Successful Project Giving Special Foods For Food Allergy From the United States To Children With Food Allergy In The Area Affected By The Great East Japan Earthquake
K. Miura1, K. Mita2, T. Yama1, R. Eto1, T. Eto1; 1Miyagi Children’s Hospital, Sendai, JAPAN, 2Volunteer, Sendai, JAPAN, 3Volunteer, Flemington, NJ.
681 Outdated Epinephrine Autoinjectors: Ejection Volume Integrity and Epinephrine Content and Dose
K. J. Simons1, O. M. Rachid1, M. A. Rawas-Qalaji2, M. Wein3, F. E. R. Simons2;
1University of Manitoba, Winnipeg, MB, CANADA, 2Nova Southeastern University, Fort Lauderdale, FL, Florida State University, Tallahassee, FL.

682 Perioperative Anaphylaxis: Clinical Features of 51 Patients
FMUSP, Sao Paulo, BRAZIL.

683 Intraoperative Anaphylaxis In A Pediatric Patient Induced By Thrombin Gel Administration
E. Khoriaty, R. Rachid;
Children’s Hospital Boston, Boston, MA.

684 Kounis Syndrome: Paradoxical Vasocostriction of a Coronary Artery During an Angiography Contrast-Induced Anaphylactoid Reaction
M. N. Le, A. Canady, S. K. Zimmerman, S. Gierer, M. Earnest; The University of Kansas Medical Center, Kansas City, KS.

685 Ropivacaine Anaphylaxis Necessitating Emergent Thoracostomy After Open Reduction Internal Fixation Of Left Tibial Fracture Confirmed Through Percutaneous Testing, Intradermal Testing and Subcutaneous Challenge
J. D. Martinez, M. N. Le, D. J. Stechschulte;
The University of Kansas Medical Center, Kansas City, KS.

686 Is Severity Of Drug Induced Anaphylaxis Dependent Of Its Etiology?
FMUSP, Sao Paulo, BRAZIL.

687 Risk of Anaphylaxis in Narcotic Drug Addicts Being Treated For Drug Rehabilitation
U. Maurer1, R. Jarisch1, A. Pollesbeck3, W. Hemmer2, F. Wantke2, B. Spitzer2;
1University of applied sciences, Wiener Neustadt, AUSTRIA, 2Floridsorf Allergy Center, Vienna, AUSTRIA, 3Landesklinikum, Maier-Amstetten, AUSTRIA.

688 A Comparison of Tryptase Levels in Patients with Septic vs. Cardiogenic Shock
D. R. Sun1, J. R. Dye3, C. Xu1, A. Abbate1, L. B. Schwartz1;
1Virginia Commonwealth University, Richmond, VA, 2Kaiser Permanente, Oakland, CA.

689 Baseline Serum Tryptase Levels in Patients who Suffered Anaphylaxis
Hospital General Universitario Gregorio Maranon, Madrid, SPAIN.

690 Latitude Gradient of Anaphylaxis in Chile: A Potential Role of Vitamin D Status
R. Hoyos-Bachiloglu1, P. S. Morales, J. Cerda, E. Talesnik, C. Mendez, G. Gonzalez, A. Borutzky;
Pontificia Universidad Catolica de Chile, Santiago, CHILE.

691 Aspirin Administration Effect On Food-Dependent Exercise Induced Anaphylaxis
C. Motomura;
Fukuoka National Hospital, Fukuoka, JAPAN.

692 Does Concomitant Chronic Pulmonary Disease Increase the Severity of an Anaphylactic Episode?
Z. D. Mull1, F. E. R. Simons2;
1Texas Tech University Health Sciences Center, El Paso, TX, 2University of Manitoba Faculty of Medicine, Winnipeg, MB, CANADA.

693 Food-dependent Exercise-induced Anaphylaxis (fdeia) And Sensitization To Omega-5-gliadin
D. Guillen1, C. Gomez-Tracea1, R. Cabanas1, N. Prior3, S. Quirce1,2, T. Caballero1;
1Hospital Universitario La Paz, Madrid, SPAIN, 2Spanish network of centers for biomedical research on respiratory diseases (CibeRes), Madrid, SPAIN.

From 2000-2008, Statewide Hospital Admission Rates for Allergic Reaction Increased More Rapidly in the Northeast United States When Compared to Other Regions of the United States
R. C. Van Winkle2,1, J. Hossain1, C. C. Chang1, S. J. McGeady1,2;
1A.I. duPont Hospital for Children, Wilmington, DE, 2Thomas Jefferson University, Philadelphia, PA.

Comparison between Allergists and Non-allergists on Issues Related to Food-induced Anaphylaxis
M. Desjardins1, A. Clarke2, R. Alizadehfar1, D. Gnerier3, H. Eisman4, S. Carr5, T. Vander Leek6, L. Teperman4, N. Higgins1, L. Joseph5, G. Shand1, M. Ben-Shoshan1;
1Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, McGill University Health Center, Montreal, QC, CANADA, 2Division of Allergy and Clinical Immunology & Division of Clinical Epidemiology, Department of Medicine, McGill University Health Center, Montreal, QC, CANADA, 3Canadian Peadiatric Society, Ottawa, ON, CANADA, 4Montreal Children’s Hospital, Emergency Department, McGill University Health Center, Montreal, QC, CANADA, 5Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, University of Alberta, Edmonton, AB, CANADA, 6Society of Rural Physician of Canada, Shawville, QC, CANADA, 7Department of Epidemiology, McGill University Health Center, Montreal, QC, CANADA, 8Department of Epidemiology and Biostatistics, McGill University, Montreal, QC, CANADA.

Translating Science Into Meaningful Strategies That Improve Quality Of Life In Food Allergy: An Investigation Of Defined Thresholds And Risk Stratification In Consumers, Clinicians And Food Producers
A. DunnGalvin1, J. O. B. Hourihane1, S. Taylor2;
1University College Cork, Cork, IRELAND, 2University College Cork, Cork, NE.

Chemical and biological characterization of Food Allergy Herbal Formula 2 (FAHF-2) product consistency and potency
N. Yang, C. Bautista, I. Gluskin, H. Sampson, X. Li;
MountSinai School of medicine, New York City, NY.

Comparison of Systemic Absorption of Epinephrine Delivered Intranasally (5 mg) vs Intramuscularly (0.3 mg) Using Liquid Chromatography with Tandem Mass Spectrophotometry (LC-MS/MS)
R. Pensrichon;
Siriraj Hospital, Bangkok, THAILAND.

Ribavirin Desensitization in Chronic Hepatitis C Infection
O. Toker;
Hadassah Medical Center, Jerusalem, ISRAEL.

Identification of Structural Determinants Supporting The Absence of IgE Cross-Reactivity Between Caprine and Bovine β-Caseins In Patients Allergic to Goat’s Milk But Tolerant To Cow’s Milk
S. Hazebrouck1, S. Ah-Leung1, E. Paty2, E. Bidar1, M. F. Drumare1, S. Tilleul1, K. Adel-Patient1, J. M. Wail1, H. Bernard1;
1Laboratoire d’Immunno-Allergie Alimentaire INRA, Gif sur Yvette, FRANCE, 2Hopital Necker Enfants Malades, Paris, FRANCE, 3Hopital Ambroise Pare, Boulogne-Billancourt, FRANCE.

Anaphylactic Reaction To Intravenous Administration Of Of Lnic Acid: A Case Report
K. N. Syrigos1,2, E. Srygoul3, S. Hotchkiss2, M. Gambaccini2, K. Kaley3, M. W. Saif3;
Poster Session

Provider Knowledge and Training

Session Time: Monday, March 5, 2012, 9:45 AM - 10:45 AM

4208

504 Effectiveness of an Educational Intensive Course on Allergy and Immunology Clinical and Diagnostic Procedures

505 Pharmacists And Knowledge Of Asthma: Survey Of 120 Pharmacists, Comparison Between 1999 And 2009
M. L. Acebal, M. J. Dorsey, F. de Blay, H. P. Sharma; Faculty of Pharmacy, University, Strasbourg, FRANCE.

506 Food Allergy Knowledge among School Nurses in an Urban Public School District
H. Robinson, S. Twichell, L. Hanks, C. Heitz; Central Texas Health Research, New Braunfels, TX, 1Allergy Asthma Research Institute, Waco, TX, 4Teva Branded Pharmaceutical Products R&D, Inc., Horsham, PA.

507 Allergy Training and Immunotherapy in Latin America: How Survey-Results Lead to a Regional Overview
D. E. S. Larenas Linnemann, M. Gomez, G. Passalacqua, S. N. Gonzalez Diaz, V. H. Croce, G. W. Canonica, C. Baena Cagnani; 1Hospital Medica Sur, Mexico, MEXICO, 2Centro Investigacion Medicina Respiratoria (CIMER-UCC), Cisai, ARGENTINA, 6Allergy & Respiratory Diseases (DIMI), Universita Degli Studi Di Genova, Genoa, ITALY, 7Latin American Society of Allergy, Asthma & Immunology, Monterrey, MEXICO.

508 Pharmacists’ Understanding of Patient Education on Inhalers
J. JEONG, C. Park; 1Ilsan Paik Hospital, Goyang, KOREA, REPUBLIC OF, 2Haeundae Paik Hospital, Busan, KOREA, REPUBLIC OF.

Session Time: Monday, March 5, 2012, 9:45 AM - 10:45 AM

4209

509 A Scintigraphy Study Evaluating The Nasal Deposition And Retention Of Ciclesonide Hydrofluoroalkane Nasal Aerosol And Mometasone Furoate Aqueous Nasal Spray In Patients With Perennial Allergic Rhinitis
J. Karafilidis, B. Wang; Sunovion Pharmaceuticals, Marlborough, MA.

510 Effective Nasal Symptom Relief and Improvement in Health-Related Quality of Life in Subjects with Perennial Allergic Rhinitis Following 6-Week Once-Daily Treatment with Beclomethasone Dipropionate Hydrofluoroalkane Nasal Aerosol

511 Once-Daily Treatment With Beclomethasone Dipropionate Hydrofluoroalkane Nasal Aerosol (320 mcg/d) Is Not Associated With Hypothalamic-Pituitary-Adrenal Axis Suppression in Adolescent Subjects With Perennial Allergic Rhinitis

512 Once Daily Treatment with Beclomethasone Dipropionate Hydrofluoroalkane Nasal Aerosol Is Safe and Effective in Children (6-11 Years of Age) With Seasonal Allergic Rhinitis
N. Segall, L. Mansfield, N. Amar, P. M. Dorinsky, L. Kelley, Y. Ding, S. K. Tantry; 1Georgia Allergy & Respiratory, Atlanta, GA, 2Allergy, Immunology & Asthma, El Paso, TX, 3Allergy Asthma Research Institute, Waco, TX, 4Teva Branded Pharmaceutical Products R&D, Inc., Horsham, PA.

513 Long-Term (52-Week) Treatment With Beclomethasone Dipropionate Hydrofluoroalkane Nasal Aerosol (320 mcg Once Daily) Is Safe and Effective in Adult and Adolescent Subjects With Perennial Allergic Rhinitis

514 Once-Daily Treatment With Beclomethasone Dipropionate Hydrofluoroalkane Nasal Aerosol (320 mcg/d) Provides Substantial Nasal Symptom Relief in Subjects With Perennial Allergic Rhinitis
B. M. Premer, S. Weinstein, W. Pleskow, A. Tankelevich, Y. Ding, S. K. Tantry, P. M. Dorinsky; 1Allergy Associates Medical Group, Inc., San Diego, CA, 2Allergy & Asthma Specialists Medical Group, Huntington Beach, CA, 3Warren W. Pleskow, MD, Encinatus, CA, 4Teva Branded Pharmaceutical Products R&D, Inc., Horsham, PA.
715 Use of In Vivo Confocal Microscopy to Assess Allergic Inflammation following Conjunctival Allergen Challenge
E. Angjeli, K. J. Lane, M. Contractor, P. Gomes, M. B. Abeleson; Ora, Inc, Andover, MA.

716 Dry Eye Syndrome in an Allergy Practice and Effect of Cyclosporine Treatment
R. Tharackal Ravindrana, S. Breithartb, L. Bielyc; 1Overlook Hospital, Summit, NJ, 2Englewood Hospital and Medical Center, Englewood, NJ, 3Rutgers University, New Brunswick, NJ.

717 Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5% Improves Morning (AM) Ocular Redness Scores in a Placebo-Controlled Environmental Study of Seasonal Allergic Rhinoconjunctivitis (SAR)
J. I. Williams, J. A. Gow, M. Munoz, T. McNamara; ISTA Pharmaceuticals, Irvine, CA.

718 Comparison of Environmental and Allergen-Challenge based Assessments of Allergic Conjunctivitis Treatment using an Antihistamine-Steroid Combination Therapy
P. Gomes1, M. B. Abeleson1,2;
1Ora, Inc, Andover, MA, 2Harvard Medical School, Schepens Eye Research Institute, Boston, MA.

719 Lower Symptom Severity Scores in Cetirizine-Treated Patients with Moderate/Severe Seasonal Allergic Rhinitis

720 Satisfaction With And Preference For Ciclesonide Hydrofluorokane Nasal Aerosol Or Mometasones Furoato Nasal Aqueous Spray In Patients With Perennial Allergic Rhinitis: Results From A Validation Study

721 Lower Symptom Severity Scores in Cetirizine-Treated Patients with Moderate-Severe Perennial Allergic Rhinitis

722 A 26-week, Open-label Extension Study Evaluating The Long-term Safety And Tolerability Of Ciclesonide Hydrofluoroalkane Nasal Aerosol In Patients With Perennial Allergic Rhinitis
W. Storms1, G. Gross2, S. Spector5, H. Huang3, S. Y. Desai1; 1Storm Clinical Research Institute, Colorado Springs, CO, 2Pharmaceutical Research & Consulting, Inc., Dallas, TX, 3California Allergy & Asthma Medical Group, Los Angeles, CA, 4Sunovion Pharmaceuticals Inc., Marlborough, MA.

723 Loteprednol Etabonate Ophthalmic Suspension, 0.2% Is As Safe as Olopatadine Hydrochloride Ophthalmic Solution, 0.1% With Superior Relief of Signs and Symptoms In The Treatment of Seasonal Allergic Conjunctivitis
A. Elion-Mboussa1, L. Gong2, L. Roy3, B. Zhu4, H. DeCory3, E. Chu1; 1Bausch & Lomb Incorporated, Rochester, NY, 2Eye, Nose & Throat Hospital of Fudan University, Shanghai, CHINA, 3Bausch & Lomb (S) Pte Ltd., Singapore, SINGAPORE, 4Shandong Bausch & Lomb Freda Pharmaceutical Co.,Ltd., Shanghai, CHINA.

724 Comparison of Health Outcomes of Patients with Allergic Rhinitis Receiving Pressurized Metered-Dose Inhaler Versus Aqueous Intranasal Corticosteroid Formulations
P. O. Buck1, L. Cox2, D. Lang3, C. S. Hankin4, Z. Wang5, A. Bronstone6, M. Lepore1; 1Teva North America Branded Pharmaceuticals, Inc., Horsham, PA, 2Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, FL, 3Cleveland Clinic, Cleveland, OH, 4BioMedicon, Moss Beach, CA.

Poster Session

Immunotherapy Outcomes

4210
Session Time: Monday, March 5, 2012, 9:45 AM - 10:45 AM

725 Allergen Immunotherapy: More Stuttering than Finishing
K. M. Payne, R. J. M. Engler, R. L. McCoy, M. R. Nelson; Walter Reed National Military Medical Center, Bethesda, MD.

726 Efficacy of Sublingual Immunotherapy In a Typical American Practice
J. G. Sanchez, R. Garcia-Ibanez; The AllergiGroup, Tampa, FL.

727 Incidence of Respiratory Tract Infections in Clinical Trials of Intravenous and Subcutaneous Immunoglobulin
J. S. Baggish1, M. Bexon2, M. Rojavin3, O. Zenker4, M. Berger1; 1CSL Behring LLC, King of Prussia, PA, 2CSL Behring AG, Bern, SWITZERLAND, 3CSL Behring GmbH, Marburg, GERMANY.

728 Hints to Increase Therapeutic Benefits by Initiating Conventional Allergen Immunotherapy As Soon As Possible Regardless of Age
H. Nagaya; Kuyagama Institute of Clinical Allergy and Allergy Clinic, TOKYO, JAPAN.

729 Integrated Database of Eight Prospective IgG Studies in Primary Immunodeficiency: New Tool for Pooled Analysis
M. A. Rojavin1, M. Bexon2, M. Pruss3, C. Miede3, O. Zenker4; 1CSL Behring LLC, King of Prussia, PA, 2CSL Behring AG, Bern, SWITZERLAND, 3Accovion GmbH, Marburg, GERMANY, 4CSL Behring GmbH, Marburg, GERMANY.

730 Increased Frequency of Infections at the End of the IVIG Dosing Cycle: Effect Characterization from Three Phase III Studies
M. Bexon1, J. S. Baggish2, M. Rojavin2, M. Berger3, Z. Wang3; 1CSL Behring AG, Berne, SWITZERLAND, 2CSL Behring LLC, King of Prussia, PA, 3CSL Behring GmbH, Marburg, GERMANY.

731 Evaluation of the Relationship between Injection Site Reaction Rate and SCIG Doses in Patients with Primary Immunodeficiencies
O. Zenker1, M. Rojavin2, J. Baggish2, M. Bexon2; 1CSL Behring GmbH, Marburg, GERMANY, 2CSL Behring LLC, King of Prussia, PA, 3CSL Behring AG, Berne, SWITZERLAND.

732 Multiple-allergen And Single-allergen Immunotherapy Strategies In Polyallergenized Patients: Looking At The Published Evidence
P. Demoly1, L. Cox2, T. B. Casale3, M. Poingnet4, M. A. Calderon4; 1Allergy Division, Pneumology Department, INSERM U657, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, FRANCE, 2Department of Medicine, Nova Southeastern University, davie, FL, 3Division of Allergy and Immunology,
AB292 Abstracts

J. C. Turbyville; Ireland Army Community Hospital, Fort Knox, KY.

733 Adverse Reactions To Subcutaneous Allergen Immunotherapy Following Thunderstorms

W. Busse, Antony, FRANCE, C. Ple Th17 Polarization In Allergic Diseases

734 Modifying Target Doses and Premedication Protocols Results in Less Systemic Reactions to Aeroallergen Rush Immunotherapy (RIT)

M. L. Alvares, D. Min, K. Hilton, T. Walton, D. A. Khan; UT Southwestern, Dallas, TX.

735 Systemic Reactions to Allergen Immunotherapy in a Community Practice

D. Gadde1, P. Creticos2, D. Beakes3, L. Wu1, B. Joseph3, K. Fouche1, J. Gadde1; 1George Washington, Washington, DC, DC, 2Creticos Research Group, Annapolis, MD, 3Allergy and Asthma Specialists of Greater Washington, Warrenton, VA.

736 Allergen Immunotherapy Administration Errors: Assessing The Reporting Measure

S. Patel, K. L. Rossow, P. LaCanne, K. Poe, J. T. C. Li, M. A. Rank; Mayo Clinic, Rochester, MN.

737 Relationship Between Ragweed Specific IgE and Acute Allergic Events During Ragweed Rush Immunotherapy (RIT)

P. S. Jonsson-Razdan1, J. Stokes1, P. D. Turner1, R. Walters1, W. W. Busse2, J. N. Kline1, Z. K. Ballas1; 1Creighton University Medical Center, Omaha, NE, 2University of Wisconsin, Madison, WI, 3University of Iowa, Iowa City, IA.

Poster Session

742 A Non-redundant Role of ERK1 in Th2 Cell Differentiation, Survival and Development of Asthma

R. Alam1, N. Goplen1, Z. Karim1, L. Guo1, Y. Zhuang1, H. Huang2, M. M. Gorska1, E. Gelfand2, G. Pages3, J. Pouyssgur4; 1National Jewish Health, Denver, CO, 2University of Nice Sophia Antipolis, Nice, FRANCE.

743 Ex Vivo Characterization of the Epitope-Specific T Cell Response to Alternaria

J. H. DeLong1, E. Wambere1, R. LaFond1, N. Torres-Chinn1, E. A. James1, D. Robinson1, W. W. Kwok1; 1Benaroya Research Institute, Seattle, WA, 2Virginia Mason Medical Center, Seattle, WA.

744 Th2 Profile of Stimulated PBMC from Atopic Patients is Enhanced by C. Pneumoniae and is Switched to Th1 by Lactobacillus GG

D. Erstein1, R. Joks, H. Durkin, S. Kohlhoff; SUNY Downstate Medical Center, Brooklyn, NY.

745 Control Of T-regulatory Cells By Stat6 During Allergic Lung Inflammation

N. Dorsey1, S. Chapoval1, E. Smith1, J. Skupsy1, D. Scott1,2, A. Keegan1; 1University of Maryland Baltimore School of Medicine, Baltimore, MD, 2Uniformed Services University, Bethesda, MD.

Cytokines and Chemokines

4212 Session Time: Monday, March 5, 2012, 9:45 AM - 10:45 AM

746 Exposure to Airborne Allergens Induces Rapid Extracellular Release of Stored IL-1b from Airway Epithelial Cells

H. Kouzaki1,2, K. ijima2, T. Kobayashi2, S. OGrady3, H. Kita2,4; 1Otorhinolaryngology, Shiga University of Medical Science, Otsu, Shiga, JAPAN, 2Division of Allergic Diseases and Department of Internal Medicine, Mayo Clinic, Rochester, MN, 3Departments of Integrated Biology and Physiology and Animal Science, University of Minnesota, St. Paul, MN, 4Department of Immunology, Mayo Clinic, Rochester, MN.

747 Changes in Serum Vascular Endothelial Growth Factor and Interleukin-5 in Atopic Children With Mycoplasma Pneumonia J. Oh, J. Kim, Y. Jeong, H. Lee; Hanyang University Guri Hospital, Kyunggi-do, KOREA, REPUBLIC OF.

748 Serum TSLP and IL-33 Levels are Lower in Young Children Raised on Farms

M. C. Bell, K. A. Grindle, C. J. Tisler, R. F. Lemanske, Jr., J. E. Gern; University of Wisconsin Hospital and Clinics, Madison, WI.

749 Endotoxin Challenge Increases Production of IL-1b in the Peripheral Blood but not in Sputum of Allergic Asthmatics

A. R. Auerbach, W. Wu, D. Peden, M. Hernandez; UNC Hospitals, Durham, NC.

750 Cysteine Proteases Induce Production and Extracellular Release of IL-33 in Airway Epithelial Cells

S. Seno1,2, K. Iijima1, S. M. O’Grady3, H. Kita1; 1Mayo Clinic, Rochester, MN, 2Department of Otorhinolaryngology, Shiga University of Medical Science, Otsu, JAPAN, 3Departments of Integrated Biology and Physiology and Animal Science, University of Minnesota, St. Paul, MN.
751 Novel Analysis Methods for Longitudinal Cytokine Response Data in a Birth Cohort Study
C. M. Visness1, K. F. Jaffe1, A. Calatroni1, R. A. Wood2, P. J. Gergen3, J. E. Gem4;
1Rho Federal Systems Division, Inc., Chapel Hill, NC, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Division of Allergy, Immunology, and Transplantation, National Institutes of Health, Bethesda, MD, 4University of Wisconsin School of Medicine and Public Health, Madison, WI

752 IL-17A-mediated STAT6 Independent Mucus Production in Mice
M. G. Boswell1, D. C. Newcomb1, K. Goleniewska1, S. Reiss1, K. B. Adler2, R. S. Peebles, Jr1;
1Vanderbilt University Medical School, Nashville, TN, 2North Carolina State University, Nashville, TN

753 The Effect of TNF- alpha on Glucocorticoid Receptor Translocation
I. A. Etuk, L. Kaphalia, W. J. Calhoun; The University of Texas Medical Branch, Galveston, TX

754 Bacterial PAMP Induced Cytokine Profiles in Children from a Boston-area Birth Cohort
1Channing Laboratory, Boston, MA, 2Harvard School of Public Health, Boston, MA, 3Roswell Park Cancer Institute, Buffalo, NY, 4University of Virginia, Charlottesville, VA, 5Reduced Cord Blood IFN-γ and IL-10 are Associated with Reduced Lung Function at School Age
S. R. Durrani1, R. F. Lemanske, V. Rajamanickam, R. E. Gangnon, J. E. Gern, D. J. Jackson; University of Wisconsin School of Medicine and Public Health, Madison, WI

755 Asthmatics Infected with Rhinovirus (RV) Demonstrate Up-regulation of IL-15
J. L. Kennedy, J. W. Steinker, D. Murphy, H. Carper, A. P. Stallings, T. A. E. Platts-Mills, L. Borish, P. W. Heymann; University of Virginia, Charlottesville, VA.

Oral Abstract Session

Update in Asthma Therapeutics and Monitoring
4601
Session Time: Monday, March 5, 2012, 2:00 PM - 3:15 PM

757 Early Non-Respiratory Symptom Patterns Precede Loss of Asthma Control in Children
L. Newton1, Y. Osei-Akosa2, R. Strunk1, M. Krauss1, L. Bacharier1, J. Garbutt1, K. Rivera-Spoljaric2;
1Cleveland Clinic, Cleveland, OH, 2Washington University in St. Louis, St. Louis, MO, 3Washington University School of Medicine, St. Louis, MO

758 Adverse Reaction Preparedness for Allergen Immunotherapy in the Primary Care Setting
V. Reddy, P. Jhaveri, T. J. Craig; Division of Pulmonary, Allergy, and Critical Care Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA

759 Clinical Efficacy and Safety of Combined Mometasone Furoate and Formoterol in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
E. Kerwin1, D. P. Tashkin2, C. E. Matiz-Bueno1, D. E. Doherty4, T. Shekar5, S. Banerjee6, B. Knorr7, H. Staudinger8;
1Clinical Research Institute of Southern Oregon, Medford, OR, 2David Geffen School of Medicine at UCLA, Los Angeles, CA, 3Fundacion Salud Bosque, Bogota, COLOMBIA, 4University of Kentucky, Lexington, KY, 5Merck Research Laboratories, Kenilworth, NJ

760 ASHMI (Antiasthma Simplified Herbal Medicine Intervention) is a Potent Inhibitor of Interferon-α Production from Human Dendritic Cells by Increasing Pro-inflammatory Cytokines
J. R. Tversky; The Mount Sinai School of Medicine, New York, NY

761 Efficacy and Safety of AMG 853 in Asthma: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
1University of Wisconsin, Madison, WI, 2University of Pittsburgh Medical Center, Pittsburgh, PA, 3Allergy and Asthma Medical Group and Research Center, San Diego, CA, 4Clinical Research Institute of Southern Oregon, PC, Medford, OR, 5Johns Hopkins Asthma and Allergy Center, Baltimore, MD, 6Amgen Inc., Thousand Oaks, CA, 7Amgen Inc., Thousand Oaks, CA.

Oral Abstract Session

Immunoglobulin and Biological Therapy
4602
Session Time: Monday, March 5, 2012, 2:00 PM - 3:15 PM

762 The Sialylated Fractio nan Fraction Of IgVg Suppresses Th2-driven Airway Inflammation Via The Induction Of Tolerogenic Dendritic Cells A. Massoud1, A. Ablona1, C. Piccirillo2, W. Mourad3, B. Mazer4;
1McGill University / Meakins Christie Laboratories, Montreal, QC, CANADA, 2McGill University / Dept. of Immunology, Montreal, QC, CANADA, 3Universit de Montréal / L’Hpital Saint-Luc, Montreal, QC, CANADA

763 The Effect of Anti-IL-5 Therapy on Esophageal Mastocytosis in Pediatric Eosinophilic Esophagitis
I. M. Otani, M. Bhagat, R. O. Newbury, R. Dohil, D. H. Broide, S. S. Acesves; University of California, San Diego, La Jolla, CA

764 Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients With Primary Immunodeficiency Disease (PIDD)
I. Melamed1, R. L. Wasserman2, M. Stein1, J. Pack3, S. Gupta4, W. Engel5, H. Leib6, D. Gelmon7, R. I. Schiiff, on behalf of IGSC 10% HuPH20 Study Group8;
1Allergy Associates of the Palm Beaches, North Palm Beach, FL, 2Dallas Allergy Immunology, Dallas, TX, 3IMMUNOe, Centennial, CO, 4University of California, San Francisco, CA, 5University of California, Irvine, CA, 6Baxter BioScience, Vienna, AUSTRIA, 7Baxter BioScience, Westlake Village, CA

765 A Scoring System to Guide Decisions on Immunoglobulin Replacement Treatment in Hypogammaglobulinemia
S. Agarwal, C. Cunningham-Randles; Mount Sinai School of Medicine, New York, NY.

766 Long-term Safety And Efficacy Of Mepolizumab For The Treatment Of Hypereosinophilic Syndrome
A. D. Klon1, F. E. Roufosse2, J. Kahn3, G. J. Gleich4, L. B. Schwartz5, A. Singh6, L. J. Rosenwasser2, J. Denburg6, J. Ring6,
Oral Abstract Session

The Effect of Pollution on Allergic Disease
4603
Session Time: Monday, March 5, 2012, 2:00 PM - 3:15 PM

767 Postnatal Ozone Exposure Enhances House Dust Mite Induced Airway Hyperresponsiveness Without Increasing Inflammation
National Jewish Health, Denver, CO.

768 Frequent Allergy Symptoms Among Children Living Near The World Trade Center Associated With Elevated Peripheral Airways Resistance
Stony Brook University Department of Medicine, Stony Brook, NY, Stony Brook University Department Preventative Medicine, Stony Brook, NY, Stony Brook University Department of Preventative Medicine, Stony Brook, NY.

769 Annual New York City Trends Of Ambient Fine Particulate Matter, Black Carbon And Ambient Metals Implicated In Airway Disease
F. L. Kuang, K. H. Jung, B. Yan, S. N. Chillrud, R. L. Miller;
Internal Medicine Residency, Department of Medicine, College of Physicians and Surgeons, Columbia University, PHBE 630 W. 168th St., New York, NY, Division of Pulmonary, Allergy and Critical Care of Medicine, Department of Medicine, College of Physicians and Surgeons, Columbia University, PHBE 630 W. 168th St., New York, NY, Lamont-Doherty Earth Observatory, Columbia University, 61 Rt. 9W, Palisades, NY, Mailman School of Public Health, Department of Environmental Health Sciences, Columbia University, 722 W. 168 St., New York, NY.

770 Relationship Between Environmental Phenols And Aeroallergen And Food Allergies In The US: Results From The National Health And Nutrition Examination Survey 2005-2006
N. Vernon, E. Jerschow, S. Jariwala, G. de Vos, D. Rosenstreich; Montefiore Medical Center, Bronx, NY.

771 Distance From A Heavily Trafficked Highway Is Implicated In The Presence Of Allergic Rhinoconjunctivitis And Asthma In Adults
M. Vastardi, I. Katayeva, D. Puebla-Neira, R. Joks;
1SUNY Downstate Medical Center, Brooklyn, NY, 2Lutheran Medical Center, Brooklyn, NY.

Oral Abstract Session

Genetic and Other Mechanisms of Atopic & Skin Diseases
4604
Session Time: Monday, March 5, 2012, 2:00 PM - 3:15 PM

772 Effect of Th2 and Th17 Cytokines on Human Epidermal Tight Junctions
1University of Rochester, Rochester, Rochester, NY, 2National Jewish Health, Denver, CO.

773 The Association Between HLA B7 Alleles and Human Atopic Dermatitis Complicated by Eczema Herpeticum
1Johns Hopkins University, Baltimore, MD, 2National Jewish Health, Denver, CO, 3UCSD Medical Center, San Diego, CA, 4Children’s Hospital Boston, Boston, MA, 5Oregon Health & Science University, Portland, OR, 6Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 7University of Rochester Medical Center, Rochester, NY.

774 C3a Receptor (C3aR) is Important for Viral Containment in Mice Infected with Vaccinia Virus (VV) at Sites of Allergic Skin Inflammation
L. Kumar, R. S. Geha;
Division of Immunology, Children’s Hospital, Boston and Department of Pediatrics, Harvard Medical School, Boston, MA.

775 Staphylococcus Aureus Alpha-Toxin Augments Viral Load In Keratinocytes
L. Bin, E. Goleva, J. Streib, C. Hall, P. M. Schlievert, D. Y. Leung;
1National Jewish Health, Denver, CO, 2The University of Iowa, Iowa City, IA.

776 Genetic Variants Associated with Asthma and Related Phenotypes are Also Risk Factors for Food Allergy
1Division of Allergy and Clinical Immunology, Department of Medicine, The Johns Hopkins University, Baltimore, MD, 2Department of Epidemiology, Bloomberg School of Public Health, HU, Baltimore, MD, 3University of Arkansas for Medical Sciences, Little Rock, AR, 4Duke University Medical Center, Durham, NC, Mount Sinai School of Medicine, New York, NY, 6The EMMES Corporation, Rockville, MD, 7Department of Dermatology, University of Rochester Medical Center, Rochester, NY, 8Department of Pediatrics, National Jewish Health, Denver, CO, 9Division of General Internal Medicine, Department of Medicine, The Johns Hopkins University, Baltimore, MD.

Oral Abstract Session

New Insights Into Allergy and Asthma Assessment
4605
Session Time: Monday, March 5, 2012, 2:00 PM - 3:15 PM

777 Reliability, Validity, and Responsiveness of the Asthma Control Questionnaire among Pediatric Patients
A. Boyd, K. Estell, M. Dransfield, L. M. Schwiebert; University of Alabama Birmingham, Birmingham, AL.

The Effects Of Asthma On REM-related Sleep-disordered Breathing In Children With Obstructive Sleep Apnea (OSA)
M. J. Gutierrez1, C. L. Nino2, G. Graft3, G. Nino4; 1Division of Pulmonary, Allergy and Critical Care Medicine, Pennsylvania State University College of Medicine, Hershey, PA, 2Department of Electronics Engineering, Juveriana University, Bogota, COLOMBIA, 3Division of Pediatric Pulmonary Medicine, Pennsylvania State University College of Medicine, Hershey, PA, 4Penn State Sleep Research and Treatment Center, Pennsylvania State University College of Medicine, Hershey, PA.

Positive Bronchial Responses To D. Pteronyssinus In Subjects With Confirmed Local Allergic Rhinitis
P. Campo1, C. Mayorga2, C. Rondon3, L. Galindo1, R. Garcia1, J. Garcia-Campos1, L. Melendez2, J. Rodriguez-Bada3, M. Blanca1; 1Allergy Department, Hospital Carlos Haya, Malaga, SPAIN, 2Allergy Laboratory, F. IMABIS, Malaga, SPAIN.

Relationships Between Airway Hyperresponsiveness to Methacholine, Blood Eosinophil Markers and FeNO in Asthmatic Children
Y. Yoo1,2, S. Bauer1, K. S. La1, H. S. Seo1, S. C. Seo2, D. J. Song1,2, J. T. Choung1,2; 1Department of Pediatrics, College of Medicine, Korea University, Seoul, KOREA, REPUBLIC OF, 2Environmental Health Center, Korea University Anam Hospital, Seoul, KOREA, REPUBLIC OF.

Comparison of Respiratory Impedance Data Measured by the MostGraph and Master Screen IOS in Adults with Bronchial Asthma
T. Shimoda1, Y. Obase2, M. Imaoka1, R. Kishikawa1, T. Iwanaga1; 1Fukuoka National Hospital, Fukuoka, JAPAN, 2Kawasaki Medical School, Kurashiki, JAPAN.

Maternal Diet during Pregnancy and Wheeze and Eczema in Infants; the Japanese Birth Cohort (T-CHILD) Study
M. Narita1, D. Qiu1, M. Hamaguchi2, M. Doi2, M. Futamura1, N. Sakamoto2, H. Saito3, Y. Ohy3; 1Division of Allergy, National Center for Child Health and Development, Tokyo, JAPAN, 2Division of Epidemiology, Research Institute, National Center for Child Health and Development, Tokyo, JAPAN, 3Research Institute, National Center for Child Health & Development, Tokyo, JAPAN.

The Elevation Of Th2 cytokines In Airway with Rsv Infection Is High Risk For Recurrent Wheeze In Young Children
H. Murai1,2, A. Terada1,2, S. Shimizu1, M. Asai1, M. Mizuno1, N. Kamio1ka, H. Togari1; 1Nagoya-city West medical center, Nagoya-city, Aichi, JAPAN, 2Nagoya city University, Nagoya-city, Aichi, JAPAN, 3Terada Kid’s allergy clinic, Nagoya-city, Aichi, JAPAN, 4Daido Hospital, Nagoya-city, Aichi, JAPAN.

Unmet Awareness of Allergic Asthma
T. M. Nsouli1, C. D. Schlackebier2, E. J. McSorley-Gerard3, C. M. Davis2, S. T. Nsouli2, S. T. Nsouli2; 1Georgetown University, Washington, DC, 2Burke Allergy and Asthma Treatment Center, Burke, VA.

Loops to Modulate the Inflammatory Axis in Arthritis
M. Goldberg, O. Nadin, N. Kovalchuk, G. Agar, Y. Beer, Y. Katz; Assaf Harofeh Medical Center, Zerifin, ISRAEL.

A Review of Churg-Strauss Syndrome in Childhood at the Cleveland Clinic
S. Gendelman, S. Spalding; Cleveland Clinic, Cleveland, OH.

Suppression of Delayed Type Hypersensitivity by Fullerene Derivatives
A. A. Babakhin1, S. M. Andreev3, E. N. Bashkatova1, M. R. Khaitov1, L. M. Dubuske2; 1Institute of Immunology, Moscow, RUSSIAN FEDERATION, 2Immunology Research Institute of New England, Gardner, MA.

Immunologic Phenotype Of GRK3-null Mice At Baseline And In Inflammatory Disease
R. G. Timoshchencko1, L. R. Rothlein1, M. W. McGinnis2, O. Foreman2, D. Esserman3, D. M. Lee3, D. D. Patel1, D. P. Siderovski1, T. K. Tarrant; 1University of North Carolina, Chapel Hill, NC, 2The Jackson Laboratory, Bar Harbor, ME, 3Novartis Institutes, Basel, SWITZERLAND.

Cytokine Status In Patients With Systemic Lupus Erythematosus
K. A. Chyzh1, A. Y. Hancharou2, T. A. Ryabzeva1, L. P. Titov2, N. F. Soroka1, L. M. Dubuske3; 1Belarusian State Medical University, Minsk, BELARUS, 2Research Institute for Epidemiology and Microbiology, Minsk, BELARUS, 3Immunology Research Institute of New England, Gardner, MA.

Exhaled nitric oxide a biomarker for activity of Systemic Lupus Erythematosus in children
R. Karanicolas, S. Kumar, G. Henry, S. Kimble, J. Moulelm; SUNY at Downstate, Brooklyn, NY.

Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA) Syndrome: Evaluation of Patients in San Diego, California
L. Broderick, D. Carvalho, A. Magit, W. Jiang, M. Bothwell, D. Kearns, S. Pransky, H. M. Hoffman; University of California, San Diego, California, CA.

Clinical Features And Prognostic Factors Of Churg-strauss Syndrome
M. Kim1,2, S. Lee1,2, W. Song1,2, S. Lee1,2, H. Kang1,2, S. Kim1,2, S. Cho1,2, K. Min1,2, Y. Kim1,2; 1Department of Internal Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF, 2Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, KOREA, REPUBLIC OF.

B Cell Reconstitution Following Rituximab in Autoimmune Disorders
P. D. Patel, A. Rubinstein; Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY.

Effects Of Short-chain Galacto- And Long-chain Fructo-oligo-saccharides On Systemic And Local Immune Status During Pregnancy
J. Garssen1,2, A. Hogenkamp1, N. van Vliet1, S. Thijssen1, G. M. Dingjan1, K. Knipping1,2, L. Knipps1,2; 1Pharmacology, Utrecht Institute for Pharmaceutical science, Faculty of Science, Utrecht University, Utrecht, NETHERLANDS, 2Danone Research-Centre for Specialised Nutrition, Wageningen, NETHERLANDS.

Eosinophil And Interleukin-5 In Urine Of Patients With Systemic Lupus Erythematosus
V. S. F. Sales1, M. J. P. Villar1, L. K. P. Arruda2, L. B. F. C. Souza2, A. L. S. B. Faria2, S. D. V. Medeiros3, T. N. S. Brito1; 1Federal University of Rio Grande do Norte, Natal, BRAZIL, 2University of Sao Paulo, Sao Paulo, BRAZIL, 3University of Sao Paulo, Sao Paulo, BRAZIL.
811 Immunologic and Rheumatologic Diseases Temporally Associated with Mycoplasma pneumoniae Infection in Children
P. S. Morales, M. Irretagoyena, E. Talesnik, M. Lizama, A. Borutzky;
Pontificia Universidad Catolica de Chile, Santiago, CHILE.

812 Varied Manifestations and Treatment of Pediatric Wegener’s Granulomatosis
M. R. Shams1, R. Kado1, N. Seth1, J. M. El-Dahr2;
1Tulane University School of Medicine, New Orleans, LA, 2Tulane University School of Medicine, Section of Pediatric Allergy and Clinical Immunology, New Orleans, LA.

813 Chronic Urticaria as Possible Manifestation of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dysplasia (APECED)
S. Huebner, M. Nelson, B. Martinez;
Walter Reed National Military Medical Center, Bethesda, MD.

Poster Session
Mechanisms of Allergy, HIV
5203 Session Time: Tuesday, March 6, 2012, 9:45 AM - 10:45 AM

814 Therapeutic Effects Of Recombinant Salmonella Typhimurium Expressing Cwl22 mirna On Atopic Dermatitis
W. Yoon1, B. Kang1, Y. Park1, Y. Chae2, J. Choung3, Y. Yoo4;
1Department of Life Science and Biotechnology, Korea University, Seoul, KOREA, REPUBLIC OF, 2Department of Pathology, College of Medicine, Korea University, Seoul, KOREA, REPUBLIC OF, 3Department of Pediatrics, College of Medicine, Korea University, Seoul, KOREA, REPUBLIC OF, 4Department of Pediatrics, College of Medicine, Korea University, Seoul, KOREA, REPUBLIC OF.

815 Development of an Airway Epithelium In Vitro Model System D. Papazian1,2, M. Arge2, T. Chhoden2, T. Vorup-Jensen1, C. Nielsen1, K. Skjødt2, K. Lund1, P. A. Wurtzen1, S. Hansen7;
1Pharmacology, Horsholm, DENMARK, 2Molecular Medicine, Odense, DENMARK, 3Medical Microbiology & Immunology, rhuz, DENMARK, 4Inflammation Research, Copenhagen, DENMARK.

Poster Session
Urticaria and Angioedema
5204 Session Time: Tuesday, March 6, 2012, 9:45 AM - 10:45 AM

820 Efficacy of Icatibant in Non-Laryngeal Attacks of Type I and II Hereditary Angioedema: Integrated Results from Three Phase III Trials
H. Farkas1, M. Riedl2;
1Semmelweis University, Budapest, HUNGARY, 2UCLA - David Geffen School of Medicine, Los Angeles, CA.

821 Efficacy of Icatibant in Laryngeal Attacks of Type I and II Hereditary Angioedema (HAE): A Pooled Analysis of Three Phase III Trials
W. Lumry1, B. Ritchie2, M. Baš3;
1Allergy and Asthma Research Associates Research Center, Dallas, TX, 2University of Alberta, Edmonton, AB, CANADA, 3Technische Universitat Munchen, Munich, GERMANY.

822 Efficacy of Icatibant is Consistent by Attack Frequency and Baseline Severity in the Treatment of Type I and II Hereditary Angioedema (HAE) Attacks
A. Reshef1, R. Levy2, T. Craig3;
1Sheba Medical Center, Tel-Aviv, ISRAEL, 2Family Allergy and Asthma Center, Atlanta, GA, 3Penn State University, Hershey, PA.

823 Efficacy of Icatibant for Cutaneous and Abdominal Attacks of Type I and II Hereditary Angioedema: A Pooled Analysis of Three Phase III trials
A. Malbran1, H. H. Li2;
1Hospital Britnico de Buenos Aires, Buenos Aires, ARGENTINA, 2Institute for Asthma and Allergy, Chevy Chase, MD.

824 Icatibant in Patients with Acquired Angioedema Who Did Not Respond to pdC1INH
A. Zanichelli1, M. Bova2, A. Corezza3, A. Petraroli2, M. Triggiani3, M. Cicardi1;
1Universit degli Studi di Milano, Milano, ITALY, 2Universit degli Studi di Napoli Federico II, Napoli, ITALY, 3Fondazione Don Carlo Gnocchi ONLUS, Milano, ITALY.

825 Rates of Rebound or Relapse Among Acute Attacks of Hereditary Angioedema Treated with Ecallantide in Open-Label, Repeat-Treatment Study
1Institute for Asthma and Allergy, Wheaton, MD, 2University of Cincinnati, Cincinnati, OH, 3Asthma & Allergy Associates, PC, Colorado Springs, CO, 4UCLA - David Geffen School of Medicine, Los Angeles, CA, 5AARA Research Center, Dallas, TX, 6Pennsylvania State University, Hershey, PA, 7Children’s Hospital Boston, Boston, MA, 8Dyax Corp., Cambridge, MA.

826 Ecallantide Reverses Laryngeal Hereditary Angioedema Attacks: Experience from the EDEMA Clinical Development Program
A. L. Sheffer1, A. J. MacGinnitie2, M. Campion3, L. E. Stolz4, W. E. Pullman5;
1Brigham and Women’s Hospital, Boston, MA, 2Children’s Hospital Boston, Boston, MA, 3Independent Statistical Consultant, Newton, MA, 4Dyax Corp., Cambridge, MA.

827 Hypersensitivity Reactions to Ecallantide: an Update of the Clinical Trial Experience and Post-Market Surveillance for Treatment of Attacks of Hereditary Angioedema
T. J. Craig1, M. Riedl2, H. H. Li3, J. A. Bernstein4, A. J. MacGinnitie3, D. F. Soteres4, W. R. Lumry5, W. E. Pullman6; 1Penn State University, Hershey, PA; 2UCLA - David Geffen School of Medicine, Los Angeles, CA, 3Institute for Asthma & Allergy, Wheaton, MD; 4University of Cincinnati, Cincinnati, OH; 5Children’s Hospital Boston, Boston, MA; 6Asthma and Allergy Associates, PC, Colorado Springs, CO; 7AAR Research Center, Dallas, TX; 8Dyax Corp., Cambridge, MA.

828 Prompt Reversal of Airway Obstruction Secondary to Angiotensin Converting Enzyme Inhibitor (ACEI) Induced Angioedema by Ecallantide: A Case Report

J. R. Cohn1,2, C. McDaniel1, N. Richards1, C. Au2, M. Baram3; 1Asthma, Allergy and Pulmonary Associates, Philadelphia, PA; 2Thomas Jefferson University & Hospitals, Philadelphia, PA.

829 Efficacy and Safety of Ecallantide Treatment for HAE Attacks in Patients Treated with Both Ecallantide and Placebo

W. R. Lumry1, H. H. Li2, A. J. MacGinnitie3, J. A. Bernstein4, D. F. Soteres4, M. Riedl5, T. J. Craig3, M. Campion6, W. E. Pullman6; 1AAR Research Center, Dallas, TX; 2Institute for Asthma & Allergy, Wheaton, MD; 3Children’s Hospital Boston, Boston, MA; 4University of Cincinnati, Cincinnati, OH; 5Asthma and Allergy Associates, PC, Colorado Springs, CO; 6UCLA - David Geffen School of Medicine, Los Angeles, CA; 7Pennsylvania State University, Hershey, PA; 8Independent Statistical Consultant, Newton, MA; 9Dyax Corp, Cambridge, MA.

830 Absence of Inhibitory Anti-C1 Esterase-Inhibitor Antibody Formation in Subjects Treated With C1 Esterase-Inhibitor Concentrate (Berinert®) for Successive Hereditary Angioedema Attacks

D. S. Hurewitz1, J. A. Bernstein2, A. K. Bewtra1, U. Kalina1, T. Machnig1, T. J. Craig1; 1Allergy Clinic of Tulsa, Tulsa, OK; 2University of Cincinnati Medical Center and Bernstein Clinical Research Center, Cincinnati, OH; 3Creighton University School of Medicine, Omaha, NE; 4CSL Behring, Marburg, GERMANY; 5Penn State University, Hershey, PA.

831 Effect of Time to Treatment on Treatment Response With C1 Esterase-Inhibitor Concentrate (Berinert®) for Acute Hereditary Angioedema Attacks

J. A. Bernstein1, D. S. Hurewitz2, A. K. Bewtra1, T. Machnig3, H. Keinecke1, T. J. Craig3; 1University of Cincinnati Medical Center and Bernstein Clinical Research Center, Cincinnati, OH; 2Allergy Clinic of Tulsa, Tulsa, OK; 3Creighton University School of Medicine, Omaha, NE; 4CSL Behring GmbH, Marburg, GERMANY; 5Accovion GmbH, Marburg, GERMANY; 6Penn State University, Hershey, PA.

832 Management of paediatric patients with Hereditary Angioedema (HAE)- A retrospective evaluation of 120 patients from 91 families

I. Martinez-Sager1, E. Aygooren-Puersuen, E. Rusicke, T. Klingebiel, W. Kreuz; 1,J.W. Goethe University Hospital Frankfurt, Germany, Frankfurt, GERMANY.

833 Efficacy of Recombinant Human C1 Inhibitor Treatment for Abdominal Attacks of Hereditary Angioedema

D. Suez1, D. Moldovan2, J. W. Baker3, S. Kivity4, A. Relan5, A. Reshef6, R. Levy1; 1Allergy, Asthma and Immunology Clinical RA, Irving, TX; 2University of Medicine and Pharmacy, Mures County Hospital, Tirgu Mures, ROMANIA; 3Baker Allergy, Asthma and Dermatology Research Center, Lake Oswego, OR; 4Tel Aviv Medical Center, Tel Aviv, ISRAEL; 5Pharming Technologies BV, Leiden, NETHERLANDS; 6Immunology & Angioedema Center, Sheba Medical Center, Tel Hashomer, ISRAEL; 7Family Allergy and Asthma Center, Atlanta, GA.


R. Y. Lin1, R. J. Levine2; 1New York Downtown Hospital, New York, NY; 2New York Medical College, Valhalla, NY.

835 Icatibant Duration of Action During Bradykinin Challenge

K. Leach1, B. Rosenkrantz2, B. J. Bloom3, T. G. McCauley1; 1Shire HGT, Lexington, MA; 2University of Stellenbosch, Tygerberg, SOUTH AFRICA.

836 Review of the Long-Term Safety of a Human Pasteurized C1 Inhibitor Concentrate

K. Bork1, G. Koger2, W. Kreuz3; 1Department of Dermatology, University of Mainz, Mainz, GERMANY; 2CSL Behring, Marburg, GERMANY; 3Center of Pediatrics, University of Frankfurt, Frankfurt, GERMANY.

837 Association of C1 Esterase-Inhibitor Functional Activity and Treatment Response With C1 Esterase-Inhibitor Concentrate (Berinert®) for Acute Attacks of Hereditary Angioedema

A. K. Bewtra1, D. S. Hurewitz2, J. A. Bernstein3, T. Machnig4, H. Keinecke1, T. J. Craig5; 1Creighton University School of Medicine, Omaha, NE; 2Allergy Clinic of Tulsa, Tulsa, OK; 3University of Cincinnati Medical Center and Bernstein Clinical Research Center, Cincinnati, OH; 4CSL Behring, Marburg, GERMANY; 5Accovion GmbH, Marburg, GERMANY; 6Penn State University, Hershey, PA.

838 High Doses of C1 Esterase Inhibitor as Treatment for a Patient with Exacerbating Hereditary Angioedema During Pregnancy

W. Chan1, N. Berlin2, G. Sussman1,2; 1Gordon Sussman Clinical Research Inc., Toronto, ON, CANADA; 2University of Toronto, Toronto, ON, CANADA.

839 Self Intravenous (IV) Administration of C1-INH Concentrate for Hereditary Angioedema: A Retrospective Analysis of Patient Outcomes

R. S. Shapiro; Midwest Immunology Clinic, Plymouth, MN.

840 Gaining Weight And Loosing Appetite: A Case Of Recurrent Diffuse Angioedema, Weight Gain and Peripheral Eosinophilia Without Visceral Organ Damage

B. Q. Khan, G. D. Marshall; University of Mississippi Medical Center, Jackson, MS.

841 Auto-antibodies in Chronic Idiopathic Urticaria (CIU) and Non-urticarial Systemic Autoimmune Disorders

S. A. Stutes1, C. B. Cho1, M. Altrich2, S. P. Ardon1, P. U. Ogbugo3; 1The Ohio State University Medical Center, Columbus, OH; 2Vira-cor-IBT Laboratories, Lee’s Summit, MO.

842 Autoimmune Proﬁling in Chronic Idiopathic Urticaria – Is there Utility or Futility?

R. K. Viswanathan1,2, M. J. Biatun2, S. K. Mathur1,2; 1Univ of Wisconsin Hosp & Clinics, Madison, WI; 2William S Middleton Veterans Hospital, Madison, WI.

843 Prevalence Of Popular Urticaria By Flea Bite And Associated Factors In Children Of 1-6 Years Old In Bogota D.C.

P. E. Chaparro; Universidad del Valle, Bogota, COLOMBIA.

844 Efficacy of Hydroxychloroquine in the Treatment of 19 Patients with Antihistamine-refractory Chronic Urticaria

R. M. Pongonis, J. M. Fahrenholz; Vanderbilt University, Nashville, TN.

845 Metabolic Syndrome In Patients With Chronic Urticaria

Y. Ye1, H. Jin, E. Hwang, Y. Nam, J. Kim, Y. Shin, H. Park; Ajou University School of Medicine, Suwon, KOREA, REPUBLIC OF.

846 The Urticaria Severity Score May Serve As An Early Clinical Indicator In Monitoring Patients With Chronic Urticaria

D. E. Ferastraoaru1, S. Jarwala1, E. Lobell2, P. Parikh2, P. Walters1, M. Altrich1, G. Hudes3, D. Rosenstreich4; 1Albert Einstein College of Medicine / Jacobi Medical Center, Bronx, NY; 2Montefiore Medical Center / Division of Allergy- Immunology, Bronx, NY; 3ViraCor-IBT Laboratories, Lee’s Summit, MO.
847 Omalizumab (Xolair) in the Treatment of Severe Refractory Chronic Urticaria (SRCU)
M. Giruparajah, N. Berlin1, S. Maclachlan1, G. Sussman1,2,
1Gordon Sussman Clinical Research Inc., Toronto, ON, CANADA,
2University of Toronto, Toronto, ON, CANADA.

848 Treating Chronic Urticaria With Omalizumab - Our Experience In An Immunology Department
A. C. Costa, P. M. Silva, J. G. Dias, A. Mendes, E. Pedro, M. P. Barbosa;
Hospital de Santa Maria EPE, CHLN, Lisboa, PORTUGAL.

849 Neutrophil Predominant Urticaria: A Systematic Review of Patients Undergoing Skin Biopsies in an Allergy Practice
S. H. Axelrod1, M. Punsoni1, B. Arendash1, B. Kim1, M. Feuerman1, M. Jacobson1, L. Fonacier1;
1Winthrop University Hospital, Mineola, NY, 2DermPath Diagnostics, Port Chester, NY.

850 Mutations in the Factor XII Gene in Solitary Cases of Recurrent Angioedema with Normal C1 Inhibitor Induced or Worsened by Oral Contraceptives or Hormonal Replacement Therapy
C. Stanger1, K. Wulff1, J. Hardt1, G. Witzke1, K. Bork1;
1Department of Dermatology, University of Mainz, Mainz, GERMANY, 2Institute of Human Genetics, University of Greifswald, Greifswald, GERMANY, 3Department of Medical Psychology and Medical Sociology, University of Mainz, Mainz, GERMANY.

851 Effect of Topical Minocycline on Immediate and Late Phase Allergic Skin Responses
G. Dapul-Hidalgo, R. Joks;
SUNY Downstate Medical Center, Brooklyn, NY.

852 Vaccination-induced Severe Bullous Eruption in a Child with Diffuse Cutaneous Mastocytosis
L. G. Bankova1, J. E. Walter2, S. R. Iyengar2, M. E. Lorenzo3, J. L. Hornick1, M. C. Castells1;
1Department of Rheumatology, Allergy and Immunology, Brigham and Womens Hospital, Harvard Medical School, Boston, MA, 2Division of Allergy, Immunology and Pulmonology, Massachusetts General Hospital for Children, Harvard Medical School, Boston, MA, 3Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Department of Pathology, Brigham and Womens Hospital, Harvard Medical School, Boston, MA.

853 Drug Rash Eosinophilia and Systemic Symptoms (DRESS) Syndrome in Association With Vancomycin
J. McNeil-Glassford, Y. Yilmaz Demirdag;
West Virginia University School of Medicine, Morgantown, WV.

854 Is It Contact Dermatitis Or Something More Serious?
B. Dyer, L. Wild;
Tulane University, New Orleans, LA.

855 Gabapentin for the Treatment of Neurogenic Pruritis
H. J. Hajjar, D. Sun, L. B. Schwartz;
VCU, Richmond, VA.

857 Use To The Recombinant Species-Specific In The Diagnosis Of Hymenoptera Venom Allergy
P. F. Jara, MD1, E. Hernandez, MD2, M. Fernandez, MD2, J. Sastre, PD2;
1FundaciOn Jimenez Diaz, Madrid, Spain, 2Fundacion Jimenez Diaz, Madrid, Spain.

Poster Session

Insect Hypersensitivity, Food Epidemiology, Food Allergens

5205 Session Time: Tuesday, March 6, 2012, 9:45 AM - 10:45 AM

856 Ability of Medical Students and Allergists to Correctly Identify Flying Hymenoptera Species
S. J. Ramey1, S. Bozeman2, J. T. Ramey1, R. L. Franck3, A. T. Vu4, R. F. Lockey5, J. E. Walsh6;
1Medical University of South Carolina, Charleston, SC, 2University of Mississippi Medical Center, Jackson, MS, 3University of South Florida, Tampa, FL, 4Orlando Department of Veterans Affairs Medical Center, Orlando, FL.

858 Possible Association Between Elevated Basal Serum Tryptase Levels and Systemic Reactions To Stings From Blood-Feeding Insects
W. Hemmer1, B. Zahel2, R. Jarisch3;
1Floridsdorf Allergy Center, Vienna, AUSTRIA, 2Dept. of Dermatology, General Hospital Linz, Linz, AUSTRIA.

859 Measurement Of Hymenoptera Venom Specific Ige By The Immulite 3gallery In Subjects With Negative Or Positive Results
Division of Pediatric Allergy/Immunology/Rheumatology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, THAILAND.

860 Reported Ant Re-sting Reaction in Thai Children with Ant Anaphylaxis Receiving Immunotherapy
S. Sridhara, C. Weiler, J. Butterfield;
Mayo Clinic, Rochester, MN.

861 Venom Allergy In Systemic Mastocytosis
S. R. Gupta1, R. S. Gupta2, 1J. O. Hourihane1, C. A. Keet, R. A. Wood;
1University College, Cork, IRELAND.

862 Growth Characteristics Of Children Aged 2-17 Years With Food Allergy
K. Robbins, C. A. Keet, R. A. Wood;
Johns Hopkins School of Medicine, Baltimore, MD.

863 Feeding Difficulties and Food Allergy
M. E. Groetch1, A. Tran2, J. Wang1;
1Mount Sinai School Medicine, New York, NY, 2University of Cincinnati College of Medicine, Cincinnati, OH.

864 Children’s Food Allergies (FA): Development of the Food Allergy Adaptation and Management Scale (FAMAS)
M. D. Klinnert1,2, D. Atkins1, D. Fleischer1,2, E. L. McQuaid1, J. Robinson1,2, J. O. Hourihane3, S. Cohen4, H. Fransen5;
1National Jewish Health, Denver, CO, 2University of Colorado School of Medicine, Aurora, CO, 3Brown School of Medicine, Providence, RI, 4University College Cork, IRELAND.

865 Relationship of Asthma and Food Allergy In An Urban Pediatric Population
H. Mehta;
The Mount Sinai School of Medicine, New York, NY.

866 Food Allergy is an Independent Risk Factor for Decreased Lung Function in Children
A. M. Singh1,2, R. Kumar1, L. M. Arguelles1, D. Caruso1, X. Wang3, J. A. Pongracic1;
1Northwestern Feinberg School of Medicine, Chicago, IL, 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

867 Diagnosis of childhood food allergy in the United States
R. S. Gupta1,2, C. H. Lau3, E. E. Springston3, B. Smith3,4, M. R. Warrier3, J. Pongracic1, J. Holt3;
1Children’s Memorial Hospital, Chicago, IL, 2Northwestern University Feinberg School of Medicine, Chicago, IL, 3Edward Hines Jr. VA Hospital, Hines, IL, 4Loyola University, Maywood, IL, 5Allergy, Asthma, and Sinus Care, St. Louis, MO.
868 Prevalence of IgE-mediated Food Allergy in Korean schoolchildren: A Population-based Study
K. Ahn; Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, KOREA, REPUBLIC OF.

869 Increase In Prevalence Of Food Allergy On The National And State Level In The National Survey Of Children’s Health
K. A. DeMath, C. McCracken; Emory University, Atlanta, GA.

870 Prevalence Of Food Allergy In Urban Children
S. A. Taylor-Black, J. Wang; Mount Sinai School of Medicine, New York, NY.

871 The Development of Atopic Dermatitis according to Age of Onset and the Association with Prenatal and Early Life Exposures
C. Roduit1, R. Frei2, C. Braun-Fahrländer3, R. Lauener4; 1University of Zurich, Zurich, SWITZERLAND, 2Swiss Institute of Allergy and Asthma Research, Davos, SWITZERLAND, 3Swiss Tropical and Public Health Institute, University of Basel, Basel, SWITZERLAND, 4Children’s Allergy and Asthma Hospital, Hochgebirgsklinik, Davos, SWITZERLAND.

872 Do Factors Known to Alter Infant Microbial Exposures Alter the Risk of Food Allergy and Eczema in a Population-based Infant Study?
J. J. Koplin1, P. E. Martin1, M. L. K. Tang1,2, L. C. Gurin3, A. J. Lowe1, N. J. Osborne4, M. N. Robinson5, A. Ponsonby1, S. C. Dharman6, K. J. Allen1; 1Murdoch Childrens Research Institute, Parkville, VICTORIA, AUSTRALIA, 2Royal Children’s Hospital, Parkville, AUSTRALIA, 3University of Melbourne, Parkville, VICTORIA, AUSTRALIA, 4European Centre for Environment and Human Health, Peninsula College of Medicine and Dentistry, University of Exeter, UNITED KINGDOM.

873 Goji Berries, a Novel Potent Allergenic Source with High Cross-reactivity with Other Fruits
M. A. Lopez-Matas1, J. Carnes1, C. H. de Larramendi2, A. Ferrer3, A. J. Huertas4, J. A. Pagan1, L. A. Navarro5, J. L. Garcia-Ahujeta6, M. Pena7, S. Vicario7; 1Laboratorios LETI, S.L., Tres Cantos (Madrid), SPAIN, 2Hospital Marina Baixa. Villajoyosa (Alicante), SPAIN, 3Hospital Vega Baja, Orihuela (Alicante), SPAIN, 4Hospital Santa Mara del Rosell, Cartagena (Murcia), SPAIN, 5Hospital Virgen de la Arrixaca, Murcia, SPAIN, 6Centro de especialidades El Espauleto, Jativa (Valencia), SPAIN.

874 State Health Departments’ Misinformation on Shellfish Allergy and use of KI in the Aftermath of Fukushima
S. Teuber; University of California, Davis, Davis, CA.

875 In-silico Assessment of Potential Allergenicity of Transgenes Used For The Development of Genetically Modified Food Crops
A. Mishra1, S. N. Gaur2, N. Arora1; 1Institute of Genomics and Integrative Biology, Delhi, INDIA, 2Val-labh bhavi Patcl Chest Institute, Delhi, INDIA.

876 Similar IgE Binding to Soybean Proteins from a Genetically Modified Soybean Line, A Near-isogenic Line and Three Other Non-GM Soybean Lines Using 10 Sera from Soybean Allergic Subjects
R. Panda1, A. Capt2, C. Herouet-Guicheny3, R. E. Goodman1; 1University of Nebraska Lincoln, Food Allergy Research and Resource Program, Lincoln, NE, 2Bayer S.A.S., Bayer CropScience, Regulatory Science, Sophia-Antipolis, FRANCE.

877 Identification And Analysis Of The IgE Binding By Parvalbumin And Other Potential Allergens In Different Fish And Frog Species
P. Lee1, J. A. Nordlee1, S. J. Koppelman2, J. L. Baumert1, S. L. Taylor1; 1University of Nebraska, Lincoln, NE, 2University of Nebraska, De-Bilt, NETHERLANDS.

878 Monoclonal Antibodies for Defining Conformational Epitopes in Ara h 2 and Ara h 6
J. Glesner1, S. Wuenischmann1, A. Koidl1, G. A. Mueller2, L. C. Pedersen2, M. D. Chapman1, A. Pomes1; 1INDOOR Biotechnologies, Inc., Charlottesville, VA, 2National Institute of Environmental Health Sciences, Research Triangle Park, NC.

879 Similar Repeated Sequences May account For Cross-Reactions Caused By Many Different Nuts
S. J. Maleki1, S. S. Teuber2, C. H. Schein3; 1US Dept. of Agriculture, New Orleans, LA, 2University of California, Davis, School of Medicine, Davis, CA, 3University of Texas Medical Branch, Galveston, TX.

880 Effect of High Pressure on Peanut Allergens in Presence of Polyphenol Oxidase and Caffeic Acid
S. Chung1, M. Houska2, S. Reed3; 1USDA, Southern Regional Research Center, New Orleans, LA, 2Food Research Institute, Prague, CZECH REPUBLIC.

881 A Combination of Boiling and Frying, but not Pressure or Temperature, Decreases Soluble Peanut Allergens but Does not Generate Hypoallergenic Peanuts
S. S. Comstock1, S. S. Teuber2; 1University of Illinois, Urbana, IL, 2University of California, Davis, CA.

882 Milk Is The Predominant Undeclared Allergen In Us Food Product Recalls
I. Malyskova, S. M. Gendel, S. Luciolli; Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, Food and Drug Administration, College Park, MD.

883 Life-threatening Allergic Reactions To Foods In Adult Patients From Spain

884 Overall Prevalence Of Self-reported Food Allergy In Canada
L. Soller1, M. Ben-Shoshan2, D. W. Harrington3, J. Fragapani4, L. Joseph1, Y. St-Pierre1, S. B. Godfrey2, S. La Ville3, S. J. Elliott4, A. E. Clarke1; 1McGill University, Montreal, QC, CANADA, 2University of Toronto, Toronto, ON, CANADA, 3Health Canada, Ottawa, ON, CANADA, 4University of Waterloo, Waterloo, ON, CANADA.

885 Prevalence of Common Food Allergies in Canada: Targeting Specific Demographic Groups across Canada
M. Ben-Shoshan1, M. Knoll2, L. Soller3, D. Harrington1, J. Fragapani3, L. Joseph1,4, Y. St-Pierre1, S. La Ville3, S. Elliott4, A. Clarke2; 1McGill University Montreal Children Hospital, Montreal, QC, CANADA, 2Division of Clinical Epidemiology, Department of Medicine, McGill University Health Center, Montreal, QC, CANADA, 3School of Geography and Earth Sciences, McMaster University, Hamilton, Ontario, Canada, Hamilton, ON, CANADA, 4Departments of Epidemiology and Biostatistics, McGill University, Montreal, QC, CANADA, 5Food Directorate, Health Canada, Ottawa, Ontario, Canada, Ottawa, ON, CANADA, 6Applied Health Sciences, University of Waterloo, Ontario, Canada, Waterloo, ON, CANADA, 7Division of Allergy and Clinical Immunology, Department of Medicine, McGill University Health Center, Montreal, QC, CANADA.

886 Low Level Specific IgE Sensitization in Parents of Food Allergic Children
R. G. Robison1, M. Makhija1, L. M. Arguelles2, D. M. Caruso2, C. Szychulinski1, R. Kumar1, X. Wang1, J. Pongracic1; 1Children’s Memorial Hospital, Chicago, IL, 2Northwestern University Feinberg School of Medicine, Chicago, IL, 3Mary Ann and J. Miburn Smith Child Health Research Program, Children’s Memorial Hospital, Children’s Memorial Research Center, Chicago, IL, 4John’s Hopkins Bloomberg School of Public Health, Baltimore, MD.
887 Increasing The Accuracy Of Peanut Allergy Diagnosis Using Ara H2
T. D. Dang, 1, 2 N. V. Dinh, 1, 2 T. Tan, 1, 2 L. C. Gurrin, 1, 2 D. Tey, 1, 2 M. Robinson, 1, 2 S. Dharmagadde, 1, 2 M. Tang, 1, 2 K. J. Allen for the Healthnuts study 1, 2 1 Murdoch Childrens Research Institute, Melbourne, AUSTRALIA, 2 Department of Paediatrics, University of Melbourne, Melbourne, AUSTRALIA, 3 Department of Allergy & Immunology, Royal Childrens Hospital, Melbourne, AUSTRALIA, 4 School of Population Health, University of Melbourne, Melbourne, AUSTRALIA.

888 Peanut Allergen (Ara h 2) in Settled Dust Samples of Inner-City Schools and Homes of Children with Asthma
W. J. Sheehan, 1 E. B. Hoffman, 2 J. L. Friedlander, 1 D. R. Gold, 3 W. Phipatanakul 1 1 Children’s Hospital Boston; Harvard Medical School, Boston, MA, 2 Department of Biostatistics, Harvard School of Public Health, Boston, MA, 3 Division of Respiratory Epidemiology, Channing Laboratory, Brigham and Womens Hospital; Harvard Medical School, Boston, MA.

889 Peanut Protein Contamination in Peanut Hulls/Shells Used in Compost and Other Lawn Service Applications
T. Stelk, D. West, J. L. Baumert, S. L. Taylor; University of Nebraska, Lincoln, Lincoln, NE.

890 In Vitro Assessment of the Allergenicity of Novel H1N1 Influenza Vaccine Produced in Dog Kidney Cells in Subjects with Dog Allergy
S. Leonard, 1 R. Bencharithwong, 1 T. Tsai, 2 A. Nowak-Wegrzyn, 1 1 Mt. Sinai School of Medicine, New York, NY, 2 Novartis Vaccines, Cambridge, MA.

891 Amoxicillin-induced Aseptic Meningitis with Neutrophil Pre-dominance
J. Leung, M. Wilson; Massachusetts General Hospital, Boston, MA.

892 The Impact of Parasite Infection Associated With Hyper-IgE on Tolerance of Aspirin and Desensitization
N. V. Dinh, 1 C. C. Hieu, 1 N. V. Doan, 1 S. van Nunen, 2 T. Craig, 3 1 Allergy Department, Hanoi Medical University, Hanoi, VIET NAM, 2 Department of Allergy, Royal North Shore Hospital and Sydney Medical School; Northern, University of Sydney, Sydney, AUSTRALIA, 3 Penn State University, Hershey, PA.

Poster Session

Epidemiology of Rhinitis

5206 Session Time: Tuesday, March 6, 2012, 9:45 AM - 10:45 AM

893 Prevalence and Co-morbidities of Ocular Allergy in Adolescents
M. Geraldini, N. A. Rosario, H. J. Chong Neto, C. A. Riedi, G. GEA; Federal University of Paraña, Curitiba, BRAZIL.

894 The High Prevalence Of Allergic Rhinoconjunctivitis And Correlation With Cedar And Cypress Pollen Counts In Japanese Schoolchildren
K. Yoshida, 1 M. Furukawa, 1 Y. Adachi, 2 H. Odajima, 3 Y. Ohyaa, 4 A. Akasawa 1 1 Tokyo Metropolitan Children’s Medical Center, Tokyo, JAPAN, 2 University of Toyoama, Toya, JAPAN, 3 Fukuoka National Hospital, Fukuoka, JAPAN, 4 National Center for Child Health and Development, Tokyo, JAPAN.

895 Allergic Rhinitis Symptoms in Infancy: Prevalence, Clinical Characteristics and Treatment

896 How Commonly Does Symptom Severity Vary by Season in Nonallergic Rhinitis?
S. A. Samant, S. Patel, J. B. Hagan, M. A. Rank; Mayo Clinic, Rochester, MN.

897 Exhaled NO May Predict Development of Allergic Rhinitis in Children
Y. Rha, 1 H. Ko, 1 S. Choi; 1 Kyung Hee University Hospital, Seoul, KOREA, REPUBLIC OF, 2 Kyung Hee University Gandong Hospital, Seoul, KOREA, REPUBLIC OF.

898 Higher Levels of Perceived Stress Lead To More Allergy Symptoms
A. M. Patterson, 1, 2 V. O. Yildiz, 2 W. B. Malatkey, 3 1 The Ohio State University, Columbus, OH, 2 Nationwide Children’s, Columbus, OH.

899 Impact Of Allergic Rhinitis On Physical Activity In Children
M. Sugimoto, 1 M. Nagao, 1 K. Hosoki, 1 K. Togashi, 2 T. Fujisawa, 1 1 Me National Hospital, Tsu, JAPAN, 2 Me University, Tsu, JAPAN.

Poster Session

Allergenic products: Diagnostics and Standardization

5207 Session Time: Tuesday, March 6, 2012, 9:45 AM - 10:45 AM

900 To Bee or Not to Bee - Bee Pollen Sensitive
P. Hemmers, Z. Li, J. Santilli; St. Vincent’s Medical Center, Bridgeport, CT.

901 Are Pseudopods On Skin Prick Testing Reproducible?
M. Serota, J. Portnoy, Z. Jacobs; Children’s Mercy Hospital, Kansas City, MO.

902 Optimal Concentration Of Dermatophagoides Pteronyssinus allergen Extract (Dp) For Skin Prick Testing (SPT) In Thai Population With Allergic Rhinitis (AR)
P. Prittasan, 1 C. Bunnag, 1, 2 P. Tantilipikorn, 1, 2 T. Suwanwech, 1, 2 N. Visitsunthorn, 1, 2 O. Jirapongsananuruk, 1, 2 P. Pacharn, 1, 2 P. Vi- chyanont, 1, 2 Sriniraj Hospital, Bangkok, THAILAND, 2 Department of Pediatri- cs, Faculty of Medicine, Bangkok, THAILAND, 3 Department of Otorhinolaryngology, Faculty of Medicine, Bangkok, THAILAND.

903 Histamine Skin Prick Test (SPT) Titration Following Antihista-mine Administration: Wheal Comparison of Histamine Strength Using Different Devices
G. Plunkett, J. Young, R. Erskine, S. Young; ALK-Abello, Inc., Round Rock, TX.

904 Evaluation of Fungal Sensitization in the Greater New Orleans Area
K. Z. Dhanani, 1 J. G. Black, 1 H. Weaver, 2 J. C. Carlson, W. E. Davis; 1 Tulane Medical Center, New Orleans, LA, 2 Ochsner Clinic Foundation, New Orleans, LA.
Oral Abstract Session

Novel Mechanisms in Asthma Therapeutics

5601
Session Time: Tuesday, March 6, 2012, 2:00 PM - 3:15 PM

910 Suppression of Allergic Airway Inflammation by Low Dose, Intranasally Administered Der p 1 Derived Peptides, in a Murine Model of House Dust Mite Allergy
D. M. Moldaver1, M. S. Bharhaní1, J. Watti1, R. P. Hafner1, M. Inman1, M. Larché1; 1McMaster University, Hamilton, ON, CANADA; 2Circassia Ltd., Oxford, UNITED KINGDOM.

911 A Comparison of the Local and Systemic Effects of AZD3199, an Inhaled Ultra-long-acting β2-adrenoceptor Agonist (uLABA), With Formoterol in Patients With Asthma
L. Bjørner1, T. Bengtsson2, C. Jorup3; 1Skane University Hospital, Lund, SWEDEN; 2AstraZeneca R&D, Molndal, SWEDEN.

912 Selective Blockade of Pulmonary Epithelial Stat3 for the Treatment of Asthma
S. De Golovine, A. Kim, D. Tewariday; Baylor College of Medicine, Houston, TX.

913 Maternal Asthma Therapy Reduces Offspring Susceptibility To Developing Airway Inflammation In A Murine Model
K. D. Srivastava, H. A. Sampson, X. Li; The Mount Sinai School of Medicine, New York, NY.

914 Myeloid Derived Suppressor Cells Attenuate Murine Allergic Airway Inflammation
Q. Guan, S. Moreno, C. Weiss, Q. Gefeí, A. Halayko, R. Warrington, Z. Peng; University of Manitoba, Winnipeg, MB, CANADA.

Oral Abstract Session

Cellular Mechanisms of Allergy

5602
Session Time: Tuesday, March 6, 2012, 2:00 PM - 3:15 PM

915 Expression of the Regulatory Protein Caveolin-1 is reduced in Asthma
S. N. Bains1, C. Atkinson1, E. Tourkina1, H. W. Chu2, R. Martin3, E. C. Riemer4, A. P. Kaplan5, S. Hoffman1; 1Medical University of South Carolina, Charleston, SC; 2National Jewish Health and the University of Colorado Health Sciences Center, Denver, CO.

916 Mechanical Skin Injury Induces TLR4/MyD88 Dependent IL-23 Expression In Epidermal Keratinocytes
J. Yoon; Childrens hospital boston, Boston, MA.

917 Human Dendritic Cells Stimulated with a Novel Peanut Protein Express High Levels of RALDH2 and Induce RA-Sensitive Genes in Naïve T Cells
B. Ruiter1, G. Grishina2, C. F. den Hartog Jager3, E. F. Kno1, P. Oziás-Akins1, H. A. Sampson2, W. G. Shreffler3; 1Massachusetts General Hospital, Boston, MA; 2Mount Sinai School of Medicine, New York, NY; 3University Medical Center Utrecht, Utrecht, NETHERLANDS.

918 Interaction With Myd88-dependent CD8-CD11c+ Cells Mediates Rapid Induction Of Antigen-specific IgG- and-IgE-suppressive Gamma Delta T Cells
y. huang1, M. K. MacLeod1, A. S. McKee1, M. K. Aydintug1, C. V. Jacobzick1, R. M. Kedl1, D. Sun1, R. L. O’Brien1, W. K. Born2; 1national jewish health, denver, CO; 2Doheny Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.

919 Combined Blockade Of The Histamine H1 and H4 Receptor Suppresses Peanut-Induced Diarrhea And Intestinal Inflammation By Regulating Dendritic Cell Function
M. Wang1, J. Domenico1, G. Kirchenbaum3, S. K. Oda3, Y. Shin1, J. Han1, E. W. Gefland2; 1National Jewish Health, Denver, CO; 2University of Colorado Denver and National Jewish Health, Denver, CO.

Oral Abstract Session

Viral Bronchiolitis and Asthma in Children

5603
Session Time: Tuesday, March 6, 2012, 2:00 PM - 3:15 PM

920 Upregulation Of Glucocorticoids Beta Receptors In Severe Rsv Bronchiolitis In Infants
P. V. Diaz, R. Mammani1, R. A. Pinto1, A. A. Gaggero1, M. R. Bono2, J. Guerrero1, A. Goecke1; 1Faculty of Medicine, University of Chile, Santiago, CHILE; 2Faculté of Science, University of Chile, Santiago, CHILE.

921 Sequence Analysis of a Cloned Human Rhinovirus Designed For Use in Human Inoculation Studies
K. Nakagome1, Y. A. Bochkov1, W. Lee2, S. B. Liggett3, G. Cri-safi1, J. E. Gern1; 1University of Wisconsin School of Medicine and Public Health, Madison, WI; 2University of Maryland School of Medicine, Baltimore, MD.

922 Risk of Childhood Asthma Following Infant Bronchiolitis During RSV Season

Oral Abstract Session

Mechanisms of EGID

5604 Session Time: Tuesday, March 6, 2012, 2:00 PM - 3:15 PM

925 Proton-sensing Receptor GPR65 regulates Allergic Gastrointestinal Eosinophilia
X. Zhu, E. Mose, S. Hogan, N. Zimmermann; Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

926 Twin Shared Environment Increases Risk of Eosinophilic Esophagitis in Families
E. S. Alexander,1,2 L. J. Martin,3,4 J. P. Abonia,4,5 M. H. Collins,5,6 P. A. Succop,7 A. J. Greenler,2, E. S. Dellon,6 J. G. Demain,1,3 J. P. Francis,1,3 S. E. Furuta,1,2,5 L. E. Gurian,1,3 R. J. Hopp,1,2 A. Kaul,1,2,5 K. Nadeau,1,3,4 R. J. Noel,1,2,5,13 R. E. Putnam,1,2,5 K. F. von Tiehl,1,2,5 M. D. Eby,1 H. Foote,1,2,5 A. C. Ellison,5 M. E. Rothenberg1,16
1University of Cincinnati College of Medicine, Cincinnati, OH, 2Cincinnati Children’s Hospital Medical Center Division of Biostatistics and Epidemiology, Cincinnati, OH, 3Cincinnati Children’s Hospital Medical Center Division of Human Genetics, Cincinnati, OH, 4Cincinnati Children’s Hospital Medical Center, Division of Allergy & Immunology, Cincinnati, OH, 5Cincinnati Children’s Hospital Medical Center, Division of Pathology, Cincinnati, OH, 6University of North Carolina School of Medicine, Division of Gastroenterology and Hepatology, Center for Esophageal Diseases and Swallowing, Chapel Hill, NC, 7Director, Allergy, Asthma & Immunology Center of Alaska, Anchorage, AK, 8Cincinnati Children’s Hospital Medical Center, Division of Gastroenterology, Hepatology & Nutrition, Cincinnati, OH, 9Children’s Hospital of Wisconsin, Milwaukee, WI, 10Medical College of Wisconsin, Milwaukee, WI, 11Cincinnati Children’s Hospital Medical Center, Director, Division of Allergy & Immunology, Cincinnati, OH.

927 Interleukin (II)-15 Overexpression In The Esophagus Promotes IgE Associated Experimental EoE
P. Rajavelu, M. Rayapudi, S. Narayanan, A. Mishra; Cincinnati Children’s Hospital and Medical Center, Cincinnati, OH.

928 Increased CD3+CD69+ T-Cells and CD40+ Eosinophils in the Esophageal Tissue of Eosinophilic Esophagitis
M. Le-Carlson, S. Seki, K. Cox, K. Nadeau; Stanford University Medical Center, Palo Alto, CA.

929 Dietary Therapy and Topical Corticosteroids Can Reverse Esophageal Fibrosis in Patients with Eosinophilic Esophagitis
J. Lieberman, R. Morotti, O. Yershov, M. Chehade; Mount Sinai School of Medicine, New York, NY.

Oral Abstract Session

Immunotherapy

5606 Session Time: Tuesday, March 6, 2012, 2:00 PM - 3:15 PM

935 How Molecular Diagnosis Can Change Allergen-specific Immunotherapy Prescription In A Complex Area Of Pollen Sensitization (madrid, Spain)

936 Bispecific Antibody-induced Allergen-specific Regulatory T cells (Tregs) Suppress Der-P-1-induced Airway Inflammation B. S. Prabhakar,1 A. S. Nayak,2 P. Bhattacharya,1 N. A. Nayak2; 1College of Medicine, University of Illinois, Chicago, IL, 2Sneeze, Wheeze and Itch Associates, Normal, IL.

937 Long-term Safety Of A 300IR Sublingual Tablet Of 5-grass-pollen Allergen Extract In Adults With Grass-pollen-induced Allergic Rhinoconjunctivitis
A. Didier,1 M. Worm,1 F. Horak1, H. Malling4, A. Montagut5, R. K. Zelden1; 1Rangueil-Larrey Hospital, Respiratory Diseases Department, Toulouse, FRANCE, 2Allergy-Centrum-Charit, Klinik fr Dermatologie, Venerologie und Allergologie, Berlin, GERMANY, 3Allergy Centre
Oral Abstract Session

Mechanism of Allergic Sensitization

5607
Session Time: Tuesday, March 6, 2012, 2:00 PM - 3:15 PM

938 Ragweed Allergy Immunotherapy Tablet Reduces Nasal and Ocular Symptoms of Allergic Rhinocconjunctivitis Over the Peak Ragweed Pollen Season in North America
G. Berman1, H. Nolte2, J. Maloney3, P. Creticos3, A. Cheema4, A. Kaur5; 1Minneapolis Allergy & Asthma Specialists, Minneapolis, MN, 2Merck Research Laboratories, Kenilworth, NJ, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Alpha Medical Research, Mississauga, ON, CANADA, 5Centre de Recherche Appliquee en Allergie de Quebec, Quebec, QC, CANADA.

939 Age-related Differences in Antigen Sensitization and the Allergic Airway Responses in Acute and Resolved Viral Respiratory Infection
J. Birmingham, K. Srivastava, X. Li, P. Busse; Mount Sinai School of Medicine, New York, NY.

940 Diesel Exhaust Particles Induce Cysteine Oxidation and S-Glutathionylation in House Dust Mite Induced Murine Asthma
G. B. Lee1, E. B. Brandt2, A. M. Gibson2, T. D. Le Cras2, L. S. Brown1, A. M. Fitzpatrick2, G. K. Khurana Hershey2; 1University of Louisville School of Medicine, Louisville, KY, 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Emory University School of Medicine, Atlanta, GA.

941 The Gut Mucosa Microenvironment Affects Allergic Sensitization vs tolerance to Food proteins
K. Adel-Patient, H. Bernard, S. Wavrin, S. Ah-Leung, J. Wal; INRA, Gif-sur-Yvette, FRANCE.

942 Rhinovirus Matures Dendritic Cells (DCs) and Primes Them for Antigen Presentation
J. W. Steinke, J. A. Woodfolk, R. Agrawal, L. Liu, T. Braciale, L. Borish; Asthma and Allergic Diseases Center, Charlottesville, VA.

943 Leukocyte Ig-like Receptor LILRB4 (LILRB4) Downregulates Key Events in the Migration of Antigen (Ag)-bearing Lung Dendritic Cells in Th2 Inflammation
L. B. Fanning, C. C. Buckley, W. Xing, R. G. Breslow, H. R. Katz; Div. of Rheumatology, Immunology and Allergy, Brigham and Womens Hospital and Dept. of Medicine, Harvard Medical School, Boston, MA.